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Abstract 
 Esophageal cancer is the eighth most commonly diagnosed cancer and the sixth most 
common cause of cancer related mortality globally. There are two different types of esophageal 
cancer, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), each 
accounting for half of the cases. EAC develops in the lower one third of the esophagus as a 
consequence of chronic gastroesophageal reflux disease (GERD) from precancerous metaplastic 
condition Barrett's esophagus (BE). Apart from GERD and BE which are major risk factors for 
EAC, other known risk factors include age, male gender, obesity, Caucasian race, low intake of 
fruits and vegetables in diet, and Helicobacter pylori negative status. Due to changing life style and 
prevalence of risk factors, the incidences of EAC have been rising for past few decades and now it 
has become one of the fastest growing malignancies. The survival rate is very poor with only 1 in 5 
patients survive more than 5 years after EAC diagnosis, likely due to diagnosis at late stages. To 
diagnose early treatable dysplastic changes in progression from BE to EAC, BE patients undergo 
routine endoscopy-biopsies, with the biopsy evaluated by a histopathologist to confirm the 
dysplastic changes. This current method is invasive and prone to sampling error as well as 
interobserver variability. Endoscopy requires patient hospitalization and specialist appointment, 
leading to high expense. Moreover, BE is an asymptomatic condition which means a pool of BE 
patients are undiagnosed hence not enrolled into the surveillance program. Collectively, it has been 
shown that current endoscopy-biopsies based diagnostic is impractical and expensive for population 
wide BE screening or surveillance programs. 
 In contrast to endoscopy-biopsy, biomarkers from the blood are amenable to population-
screening strategies, due to the ease of access and low cost of testing. Moreover, EAC pathogenesis 
has been associated with changes in the serum glycan profile. However, specific glycoproteins that 
undergo differential glycosylation are unknown. Therefore, the aims of this thesis were to (i) 
identify serum diagnostic glycoprotein biomarker candidates for BE and EAC using biomarker 
discovery pipeline, (ii) develop a targeted proteomics approach to measure biomarker candidates for 
timely verification, (iii) verify serum glycoprotein candidates in an independent patient cohort, and 
(iv) test feasibility of using electrochemical detection methodology for the glycoprotein detection.  
 This translational research project utilizes lectins, naturally occurring proteins with 
specificity to bind with glycan structures, as affinity agents to isolate glycoproteins with different 
glycan structures. Our laboratory has previously established lectin magnetic bead array (LeMBA) 
methodology to identify serum glycoprotein biomarker candidates showing differential lectin 
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binding (Loo et al., J Proteome Res 2010 and Choi et al., Electrophoresis 2011). With the help of a 
bioinformatician and biostatisticians, GlycoSelector database incorporating statistical analysis 
pipeline was developed for biomarker discovery using LeMBA platform 
(http://glycoselector.di.uq.edu.au). Serum samples from 29 patients (healthy - 9, BE - 10 and EAC - 
10) were screened using LeMBA-GlycoSelector pipeline. A ranked list of candidate glycoprotein 
biomarkers that distinguish (i) EAC from BE (ii) BE from healthy and (iii) EAC from healthy group 
was identified. GlycoSelector analysis resulted in identification of total 183 unique lectin-protein 
biomarker candidates for targeted verification. 
 Out of the 20 lectins employed for the biomarker discovery, 6 lectins showing differential 
binding with glycoprotein candidates were selected for verification. Multiple reaction monitoring-
mass spectrometry (MRM-MS) assay was set up for 41 promising glycoprotein candidates. After 
testing linearity and reproducibility of MRM-MS assay, serum samples from an independent patient 
cohort were screened using customized LeMBA coupled with MRM-MS. Online web-portal Shiny 
mixOmics (http://mixomics-projects.di.uq.edu.au/Shiny) was used for statistical analysis. Of the 
246 glycoforms measured in the verification stage, 40 glycoforms (as measured by lectin affinity) 
verified as candidate serum markers. The top candidate for distinguishing healthy from BE was 
Narcissus pseudonarcissus lectin (NPL)-reactive Apolipoprotein B-100; BE vs EAC, Aleuria 
aurantia lectin (AAL)-reactive complement component C9; healthy vs EAC, Erythroagglutinin 
Phaseolus vulgaris (EPHA)-reactive gelsolin. A panel of 8 glycoforms showed an area under 
receiver operating characteristic curve (AUROC) of 0.94 to discriminate EAC from BE. Two 
biomarker candidates were independently verified by LeMBA-immunoblotting, confirming the 
validity of the relative quantitation approach employed. 
 Mass spectrometry methods employed for biomarker discovery and verification are best 
suited for research laboratories but not for routine clinical practice whereas electrochemical 
detection methods have been successfully applied for development of point-of-care diagnostics e.g. 
glucose biosensor. In this thesis, the feasibility of using electrochemical method for glycoprotein 
detection has been tested with success using a model glycoprotein ovalbumin with Sambucus nigra 
agglutinin (SNA lectin). A detection limit of 10 pg/mL was demonstrated, in the background of 
diluted human serum. 
 Taken together, this study firstly identified and then verified serum diagnostic glycoprotein 
biomarker candidates using two independent patient cohorts for BE/EAC. The biomarker candidates 
described here require further clinical evaluation in a large patient cohort including early dysplastic 
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patient samples. Electrochemical detection method described in the last part of this thesis can be 
developed further into in vitro diagnostic for clinical use employing glycoprotein biomarker 
candidates.        
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Chapter 1. Introduction 
1.1 General overview 
 The esophagus is 18 to 25 cm long muscular tube that connects pharynx to the stomach and 
pushes food toward the stomach. The upper and lower esophageal sphincter prevents the backflow 
of the food. The upper esophageal wall is composed of striated muscle and lower part is composed 
of smooth muscle while combination of both striated and smooth muscle make up the middle of the 
tissue. The gross anatomy of the food pipe along with blood supply and lymphatic is illustrated in 
the Figure 1.1. In particular, arteries, veins and lymph nodes for lower esophagus, where esophageal 
adenocarcinoma (EAC) develops, are highlighted.         
 
Figure 1.1. (A) Blood supply, (B) venous drainage and (C) lymph drainage of the esophagus. 
Adapted from Kuo and Daniela (4). 
 Following heart disease, cancer is the second leading cause of death globally. Four major 
cancer sites account for half of the cancer related mortalities: lung, colorectal, prostate in men and 
breast in women. In past two decades, a steady decrease in deaths of these four major site 
malignancies lead to an overall decrease in cancer related death rates in men and women (5, 6). In 
contrast, the incidence of EAC is increasing faster than any other cancer type. Before mid 1970s the 
incidence of EAC represented less than 5% of total esophageal cancer. Over a period of three 
decades, the incidence rose continuously and now almost half of the esophageal malignancy cases 
diagnosed are EAC type (7, 8). EAC together with esophageal squamous cell carcinoma (ESCC) is 
the eighth (tenth in USA) most prevalent cancer and the sixth (eighth in USA) most common cause 
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of cancer related death globally (6, 9). EAC is generally diagnosed at a late stage, leading to a poor 
5 year-survival of less than 20% (6, 10).  
 EAC arises in the distal one-third of the esophagus as a consequence of gastro-esophageal 
reflux disease (GERD) and Barrett's esophagus (BE). In response to chronic GERD, normal 
stratified squamous epithelium of esophagus gets converted into metaplastic columnar epithelium, a 
condition called Barrett's esophagus (BE) (11-13). BE is a successful adaptation of the distal 
esophagus in response to chronic GERD. Typically EAC develops through a metaplasia-dysplasia-
carcinoma sequence involving genetic and epigenetic modifications leading to uncontrolled cell 
proliferation. It is characterized by presence of intestinal metaplasia (IM) with low-grade (LGD) to 
high-grade dysplasia (HGD), the latter of which may develop into invasive carcinoma (14). Figure 
1.2 is schematic overview of EAC development. 
Figure 1.2. Schematic representation of EAC development. In response to chronic GERD, 
normal stratified squamous epithelium of esophagus is converted into acid resistant columnar 
epithelium, condition called Barrett's esophagus (BE). Up to 1% of BE patients develop dysplasia 
and EAC. The blue colored cells represent goblet cells. Adapted from Anaparthy and Sharma (15).    
 Majority of BE/EAC patients are asymptomatic hence it is difficult to identify early EAC. In 
advanced stages, patients may present symptoms like dysphagia (difficulty in swallowing), chest 
pain, weight loss and anemia. Significant number of patients are diagnosed accidentally when they 
undergo endoscopy for other gastrointestinal abnormalities (16). In majority of cases clinicians have 
very limited scope for the treatment as tumor has already reached advanced stage at the time of 
diagnosis. Treatment mainly includes surgery, radiation and chemotherapy either alone or in 
combination (17). Cisplatin in combination with fluorouracil is the drug of choice as a combination 
chemotherapy (18). Recent research on EAC has focused on understanding risk factors and 
identification of early diagnostic biomarkers.  
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1.2 Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) 
 Historically, esophageal ulcers resembling peptic ulcers of the stomach were first described 
by Albers in the year 1839 (19) and later on by many others including description of the columnar 
phenotype of the lower esophageal lesions (19-21). In fact until the mid 20
th
 century, confusion 
exists between the terms "esophagitis" and "peptic ulcer of the esophagus". Australian born 
physician Norman Rupert Barrett clearly demarcated the two terms in the article published in the 
year 1950 (22). According to the seminal article, "peptic ulcer of the esophagus" term was mainly 
used by pathologists and most of these cases were in fact examples of congenital short esophagus. 
On contrary, esophagitis had become a blunderbuss term which covered many different 
pathological lesions. So to describe the phenomenon of gastric acid reflux that can give rise to 
ulceration of esophagus, Dr. Barrett specifically coined the term "reflux esophagitis" (22). Although 
Dr. Barrett was not the first one to describe the columnar lining of the esophagus, the disease later 
termed as Barrett's esophagus in honor of contributions made by the pioneer thoracic surgeon (23). 
Although there is no universally accepted definition of BE, it is formally characterized by presence 
of metaplastic columnar epithelium in the proximity of the gastroesophageal junction (11). 
Disagreement still exists between physicians about esophageal intestinal metaplasia to be 
prerequisite for diagnosis of BE (24). In 1975, the clear link between this columnar lined lower 
esophagus (or BE) and EAC was established by patient follow-up using repeated esophagoscopies 
(25). Out of 140 cases of extensive columnar metaplasia followed, 10% of patients developed EAC 
and this disease progression was irreversible and could not be stopped by an anti-reflux operation 
(25).     
1.2.1 Epidemiology and prevalence 
 Out of two major types of esophageal cancers, ESCC and EAC, the latter has undergone 
dramatic epidemiological changes in past few decades. The overall incidence rate of ESCC has 
remained stable or declined since 1970s (26). On the contrary, the incidence of EAC has risen 7-
fold from 3.6 cases per million in 1973 to 25.6 per million in 2006, both in men and women 
combined (26, 27). This rising incidences of EAC cannot be attributed to overdiagnosis due to 
improved imaging techniques implied in the screening program (26, 27). According to an estimate, 
the rate of rise in incidences has slowed down in the past decade and we may have reached a peak 
but this needs to be carefully monitored over next few years (27). EAC and ESCC showed marked 
differences in their geographical spread. EAC is more common in developed countries such as the 
UK (8 in 100,000 individuals) (28), Australia and the USA. Within Europe, southern Europe has the 
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highest EAC incidence (28). On the other side, ESCC is most common type of esophageal cancer 
amongst developing Asian countries (29). Racial disparity also occurs between the two types of 
esophageal cancer. ESCC is more prevalent amongst blacks while EAC is at least twice as common 
in whites as compared to other ethnic groups (30, 31). Once diagnosed, black patients showed 
poorer overall survival than whites (32, 33). Taken together, strong genetic and environmental 
factors relating to ethnicity and geographic distribution seem to be playing critical roles in the 
incidence of esophageal cancer. Studies also suggest possible link between socioeconomic status 
and prevalence of esophageal cancer phenotype (29). 
 As far as prevalence of gastroesophageal reflux disease (GERD) is concerned, it varies 
considerably according to geography. GERD affects 10-30% of the world population except East 
Asian countries where its prevalence has reported to be less than 10% (34). Although it is very 
challenging to screen the general population for the presence of BE using endoscopy, according to a 
study conducted in a Swedish cohort, around 1.6% of the population harbor either short or long 
segment BE (35). This number is estimated to be even higher around 5-6% according to 
mathematical modeling (36) which is very close to the results of endoscopic screening conducted in 
the patients undergoing colonoscopy (37, 38). Almost 95% and 80% of EAC patients have no prior 
diagnosis of BE or GERD respectively (39). The conversion rate from BE to EAC is estimated to be 
0.12-1.0% per patient-years with large cohort studies suggesting lower conversion rate, contrary to 
studies conducted in small sample size (40-42). Taken together, incidences of BE/EAC have been 
rising and show marked differences according to geography. 
1.2.2 Risk Factors 
 Esophageal cancer is unlikely to develop in individuals below age of 40 years, however after 
that its incidence rises significantly with each decade of life (32). Changing life style and food 
habits are primarily responsible for the dramatic epidemiological changes in EAC as described in 
reviews (10, 39, 43). Known EAC risk factors include accumulation of visceral fat in the abdomen 
(44), male gender, high intake of dietary fat and cholesterol with low intake of fruits and vegetables 
(45), tobacco smoking (46), reduction in Helicobacter pylori infections (47) and Barrett’s 
esophagus (BE), a metaplastic change to the esophageal lining. Individuals with BE carries 30-125 
times more risk for EAC development (48). 
1.2.2.1 Gastroesophageal reflux disorder (GERD) and Barrett’s esophagus (BE) 
 Patients suffering from recurrent GERD have 7 to 8 fold increased risk for developing 
specifically EAC without having any effect on development of ESCC, gastric cardia 
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adenocarcinoma or non-cardia gastric adenocarcinoma (49). The rate of EAC is even higher in 
individuals with bile reflux. Erosive reflux disease as compared to non-erosive reflux is responsible 
for esophageal inflammation and ulceration leading to EAC (43). However, GERD alone is not 
capable of explaining dramatic rise in the EAC incidences. Furthermore, only about 10% to 20% of 
GERD patients develop BE and this percentage even reduces when we consider EAC suggesting 
involvement of other risk factors (50).  
 Barrett’s esophagus (BE) is a successful adaptation in response to chronic GERD and 
characterized by replacement of normal stratified squamous epithelium with metaplastic columnar 
epithelium (39). Amongst three different types of columnar epithelium named as intestinal, cardia 
gastric fundic and gastric junctional, only intestinal metaplasia seems to be associated with 
increased cancer risk and histologically diagnosed by presence of mucous secreting goblet cells 
(50). Being a strongest risk factor for developing EAC, typically BE patients carry 100 folds 
increased risk for developing EAC equally for both men and women. The process of EAC 
development from BE typically involves stages like low-grade dysplasia (LGD), high-grade 
dysplasia (HGD), early EAC and invasive carcinoma (43, 51). The predominance of BE is almost 
double in men with typical age of diagnosis 50-59 years (51, 52).  
1.2.2.2 Obesity 
 At the same time while incidences of EAC are increased, obesity has reached epidemic level 
globally with more than 1.7 billion adults overweight and 300 million people are clinically obese 
(53). Epidemiological studies have shown strong implication between increasing body mass index 
(BMI) and risk of EAC, with 2-3 fold increased risk for those with BMI ≥ 30 kg/m2 and 1.5-2 fold 
in those with BMI = 25.0 to 29.9 kg/m
2
 independent of reflux (39, 44, 54). Obesity can cause hiatal 
hernia and can simply provoke reflux through increasing intra-abdominal pressure. Independent of 
reflux, obesity can also lead to EAC by other mechanisms (50, 55).  It has been realized that rather 
than only weight, it is actually distribution of the fat that affects the disease progress. Visceral fat is 
metabolically more active and has been associated with high levels of leptin, interleukin-6 (IL-6), 
tumor necrosis factor-α (TNF-α) and overall low serum level of adiponectin (56). This chronic low 
grade inflammation state in obesity can increase cell proliferation leading to cancer (39). Also high 
serum leptin levels are associated with BE in only men and not in women which may partly explain 
the male predominance of the disease (57).  
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1.2.2.3 Age and gender 
 EAC follows similar age distribution to that of other gastrointestinal malignancies with 
median age at the time of diagnosis of 60 years (54). Male: female occurrence ratio for EAC is 
reported to be 3-7:1, making it male predominating disease. The detailed underlying mechanism for 
this anomaly is yet to be discovered (58). One can obviously speculate a relationship between sex 
hormones and EAC development. Estrogen may be protecting female in early ages against EAC or 
it may be testosterone which predisposes men towards the disease. 
Three independent studies looking at expression levels of androgen receptor (AR) using 
immunohistochemistry in healthy, BE and EAC tissue samples (total n = 60) concluded no 
relationships between AR staining and either disease status or survival of EAC patients (59-61). In 
agreement with the tissue staining, the esophageal adenocarcinoma cell lines OE19 and OE33 do 
not express AR (62). However, stromal cells express AR which raises the possibility of indirect role 
of AR in BE/EAC (62). The paracrine effect of stromal AR and exposure with androgens i.e. serum 
testosterone can be mediated by fibroblast growth factor (FGF)/fibroblast growth factor receptor-1 
(FGFR-1) axis (62). Supporting this idea, OE19 xenografts grew faster in male mice in comparison 
with female mice along with high intensity staining for FGFR in male mice (62). In a large scale 
study including prostate cancer patients undergoing antiandrogen therapy it has been concluded that 
there is no relationship between antiandrogen therapy and secondary esophageal adenocarcinoma 
development (63). Another clinical study on prostate cancer patients concluded that risk of 
developing EAC, and not ESCC is lower in prostate cancer patient. This may be due to etiological 
factors related to prostate cancer or antiandrogen therapy (64). Overall based on the available 
evidences, testosterone alone cannot explain the gender bias for the disease. It appears that 
testosterone/AR may not have any direct role to play in EAC development; however, these studies 
are few in number and limited in scope hence require further confirmation. 
There is continuous decrease in male: female incidence ratio of EAC from more than 10:1 in 
some age groups of less than 50 years of age to 4:1 in mid 80s suggesting age associated factors 
related to sex may be playing role (58). Importantly role of ovarian hormones cannot be ruled out as 
ovarian function deteriorates with age in female. Estrogen has protective effect against certain GI 
tumors while in case of breast and ovarian cancer it promotes tumor progression however there is 
no such clear information regarding EAC (65, 66). This tissue specific anomaly of estrogen action 
is determined by distribution of estrogen receptors (ER) namely Estrogen Receptor α (ERα), 
Estrogen Receptor β (ERβ) and its downstream signaling. ERα is considered to be anti-apoptotic 
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while ERβ acts as a pro-apoptotic and both the receptors regulate expression of different set of 
genes in multiple possible ways (65). ERα and progesterone receptor (PR) are not expressed in 
EAC tissues (67-69). ERβ is present in EAC tissues (67-69) and its expression levels are correlated 
with tumor stage (69). ERβ localization also differs in BE and EAC tissue samples, in case of 
former they are present only in nucleus while EAC samples show staining for ERβ throughout 
cytosol and/or nucleus (68). Estrogen has also been found to protect against chemical carcinogen 
induced esophageal cancer in rat model (70). In another rat model using nitric oxide (NO), it has 
been confirmed that male rats showed more tissue damage in response to NO and it was suppressed 
by presence of 17-β-estradiol (71). In vitro, 2-methoxyestradiol, an endogenous by product of 17-β-
estradiol decreases cancer cell proliferation and migration by regulation of Bax/Bcl-2 and β-
catenin-E-cadherin signaling pathway. However, these effects seem to be independent of ERs (72). 
A clinical study has shown that post-menopausal women taking tamoxifen as a therapy for breast 
cancer has 60% statistically non-significant more risk of developing EAC (73). Tamoxifen is a 
selective estrogen receptor modulator (SERM) with antiestrogenic effect in breast in contrast to its 
estrogenic effect in bone and endometrium (73). If estrogen actually has a protective role against 
EAC then post-menopausal hormone use should decrease the risk for developing EAC but actually 
no correlation was found between post-menopausal hormonal medication and EAC (74). 
Apart from regulating reproduction related functions, estrogen is also implicated in the 
overall physiological metabolism in both sexes (65). High level of estrogen in premenopausal 
women by interaction with ERs in the brain and with leptin signaling can drive subcutaneous fat 
distribution which is less harmful in terms of EAC (61, 70). However, in the presence of relatively 
low levels of estrogen after menopause, visceral fat starts to accumulate predisposing women for 
increased risk of EAC (63, 70, 71, 73). The scenario for male is less clear as the majority of studies 
were done in females (65). 
 In summary, estrogen seems to play a role in EAC. Further studies in this regard may 
provide useful links to understand the male predominance of the disease. Depending upon the 
expression of the receptors and its downstream signaling in the tumor, estrogen can play either 
proliferative or apoptotic role which can be targeted using already available estrogen analogues, 
SERM or anti-estrogen to establish new supportive therapy for the deadly disease. 
1.2.2.4 Alcohol and smoking 
 Alcohol is a putative risk factor for the ESCC while there is no such correlation for EAC 
(46, 54, 75, 76). In contrast to alcohol, which is not considered to be a risk factor for the disease, 
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smokers have almost two times higher risk for EAC. The increased risk remains even a long time 
after smoking cessation (46, 75, 76).  
1.2.2.5 Helicobacter pylori Infection 
Plethora of evidences suggests inverse relationship between H. pylori infection and EAC 
(47, 55, 77). The mechanism proposed is due to the ability of H. pylori to induce atrophic gastritis 
which results in a decrease in gastric acid production. H. pylori produces ammonia from urea, 
changing the nature of refluxate which reduces the chances of esophageal damage due to reflux (10, 
54). The incidence of infection is declining in the developed countries which may contribute to the 
increased incidence of EAC (54). 
1.2.2.6 Diet 
Low intake of antioxidant rich foods, fibers, fruits and vegetables is associated with the 
incidence of the EAC (45, 78, 79). Furthermore, high intake of dietary fat, dietary cholesterol and 
animal protein are found to be potential risk factors for EAC (45). 
1.2.2.7 Medication 
 Non-steroidal anti-inflammatory drugs (NSAIDs) consumption is shown to have protective 
role against development of EAC as well as ESCC. In fact, individuals taking regular Aspirin have 
shown clinical benefits with respect to esophageal malignancy (80-83). These agents protect against 
the malignancy by reducing Cyclooxygenase-2 (COX-2) mediated inflammation (84). 
 Proton-pump inhibitors (PPIs) which reduce gastric acid production may protect against 
gastric acid mediated damage to esophagus hence show protective role against EAC. However, the 
data shows mixed results (39). 
 Overall GERD and related BE, obesity, smoking, change in dietary habits and decrease in H. 
pylori infection are responsible for increase in the EAC cases.  
1.2.3 Pathophysiology 
 Significant numbers of EAC arise as a consequence of BE and GERD. The development of 
BE is considered to be a two-step process (14). In response to chronic GERD, the first step involves 
the replacement of normal esophageal squamous mucosa to a simple columnar epithelium called 
cardiac mucosa (85-87). This first step is very rapid and can occur within 1-2 years. Cardiac mucosa 
is an unstable epithelium which can express gastric genes leading to gastric differentiation and 
formation of oxyntocardiac mucosa (88). This is considered to be a favorable change and it is not 
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premalignant. Alternatively, cardiac mucosa can express intestinal genes which cause the formation 
of goblet cells making this a pre-malignant mucosa BE. Typically goblet cells formation takes 
minimum of 5-10 years (89). 
 Different hypothesis prevail for cellular and molecular changes responsible for making 
columnar and more acid resistant epithelium in BE (12). During embryonic development, 
esophagus is initially lined by columnar epithelium which during late embryogenesis is replaced by 
squamous epithelium through the process of transdifferentiation (90, 91). On this basis it has been 
believed that columnar epithelium again develops in the esophagus as a consequence of GERD by 
reversal of the developmental pathway. In fact in vitro experiments have confirmed these changes 
(92-94). Contrary to the transdifferentiation hypothesis, the columnar epithelial cells may originate 
from the stem cells itself (12). The reprogramming of the stem cell situated in the basal layer of the 
normal squamous epithelium gives rise to metaplastic columnar type cells (12). Alternatively, stem 
cells residing in the submucosal glands of the esophagus or bone marrow derived stem cells can 
also give rise to metaplastic tissue (95, 96). 
 At the molecular level, the homebox gene CdX2 is essential for intestinal differentiation 
while CdX1 specify columnar cell phenotype (97, 98). Exposure of esophageal squamous 
epithelium to acid or bile salts can increase expression of these genes leading to phenotypic changes 
including formation of crypt like structure and expression of intestinal genes like villin and mucin 
(99, 100). SOX9 protein is shown to be expressed specifically in BE/EAC which plays a role in the 
formation of intestinal type goblet cells (101, 102). The role of developmental signaling pathways 
like Wnt signaling, Notch signaling, Hedgehog and bone morphogenic protein (Bmp) 4 pathways 
are also described in making Barrett's metaplasia (12).  
 Development of EAC from BE follows metaplasia-dysplasia-adenoma carcinoma sequence. 
Disruption of p16/Rb pathway and p53 pathway can drive molecular changes from BE towards 
EAC (12, 39). The pathogenesis involves development of early and late phase dysplasia resulting 
into invasive carcinoma (50, 103). The dysplasia is associated with the architectural and cytological 
changes in the columnar epithelium. Variations in nucleus size and shape, increased nuclear-to-
cytoplasm ratio, hyperchromatism, increased numbers of abnormal mitoses, villiform configuration 
of the mucosal surface and architectural abnormalities like budded, branched, crowded, or 
irregularly shaped glands are hallmark of dysplasia (103).   
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1.2.4 Current diagnosis scenario 
 Esophageal cancer patients do not present any symptoms until the disease is in advanced 
stages. Currently the majority of EAC patients are diagnosed symptomatically when patients 
present symptoms like dysphagia, anemia, fatigue, vomiting, and weight loss without trying etc 
(104). By this time, the tumor is already locally metastasized hence patients often show very poor 
survival (16). In contrast, more than 90% patients survive beyond 5-years if the diagnosis is made in 
the early stages of HGD before EAC develops (105).     
 In order to detect pathological changes leading to EAC development before onset of disease, 
current clinical practice involves endoscopic screening of high risk GERD patients and to 
characterize the degree of dysplasia in biopsy samples collected during endoscopy (106, 107). 
Patient enrollment into an endoscopic screening program may be facilitated by a patient 
questionnaire of self-evaluated symptoms/complications (108, 109). Once enrolled into the 
screening program, patient undergoes endoscopy-biopsy every 3 months to 2 years depending on 
the degree of dysplasia, during which 4 quadrant biopsy samples are taken every 1-2 cm and 
evaluated for histological changes by expert pathologists (106, 107). As a significant number of 
patients histologically diagnosed with HGD develop EAC, endoscopic mucosal ablation or 
esophageal resection (esophagectomy) are options to stop further disease progress in those high risk 
patients (110, 111). Significantly improved survival is observed in patients diagnosed at an early 
stage during surveillance endoscopy program as compared to symptomatically diagnosed EAC 
(112-115).  
 Although current screening methodology shows promise, outcome of endoscopy-biopsy in 
many cases is non-reproducible due to interobserver variability and sampling error (111, 116). 
Furthermore, histological dysplastic changes may be patchy and present heterogeneously in tissue 
sample. This makes the diagnosis challenging, especially in the early stages of transition to LGD 
(111, 117). In up to 40% of patients, invasive cancer has been found in resected tissue despite of 
endoscopic examination was negative for the malignancy (118). Moreover, false positive results 
also occur, meaning despite intramucosal carcinoma in a biopsy, the subsequently resected tissue 
has no signs of carcinoma (111). This evidence suggests dysplasia grading is an imperfect measure 
of cancer risk.  
 Despite extensive screening with currently available techniques, more than 80% of EAC are 
diagnosed without any prior diagnosis of BE or GERD (119, 120). According to an estimate more 
than 80% of BE are undiagnosed hence not getting benefit of the screening program (121). On the 
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other hand a large proportion of patients undergoing routine biopsy screening do not progress to 
EAC (39). These suggest inability of current methodologies in screening population to detect high 
risk patients and to distinguish between disease progressors from non-progressors. In addition, the 
screening procedure is not very cost-effective (122).  
1.2.5 Patient screening, surveillance, management and treatment 
 Table 1.1 summarizes current scenario for managing patients with GERD, BE, dysplasia and 
EAC. BE, being an asymptomatic condition by itself, is very difficult to diagnose symptomatically 
in the patients. So at present, older obese Caucasian males suffering from chronic GERD who has 
highest likelihood of BE are screened using endoscopic techniques for metaplastic/dysplastic 
changes (110). However, 44% of BE patients in the Swedish patient cohort did not present any 
GERD related symptoms and would have been not included in the BE screening according to 
current guidelines (35). Although the effectiveness of screening to reduce EAC associated mortality 
is not clearly established, emergence of newer techniques such as esophageal capsule endoscopy 
could provide a non-invasive and convenient way to diagnose columnar lining of esophagus (123). 
 For early detection of EAC in patients diagnosed with BE, routine patient surveillance is 
performed using endoscopy-biopsies method and the degree of dysplasia is determined by an expert 
pathologist as a measure of disease progression. The degree of dysplasia determines the frequency 
of screening. Patients with LGD are followed-up every 6 months while HGD requires follow-up 
every 3 months (110). Patients diagnosed with HGD can be intervened using either endoscopic 
mucosal resection technique or mucosal ablation therapy such as photodynamic therapy, 
radiofrequency balloon catheter ablation, or thermal techniques and showed improved survival 
(124). Once the patient is diagnosed with EAC, treatment depends upon the stage of the disease. For 
early stage EAC, surgery is the best option. When the disease is locally metastatic, neoadjuvant 
chemotherapy or neoadjuvant chemoradiation therapy along with surgery has become standard of 
care. Once EAC is metastasized to distant organs there are not many treatment options available. So 
patients are managed using chemotherapy and supportive care (17). Once EAC is developed then 
irrespective of stage and treatment, 5-year survival is less than 20% unfortunately.  
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Table 1.1. Current strategies to manage and treat patients in the progression from GERD to 
EAC.  
Condition Patient management and treatment 
GERD 
Majority of patients are diagnosed symptomatically. Severity and nature of 
reflux can be determined using impedance-pH measurement. PPIs are 
prescribed to control reflux. 
Barrett's 
esophagus 
High risk patients undergo endoscopy-biopsies screening to diagnose columnar 
lining of esophagus. Once diagnosed patients are enrolled into surveillance 
program to detect early dysplastic changes. However around 44% of patients 
diagnosed with BE have no prior symptomatic representation of GERD which 
means they don't get benefit of screening. Patients are managed with PPIs and 
acid control therapies. 
Early grade 
dysplasia 
Patients are followed-up with surveillance every 6 months to carefully monitor 
disease progression. 
Late grade 
dysplasia 
Patients undergo endoscopy-biopsies every 3 months to identify early 
neoplastic changes. Patients can be treated at this stage using ablation 
techniques. 
Esophageal 
adenocarcinoma 
The line of therapy is decided according to TNM staging of the tumor. Early 
stage patients are treated using surgery alone while locally metastatic patients 
are treated with surgery and chemotherapy or chemoradiotherapy. For 
metastatic disease, supportive care is the only option. 
 Taken together, an ideal strategy will be to identify BE population and monitor their 
progression for LGD/HGD when patients can be treated to reduce morbidity and mortality 
associated with EAC. To overcome challenges in the current endoscopy-biopsies based screening 
program, adjunct use of biomarker has been proposed. 
1.3 Biomarkers 
 According to United States National Institutes of Health a biological marker or a biomarker 
is "A characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention" (125). 
Biomarkers have clinical application during all stages of the disease management starting from 
early diagnosis, monitoring disease progression and predicting therapeutic response (126). A 
biomarker addresses a clinically relevant question and provides valuable information that can be 
used for patient management and decision making by the clinician. Ideal biomarker test should be 
accurate, non-invasive, easy to perform, quick, and informative (127). 
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 Based on sequence of events from exposure to disease development and therapeutic 
response (126), biomarkers can be classified into exposure (128), susceptibility [BRCA1/2 
mutations in breast cancer] (129), diagnostic [prostate-specific antigen in prostate cancer] (130), 
predictive [estrogen and progesterone receptor to predict response to endocrine therapy in breast 
cancer] (131), pharmacodynamic [receptor tyrosine kinases (RTKs) phosphorylation measurement 
to monitor pharmacological effect of RTK inhibitors] (132), and prognostic [higher CA 19-9 levels 
are associated with poor survival in pancreatic cancer] (131) markers. Any biomolecule DNA, 
RNA, protein, metabolite or lipid including circulating tumor cell and imaging measurement can 
qualify as a biomarker.   
1.3.1 Biomarker discovery and development phases 
 National Cancer Institute Early Detection Research Network (EDRN) guidelines outline 
biomarker discovery and development to a 5 phase process summarized here (133) and depicted in 
Figure 1.3. This thesis focused on Phase I and early Phase II of the 5 phase development.   
 Phase I - Preclinical exploratory study: It compares normal vs. cancer samples (body 
fluids/tissue) using technologies such as genomics, microarray expression, proteomics, 
immunohistochemistry or immunoblotting to detect significant changes in 
proteins/genes/metabolites between the groups. 
 Phase II - Clinical assay development and validation: It is aimed at developing a clinical 
assay using a minimally invasive sample collection method. The assay is meant to be robust, 
reproducible and suitable for stored clinical samples to be used in later phases of development. 
Sensitivity and specificity are determined at this stage. Sensitivity of an assay is the ability of the 
test to correctly identify those patients with the disease while specificity of a test refers to the ability 
of an assay to correctly assign patients without the disease. At the end of this phase one should 
expect high specificity and sensitivity for the assay. However, it remains to be determined how 
early the biomarker can predict the disease. 
 Phase III - Retrospective longitudinal repository studies: The assay is applied on 
prospectively collected stored samples to determine ability of biomarker to detect the disease before 
clinical presentation. If so then criteria for positive screening is determined for future use. 
 Phase IV - Prospective screening: The test is prospectively applied to real population to 
detect extent and characteristic of disease detected by the biomarker. This phase gives positive 
predictive value for the test and gives idea about feasibility for last phase of control trials. 
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 Phase V - Cancer control studies: It comprises of large scale clinical trial to determine 
impact of new screening process on the disease burden in the community.  
1.4 Biomarkers for BE/EAC 
 In transit from IM to LGD to HGD to EAC, cells acquire abilities to become self sufficient 
for growth, evade apoptosis, proliferate uncontrollably, promote angiogenesis, invade underlined 
epithelium and start to metastasize. These changes are accompanied with histological changes in 
tissue architecture, genomic instability, development of tumor microenvironment, modulation of 
immune response and therefore reflected in body fluids (serum/plasma/mucus/urine) or tissue 
samples and differentiate in terms of their genome/proteome/metabolome profile (134). Thus, a 
biomarker can be from any of these sources and reflect underlying pathological or homeostatic 
changes. Table 1.2 summarizes different classes of biomarkers proposed for BE/EAC.  
Table 1.2. Comprehensive summary of different classes of BE/EAC biomarkers. 
Biomarker Class References 
Tissue Biomarkers 
Genomic abnormalities (Ploidy and LOH) (135-139) 
DNA methylation Refer to Table 1.3 
SNPs/expression array studies Refer to Table 1.4 
Inflammatory Markers 
COX-2 
NF-κB 
Cytokines 
MMPs 
 
(140-146) 
(147-150) 
(148, 150-156) 
(157-163) 
Cell cycle abnormalities (164-166) 
miRNA Refer to Table 1.5 
Glycosylation changes (167-170) 
Circulatory Biomarkers 
DNA methylation changes (171-174) 
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Biomarker Class References 
Glycan alterations (175-180) 
Metabolic profiling (181-184) 
 With respect to EAC, none of the biomarkers, including high grade dysplasia, have been 
evaluated in phase V while very few are evaluated in phase III and IV. Figure 1.3 summarizes 
proposed EAC biomarkers and how well they are characterized in the process of biomarker 
discovery. The following sections will discuss some of the classes of BE/EAC biomarkers. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Summary of current BE/EAC biomarkers with respect to EDRN clinical phase of 
development. 
1.4.1  Genomic instability 
 Many groups have studied genomic instability induced by aneuploidy, tetraploidy, DNA 
methylation, allelic loss and demonstrated some predictive power for these changes. A role for 
hypermethylation in the promoter regions of tumor-suppressor genes during the development of 
EAC has also been well-established. Table 1.3 summarizes DNA methylation changes associated 
with metaplasia-dysplasia-carcinoma development. In the majority of patients, methylation changes 
are acquired very early during EAC development, hence these alterations could be used as an early 
diagnostic biomarker. Apart from discriminating patients at different stages of EAC development, 
Phase I & II: Preclinical
exploration, Clinical Assay
development and
validation
Phase III: Retrospective
longitudinal repository studies
Phase IV: Prospective 
screening
Phase V: Cancer control 
studies
High-grade
dysplasis
None
DNA methylation, LOH,
Ploidy, p53 loss, Cyclin D1
PCNA, Ki67, EGFR, COX-2 ,
miRNA, cMYC, HER2, NF-κB, Bcl-2,  
VEGF, E-cadherin, p16 abnormalities, 
β-Catenin, Glycoproteins etc.
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DNA methylation signatures may be useful as predictors for progression from BE to EAC (185, 
186), and to monitor response to chemotherapy and survival in EAC patients (187, 188).       
 Although the individual genomic abnormality has the potential to diagnose disease at 
different stages, best results are obtained when they are used in combination (135-137). Loss of 
heterozygosity (LOH) at chromosome 9p and 17p locus are considered to be early events during BE 
pathogenesis (138). If present with other chromosomal alterations like aneuploidy and tetraploidy, it 
increases 10-year risk for development of EAC from 12% to   80% (139). However, with the current 
flow cytometry technology, it is technically very challenging for clinical laboratories to assess these 
genomic biomarkers in the patient samples which limits widespread use of these biomarkers in the 
clinic. 
  Alternatively, genomic alterations can be detected at the protein level using 
immunohistochemistry. One of the most common and earliest genomic abnormalities occurs at 
chromosome 17p which codes for tumor suppressor p53 protein. Loss of p53 protein expression in 
tissue samples correlates very well with disease progression (189). However, as p53 expression 
only reflects alterations at one particular gene, it has lower predictive value as compared to 
techniques monitoring multiple genomic abnormalities. Furthermore, sensitivity drops as mutations 
or deletions at genomic level may not necessarily be detected at the protein level (190). 
 In line with genomic abnormalities described above, single nucleotide polymorphisms 
(SNP) based genotyping can also stratify cancer risk in BE patients. As summarized in Table 1.4, in 
the past decade, several studies conducted using advanced genomic techniques such as an array-
comparative genomic hybridization (aCGH) and SNP arrays confirmed previously reported copy 
number alterations and identified novel genomic loci undergoing changes during process of 
metaplasia-dysplasia-carcinoma development (191-197). It has been shown that as the disease 
progress from early to late stages, SNP abnormalities increases from ~2% to ~30% (191, 194). The 
total number of SNP alterations in tissue samples is tightly correlated with previously reported 
DNA abnormalities such as aneuploidy, copy number alterations and LOH highlighting the 
application of SNP based genotyping to assess genomic abnormalities (191-197). Thus, SNP based 
genotyping provide an alternative way to assess genomic abnormalities during EAC pathogenesis.  
 Studies on gene expression changes in EAC have been propelled by recent progress in 
genomic technologies, each identifying unique sets of gene expression profile which can be used as 
a biomarker panel for disease diagnosis, prognosis or to predict response to therapy (Table 1.4). 
Moreover, determination of the gene expression changes has been extremely helpful to understand 
18 
 
detailed pathogenesis and will form basis for developing future therapies. However, future 
validation using independent sample cohorts will be necessary for the majority of these potential 
biomarkers.        
 Apart from genomic abnormalities associated with the disease progression, inheriting 
genetic factors are also implicated for EAC development. Risk for BE/EAC, GERD is increased by 
2-4 fold when a first-degree relative is already affected by any of these conditions (198). A study 
conducted by The Esophageal Adenocarcinoma Genetics Consortium and The Wellcome Trust 
Case Control Consortium identified link between SNPs at the MHC locus and chromosome 16q24.1 
with risk for BE (199). They also identified SNPs associated with body weight measures were 
present with more than expected frequency in BE samples supporting epidemiological findings 
regarding obesity as a risk factor for BE and EAC (199). Wu and colleagues examined the 
relationship between presence of risk genotypes and onset of EAC. They identified 10 SNPs 
associated with the age of EAC onset. Genes associated with 5 of the 10 SNPs identified were 
known to be involved in apoptosis (200). 
 The comparative genomic analysis between EAC and ESCC reported by Agrawal and 
colleagues (201) confirmed previously very well described association of p53 gene mutations with 
esophageal cancer development. The authors also performed comparative genome-wide analysis 
between matched BE and EAC patient tissue samples and concluded that the majority of genomic 
changes occur early during EAC development, at the stage of BE (201). Similar conclusions were 
made by next-generation sequencing of matched biopsy samples obtained from the same patient at 
the stage of BE and EAC (202). The authors also identified ARID1A as novel tumor-suppressor 
gene and around 15% of EAC patient showed loss of ARID1A protein in tissue samples. In vitro 
studies suggested it to be associated with cell growth, proliferation and invasion (202). Recently 
published high-resolution methylome analysis has provided first evidence for methylation changes 
at genomic regions that encode non-coding RNAs. The authors identified long non-coding RNA, 
AFAP1-AS1 to be severely hypomethylated in BE and EAC tissue samples. Silencing of which 
significantly reduced aggressiveness of EAC cell lines OE33 and SKGT4 (203).  
 Recently published two major cancer genome sequencing studies analyzed tissue samples 
collected from more than 300 patients in total and provided deeper insights into the genomic 
abnormalities associated with EAC pathogenesis (204, 205). Dulak and colleagues sequenced 149 
tumor-normal pairs using exome sequencing including 15 pairs were subjected to whole genome 
sequencing. They identified high prevalence of A>C transversions at AA dinucleotides in EAC 
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tissue as compared to paired normal samples. Apart from identifying mutations in TP53, CDKN2A, 
SMAD4, ARID1A and PIK3CA genes which is very well-known, they identified 21 potentially novel 
genes showing mutation in EAC. Functional analyses suggested activation of the RAC1 pathway in 
EAC condition (204). In order to study the timing of these mutations in progression towards EAC, 
Weaver and colleagues analyzed mutation status of 26 genes across 66 non-dysplastic BE (NDBE) 
patients (no signs of dysplasia for median follow-up for 58 months) and 43 HGD samples. Notably, 
more than half of NDBE patients harbor mutations that are found in EAC samples suggesting 
genomic abnormalities occur very early during the pathogenesis (205).  
 Taken together, genomic abnormalities play key roles during each stage of transformation 
from normal squamous epithelium to EAC. The majority of key mutations are already acquired at 
the metaplastic stage of BE and only few driver mutations lead to progression of dysplasia and EAC 
(201, 202, 205). This finding raises the possibility of more functional level changes (e.g. protein 
expression, protein glycosylation, metabolic changes etc.) driven by early genomic alterations to be 
associated with development of dysplasia/carcinoma from metaplastic condition. 
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Table 1.3. Summary of hypermethylated genes during BE/EAC development. 
Gene Location Function Method Number (percentage) of samples showing 
hypermethylation or study findings 
Ref. 
Normal BE LGD HGD EAC 
p16 (or CDKN2A 
or INK4A) 
9p21 Cyclin 
dependent 
kinase inhibitor 
Methylation 
specific PCR 
5/9 (56%) 14/18 
(77%) 
- - 18/21 
(85%) 
(206) 
Methylation 
sensitive single-
strand 
conformation 
analysis 
0/10 (0%) 4/12 (33%) 3/11 
(27%) 
3/10 
(30%) 
18/22 
(82%) 
(207) 
Methylation 
specific PCR 
0/17 (0%) 14/47 
(30%) 
9/27 
(32%) 
10/18 
(56%) 
22/41 
(54%) 
(208) 
Methylation 
specific PCR 
2/64 (3%) 14/93 
(15%) 
- - 34/76 
(45%) 
(209) 
Methylation 
specific PCR 
- 3/10 (30%)  - - 5/11 
(45%) 
(210) 
Methylation 
specific PCR 
- 27/41(66%) 21/45 
(47%) 
17/21 
(81%) 
65/107 
(61%) 
(211) 
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Methylation 
specific PCR 
0% 1/15 (7%) 4/20 
(20%) 
12/20 
(60%) 
8/15 
(53%) 
(212) 
Methylation 
specific PCR 
Separately determined exon 1 and exon 2 methylation. 5/16 
(31%) exon-1, 8/16 (50%) exon 2 in EAC patient samples 
showed hypermethylation. Exon 2 methylation correlates with 
stage of the tumor (p=0.01) 
(213) 
O
6
-
Methylguanine-
DNA 
Methyltransferase 
(or MGMT) 
10q26 DNA repair Methylight 
technique 
2/10 (20%) 8/13 (62%) - - 84/132 
(64%) 
(214) 
Methylation 
specific PCR 
6/29 (21%) 24/27 
(89%) 
13/13 (100%) 37/47 
(79%) 
(215) 
APC 5q21-q22 Wnt/β-catenin 
signaling 
Methylation 
specific PCR 
0/17 (0%) 24/48 
(50%) 
14/28 
(50%) 
14/18 
(78%) 
20/32 
(63%) 
(208) 
Methylation-
sensitive single-
strand 
conformation 
analysis and 
methylation-
sensitive dot 
blot assay 
0/16 (0%) 11/11 
(100%) 
- - 20/21 
(95%) 
(216) 
8 out of 14 histologically normal gastric mucosa adjacent to 
EAC showed significantly different methylation of APC 
promoter. 
(217) 
GSTM2 1p13.3 Anti-oxidants Bisulfite <10% ~50% ~55% 69% (218) 
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GSTM3 
and protection 
against DNA 
damage 
pyrosequencing 
(Sample size: 
EAC-100, BE-
11, Dysplasia-
11, Normal 
esophageal/gastr
ic mucosa-37) 
<10% ~13% ~37% 15% (218) 
GPX7 1p32 <10% ~18% ~80% 67% (218) 
GPX3 5q23 
<10% ~90% ~88% 62% 
(218) 
Methylation 
specific PCR 
2/12 (17%) 13/21(62%) 9/11 (82%) 30/34 
(88%) 
(219) 
TIMP-3 22q12.3 MMP inhibitor Methylight 
technique 
1/8 (13%) 6/12 (50%) - - 9/13 
(69%) 
(220) 
Death-associated 
protein kinase 
(DAPK) 
DAPK1: 
9q21.33 
DAPK2: 
15q22.31 
DAPK3: 
19p13.3  
Tumor-
suppresor and 
mediator of 
apoptosis 
Methylation 
specific PCR 
4/20 (20%) 14/28 
(50%) 
11/21 (53%) 21/35 
(60%) 
(221) 
Tachykinin-1 
(TAC1) 
7q21-22 Smooth muscle 
contractility, 
epithelial ion 
transport, 
vascular 
permeability 
Methylation 
specific PCR 
5/67 (7.5%) 38/60 
(63.3%) 
12/19 
(63.2
%) 
11/21 
(52.4
%) 
41/67 
(61.2%) 
(222) 
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and immune 
function 
Reprimo 2q23 Regulates p53-
mediated cell 
cycle arrest in 
G2 phase 
Methylation 
specific PCR 
0/19 (0%) 9/25 (36%) - 7/11 
(64%) 
47/75 
(63%) 
(223) 
E-Cadherin 16q22.1 Ca
+2
-dependent 
intercellular 
adhesion and 
maintains 
normal tissue 
architecture 
Methylation 
specific PCR 
0/4 (0%) - - - 26/31 
(84%) 
(224) 
SOCS-3 
 
17q25.3 Inhibits 
cytokine 
signaling 
Methylation 
specific PCR 
0% 4/30 (13%) 6/27 
(22%) 
20/29 
(69%) 
14/19 
(74%) 
(225) 
 
SOCS-1 16p13.13 0% 0/30 (0%) 1/27 
(4%) 
6/29 
(21%) 
8/19 
(42%) 
Secreted frizzled-related proteins (SFRP) 
SFRP1 8p11.21 Wnt antagonist Methylation 
specific PCR 
7/28  (25%) 30/37 
(81%) 
- - 37/40 
(93%) 
(226) 
SFRP2 4q31.3 18/28  (64%) 33/37 
(89%) 
- - 33/40 
(83%) 
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SFRP1 8p11.21 Methylation-
sensitive single-
strand 
conformation 
analysis and 
methylation-
sensitive dot 
blot assay 
1/12 (8%) 6/6 (100%) - - 23/24 
(96%) 
(216) 
SFRP2 4q31.3 11/15 (73%) 6/6 (100%) - - 19/25 
(76%) 
SFRP4 7p14.1 Methylation 
specific PCR 
9/28 (32%) 29/37 
(78%) 
- - 29/40 
(73%) 
(226) 
SFRP5 10q24.1 6/28 (21%) 27/37 
(73%) 
- - 34/40 
(85%) 
Plakophilin-1 
(PKP1) 
1q32 Cell adhesion 
and intracellular 
signaling 
Methylation 
specific PCR 
5/55 (9.1%) 5/39 
(12.8%) 
- 1/4 
(25%) 
20/60 
(33.3) 
(227) 
GATA-4 8p23.1-p22  Transcription 
factor and 
regulate cell 
differentiation 
Methylation 
specific PCR 
0/17 (0%) - - - 31/44 
(71%) 
(228) 
GATA-5 20q13.33 0/17 (0%) - - - 24/44 
(55%) 
CDH13 (or H-
cadherin or T-
cadherin) 
16q24 Cell adhesion Methylation 
specific PCR 
0/66 (0%) 42/60 
(70%) 
15/19 
(78.9
%) 
16/21 
(76.2) 
51/67 
(76.1%) 
(229) 
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NELL-1 (nel-like 
1) 
11p15 Tumor 
suppressor 
Methylation-
specific PCR 
0/66 (0%) 28/60 
(46.7%) 
8/19 
(42.1
%) 
13/21 
(61.9%) 
32/67 
(47.8%) 
(230) 
Eyes Absent 4 6q23 Apoptosis 
modulator 
Methylation-
Specific PCR 
2/58 (3%) 27/35 
(77%) 
- - 33/40 
(83%) 
(231) 
A-kinase 
anchoring protein 
12 (or Gravin 
orAKAP12) 
6q24-25.2 cell signaling, 
adhesion, 
mitogenesis and 
differentiation 
Methylation-
Specific PCR 
0/66 (0%) 29/60 
(48.3%) 
10/19 
(52.6
%) 
11/21 
(52.4%) 
35/67 
(52.2) 
(232) 
Vimentin 10p13 Cytoskeleton 
protein 
Methylation-
specific PCR 
0/9 (0%) 10/11 
(91%) 
- 5/5 
(100%) 
21/26 
(81%) 
(233) 
RUNX3 1p36 Transcription 
factor  
Methylation-
specific PCR 
1/63 (2%) 23/93 
(25%) 
- - 37/77 
(48%) 
(209) 
HPP1 19pter-p13.1 Tumor-
suppressor 
2/64 (3%) 41/93 
(44%) 
- - 55/77 
(71%) 
3-OST-2 16p12 Sulfotransferase 
enzyme 
1/57 (2%) 47/60 
(78%) 
- - 28/73 
(38%) 
Wnt inhibitory 
factor-1 (WIF-1) 
12q14.3 Wnt antagonist Methylation 
specific PCR 
81% of BE patients suffering from EAC showed 
hypermethylated WIF-1 as compared to 20% BE patients 
without EAC 
(234) 
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CHFR 
(checkpoint with 
forkhead 
associated and 
ring finger) 
12q24 Mitosis check 
point protein 
Bisulfite 
pyrosequencing 
EAC samples 31% (18/58) showed significantly higher CHFR 
promoter methylation as compared to normal samples 
(p=0.01). 
(235) 
Metallothionein 3 
(or MT3) 
16q13 Metal 
homeostasis and 
protection 
against DNA 
damage 
Bisulfite 
pyrosequencing 
(Sample size: 
Normal-33, BE-
5, EAC-78) 
Identified two regions (R2 and R3) of CpG nucleotides which 
showed significantly higher methylation in EAC as compared 
to normal epithelium (FDR<0.001). Increased DNA 
methylation of MT3 promoter R2 correlates with advanced 
tumor stage (p=0.005) and lymph node metastasis (p=0.03). 
DNA methylation of MT3 promoter R3 correlates with tumor 
staging (p=0.03) but not with lymph node status (p=0.4). 
(236) 
Methylation marker panel 
Sample size Method Findings Ref. 
EAC-35 undergoing 
chemoradiation therapy 
Methylation specific 
PCR 
Combined mean of promoter methylation of p16, Reprimo, p57, p73, RUNX-
3, CHFR, MGMT, TIMP-3, and HPP1 was lower in patients who responded 
to chemoradiotherapy (13/35) as compared to patients who didn't respond 
(22/35). (p=0.003). 
(188) 
BE-62 (28 BE patients 
progressed to EAC and 
remaining 34 BE patients 
were non-progressors) 
Methylation specific 
PCR 
3 tiered stratification model was developed using methylation index (p16, 
HPP1, and RUNX3), BE length and pathology. Combined model based on 2 
year (AUROC: 0.8386) and 4 year (AUROC: 0.7910) prediction was able to 
categorize BE patients into low-risk, intermediate-risk and high-risk groups 
for EAC development. 
(186) 
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BE-195 (145 BE patients 
progressed to EAC and 
remaining 50 BE patients 
were non-progressors) 
Methylation specific 
PCR 
HPP1 (p = 0.0025), p16 (p=0.0066) and RUNX3 (p=0.0002) were 
significantly hypermethylated in progressors as compared to non-
progressors. In combination, panel of 8 methylation markers (p16, HPP1, 
RUNX3, CDH13, TAC1, NELL1, AKAP12 and SST) showed sensitivities of 
0.443 and 0.629 at specificity of 0.9 and 0.8 for EAC progression in BE 
patients using combined model designed based on 2 and 4 years of follow-
up.   
(185) 
EAC-41 (Adjacent normal 
samples as control) 
Methylation specific 
PCR 
Patients having >50% of their genes methylated (APC, E-cadherin, MGMT, 
ER,p16, DAP-kinase and TIMP3) showed significantly poor 2-year survival 
(p=0.04) and 2-year relapse-free survival (p=0.03) as compared to the 
patients having <50% methylation. 
(187) 
BE-18, EAC-38 (Multiple 
biopsies were taken and 
classified into normal, BE, 
HGD and EAC) 
Bisulphite modified 
DNA with PCR 
The methylation frequencies of nine genes (APC, CDKN2A, ID4, MGMT, 
RBP1, RUNX3, SFRP1, TIMP3, and TMEFF2) found to be 95%, 59%, 76%, 
57%, 70%, 73%, 95%, 74% and 83% respectively in EAC samples while 
95%, 28%, 78%, 48%, 58%, 48%, 93%, 88% and 75% respectively in BE 
samples which was significantly higher as compared to normal squamous 
epithelium. The methylation frequency for CDKN2A and RUNX3 was 
significantly higher for EAC as compared to BE biopsy samples. 
(237) 
Normal-30, BE-29, HGD-8, 
EAC-29 
Illumina GoldenGate 
methylation bead array 
Overall median methylation at the total 706 numbers of most informative 
CpG sites gradually increased from normal-BE-HGD/EAC (p<0.001). The 
authors differentiated between EAC vs. normal, HGD vs. normal, BE vs. 
normal, EAC vs. BE and HGD vs. BE based on 422, 225, 195, 17 and 3 
numbers of CpG sites which is showing differential methylation between 
respective groups.  
(238) 
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Identification phase (BE-22, 
EAC-24); Retrospective 
validation phase (BE-60, 
LGD/HGD-36, EAC-90); 
Prospective validation phase 
(98 patients under 
surveillance). 
Identification phase: 
Illumina Infinium assay; 
Retrospective/ 
Prospective validation 
phase: Pyrosequencing  
Based upon initial identification phase, 7 genes (SLC22A18, ATP2B4, PIGR, 
GJA12, RIN2, RGN, TCEAL7) showing most prominent methylation changes 
were selected for validation. Combination of 4 genes (AUROC 0.988) 
SLC22A18, PIGR, GJA12 and RIN2 showed sensitivity of 94% and 
specificity of 97%. This panel of 4 genes showing differential methylation, 
stratified patients into low, intermediate and high risk groups for EAC 
development in prospective validation.  
(239) 
Non dysplastic BE (Not 
progressed to EAC)-16, BE 
mucosa from patients 
progressed to EAC-12  
Methylation-sensitive 
single-strand 
conformation analysis 
and methylation-sensitive 
dot blot assay 
BE samples collected from patients who progressed to EAC in 12 months 
time period showed 100%, 91% and 92% hypermethylation of APC, TIMP-3  
and TERT respectively as compared 36%, 23%, and 17% in BE mucosa 
collected from patients who didn't progress to EAC. 
(240) 
Table 1.4. Summary of gene expression profiling studies for BE/EAC. [aCGH:array-comparative genomic hybridization] 
Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
BE-21 (Paired normal 
esophageal and gastric 
samples as control) 
Serial analysis of 
gene expression 
Disease 
progression 
534 tags were significantly differentially expressed between 
normal esophageal squamous epithelium and BE. The most up-
regulated genes in BE as compared to normal epithelium were 
identified to be trefoil factors, annexin A10 and galectin-4 with 
each different type of tissue showed an unique cytokeratin 
expression.  
No (241) 
BE and HGD -11 cDNA microarray  Disease Using 2.5-fold cut-off, identified 131 up-regulated and 16 down- Real-time (242) 
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Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
(Matched biopsy 
samples) 
 progression regulated genes in HGD. 24 out of 28 most significantly different 
genes showed similar changes during validation.  
PCR  
EAC-91 Oligo-microarray Disease 
progression 
A 4-gene panel consists of deoxycytidine kinase, 3’- 
phosphoadenosine 5’-phosphosulfate synthase 2, sirtuin-2 and 
tripartite motif-containing 44 predicted 5-year survival. 
Immunohis
tochemistr
y  
(243) 
23 paired BE and 
normal epithelium 
samples 
Transcriptional 
profiling and 
proteomics 
Disease 
progression 
Identified 2822 genes to be differentially expressed between BE 
and normal epithelium. Significantly over-expressed genes 
during BE belonged to cytokines and growth factors, constituents 
of extracellular matrix, basement membrane and tight junctions, 
proteins involved in prostaglandin and phosphoinositol 
metabolism, nitric oxide production and bioenergetics. While 
genes encoding heat shock protein and various kinases were 
down-regulated. 
No (244) 
Lymph node metastatic 
(n=55) and non-
metastatic (n=22) EAC 
samples 
Oligo-microarray Disease 
progression 
Lymph node positive samples showed significant down-
regulation of Argininosuccinate synthetase as compared to 
lymph node non-metastatic samples (p=0.048). 
No (245) 
EAC-6 and gastric 
cardia cancer-8 
aCGH Disease 
progression 
Identified HGF(45%) and BCAS1 (27%) to be most frequently 
over-expressed genes respectively at 7q21 and 20q13 locus. 
No (246) 
11 matched sample 
sets (healthy-BE-EAC 
SNP microarray Disease 60% of BE and 57% of EAC samples contained at least one of 
the genomic alterations in the form of deletions, duplications, 
No (247) 
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Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
matched-6, normal-BE 
matched-4 and normal-
EAC matched-1) 
progression amplifications, copy-number changes and neutral loss of 
heterozygosity. 
Normal-39, BE-
25,EAC-38 and ESCC-
26 
cDNA microarray Disease 
progression 
Clustering showed the separation of samples into 4 distinct 
groups. 2158 clones were differentially expressed between 
normal and BE samples while 1306 between BE and EAC. 
BE/EAC samples showed differential expression of hydrolases, 
lysozyme, fucosidase, transcription factors, mucins and the 
trefoil factors. 
No (248) 
BE-20, LGD-19, 
HGD-20 and EAC-42 
SNP microarray Disease 
progression 
Increasing numbers of SNPs and loss of chromosomes with 
disease progression. Chromosomal disruption was identified in 
the FHIT, WWOX, RUNX1, KIF26B, MGC48628, PDE4D, 
C20orf133, GMDS, DMD, and PARK2 genes in EAC.  
No (249) 
EAC-75 specimens 
from 64 patients, 
Adjacent paired 
Normal tissue from 
EAC patients-28 
DNA microarray Disease 
progression 
Identified AKR1B10, CD93,CSPG2, DKK3, LUM, MMP1, 
SOX21, SPP1, SPARC and TWIST1genes as biomarker based on 
transcriptomics data. Quantitative real-time PCR identified 
SPARC and SPP1 genes to be associated with EAC patient 
survival (p < 0.024).  
Real-time 
PCR 
(250) 
EAC-8, Gastric cardia 
cancer-3 
aCGH and cDNA 
microarray 
Disease 
progression 
Transcriptomics data identified 11 genes to be differentially 
expressed (ELF3, SLC45A3, CLDN12, CDK6, SMURF1, 
ARPC1B, ZKSCAN1, MCM7, COPS6, FDFT1 and CTSB). IHC 
No (251) 
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Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
analysis revealed significant over-expression of CDK6 a cell-
cycle regulator in tumor samples. 
BE-20 aCGH arrays and 
high density SNP 
genotyping  
Disease 
progression 
Copy number losses were detected at FRA3B (81%), FRA9A/C 
(71.4%), FRA5E (52.4%) and FRA 4D (52.4%) sites in early 
BE. Validation study confirmed loss of FRA3B and FRA16D in 
early BE samples. 
Real-time 
PCR and 
Pyroseque
ncing  
(252) 
BE-11, Gastro-
esophageal junction 
(GEJ) 
adenocarcinoma-11 
aCGH with a whole  
chromosome 8q 
contig array 
Disease 
progression 
Over-expression of MYC and EXT1 while down-regulation of 
MTSS1, FAM84B and C8orf17 is significantly associated with 
GEJ adenocarcinoma. 
 (253) 
BE-14, EAC-5, ESCC-
3 
cDNA microarray Disease 
progression 
Identified 160 genes that can differentiate between BE and 
esophageal cancer. 
No (254) 
24 paired samples of 
normal, BE and EAC 
phenotype 
cDNA microarray Disease 
progression 
214 differentially regulated genes could differentiate between 
normal, BE and EAC phenotype. Genes involved in epidermal 
differentiation are under-expressed in EAC as compared to BE. 
Expression ratio of GATA6 to SPRR3 can differentiate between 
three phenotypes studied.  
No (255) 
Pooled biospy samples 
from BE, esophageal 
squamous, gastric and 
Oligo-microarray Disease 
progression 
Differentiate different tissue clusters based on gene expression 
profile. Identified 38 genes that are up-regulated in BE tissue 
cluster which belong to cell cycle (P1cdc47, PCM-1), cell 
migration (urokinase-type plasminogen receptor, LUCA-
No (256) 
32 
 
Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
duodenum 1/HYAL1), growth regulation (TGF-β superfamily protein, 
amphiregulin, Cyr61), stress responses (calcyclin, ATF3, TR3 
orphan receptor), epithelial cell surface antigens (epsilon-BP, 
ESA, integrin β4, mesothelin CAK-1 antigen precursor) and four 
mucins. 
Normal-24, BE-18, 
EAC-9 
cDNA microarray Disease 
progression 
Identified 457, 295 and 36 differentially expressed genes 
respectively between normal-EAC, normal-BE and BE-EAC 
groups.  
No (257) 
89-EAC cDNA-mediated 
annealing, selection, 
extension, and 
ligation assay with 
502 known cancer 
related genes 
Disease 
progression 
Identified differential gene expression between early stages of 
EAC (T1 and T2) vs. late (T3 and T4). Gene expression profile 
revealed ERBB4, ETV1, TNFSF6, MPL genes to be common 
between advanced tumor stage and lymph node metastasis.  
No (258) 
Normal esophageal 
mucosa-9, esophagitis-
6, BE-10, EAC-5, GEJ 
adenocarcinoma-9, 
stomach samples-32 
(normal mucosa-11, 
IM-9, intestinal-type 
adenocarcinoma-7, and 
cDNA microarray Disease 
progression 
Based on the expression profile, genes associated with the lipid 
metabolism and cytokine nodule are found to be significantly 
altered between EAC and other groups. 
No (259) 
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Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
diffuse carcinoma-5) 
17 paired samples of 
normal, BE/EAC 
cDNA microarray Disease 
progression 
Each tissue type expresses distinct set of genes which can 
differentiate between their phenotypes. BE and EAC expresses 
similar set of stromal genes that are different from normal 
epithelium.  
No (260) 
BE-19, EAC-20 (98 
tissue specimens were 
collected and 
categorized into 
different groups) 
Based on previous 
microarray studies 
23 genes were 
validated using 
Real-time PCR  
Disease 
progression 
Out of 23 genes, panel of 3 genes (BFT, TSPAN, TP) was able to 
discriminate between BE and EAC in internal validation with 0% 
classification error. 
N.A. (261) 
Normal-30, BE-31, 
Gastric mucosa-34, 
Duodenum-18 
Biomarkers for BE 
were identified 
using three 
publically available 
microarray datasets 
and validated using 
Real-time PCR and 
Immunohistochemis
try. 
Disease 
progression 
Out of 14 genes identified, dopa decarboxylase (DDC) and 
Trefoil factor 3 (TFF3) were validated to be up-regulated in BE. 
N.A. (262) 
EAC-56 Oligonucleotide 
microarray and 
Disease 
progression 
Identified four new genes (EGFR, WT1, NEIL2 and MTMR9) to 
be over-expressed in 10-25% EAC. Expression levels of these 
Immunohis
tochemistr
(263) 
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Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
aCGH four genes differentiated EAC patients into three groups namely 
good, average and poor depending upon their prognosis (p < 
0.008) 
y 
BE/LGD-72, HGD-11, 
EAC-15 
Bacterial Artificial 
Chromosome array 
comparative 
genomic 
hybridization 
Disease 
progression 
Copy number changes were more common and larger as disease 
progress to later stages. Patients having copy number alterations 
involving >70 Mbp were at increased risk of progression to EAC 
(p=0.0047) 
No (197) 
EAC-30, BE-6, LGD-
9, HGD-10 
Genome-wide CGH Disease 
progression 
Loss of 7q33-q35 was found in HGD as compared to precursor 
LGD (p=0.01). Loss of 16q21-q22 and gain of 20q11.2-q13.1 
was significantly different between HGD and EAC (p=0.02 and 
p=0.03 respectively). 
No (193) 
EAC-30, Lymph node 
metastasis-8, HGD-11, 
LGD-8 and BE-6 from 
30 EAC patient biopsy 
samples 
CGH Disease 
progression 
Identified regions undergoing copy number loss and 
amplification during each stage of transition. Average number of 
chromosomal imbalance sequentially increased from BE-LGD-
HGD-EAC-lymph node metastasis. 
No (191) 
42 patients represent 
different stages of 
disease 
SNP array Disease 
progression 
SNP abnormalities increases from 2% to more than 30% as the 
disease progress from BE to EAC. Total number of SNP 
alterations in tissue samples is tightly correlated with DNA 
abnormalities such as aneuploidy and LOH. 
No (194) 
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Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
EAC-27 and matched 
normal-14 
SNP array Disease 
progression 
Confirmed previously described genomic alterations such as 
amplification on 8q and 20q13 or deletion/LOH on 3p and 9p. 
Also identified alterations in several novel genes and DNA 
regions in EAC samples.  
No (195) 
EAC-26 SNP array Disease 
progression 
Confirmed previously reported frequent changes to FHIT, 
CDKN2A, TP53 and MYC genes in EAC. Identified PDE4D and 
MGC48628 as tumor-suppressor genes. 
No (196) 
EAC-35  cDNA microarray Response to 
chemotherap
y 
Identified 165 differentially expressed genes between poor 
(n=17) and good outcome (n=18) patient groups. Top functional 
pathway based on differential gene expression was identified to 
be TOLL-receptor signaling. 
No (264) 
EAC-47 (locally 
advanced tumor) 
cDNA microarray Response to 
chemotherap
y 
Identified 86 genes showing at least 2-fold difference between 
chemotherapy responders (n=28) and non-responders (n=19). 
Ephrin B3 receptor, which showed highest difference between 
the groups, showed strong membrane staining in chemotherapy 
responding tumors using immunohistochemistry.   
No (265) 
EAC-19 patients 
undergoing 
chemoradiotherapy 
Oligo-microarray Response to 
chemoradiot
herapy 
Reduced expression of IVL, CRNN, NICE-1, S100A2, and SPPR3 
gense correlated with poor survival and non-response to 
chemotherapy.  
No (266) 
19 patients (EAC-16, Oligo-microarray Response to Lower expression for panel of genes PERP, S100A2, and SPRR3 No (267) 
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Sample Size Array Description Outcome  Findings External 
validation 
Ref. 
ESCC-2 and 
adenosquamous 
carcinoma-1) 
undergoing 
chemoradiotherapy 
chemoradiot
herapy 
was associated with non-response to therapy. Pathway analysis 
identified down-regulation of apoptosis in non-responders. 
EAC-174, ESCC-36 SNPs associated 
with the 
chemotherapy drug 
action pathway  
Response to 
chemoradiot
herapy 
Identified association between genetic polymorphisms and 
response to pre-operative chemotherapy (fluorouracil and 
platinum compounds) and radiotherapy.    
No (268) 
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1.4.2 Cancer related inflammation 
 Gastric and bile acid exposure in the esophageal epithelium leads to the development of 
chronic inflammatory conditions mainly driven by elevated levels of pro-inflammatory cytokines. 
Chronic inflammatory responses induce cell survival and increase cell proliferation hence play key 
roles in the development of EAC (156, 269). Expression of various inflammatory molecules like 
Cyclooxygenase-2 (COX-2), NF-κB, IL-6, IL-8 and Matrix metalloproteinases (MMPs) have been 
evaluated as prognostic biomarkers for BE/EAC development.   
 Exposure to gastric/bile acid and cytokines leads to increased COX-2 expression (142). 
COX-2 is a rate-limiting enzyme that regulates synthesis of prostaglandins from its precursor 
arachidonic acid. COX-2 directly increases cell proliferation and promote tumor invasion (142), and 
COX-2 mediated increase in prostaglandins synthesis could result in tumor growth and 
angiogenesis (270). COX-2 expression has been detected in disease-free esophageal tissue 
homogenates using immunoblotting (142). In comparison to GERD, patients suffering from erosive 
reflux show slightly higher gene expressions of this enzyme in tissue samples (271). Several studies 
have shown significantly increased COX-2 expression correlating with the disease progression from 
BE to dysplasia and EAC (140-144). Furthermore, expression levels of COX-2 have been 
demonstrated to have a prognostic value in EAC with higher levels associated with poor survival 
and increased chances of tumor relapse (145, 146).  
 Another well studied inflammatory biomarker NF-κB is activated in response to exposure 
with bile acid and elevated NF-κB expression levels are found in BE, dysplasia, and 
adenocarcinoma (147-149). Activated NF-κB translocates from cytoplasm to nucleus and up-
regulates transcription of the genes involved in inflammatory processes. Moreover, nuclear NF-κB 
expression has been shown to be correlated with the patient response to chemoradiation therapy. All 
of the patients who showed complete response to chemoradiation therapy had elevated NF-κB 
levels pre-treatment and showed lack of active NF-κB post-treatment (150).  
 In line with NF-κB and COX-2, expression of individual or combinations of pro-
inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α is significantly increased in BE and EAC as 
compared to squamous epithelium (151, 152, 154). IL-1β and IL-8 expression levels also correlate 
with the stage of EAC (148). Patients who responded to neoadjuvant chemotherapy treatment 
showed significantly reduced expressions of IL-8 and IL-1β in post-chemotherapy esophageal tissue 
sections (150). IL-6 is activated in response to reflux and the IL-6/STAT3 anti-apoptotic pathway 
may underlie the development of dysplasia and tumor (153). Serum IL-6 levels was reported to 
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provide 87% sensitivity and 92% specificity for EAC diagnosis in a retrospective study (155). 
However, the study only compared between healthy and EAC groups. It would be interesting to see 
how early it can diagnose EAC during the process of metaplasia-dysplasia. Combination of 
cytokines IFN-γ, IL-1α, IL-8, IL-21, IL-23 along with platelet proteoglycan and miRNA-375 
expression profiling has been demonstrated to build an inflammatory risk model which has clinical 
utility to determine prognosis for EAC patients (156). 
 MMPs are a family of proteolytic enzymes involved in the degradation of extracellular 
matrix components. MMPs play a role in both inflammation and tumor metastasis. 
Immunohistochemical staining for MMP-1, MMP-2, MMP-7 and MMP-9 has been reported to be 
significantly higher in EAC as compared to healthy individuals (157, 158). Higher level of MMP-1 
expression has been associated with the lymph node metastases and possibly poor patient survival 
(159). Expression of MMP-9 is shown to be an early event during the EAC transformation and its 
expression levels are correlated with the progression of the disease (160-162). Activity of MMPs is 
inhibited by a family of proteins called tissue inhibitors of metalloproteinases (TIMPs). 
Specifically, TIMP-3 gene is methylated in EAC development and its reduced expression is 
associated with stage of the tumor and patient survival (163). On contrary, Salmela et al. described 
elevated TIMP-1 and TIMP-3 expression in EAC tumor samples (158).  
 Although the underlying tissue inflammation is very closely associated with EAC 
development and several inflammatory related biomarkers have been identified, these remain to be 
validated in large scale biomarker studies. 
1.4.3 Cell cycle-related abnormalities 
 To compensate for the tissue damage induced by gastric/bile acid, the underlying epithelium 
starts to proliferate rapidly and become uncontrolled resulting in neoplasia. In order to meet the 
proliferation requirements, the cells have to overcome cell cycle check points. CyclinD1 over-
expression is one such means by which cells overcome G1/S-checkpoint, and cyclinD1 
immunohistochemical staining has been proposed to identify BE patients with an increased risk for 
EAC (164). In contrast to cyclinD1, expression of p16 protein results in cell cycle arrest in G1 
phase as it has been shown to inhibit cyclin dependent kinase-induced phosphorylation of 
retinoblastoma protein. Early genomic abnormalities during EAC development significantly affects 
p16 protein expression which can be determined using immunostaining and implemented as a 
potential biomarker (165). Further large scale trials are required to confirm cell cycle abnormalities 
during EAC development to implement them as a biomarker. 
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 Bottom of the pyramid in Figure 1.3 represents list of biomarkers in initial stages of 
development. Tumors harboring over-expression of growth factor receptors (EGFR and HER-2) are 
associated with poor patient survival (272, 273), while those over-expressing apoptosis regulator 
Bcl-2 protein showed prolonged survival (274). Incipient angiogenesis is a marked feature of BE 
and underlining tissue expresses angiogenesis markers VEGF and its receptors (275). 
Neovascularization continues as the disease progress from BE to EAC. Measuring degree of 
neovascularization correlated with histopathological grade of the tumor and associated with the 
patient survival (276). Expressions of two prominent cell proliferation markers, PCNA and Ki-67 
have been described to be altered during BE-EAC development (166). 
1.4.4 microRNA 
 MicroRNA (or miRNA) was first discovered in Caenohabditis elegans (277) and from then 
it has been widely studied in range of biological phenomena. These short stretches of approximately 
21 nucleotides do not code for protein but play important roles in gene regulation by either 
suppressing protein synthesis or cause mRNA cleavage. Unlike siRNA, miRNA can target multiple 
genes on remote loci hence control diverse group of proteins. Several key properties of 
carcinogenesis have been demonstrated to be regulated via miRNA, for example, angiogenesis and 
metastasis (278). 
 With increased biological understanding of miRNAs and their role in cancer, they have been 
proposed in several different clinical applications including cancer diagnosis and tumor prognosis, 
tumor classification and also as a therapeutic target for disease intervention. Differential tissue 
miRNA expression has been observed in several different malignancies and these changes can be 
utilized for diagnosis and classification of the tumors (278). MicroRNA arrays were first used to 
show differential miRNA expression in healthy, BE and EAC tissue samples (279). Since then, a 
number of different studies have identified miRNA changes associated with the development of the 
BE/EAC. Table 1.5 summarizes primary findings of miRNA expression profiling studies along with 
statistical significance and fold change values. Biological significance for some of the miRNA 
related changes is discussed below.  
 Smith and colleagues identified reduced expression of miR-200 and miR-141 in BE and 
EAC tissue samples. They performed bioinformatics analysis and correlated these miRNA 
expression changes with cellular processes such as cell cycle, cell proliferation, apoptosis and cell 
migration (280). MiR-196a, which is described as a marker of progression from BE to EAC, can 
increase cell proliferation and anchorage-independent growth and inhibit apoptosis in EAC cell 
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lines in vitro (281). The down-stream target for miR-196a are verified to be Annexin A1, S100 
calcium-binding protein A9, Small proline-rich protein 2C and Keratin 5 which showed reduced 
expression in EAC patient tissue samples as compared to normal epithelium (281, 282). Several 
studies described in Table 1.5 report over-expression of miR-192 during EAC carcinogenesis. MiR-
192 has been reported to be a target of p53 and has been able to suppress cancer progress in 
osteosarcoma and colon cancer cell lines through p21 accumulation and cell cycle arrest (283). As 
shown in Table 1.5 miR-21 is over-expressed during BE/EAC and it can function as an oncogene as 
shown in tumors of breast, brain, lung, prostate, pancreas, colon, liver and chronic lymphocytic 
leukemia. It negatively regulates tumor and metastasis suppressor genes PTEN, TPM1, PDCD4 and 
Sprouty2 (284-287). MiR-194 expression is regulated by hepatocyte nuclear factor (HNF)-1α 
transcription factor which is induced during BE/EAC and may lead to up-regulation of miR-194 
(284). Higher expression of miR-194 is also observed in metastatic pancreatic cell lines (288). 
Amongst miRNAs found to be down-regulated during EAC development, let-7 family of miRNAs 
are tumor-suppressor and negatively regulates Ras oncogene. Fassan and colleagues confirmed up-
regulation of HMGA2 which is one of the targets of let-7 miRNA using immunohistochemistry in 
tissue samples (285, 287, 289).  
 A study published by Wu and colleagues compared miRNA expression profile between 
healthy (adjacent normal), BE and EAC patient tissue samples (Adjacent normal-35, BE-11, LGD-
13, HGD-10, EAC-36) using real-time PCR-based TaqMan Human Micro-RNA array that enabled 
accurate quantitation of 754 human miRNAs (290). Unsupervised hierarchical clustering according 
to miRNA expression profiling suggested that there is clear distinction between healthy and 
BE/EAC phenotype in terms of miRNA expression, whereas BE and EAC samples were 
indistinguishable from each others as they showed clear overlap. In comparison with healthy 
samples, 148 and 122 miRNAs were found to be up-regulated in BE and EAC tissue respectively 
whereas 16 miRNAs were down-regulated in BE and EAC sample as compared to normal 
epithelium. Amongst handful of miRNAs that were significantly different between BE and EAC 
include miR-375 (down-regulated in EAC) and miR-106-3b, miR-18, miR-18-3p, miR-20b, and 
miR-92a-1-3p (up-regulated in EAC). Furthermore, they compared miRNA profiling results with 
mRNA expression in normal, BE and EAC tissue samples previously published by Nancarrow and 
colleagues (291). Interestingly, they found that 19 of the top 20 differentially expressed miRNAs 
targeted one or more of 54 most frequently altered mRNAs from the list published by Nancarrow 
and colleagues. Moreover, 77.8% (42 of 54) of the differentially expressed mRNAs were potential 
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targets for the top 20 differential miRNAs which includes miR-203 with 12 potential target mRNAs 
and let-7c with 11 target mRNAs (290).  
 Another study by Streppel and colleagues attempted to validate previous published 7 
different miRNAs targets in BE/EAC (292). Out of 7 target miRNAs studies, 5 miRNAs (miR-
199a/b-3p, -199a-5p, -199b-5p, -200b, and -223) were found to be significantly different between 
EAC and adjacent normal tissue. Out of 5, only miR-223 showed a stepwise increase during EAC 
development (292). Functional characterization of miR-223 using miR-223 over-expressing OE33 
and JHesoAD1 showed more aggressive phenotype and also showed higher sensitivity for DNA-
damaging agents (292).  
 Further studies in the regards of miRNA and miRNA target genes will improve the 
biological understanding of EAC pathogenesis and may also provide novel molecular targets for 
disease intervention. Notably, miRNAs are found to be stable in serum encapsulated in 
microvesicles hence can be accessed easily (293). In fact circulating miRNA profiling has shown 
distinct expression patterns in a number of cancers, other than EAC (294). This opens up new 
avenues for circulating miRNA changes as a potential biomarker for EAC. 
Table 1.5. Summary of literature describing miRNA expression changes in BE/EAC. 
(Wherever needed, fold change values are calculated/adapted from the expression/fold change 
values described in the original article to have uniform format for the purpose of this literature 
review). 
Sample Size Up-regulated in BE/EAC Down-regulated in BE/EAC Ref. 
71 (BE-12, BE 
without dysplasia-
20, LGD-27, 
EAC/HGD-12)  
miR-192 (p<0.00001), miR-196a 
(p<0.05): Up-regulated in BE as 
compared to healthy tissue.  
miR-196a expression is correlated 
with progression from IM-LGD-
HGD-EAC (p<0.005) 
miR203 (p<0.00001): Down-
regulation in BE as compared 
to healthy tissue  
(295) 
22 (BE without 
dysplasia-11, BE 
with dysplasia-11) 
miR-15b (3.3 fold, p<0.05), miR-
203 (5.7 fold, p<0.05): Up-
regulated in dysplasia as compared 
to non-dysplastic BE  
miR-486-5p (4.8 fold, 
p<0.05),miR-let-7a (3.3 fold, 
p<0.05): Down-regulated in 
dysplasia as compared to non-
dysplastic BE  
(285) 
100 (EAC-100, 
Adjacent normal 
tissue as control) 
miR-21 (~3 fold, p<0.05), miR-223 
(~2 fold, p<0.05), miR-192 (~3.5 
fold, p<0.05), and miR-194 (~3.5 
fold, p<0.05): Up-regulated in EAC 
miR-203 (~3 fold, p<0.05): 
Down-regulated in EAC as 
compared to adjacent normal 
tissue  
(286) 
42 
 
Sample Size Up-regulated in BE/EAC Down-regulated in BE/EAC Ref. 
as compared to adjacent normal 
tissue  
25 (Healthy-9,BE-
5, HGD-1, EAC-
10) 
miR-192 (1.7 fold, FDR<1e-07), 
miR-194 (2 fold, FDR<1e-07), 
miR-21 (3.7 fold, FDR=0.0003), 
miR-200c (1.9 fold, FDR=0.0015), 
miR-93 (1.3 fold, FDR=0.0108): 
Up-regulated in EAC as compared 
to BE 
miR-27b (1.43 fold, 
FDR=0.0003), miR-342 (1.25 
fold, FDR=0.0015), miR-125b 
(2 fold, FDR=0.0108), miR-100 
(1.25 fold, FDR=0.011): Down-
regulated in EAC as compared 
to BE 
(279) 
75 (Healthy-15, 
BE-15, LGD-15, 
HGD-15, EAC-15)  
miR-215 (62.8 fold, p<1e-07), miR-
192 (6.34 fold, p<1e-07): Up-
regulated in BE in comparison with 
normal tissue and remained at 
similar levels with disease progress  
miR-205 (10 fold, p=1.39e-
0.5), let-7c (2.04 fold, p=3.11e-
05), miR-203 (6.67 fold, 
p=3.2e-0.5): Down-regulated in 
BE in comparison with normal 
tissue and remained at similar 
levels as disease progresses 
(289) 
91 (LGD-31, 
HGD-29, EAC-31, 
In all cases 
adjacent normal 
tissue used as a 
control) 
miR-200a (13.5 fold, p=0.02), miR-
513 (1.58 fold, p=0.03), miR-125b 
(9.2 fold, p=0.04), miR-101 (1.83 
fold, p=0.04), miR-197 (1.61 fold, 
p=0.04): Up-regulated in LGD to 
HGD transition  
 
miR-23b (1.45 fold, p=0.007), 
miR-20b (1.56 fold, p=0.01), 
miR-181b (2.22 fold, p=0.03), 
miR-203 (1.49 fold, p=0.03), 
miR-193b (2.70 fold, p=0.04), 
miR-636 (4.17 fold, p=0.04): 
Down-regulated in LGD to 
HGD transition.  
let-7a (1.75 fold, p=0.01), let-
7b (1.59 fold, p=0.009), let-7c 
(1.69 fold, p=0.03), let-7f (1.69 
fold, p=0.03), miR-345 (2 fold, 
p=0.02), miR-494 (1.72 fold, 
p=0.03), miR-193a (2.27 fold, 
p=0.05): Down-regulated in 
HGD-EAC development 
process  
(287) 
48 (BE-19, EAC-
29) 
miR-21 (~2.8 fold, p<0.05), miR-
143 (~11.3 fold, p<0.05), miR-145 
(~3.4 fold, p<0.05), miR-194 (~126 
fold, p<0.05), miR-215 (~18 fold, 
p<0.05): Up-regulated in BE as 
compared to adjacent normal tissue.  
miR-203 (~17 fold, p<0.05), 
miR-205 (~175 fold, p<0.05): 
Down-regulated in BE as 
compared to adjacent normal 
tissue.  
miR-143 (~3 fold, p<0.05), 
(284) 
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Sample Size Up-regulated in BE/EAC Down-regulated in BE/EAC Ref. 
 
miR-145 (~1.8 fold, p<0.05), 
miR-215 (~3.1 fold, p<0.05): 
Lower expression in EAC as 
compared to BE  
49 (IM-15, HGD-
14, and EAC-20, 
Adjacent normal 
tissue) 
- miR-31 (>4 fold, p<0.02), miR-
375 (>4 fold, p<0.001): Down-
regulated in transition from BE 
to EAC  
(296) 
37 (BE-17, EAC-
20, 9 adjacent 
normal tissue 
samples) 
- miR-141 (~2 fold, p=0.0126), 
miR-200a (~2.5 fold, 
p=0.0001), miR-200b (~2.1 
fold, p<0.0001), miR-200c 
(~1.9 fold, p=0.0014), miR-429 
(~1.8 fold, p=0.0031): Under-
expressed in EAC as compared 
to BE 
(280) 
11 (EAC-11, 
Different lesions 
were collected 
from these patients 
and classified into 
BE, LGD, HGD, 
EAC) 
miR-196a is over-expressed in early 
EAC (151 fold)>HGD (62.2 fold, 
p=0.00002)>LGD (31.1 fold, 
p=0.0005)>BE (28.9 fold, 
p=0.00001). Fold changes are 
calculated as compared to normal 
epithelium. 
- (282) 
45 (EAC patients 
undergoing 
surgery) 
miR-143 (p=0.0148), miR-199a_3p 
(p=0.0009), miR-199a_5p 
(p=0.0129), miR-100 (p=0.0022) 
and miR-145 (p=0.1176) expression 
predicted a worse survival followed 
by esophagectomy. 
Overexpression of miR-199a_3p/ 
_5p and 
miR-99b was associated with 
lymphnode metastasis 
Down-regulation of miR-143 
(p=0.0049) and miR-145 
(p=0.0069) in EAC as 
compared to adjacent normal 
tissue 
 
(297) 
24 (BE-24, 
Progression to 
EAC-7, Not 
Progressed to 
EAC-17 in at least 
5 year follow-up) 
miR-192 (AUROC=0.61), 194 
(AUROC=0.70), 196a 
(AUROC=0.80), and 196b 
(AUROC=0.74) showed 
significantly higher expression in 
BE samples from patients who 
- (298) 
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Sample Size Up-regulated in BE/EAC Down-regulated in BE/EAC Ref. 
progressed to EAC as compared 
with those who did not progress to 
EAC 
5 (EAC patients 
undergoing 
surgery. Adjacent 
benign tissue as a 
control) 
MiR-296 is over-expressed ~2 fold 
in EAC as compared to adjacent 
benign tissue.  
- (299) 
22 locally 
advanced EAC 
tumor patients 
undergoing 
surgery 
Negative association between miR-
148a expression and tumor 
differentiation (p<0.001). 
Significantly higher expression of 
miR-148a in tumors located in the 
lower esophagus as compared to 
tumors in the middle esophagus 
(p=0.021). 
- (300) 
99 EAC patient 
tissue samples 
undergoing 
surgery 
miR-30e (p=0.002) and miR-200a 
(p=0.044) expression were 
associated with poor overall 
survival. miR-16-2 (p=0.027) and 
miR-30e (p=0.002) expression were 
associated with poor disease-free 
survival. 
- (301) 
60 (Healthy-10, 
BE-10, Gastric 
metaplasia-10, 
LGD-10, HGD-10, 
EAC-10) 
- miR-125a-5p (p=0.008) and 
miR-125b were progressively 
down-regulated in lesions from 
IM to LGD/HGD to EAC. 
(302) 
32 (EAC-32, 
Adjacent normal 
tissue as control) 
miR-21 (FDR=0.000067) miR-203 (FDR=0.000201) (303) 
 
1.4.5 Glycoproteins 
 Protein glycosylation is a common post-translational modification with almost half of the 
proteins synthesized undergoing one of the two major types either N-linked or O-linked glycan 
modifications. The biosynthetic process of glycosylation is not template driven and occurs co- or 
post-translationally. N-glycosylation initiates (synthesis of N-glycan precursors) on the cytoplasmic 
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side of the rough endoplasmic reticulum and targets the asparagine in the sequence of Asn-X-
Ser/Thr, where X is any amino acid other than proline. The process continues when protein moves 
further along the secretory pathway and finally expresses one of the three common glycan types. 1. 
High Mannose, 2. Complex or 3. Hybrid type (Figure 1.4). In O-type glycosylation, the Ser/Thr 
residue of the protein is involved in making a glycosidic linkage with the glycan moiety (Figure 
1.4) (304). The process of glycosylation is regulated by the expression and localization of 
glycosyltransferases/glycosidases, protein trafficking, and the availability of substrate glycans 
(304). The other less common type of glycosylation is known as C-mannosylation where Trp is 
covalently attached to mannose residues (Figure 1.4). At least 10 different monosaccharides can 
participate in the process to generate diverse range of glycan structures with numerous possibilities 
for branching and anomeric linkages which make them difficult to study in comparison with 
proteins or nucleic acids (Figure 1.4) (304). Despite being heterogenous, glycan modification at 
each glycosylation site is very specific and stable for a given cell type and physiological state (305). 
Figure 1.4. Glycan-protein linkages, types of N-glycans and symbolic representation of 
common monnosaccharides found in nature. Asn, asparagine; Arg, arginine; Trp, tryptophan; 
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Thr, threonine; Ser, serine; Tyr, tyrosine; Hyl, hydoxylysine; Hyp, hydroxyproline. Adapted from 
Varki et al. (306) and Stanley et al. (307). 
 Aberrant glycosylation changes have previously been reported for several different cancers 
including breast cancer, prostate cancer, melanoma, pancreatic cancer and ovarian cancer (308, 
309). These changes include truncated forms of O-glycans, increased degree of branching in N-
glycans, and elevated sialylation, sulfation, and fucosylation with range of other possible variations 
(309). The differential glycosylation can alter protein interactions, stability, trafficking, 
immunogenicity and function (308). Tumor specific glycosylation changes are actively involved in 
neoplastic progression, namely metastasis, as glycoproteins are found abundantly on cell surfaces 
and extracellular matrices hence play vital role in cellular interactions.  
 Lectins are a family of glycan-binding proteins used by nature for cell-cell and cell-protein 
communication in humans and in host-pathogen interactions. Moreover, they are extensively used 
in glycobiology due to preferential binding of each lectin to recognize specific glycan structures on 
proteins, lipids and other biomolecules (309, 310). The first effort to identify differential 
glycosylation in the progression to BE and EAC was made in 1987 by Shimamoto and colleagues 
using differential binding pattern to 5 lectins in tissue specimens (167). The glycoconjugate 
expression profile in BE was found to be significantly different from normal esophageal epithelium. 
Interestingly, glycoconjugate expression between BE and normal duodenum was quite similar. 
There were minimal glycoconjugate expression changes between BE and LGD. However, EAC 
tissue samples showed significantly different lectin binding pattern than BE/LGD (167). Using 
rabbit esophageal epithelium Poorkhalkali and colleagues showed differential lectin binding in 
response to acid/pepsin exposure suggesting acid exposure can induce cell surface glycosylation 
changes (311). In 2008 Neumann and colleagues used 4 different lectins to identify pathological 
mucosal changes (168). They observed two distinct lectin binding patterns. One which is associated 
with the GERD while the other pattern was characteristic for BE mucosa. Specifically UEA (Ulex 
europaeus) lectin binding was up-regulated in BE tissue sections which suggests possible increase 
in fucosylation during the disease progress (168). A recently published study has concluded that 
dysplasia can alter glycan expression hence lectin binding pattern to the tissue samples. 
Fluorescently labeled WGA (Wheat germ agglutinin) lectin binding intensity was found to be 
inversely related to the degree of dysplasia (169). Furthermore, the authors used fluorescent capable 
endoscope ex vivo in the study and followed all the protocols in a manner that exactly mimics a 
clinical study in vivo. Followed by topical fluorescein-labeled WGA spray, the authors measured 
fluorescence in the tissue samples. Measurement of lectin fluorescence was more sensitive approach 
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to identify dysplastic lesions as compared to white light endoscopic technique. Their data 
demonstrate clinical utility of such a lectin based endoscopic technique if developed further (169). 
In a phase III biomarker clinical trial study Bird–Liberman and colleagues combined 3 different 
abnormalities to predict EAC progression in BE patients. Along with using conventional LGD and 
DNA content abnormalities they used AOL (Aspergillus oryzae) lectin binding to the tissue samples 
which detects presence of α1-6 fucose on the cell surface (174). Thus, monitoring tissue glycan 
changes can be combined with existing biomarkers in order to improve the predictive power of the 
currently used biomarkers. 
 A potential mechanism responsible for these changes is considered to be bile acid exposure-
induced gene expression and secretory pathway changes in esophageal epithelium (312). Using 
carbohydrate specific lectins that detect N and O-linked glycosylation and core fucosylation, Byrne 
and colleagues have shown differential lectin binding to the cell surface and differential 
intracellular localization when normal squamous and barrett's metaplastic cell lines were treated 
with deoxycholic acid (312). Nancarrow and colleagues profiled mRNA expression in normal 
squamous esophageal epithelium, BE, and EAC and concluded that BE is a tissue with enhanced 
glycoprotein synthesis machinery in order to provide strong mucosal defense against acid exposure 
(291).  
1.4.6 Outlook - circulating biomarkers  
 Last four decades showed continuously increased EAC incidences and similar trend may be 
expected in future because of rising incidences of obesity and GERD in the population. Current 
endoscopic screening program might benefit the highest risk population to monitor disease 
progression. Monitoring dysplasia in the tissue samples has not provided fruitful outcome for early 
diagnosis, however inclusion of the genomic and cell cycle biomarkers has shown definite 
improvement in the predictive power over currently used histological technique. Any biomarker 
requiring tissue samples is going to be difficult to implement for population screening and will not 
be viable economically. An alternative to tissue-based techniques is to investigate changes in 
circulating biomarkers. Blood is relatively easy to access and, hence, can be monitored frequently 
ultimately increasing possibility of detecting early dysplastic changes.  
 Circulating tumor cells could be one source of biomarkers. Although readily found in the 
blood, technological advancements are required for sensitive early detection of the low number of 
tumor cells present in the circulation (313, 314). Alternatives to the detection of circulating tumor 
cells, Zhai and colleagues applied genome-wide DNA methylation profiling approach to cell free 
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circulating DNA. They found that cell free circulating DNA methylation profile is a replica of 
methylation profile found in matched tumor tissue samples and can discriminate between control, 
BE and EAC conditions (171). Kawakami and colleagues studied methylation of APC gene in 
matched tumor samples and plasma (172). Unlike tumor samples which showed hypermethylation 
of APC DNA early during the EAC development, matched plasma samples from patients suffering 
from BE and gastritis were found to be negative for APC methylation changes. Moreover, as 
compared to 92% (48/52) of EAC tissue samples, only 25% (13/52) plasma samples were positive 
for circulatory APC methylation changes. However, there was strong correlation between stage of 
the tumor and plasma positivity for methylated APC (172). In combination with DAPK methylation, 
measurement of pre-operative APC methylation in peripheral blood was able to discriminate 
between long (>2.5 years) and short survivors with a sensitivity of 99.9% and specificity of 57.1% 
(173). Taken together, tracking circulatory DNA methylation changes during EAC development 
may be an alternative approach to predict early EAC.  
 Tumor cell moulds the microenvironment to support oncogenesis by releasing soluble and 
vesicular components, including enzymes, microvesicles, proteoglycans, chemokines and cytokines 
(315). The tumor microenvironment components are shed into the circulation and may be extremely 
useful as an early diagnostic biomarker. This concept was demonstrated by Pitteri and colleagues 
using an inducible HER2/neu mouse model (316). They showed that plasma proteome profiling has 
ability to detect the cancer before it actually develops. Furthermore, a linear correlation was 
demonstrated for plasma levels of candidate biomarker proteins with the tumor progression, which 
were reversed upon tumor regression (316).  
 Both encapsulated miRNAs and secreted glycoproteins are prime candidates for circulating 
biomarkers released by the tumor microenvironment. Circulating miRNAs are secreted in 
nanometer-sized vesicles called exosomes or microvesicles. An advantage of circulating miRNA 
over protein biomarkers is the ability for amplification, increasing the sensitivity of detection. 
Comparative analysis of circulating miRNA can be performed using miRNA microarray and 
quantitative real-time PCR (294). Future studies should aim to discover and validate circulating 
miRNA changes associated with EAC development and progression.  
1.4.6.1 Glycan profiling 
 For BE and EAC, serum glycan profiling using mass spectrometry has identified differential 
expression of glycan structures in different disease states. Mechref and colleagues analysed N-
linked glycan diversity present in 84 patient serum samples (Healthy-18, BE-5, HGD-11, EAC-50) 
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(175). They identified 98 glycan features with different intensities in disease onsets and 26 of them 
correspond to known glycan structures. They demonstrated statistically significant glycan changes 
between 4 different conditions (Healthy/BE/HGD/EAC) with three of the known potential N-glycan 
biomarker predicted EAC with 94% sensitivity and 60% specificity (175). Another similar study 
used microchip electrophoresis with laser-induced fluorescence detection for N-glycan profiling and 
able to differentiate between the healthy, BE, HGD, and EAC conditions (176). Similar to above 
mentioned N-glycan profiling studies, very recently, Gaye and colleagues showed that ion mobility-
mass spectrometric analysis of serum N-glycan can also distinguish between normal and EAC 
phenotype (177). All of these studies unanimously suggest circulatory N-linked glycan changes 
during EAC pathogenesis. Mann and colleagues enriched fucosylated serum glycoproteins using 
lectins and then used shot gun proteomics to identify protein in different physiological states, 
including healthy, BE, and EAC (178). Although the study showed promising trends, the statistical 
power was not achieved due to the very low number of samples. To improve the throughput of 
glyco-centric proteomics studies, we have developed lectin magnetic bead array-mass spectrometry 
(LeMBA-MS), a high-throughput platform where a panel of lectins individually immobilized the 
magnetic beads is used to capture glycoproteins followed by on-bead trypsin digest and liquid-
chromatography-tandem mass spectrometry for protein identification (317, 318). Parallel screening 
of a panel of lectins may be helpful to identify differentially glycosylated circulating proteins during 
EAC pathogenesis. 
1.4.6.2 Metabolic profiling 
 In recent past, efforts have been made to profile metabolic changes associated with EAC 
pathogenesis. Metabolic profiling studies have identified changes associated with nucleoside 
metabolism, tri-carboxylic acid cycle, fatty acid and amino acid metabolism during EAC 
development in tissue samples and more importantly using easily accessible bio-fluids, blood and 
urine. Early metabolic changes in the histologically normal epithelium were observed, particularly 
for phosphocholine, glutamate, myo-inositol, adenosine-containing compounds, uridine-containing 
compounds and inosine (319). Djukovic and colleagues used targeted approach to profile eight 
different serum nucleosides between healthy subjects (n = 12) and EAC patients (n = 14) using 
high-performance liquid chromatography (HPLC) coupled with triple quadrupole mass 
spectrometer. Amongst eight nucleosides they profiled, five were significantly different between the 
two groups. 3 out of 5 significantly different nucleosides namely 1-methyladenosine, N
2
,N
2
-
dimethylguanosine, N
2
-methylguanosine were methylated nucleosides indicating increased tRNA 
methylation, similar to DNA hypermethylation in EAC condition (181). Zhang and colleagues 
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studied serum metabolomic changes using NMR alone and NMR in combination with LC-MS in 
EAC (n = 67), HGD (n = 9), BE (n = 3) and healthy volunteers (n = 34). Their model based on 
PLS-DA was being able to distinguish between different phenotypes by achieving area under 
receiver operating characteristics curve (AUROC) of as high as 0.95. Based on candidate 
metabolites they identified altered pathways associated with EAC development to be energy 
metabolism, fatty acid metabolism and amino acid metabolism (182, 183). Urine metabolomics 
could also distinguish between healthy, BE and EAC phenotypes. Davis and colleagues generated 
urine metabolic signatures which was able to discriminate between healthy, BE and EAC 
phenotypes, as well as distinguish EAC from pancreatic cancer (184). These metabolic profiling 
studies open up new avenue to detect early EAC using circulatory biomarkers.  
1.5 Glycoproteins as cancer biomarkers 
 The majority of United States Food and Drug Administration (FDA) approved cancer 
protein biomarkers are glycoproteins (130). Currently total glycoprotein levels are monitored in 
circulation to make the informed diagnostic decisions e.g. serum carbohydrate antigen 125 (CA125) 
level > 35 units/mL indicates gynecological abnormalities in women hence patients are referred for 
further investigation (320). Similarly, serum prostate-specific antigen levels > 4 ng/mL indicate 
prostate related abnormalities in male (321). Positive test results for total prostate-specific antigen 
measurements may be due to either prostate cancer or other non-cancerous abnormalities such as 
benign prostatic hyperplasia (BPH) or prostate infection/inflammation hence its implementation as 
a screening tool lead to overdiagnosis and overtreatment of prostate cancer (130). Recent studies 
show that monitoring aberrant glycosylation of prostate-specific antigen (fucosylation and 
sialylation) is a more specific, better predictor of prostate cancer and showed better correlation with 
Gleason score (322-326). In the case of hepatocellular carcinoma (HCC), increase in tumor size is 
closely linked to circulatory α-fetoprotein (AFP) levels. But AFP levels remain unchanged during 
early pathogenesis of HCC making total AFP measurement to be impractical as an early diagnostic 
marker. However, fucosylated AFP level changes in the circulation due to increased expression of 
α1-6 fucosyltransferase during early HCC pathogenesis (327, 328). Fucosylated AFP measurement 
test for early detection of primary HCC has been approved by the FDA and produced into a 
microfluidic based clinical immunoanalyzer test μTASWako®i30 (commercialized by Wako 
diagnostics) by measuring Lens culinaris agglutinin (LCA) (Fucose specific) bound fraction of AFP 
(AFP-L3,  Figure 1.5) (329). Increased ratio of AFP-L3/total AFP indicates increased risk for HCC 
development hence patients are monitored extensively using ultrasound for further confirmation. 
This example suggests monitoring specific glycosylation change can serve as an early diagnostic 
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marker even before imaging modalities (330-332). For several other glycoprotein biomarkers, 
studies have shown that monitoring specific glycosylation changes are better biomarker candidates 
as compared to measuring total glycoprotein levels e.g. fucosylated haptoglobin (pancreatic cancer), 
elevated levels of glycoforms containing sialyl Lewis X on haptoglobin, α1-acid glycoprotein, α1-
antichymotrypsin and immunoglobulin G (Ig G) (ovarian cancer) and fucosylated Ig G (stomach 
cancer) (327). Taken together, aberrant glycosylation changes may turn out to be more specific and 
sensitive biomarkers as compared to monitoring total glycoprotein levels.   
Figure 1.5. FDA 
approved 
μTASWako®i30 
immunoanalyzer 
measures AFP-L3 to 
diagnose early HCC. 
LCA, Lens 
culinaris agglutinin; 
HCC, Hepatocellular 
carcinoma. 
 
 
 
 Three potential mechanisms may contribute to tumor specific glycan modifications. (i) 
Altered expression of glycan processing enzymes, (ii) tumor microenvironment and (iii) local or 
systemic activation of differential cell types which otherwise are not active. Over 400 proteins are 
estimated to be involved in carbohydrate binding and metabolism (333). Genomic abnormalities 
during tumor progression can alter expression of these proteins resulting in aberrant glycosylation 
(322). Several of these glycosyltransferase/glucosidase enzymes themselves are considered as 
potential biomarker. For example N-acetylglucosamine transferase V (GlcNAcT-V) is responsible 
for β1-6 branching of N-glycans and this particular glycan alteration in target proteins such as 
cadherin, integrin, and other cytokine receptors is responsible for tumor metastasis. Furthermore 
mice lacking GlcNAcT-V have shown reduced polyomavirus antigen induced tumor growth and 
metastasis which demonstrate GlcNAcT-V as a potential therapeutic target (334). Another enzyme 
N-acetylgalactosaminyltransferase is responsible for initial steps of mucin O-glycosylation. SNPs 
associated with this enzyme are inversely related to risk for developing ovarian cancer (335). Last 
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but not the least α-L-fucosidase activity in serum has shown to predict early development of 
hepatocellular carcinoma in liver cirrhosis patients (336). α-L-fucosidase activity has also been 
correlated with progression-free survival in patients undergoing trastuzumab monotherapy. This 
study extends use of enzyme activity of α-L-fucosidase in blood circulation as a predictive 
biomarker for treatment of breast cancer with monoclonal antibody therapy (337).  
 The other potential source for circulatory tumor specific glycoprotein is the tumor 
microenvironment. The stromal components co-evolve with the cancer cells and help tumor to 
metastasize, get nutrients, evade immune response and to attain other hallmark characteristics (338). 
The microenvironment consists of cancer associated fibroblast, extracellular matrix, secretome, 
inflammatory cells, glial cells, innate/adaptive immune cells, adipocytes, vasculature and 
specialized mesenchymal cells (339). The secretome component consists of proteins, receptors, 
proteoglycans, cytokines, chemokines, growth factors, angiogenesis factors, proteases etc (315). 
Aberrant angiogenesis leads to accumulation of tissue fluids in the tumor environment and this fluid 
extravasate from the tumor site and mixes with the circulation. This fluid is rich in proteins secreted 
through classical or non-classical secretory pathway of the tumor cells and may be extremely useful 
as a diagnostic purpose as these changes can be monitored in circulation and tumor specific. The 
microenvironment and their secretions vary with tumor progression and identification of stage 
specific biomarkers can be useful to monitor the disease progress and predict therapeutic outcome. 
In fact using inducible HER2/neu mouse model Pitteri and colleagues showed that plasma proteome 
profiling has ability to detect the cancer before it actually develops (316). They have shown linear 
correlation between plasma levels of the candidate proteins with the tumor progression and these 
changes are reversible as they return to the original level with tumor regression. The majority of 
those candidate plasma proteins were acute-phase proteins, immune cell proteins, cytoskeletal, 
extracellular matrix proteins and quite a few amongst them were glycoproteins (316).  
 Different cell types express different glycosylation machinery. For example, haptoglobin 
(HP) is an acute phase protein which is mainly synthesized in liver and its main function is 
clearance of hemoglobin at the site of inflammation. The β-chain of HP undergoes N-linked 
glycosylation and has a molecular weight of about 39 kDa. However, neutrophils during their 
specific stage of development also synthesize HP but with different glycosylation leading to an 
apparent molecular weight of 45-65 kDa on western blot (340). Furthermore, upon activation this 
differentially glycosylated HP is released along with all other granular contents (340). This explains 
one more possibility for specific glycan changes in the circulatory glycoproteins.  
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1.5.1 Methodologies for glycoprotein biomarker discovery 
 The common aims in glycoprotein studies are to identify substrate protein undergoing 
glycosylation, to determine the actual site of glycan modification and to elucidate the glycan 
structure for each site. HPLC coupled mass spectrometry is the most commonly used technique to 
study glycan modifications. Advancements in the bioinformatic tools and development of relevant 
databases such as GlycoGene database, lectin frontier database, GlycoProtein database, Glycan 
mass spectral database have facilitated the glycoprotein research (341). Overall glycoprotein studies 
are mainly driven by advancements in the chromatographic, mass spectrometric and bioinformatics 
techniques.  
 Biological samples are fairly complex and significant pre-processing is required before they 
can be used for glycoprotein analysis. In order to detect medium or low abundance glycoprotein, 
various enrichment techniques are developed. Followed by glycoprotein enrichment, there are two 
main approaches for glycoprotein detection, top-down workflow (glycoprotein based) or bottom-up 
workflow (glycopeptide based) analysis. As the name suggests the top-down workflow initially 
enrich glycoprotein followed by trypsin digest while for glycopeptide based techniques, the protein 
is typsin-digested first followed by glycopeptide enrichment. Tryptic peptides can be directly 
analyzed by LC-MS to identify the underlined proteins. An additional enzymatic glycan release step 
(i.e. PNGase F treatment for N-glycan release) is required before mass spectrometric analysis and 
glycan structural elucidation (342). Alternatively, glycosylation can be detected on the glycopeptide 
level to get the connectivity between the glycan and the peptide carrier (343). The following section 
briefly discusses glycoprotein/glycopeptide enrichment techniques.  
1.5.1.1 Using lectins in the glycoprotein enrichment workflows 
 The glycoprotein enrichment workflows can be broadly categorized into two different types. 
(i) Lectin based, and (ii) non-lectin based. Lectins are carbohydrate binding proteins and occur 
abundantly in nature. They generally recognize glycan structures with low affinity but with high 
avidity mainly through hydrogen bonding, hydrophobic interactions and van der Waals forces 
(344). A range of lectins for selective enrichment of glycan moiety are commercially available in 
different formats to suit specific experimental requirements, these have been reviewed previously 
(309, 310). To name few, lectins are available as immobilized on solid support such as agarose, 
silica or even magnetic beads. They are applied in different chromatographic settings such as tubes, 
columns and microfluidic channels. One single lectin can be used in isolation to enrich narrower 
range of glycoepitopes or multiple lectins can be used in combination in order to enrich broad range 
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of glycan structures (345). Multiple lectins with different carbohydrate specificity is used serially to 
enrich selective glycan structures in a process called serial lectin affinity chromatography. This 
particular approach was successfully applied particularly to isolate O-linked glycans (346). In order 
to facilitate high-throughput glycan analysis lectin microarrays have emerged where series of lectins 
are spotted on the solid support, samples are tagged with fluorophore and detection is carried out 
using fluorescence microarray scanners (347). Recently our laboratory developed lectin magnetic 
bead array-tandem mass spectrometry (LeMBA-MS/MS), a high-throughput platform where array 
of lectins are immobilized on the magnetic beads to capture glycoproteins followed by on bead 
trypsin digest in line with mass spectrometry (317, 318). These lectin based high-throughput 
techniques have been playing key role in glycobiomarker research.  
 Apart from using lectin biology for enrichment, chromatographic technique such as 
hydrophilic interaction chromatography (HILIC) (348) and chemical modification techniques have 
been developed for isolating glycopeptides. Based on hydrazide chemistry, Zhang and colleagues in 
2003 developed solid phase extraction method for isolating glycoprotein (349) and later modified it 
to make it suitable for glycopeptides (350). Utilizing fact that Boronic acid form stable cyclic esters 
with cis-diol containing carbohydrates at higher pH, Zhou and colleagues developed magnetic 
nanoparticles to capture glycoprotein/glycopeptides and being a reversible reaction, captured 
glycoprotein/glycopeptides can be released at lower pH simply by acid elution (351). The main 
difference between lectin-based and non-lectin based protocols is that there are many lectins which 
bind to different glycan groups but chemical methods are usually not selective for a particular class 
of glycan and enrich samples for glycoproteins as a whole.  
1.5.1.2 LeMBA 
 To improve the throughput of lectin based glycoprotein biomarker discovery platforms, our 
laboratory previously developed lectin magnetic bead array (LeMBA) workflow (Figure 1.6) (317, 
318). Unlike single, serial and multi lectin affinity chromatography, LeMBA uses 20 individual 
lectin coated magnetic beads in microplate format to enrich a sub-population of serum 
glycoproteins having high-affinity to bind with a particular lectin. Table 1.6 contains details of 
lectins used in LeMBA workflow along with their general glycan specificity. LeMBA incorporates 
following key steps: (i) coupling lectins with MyOne™ Tosylactivated Dynabeads® (magnetic 
beads), (ii) Spike serum samples with internal standard ovalbumin and sample denaturation, (iii) 
glycoprotein capture, (iv) removal of unbound proteins by several washing steps and (v) elution of 
bound proteins for western immunoblotting or on-bead trypsin digest for mass spectrometric 
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analysis. With the use of magnetic beads, LeMBA allows single-step isolation of serum 
glycoprotein using 20 individual lectin-coated magnetic beads. Composition of different buffers 
used during LeMBA protocol namely denaturation buffer, binding buffer and washing buffer were 
carefully optimized for salts and detergents to avoid co-isolation of protein complexes without 
adversely affecting lectin pull-down efficiency. Internal standard chicken ovalbumin can account 
for minor variations during sample processing and pull-down steps between different time points. 
Glycoprotein capture, washing and on-bead trypsin digestion steps are performed on liquid handler 
which makes LeMBA semi-automated and reproducible over several weeks of sample preparation. 
LeMBA is a versatile platform and can be coupled with diverse protein identification, 
characterization and quantitation techniques. When coupled with nano-HPLC-MS/MS to identify 
non-glycosylated peptides from the isolated glycoproteins with lectin exclusion list for protein 
identification, it has demonstrated nanomolar sensitivity and linearity. Last but not the least it is 
applicable across different species.  
Figure 1.6. Lectin magnetic bead array (LeMBA) workflow for serum glycoprotein biomarker 
discovery and development. Adapted from Choi et al. (317). 
Table 1.6. Glycan specificity of lectins used in LeMBA. Adapted from Choi et al (317). 
Carbohydrate Abbreviations Source  Ligand motif  Supplier 
Mannose 
ConA Jack bean α-Man, α-Glc, α-GlcNAc Sigma 
GNL Galanthus nivalis Manα1-3Man terminal Vector 
NPL Daffodil Manα1-6Man Vector 
N-
acetylglucosami
ne 
DSA Datura stramonium  β1-4GlcNAc oligomers Vector 
HAA Helix aspersa  α-GlcNAc and α-GalNAc Sigma 
STL Potato GlcNAcβ1-4GlcNAc oligomers Vector 
WGA Wheat germ GlcNAcβ1-4GlcNAc , Neu5Ac Sigma 
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Carbohydrate Abbreviations Source  Ligand motif  Supplier 
Galactose 
BPL Bauhinia purpurea  Galβ1-3GalNAc Vector 
ECA Erythrina cristagalli  Galβ1-4GlcNAc Sigma 
JAC Jackfruit (Jacalin) Galβ1-3GalNAc Vector 
N-
acetylgalactosa
mine 
SBA Soy bean GalNAcα1-3Gal Sigma 
HPA Helix pomatia α-GalNAc Sigma 
WFA Wisteria floribunda GalNAcα1-6Gal/α1-3GalNAc Sigma 
Fucose 
AAL Aleuria aurantia Fucα1-6GlcNAc Vector 
PSA Pisum sativum Fucα1-6GlcNAc Sigma 
UEA Ulex europaeus Fucα1-2Galβ1-4GlcNAc Vector 
Sialic acid 
MAA Maackia amurensis Neu5Acα2-3 Vector 
SNA Elderberry Neu5Acα2-6 Vector 
Others 
EPHA  
Erythroagglutinin 
Phaseolus vulgaris 
Bisecting GlcNAc Vector 
LPHA  
Leucoagglutinin 
Phaseolus vulgaris 
Tri/Tetra-antennary β1-
6GlcNAc 
Vector 
1.6 Thesis aims and significance 
 Current endoscopy-biopsy based clinical practice for diagnosis and management of EAC 
pathogenesis hasn't been able to curb morbidity and mortality related to this lethal malignancy. 
There is an urgent need to identify circulatory biomarkers which can be developed further into a 
blood based diagnostic test (1). Out of different classes of circulatory biomarkers, serum 
glycoproteins are potential candidates. In fact, serum glycan profile differs between healthy, BE, 
dysplastic and EAC patients (167-169, 174, 311). However, specific glycoprotein biomarker 
candidates showing differential glycosylation are not known. This study hypothesized that EAC 
pathogenesis is associated with changes in the glycosylation of serum proteins hence serum 
glycoprotein can act as a potential diagnostic biomarkers to monitor EAC pathogenesis. Based on 
this working hypothesis, this thesis has the following aims. 
 (i) To discover serum glycoprotein biomarker candidates using LeMBA workflow that 
distinguish between healthy, EAC and metaplastic BE phenotype. 
 (ii) To develop a targeted proteomics approach to measure biomarker candidates for a timely 
verification.           
 (iii) To verify serum glycoprotein candidates identified in Aim 1 (Chapter 3) using targeted 
proteomics approach developed in Aim 2 (Chapter 4) in an independent patient cohort. 
 (iv) The mass spectrometric approach employed to address Aim 1 to 3 is best suited for 
research laboratory but not for routine clinical diagnostic. So final aim of this project was to test 
feasibility of using electrochemical detection methodology for the glycoprotein detection.  
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 Chapter 3 describes extension of LeMBA with development of GlycoSelector database 
incorporating statistical analysis pipeline. Using this pipeline, lectin-glycoprotein biomarker 
candidates that distinguish between healthy, BE and EAC phenotype are reported. 
 Chapter 4 addresses Aim 2, which include development of targeted proteomics assay for a 
timely verification of biomarker candidates described in Chapter 3. It also describes testing linearity 
and reproducibility of the targeted proteomics assay. 
 By screening an independent cohort of serum samples using targeted proteomics approach 
described in Chapter 4, verified list of serum glycoprotein biomarker candidate has been described 
in Chapter 5.    
 The publication of Aim 4, described in Chapter 6, has reported the proof-of-concept work to 
use electrochemical detection method for glycoprotein detection.  
 Collectively, this thesis describes discovery and verification of serum glycoprotein 
biomarker candidates for BE/EAC diagnosis. The electrochemical method has been successfully 
applied for glycoprotein detection/quantitation and can be developed further as a clinically useful 
diagnostic platform.  
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Chapter 2. Materials and methods 
 Materials and methods used frequently across different thesis chapters are described in this 
chapter. For methods belong to specific chapter please refer to respective chapter.   
2.1 Reagents 
 MyOne
TM
 Tosyl activated Dynabeads® were from life technologies. Lectins Aleuria 
aurantia lectin (AAL), Bauhinia purpurea lectin (BPL), Datura stramonium agglutinin (DSA), 
Erythroagglutinin Phaseolus vulgaris (E-PHA), Galanthus nivalis lectin (GNL), Jacalin (JAC), 
Leucoagglutinin Phaseolus vulgaris (L-PHA), Maackia amurensis agglutinin-II (MAA), Narcissus 
pseudonarcissus lectin (NPL), Sambucus nigra agglutinin (SNA), Solanum tuberosum lectin (STL) 
and Ulex europaeus agglutinin-I (UEA) were from Vector Laboratories. Modified sequencing grade 
trypsin was from Promega. Protein assay dye reagent (Bradford reagent), Triton X-100 and SDS 
solution were from Bio-rad. Tris base, glycine, sodium chloride and acrylamide/bis-acrylamide 
solution 40% w/v 29:1 were from Amresco. Glycerol, disodium hydrogen phosphate dihydrate, 
sodium dihydrogen phosphate dihydrate, calcium chloride dihydrate (CaCl2) and tween-20 were 
from Ajax Finechem. Magnesium chloride (MgCl2) and manganese chloride (MnCl2) were from 
Univar. Immobilon-P Polyvinylidene difluoride (PVDF) was from Millipore and SuperSignal West 
Pico Chemiluscent Substrate was from Thermo Scientific. Monoclonal anti-gelsolin antibody was 
from Epitomics (EP1940Y), polyclonal anti-haptoglobin was from Gen Way Biotech (GWB-
16A7EA) and HRP labeled anti-rabbit HRP was from Invitrogen (A10547). The developer and fixer 
for western blot development were from Kodak. For quadrupole time of flight runs, acetonitrile, 
isocratic HPLC grade was from Scharlau and for triple quadrupole runs, acetonitrile 
CHROMASOLV® gradient grade was from Sigma. Mass spectrometry reagents were from Agilent 
Technologies. All other reagents, including lectins not listed above, were from Sigma unless 
otherwise specified. 
2.2 Buffers and solutions 
2.2.1 LeMBA 
 Protease inhibitor cocktail (PI) 1000x stock (diluted to 1x in final solution) – 1 μg/μL 
Aprotinin, 1 μg/μL Antipain, 1 μg/μL Pepstatin A, 1 μg/μL Leupeptin and 250 mM Benzamidine  
 Lectin resuspension buffer – 20 mM sodium dihydrogen phosphate monohydrate, 80 mM 
disodium hydrogen phosphate dihydrate, 0.1 mM CaCl2, 0.1 mM MnCl2 
 Bead activation buffer – 3M ammonium sulfate (pH 7.9) 
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 Bead blocking buffer – 1 M Tris-HCl (pH 7.4), 1% w/v glycine 
 Bead storage buffer – 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM CaCl2, 1 mM 
MnCl2, 0.5% v/v Triton, 1x PI 
 Denaturation buffer – 20 mM Tris-HCl (pH 7.4), 20 mM DTT, 1% w/v SDS and 5% v/v 
Triton 
 Binding buffer A (for lectins EPHA, SNA and STL) – 20 mM Tris-HCl (pH 7.4), 0.2% w/v 
SDS, 1 mM DTT, 150 mM NaCl, 1 mM CaCl2, 1 mM MnCl2, 1% v/v Triton, 1x PI 
 Binding buffer B (for remaining all lectins) – 20 mM Tris-HCl (pH 7.4), 0.05% w/v SDS, 1 
mM DTT, 300 mM NaCl, 1 mM CaCl2, 1 mM MnCl2, 1% v/v Triton, 1x PI 
 Washing buffer A (for lectins EPHA, SNA and STL) – 20 mM Tris-HCl (pH 7.4), 0.2% w/v 
SDS, 1 mM DTT, 150 mM NaCl, 1 mM CaCl2, 1 mM MnCl2, 1% v/v Triton 
 Washing buffer B (for remaining all lectins) – 20 mM Tris-HCl (pH 7.4), 0.05% w/v SDS, 1 
mM DTT, 300 mM NaCl, 1 mM CaCl2, 1 mM MnCl2, 1% v/v Triton 
 50 mM ammonium bicarbonate for washing and trypsin resuspension  
2.2.2 SDS-PAGE and western immunoblotting 
 Laemmli sample buffer 5x stock (diluted to 1x for use) - 0.2 M Tris-HCl (pH 6.8), 10% w/v 
SDS, 50% v/v glycerol, 0.25 M DTT, 0.1% w/v bromophenol blue 
 Buffer A for resolving gel – 750 mM Tris-HCl (pH 8.8), 0.2% w/v SDS  
 Resolving gel – 
Ingredients 
Gel percentage 
6% 8% 10% 12% 15% 
MiliQ water 34.00% 29.00% 24.00% 19.00% 11.50% 
Acrylamide/Bis-acrylamide solution (40%) 15.00% 20.00% 25.00% 30.00% 37.50% 
Buffer A 50.00% 50.00% 50.00% 50.00% 50.00% 
Ammonium persulphate (APS) solution 
(10%) 
1.00% 1.00% 1.00% 1.00% 1.00% 
Tetramethylethylenediamine (TEMED) 0.05% 0.05% 0.05% 0.05% 0.05% 
 Buffer B for stacking gel – 250 mM Tris-HCl (pH 6.8), 0.2% w/v SDS  
 Stacking gel – 39% MiliQ water, 10% v/v Acrylamide/Bis-acrylamide solution (40% w/v), 
50% v/v Buffer B, 1% v/v of 10% w/v Ammonium persulphate (APS) solution, 0.1% v/v 
Tetramethylethylenediamine (TEMED) 
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 Gel running buffer 10x stock (diluted to 1x for use) – 250 mM Tris, 1.92 M glycine, 1% w/v 
SDS  
 Transfer buffer 10x stock (wet transfer) – 1.92 M glycine, 250 mM Tris  
 Transfer buffer 1x (wet transfer) – 10% v/v of 10x transfer buffer, 20% v/v methanol  
 Tris buffered saline (TBS) for western blotting (pH 7.4) 10x stock – 500 mM Tris, 1.5 M 
NaCl, approximately 0.3% v/v HCl to adjust pH 7.4 
 Tris buffered saline Tween 20 (TBST) for western blotting (pH 7.4) – 10% v/v of 10x TBS, 
0.1% v/v Tween 20   
 Strip solution – 1M glycine (or 5M sodium hydroxide), 5% v/v HCl, and 1% w/v SDS 
 Developer – 130 mL developer solution diluted in 270 ml of tap water  
 Fixer – 130 mL fixer solution diluted in 270 mL of tap water 
 Coomassie Brilliant Blue for membrane staining – 0.25% w/v Coomassie Brilliant Blue R-
250, 7% v/v acetic acid, 40% v/v methanol 
 Destain for membrane – 40% v/v methanol, 7% v/v acetic acid 
 Colloidal Coomassie blue for gel staining – 10% w/v ammonium sulfate, 10% v/v 
orthophosphoric acid, 0.12% w/v Coomassie Blue G-150, 20% v/v methanol 
 Destain for gel – 1% v/v acetic acid 
2.2.3 Mass spectrometry 
 Buffer A – 0.1% v/v mass spectrometry grade formic acid in MilliQ water 
 Buffer B – 90% v/v isocratic grade acetonitrile in 0.1% v/v mass spectrometry grade formic 
acid in MilliQ water for Chapter 3. 0.1% v/v mass spectrometry grade formic acid in gradient grade 
acetonitrile for Chapter 4 and Chapter 5. 
 Injector needle wash – 20% v/v methanol in 0.1% v/v formic acid made up in MiliQ water 
2.3 Sample collection 
 The study was approved by The University of Queensland Human and Animal Ethics 
Committees. Samples were randomized prior to all experiments. Serum samples from healthy, BE 
and EAC patients were acquired through the Australian Cancer Study (ACS) (352) and Study of 
Digestive Health (SDH) (353). All 29 serum samples (Healthy-9, BE-10 and EAC-10) used for 
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biomarker discovery phase and 79 serum samples (Healthy-20, BE-20, EAC-20 and population 
control-19) used for biomarker qualification study were age and gender matched. Healthy controls 
were individuals with no history of esophageal cancer and no evidence of esophageal histological 
abnormality at the time of sample collection. BE patients had a histologically confirmed diagnosis 
of Barrett's mucosa. EAC patients had histologically confirmed adenocarcinoma within the distal 
esophagus or gastro-esophageal junction. Although cancer staging for EAC patients was available 
for verification cohort, patients were not stratified according to disease progression due to relatively 
small sample size. The EAC cohort consists of patients from early to late stages of EAC. EAC 
patient sera were collected prior to the commencement of cancer treatment. Population controls 
were volunteers with no self-reported history of EAC or BE. All subjects signed written informed 
consent as a part of sample collection process. For categorical and numerical variables related to 
patient information, P values were calculated using Fisher's exact test and Kruskal-Wallis test 
respectively. 10 ml of serum was collected from each patient during the trial. The samples (50 μl for 
biomarker discovery and 500 μl for biomarker verification) were received from QIMR Berghofer 
Medical Research Institute and stored at -80 °C until use. Typically, samples were thawed once for 
protein estimation and at the same time samples were denatured. Particularly for biomarker 
verification, samples were aliquoted into two different tubes (50 μl each) during first freeze thaw 
for future use.      
2.4 Protein methods 
2.4.1 Bradford protein assay 
 Serum samples were diluted 1 in 100, 1 in 150 or 1 in 200 in MiliQ water. Bovine serum 
albumin (BSA) standard solutions at the concentration of 0 mg/mL (blank), 0.2 mg/mL, 0.4 mg/mL, 
0.6 mg/mL, 0.8 mg/mL and 1 mg/mL were made. 5 μL of BSA standard or 5 μL of diluted sera 
were arrayed at least in duplicate in a clear 96 well plate. Bradford reagent was diluted 5 times in 
MiliQ water and 200 μL of this dilution was added to each well. Whenever required, solution in 96 
well plate was mixed using liquid handler. Absorbance was measured at 595 nm using FLUOstar 
OPTIMA microplate reader (BMG Labtech). Raw absorbance values were exported to Microsoft 
excel. Standard curve using absorbance values of known BSA concentrations was plotted and 
protein concentration of samples was determined using slope and y-intercept of the standard curve.    
2.4.2 SDS-PAGE and western immunoblotting 
 Mini-PROTEAN
®
 tetra cell system coupled with wet transfer assembly from Bio-Rad was 
used. Protein samples were boiled in 1x Laemmli sample buffer at 95 °C for 5 min (354). For 
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LeMBA-immunoblotting, 2x or 3x concentration of sample buffer was used. The samples were 
resolved on appropriate SDS-PAGE gels and transferred to Immobilon-P polyvinylidene difluoride 
(PVDF) membranes using wet transfer. The membranes were blocked with either 5% w/v non-fat 
milk or 5% w/v BSA for 30 min at room temperature. The membranes were probed with primary 
antibody overnight at 4 °C. On next day, after washing membranes 5 times with 1x TBST for 5 min 
each, the membranes were probed with appropriate secondary antibody conjugated with horseradish 
peroxidase (HRP) for 2 hr at room temperature. After washing membranes at least 3 times with 1x 
TBST for 5 min each, the membranes were developed using SuperSignal West Pico 
chemiluminescence, and captured on film. Densitometric analysis was performed using ImageJ 
(NIH, USA) (355).    
2.5 Lectin magnetic bead array (LeMBA) 
 LeMBA was performed as described previously, with modifications (317, 318). 
2.5.1 Coupling of lectins with Dynabeads® 
 Lectins are supplied as lyophilized powder which may or may not contain necessary salts in 
the vials. Lectins were reconstituted using either MiliQ water (lectins supplied containing necessary 
salts) or lectin resuspension buffer (lectin supplied without any salts) and stored at -80 °C in 
aliquots. Lectins were covalently attached with Dynabeads via primary amine or sulphydryl group 
(https://tools.thermofisher.com/content/sfs/manuals/dynabeads_myone_tosylactivated_man.pdf). 
For each lectin, 100 μL of 100 mg/mL MyOne tosyl activated Dynabeads® were washed three times 
with lectin resuspension buffer using magnetic tube holder. To the beads, 100 μL of 3 M 
ammonium sulphate (pH 7.9) was added and beads were mixed using vortex. 100 μL of 5 mg/mL 
lectin was added to the activated beads and tubes were incubated rotating at 20 RPM for 24 hr at 37 
°C. On the next day, the supernatant was removed and non-reacted sites of the beads were blocked 
by incubation with 1 mL of 1 M Tris containing 1% w/v glycine for 16 hr at 37 °C. On third day, 
supernatant was removed and lectin-beads were washed three times using bead storage buffer. The 
beads were resuspended using 1 mL of bead storage buffer and stored at cold temperature. 50 μL of 
this lectin-bead conjugate is used for one pull-down experiment with 50 μg of denatured serum 
protein. To minimize experimental variation due to batch effect, lectin-beads sufficient for each 
phase of biomarker discovery and verification experiments were made at once and used within 3 
months. The lectin to Dynabeads coupling ratio is 10 mg of beads per 0.5 mg of lectin which is 
sufficient for 20 pull-downs after conjugation.   
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2.5.2 Serum sample preparation for LeMBA 
 The Bradford protein assay was performed to measure serum protein concentration. The 
serum samples were spiked with 10 picomole ovalbumin per reaction as an internal standard i.e. 50 
μg of serum proteins were spiked with 10 picomole of chicken ovalbumin. The serum protein 
mixture was denatured and reduced in denaturation buffer at 60 °C for 30 min followed by 
alkylation with 100 mM iodoacetamide for 1 hr at room temperature maintaining dark condition.    
2.5.3 Liquid handler assisted LeMBA pull-down and trypsin digestion 
 For each pull down experiment, lectins [all lectins (20 lectins plus control bead) for 
biomarker discovery or specified lectins for biomarker verification] were arrayed in each well of a 
96 well plate. The 20 different lectins were chosen to accommodate natural diversity of glycans. 
The lectins were selected according to glycan recognition epitopes as per literature and described by 
Choi et al (317). The Bradford protein assay was performed to measure serum protein 
concentration. The serum samples were spiked with 10 pmol ovalbumin per reaction as an internal 
standard. The serum protein mixture was denatured and reduced using denaturing buffer at 60°C for 
30 min followed by alkylation with 100 mM iodoacetamide for 1 hr at 37°C maintaining dark 
condition. 50 µg alkylated serum sample per reaction was incubated with lectin conjugated beads in 
100 µl binding buffer at 4°C for 1 hr on the plate shaker. Following glycoprotein capture, beads 
were washed (i) with binding buffer for 3 times then washed with (ii) 50 mM ammonium 
bicarbonate for seven times including changing plates three times in-between washes. For on-bead 
trypsin digest, 0.95 µg of sequencing grade trypsin in 20 µl of 50 mM ammonium bicarbonate was 
added to each reaction mixture and incubated at 37°C overnight. The next day, digested peptides 
were transferred to a new plate. Beads were washed with an equivalent volume of 50 mM 
ammonium bicarbonate, and supernatant was combined with digested peptides. Pooled peptide 
samples were dried under the vacuum and plates were stored at -80°C until further use. Bravo liquid 
handler (Agilent Technologies) was used to make the platform high throughput. 
2.5.4 LeMBA-western immunoblotting 
 LeMBA pull-down until glycoprotein capture step was performed as described above in 
section 2.5.3. After glycoprotein capture, beads were washed only with binding buffer for 3 times. 
All further washing steps with ammonium bicarbonate and trypsin digest were not required. Beads 
were directly boiled in 2x Laemmli sample buffer to elute captured glycoproteins, run on SDS-
PAGE and proteins were transferred to PVDF membrane using wet transfer. Western 
immunoblotting using antibody raised against target glycoprotein was performed as described in 
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section 2.4.2. To compare results across membranes, pull-down sample from one healthy patient 
serum (unrelated to samples used in screen) was loaded in equal amounts on all gels. Raw 
densitometric values were normalized using an internal control sample loaded onto each gel.  
2.6 Statistical analysis 
 Statistical analysis was performed using Microsoft Excel 2007, GraphPad Prism 6, R 
statistical programming language and web-based tools GlycoSelector for biomarker discovery 
(http://glycoselector.di.uq.edu.au/) and Shiny mixOmics for biomarker verification 
(http://mixomics-projects.di.uq.edu.au/Shiny). The details about steps followed for statistical 
analysis is explained in the respective result chapters. Both biomarker discovery and verification 
employed relative quantitation using internal standard chicken ovalbumin spiked at the step of 
sample denaturation. The common steps for GlycoSelector and Shiny mixOmics include, (i) 
uploading data, (ii) outlier detection, (iii) group binding difference analysis for GlycoSelector OR 
univariate statistical analysis including determination of AUROC for Shiny mixOmics, and (iv) 
Sparse partial least squares-discriminant analysis (sPLS-DA) for multivariate feature selection 
including stability assessment of a candidate using leave-one-out validation for GlycoSelector OR 
cross-validation for Shiny mixOmics.  
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Chapter 3. Serum glycoprotein biomarker discovery using LeMBA−GlycoSelector pipeline  
3.1 Introduction 
 Biomarker discovery is the first important step in the paradigm of biomarker discovery and 
development process (133, 356). In clinical practice, biomarkers can aid in prediction, cause, 
diagnosis, staging, regression, selection/monitoring of treatment or outcome of treatment for a 
disease (126, 357). The following considerations should be taken into account prior to biomarker 
discovery screen: (i) Unmet clinical need, (ii) rationale of using a particular class of biomolecule to 
be screened for biomarker purpose, (iii) biological sample to be used for screening, (iv) expected 
outcome of the screen. Usually clinical decisions are made not just based on one biomarker but it 
takes into consideration patient history, nature of illness and results from other available 
noninvasive medical imaging techniques, such as magnetic resonance imaging (MRI) and 
ultrasound (358). In the central dogma of molecular biology, DNA, RNA, protein or metabolite can 
serve as a biomarker candidate. The particular interest of using protein candidate as a biomarker 
candidate lies in the diversity of proteins found in the biology. The estimates suggest there are 
20,300 genes (359), 41,993 metabolites (360, 361) and 100,000 mRNA transcripts (358) present in 
a human being. Even with modest estimates considering the variety of post-translational 
modifications on proteins, the number of different protein species can easily be more than a million 
(362, 363). This enormous diversity of protein variants possesses an immense opportunity to 
identify biomarker candidates. At the same time, it is a challenge for available analytical 
methodologies to correctly identify and quantitate a specific protein variant in biological samples 
(358). 
 It is not surprising to know that protein biomarkers are already widely used in pathology 
laboratories to assist clinicians in decision making leading to better patient management hence 
improved health outcomes. Human plasma/serum has been described as the most comprehensive 
and complex proteome (362). It is a circulating representation of all body tissues and reflects both 
physiological and pathological processes. It is mainly composed of proteins secreted by solid 
tissues (mainly liver and intestine) that act in plasma, immunoglobulins, "long distance" receptor 
ligands that include classical peptide and protein hormones, "local receptor" ligands that include 
cytokines, temporary passengers e.g. lysosomal proteins that are secreted and then taken up via a 
receptor for sequestration in the lysosomes. It also contains tissue leakage products such as cardiac 
troponins, creatinine kinase, or myoglobin used in the diagnosis of myocardial infarction, secretions 
from blood or immune cells and foreign proteins e.g. protein originated from infectious organisms 
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or parasites (362). The remarkable progress in mass spectrometry, high-throughput antibody 
production, bioinformatics and biostatistics algorithms in the past couple of decades now enables 
the study of this complex plasma/serum proteome in a holistic manner (358). Almost half of the 
blood proteins are glycoproteins and it is a major contributor to the diversity of protein species 
observed/predicted in the serum/plasma proteome (362). As described in section 1.5.1.1 of the 
thesis, our laboratory recently developed LeMBA workflow which uses 20 naturally occurring 
glycan binding proteins lectins to enrich sub-glycoproteome from a serum sample. Here, LeMBA 
was combined with discovery proteomics platform and GlycoSelector data analysis pipeline for 
BE/EAC diagnostic biomarker discovery. 
3.1.1 Relative quantitation in proteomics based biomarker discovery pipeline 
 Three main steps in biomarker discovery pipelines are (i) sample preparation, (ii) mass 
spectrometric analysis for protein identification and quantitation, and (iii) data analysis. Sample 
preparation for glycoprotein biomarker discovery using LeMBA protocol is semi-automated, 
reproducible, and high-throughput hence suitable for screening enough number of patient samples 
required for biomarker discovery (317). Moreover, it uses serum sample as a source of biomarker 
discovery from beginning of the study (317, 318).   
 For mass spectrometry based discovery proteomics methods, the main objective is to 
identify as many candidates as possible in the sample with reliable relative quantitation approach to 
compare between different disease states. Two main approaches for protein identification exist 
based on mass spectrometry analysis (i) top-down proteomics (364-366), and (ii) bottom-up 
proteomics (367). Top-down proteomics aims for intact proteins and retain a lot of information 
about protein sequence, protein isoforms and post-translational modifications (364-366). Top-down 
proteomics of biological samples (e.g. serum) result in complex spectrum which is difficult to 
annotate hence limits the protein identification. On contrary, bottom-up proteomics is based on the 
identification of protein cleavage products (mainly peptides), and provide high sensitivity resulting 
into very high number of protein identifications in biological samples and remain the method of 
choice. Bottom-up proteomics involves the following steps: (i) protein digestion by proteolytic 
enzyme with known sequence specificity e.g. trypsin, (ii) peptide separation by LC, (iii) peptide 
ionization, (iv) peptide fragmentation, and (v) detection of mass-to-charge ratios (m/z) and 
abundance of peptide ions and their fragment ions (367). Two main types of modern day mass 
spectrometers are used for proteomics purposes. (i) Time-of-flight (TOF) analyzers combined with 
quadrupole for ion selection and electrospray ionization (ESI) source can provide high sensitivity, 
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high mass accuracy (2 to 5 ppm), high resolution (10,000 to 40,000 in MS1 and MS/MS modes 
respectively), and fast scan time (368). (ii) Combination of an Orbitrap analyzer with ion-trap for 
ion selection and ESI source provides high mass accuracy (1 to 5 ppm) in MS and MS/MS modes, 
resolution up to 240,000, and relatively fast scan speeds (369, 370). Latest instrument based on 
Fourier transform ion cyclotron resonance (LTQ-FTICR), offers capabilities of an Orbitrap with 
resolutions up to 750,000 (371, 372). 
 There are three main approaches for incorporating quantitation into biomarker discovery 
pipeline: (i) Metabolic and enzymatic labeling, (ii) chemical labeling, and (iii) Label-free 
quantitation. Stable isotope labeling with amino acids in cell culture (SILAC) is a common form of 
metabolic labeling whereby treated (experiment group) cells are grown in media containing heavy 
isotope-labeled (
13
C6 and 
15
N7) amino acids as compared to control cells which are grown in light 
isotope-lebaled (
12
C6 and 
14
N7) amino acids or vice versa. Upon more than 5 cell divisions in the 
respective media, these amino acids are incorporated into protein sequence during translation in the 
cells. Equimolar mixture of these cell lysates is mixed and analyzed by discovery proteomics 
methods using mass spectrometric analysis. The peptides from heavy labeled amino acids differ 
from light counterpart in terms of mass hence show mass shift in precursor ion m/z. The final result 
is reported in the form of ratio between heavy and light peptide levels (373). When 
18
O containing 
water (H2
18
O) instead of normal water (H2
16
O) is used during enzyme digestion, enzymatic labeling 
takes place. Exchange of two 
16
O atoms for two 
18
O atoms on C-terminal of peptides occurs which 
is observed in the form of mass shift of 4 Da (374). Chemical labeling can be accomplished using 
heavy or light isotope-labeled and chemically reactive tags. Example includes isotope-coded 
affinity tags (ICAT) that allow for labeling of cysteine residues in proteins with either heavy or light 
version, followed by affinity purification and mass spectrometric analysis to determine ratio of 
heavy and light isotope-labeled tags for quantification (375). Isobaric tags for relative and absolute 
quantification (iTRAQ) (376) or tandem mass tags (TMT) (377) produce reporter ions upon peptide 
fragmentation for quantitation and also allow multiplexing up to some extent. The limitation of 
metabolic or chemical labeling procedure is addition of one more step to already complex sample 
preparation workflow, with more chance for sample loss, inaccuracies and mix-ups. Moreover, 
labeling techniques are not plausible for screening many patient samples (358). Label-free 
quantitation offers a cheap alternative as opposed to labeling method, allows wider coverage of 
dynamic range, and suitable for screening large number of patient samples (378). Spectral counting 
or extracted ion chromatograms are two main options to implement label-free proteomics 
quantitation. It has also been demonstrated that addition of internal standard protein in complex 
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biological sample results into accurate relative quantitation using label-free proteomics workflow 
(378).  
 Most proteomics workflow generates list of peptides/proteins identified for each sample 
with some quantitative information. Many commonly used software tools can handle conventional 
proteomics data sets and spits out list of candidates that differentiate two groups being compared. 
Inclusion of 20 different lectin pull-down per sample to capture glycosylation differences adds one 
more dimension to LeMBA data sets hence development of appropriate data analysis platform is 
warranted. Generally multivariate approaches such as principal component analysis (PCA) and 
partial least squares (PLS) are employed for analyzing omics data sets (379). It is advisable to 
validate the multivariate analysis model using ideally an independent data set. In case when 
independent data is not available then internal validation such as leave-one-out or cross-validation 
approaches can be utilized (379, 380). 
 The aim of this chapter is to extend LeMBA workflow with development of GlycoSelector 
database incorporating statistical analysis pipeline. Using this LeMBA-GlycoSelector workflow, 
serum samples from healthy, BE and EAC patients were screened to identify diagnostic 
glycoprotein biomarker candidates. 
3.2 Experimental procedures 
3.2.1 Sample information 
 Serum samples from 29 patients (healthy - 9, BE - 10 and EAC - 10) were randomized 
across 8 plates in the given order for LeMBA pull-down and mass spectrometry analyses (Plate 1 - 
2, 30, 16, 24; Plate 2 - 14, 22, 8, 27; Plate 3 - 23, 3, 12, 9; Plate 4 - 10, 17, 28, 18; Plate 5 - 29, 6, 
19; Plate 6 - 13, 26, 4, 25; Plate 7 - 15, 5, 21, 1; and Plate 8 - 7, 11). Details regarding source of the 
serum samples is described in section 2.3. Table 3.1 contains information of the samples used for 
biomarker discovery. For categorical and numerical variables related to patient information, P 
values were calculated using Fisher's exact test and Kruskal-Wallis test respectively. Table 3.2 
summarizes clinical characteristics of the patient cohort for biomarker discovery. 
Table 3.1. Details of samples used for biomarker discovery. 
Sample 
number 
Mass 
spec run 
round 
GlycoSelector 
sample ID 
GlycoSelector 
run ID 
Study 
ID 
Patient 
phenotype 
Gender 
Ref 
age 
Protein 
(mg/mL) 
2 1 31 35 47024 SDH control M 43.02 80.63 
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Sample 
number 
Mass 
spec run 
round 
GlycoSelector 
sample ID 
GlycoSelector 
run ID 
Study 
ID 
Patient 
phenotype 
Gender 
Ref 
age 
Protein 
(mg/mL) 
3 1 32 36 45180 SDH control M 68.23 107.58 
4 3 52 56 43187 SDH control M 56.76 133.68 
5 2 45 49 92365 Population control M 76.46 67.92 
6 3 53 67 96191 Population control M 71.42 106.31 
7 3 54 58 94429 Population control M 56.72 94.80 
8 2 46 50 93411 Population control M 62.07 79.90 
9 1 33 37 95091 Population control M 66.35 88.01 
10 1 34 38 96190 Population control M 70.93 97.02 
1 2 44 48 43084 
SDH control (later 
on developed BE 
so classified as 
BE) 
M 67.81 65.57 
11 3 55 59 45004 BE no dysplasia M 76.07 87.17 
12 1 35 39 43026 BE no dysplasia M 72.19 99.81 
13 3 56 60 43004 BE no dysplasia M 72.81 106.76 
14 2 47 51 45052 BE no dysplasia M 78.07 83.86 
15 2 48 52 45050 BE no dysplasia M 33.91 86.92 
16 1 36 40 43113 BE no dysplasia M 55.95 107.58 
17 1 37 41 45137 BE no dysplasia M 39.07 82.68 
18 1 38 42 47007 BE no dysplasia M 55.10 83.46 
19 3 57 61 43115 BE no dysplasia M 56.64 77.16 
21 2 49 53 33100 EAC patient M 55.86 73.42 
22 2 50 54 33072 EAC patient M 56.53 106.63 
23 1 39 43 25017 EAC patient M 78.97 84.98 
24 1 40 44 61043 EAC patient M 65.25 81.84 
25 3 59 63, 68 25011 EAC patient M 65.97 67.40 
26 3 60 64 61040 EAC patient M 75.77 95.19 
27 2 51 55 21139 EAC patient M 69.74 97.71 
28 1 41 45 21113 EAC patient M 60.35 78.35 
29 3 61 65 40259 EAC patient M 66.78 70.72 
30 1 42 46 21233 EAC patient M 54.58 82.24 
Table 3.2. Clinical characteristics of the patient cohort for biomarker discovery.  
Variables Healthy BE EAC P value (Healthy vs 
BE vs EAC) 
Sample size 9 10 10  
Age (Median ± SD) 66 ± 10 62 ± 15 66 ± 8 0.9311 
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Variables Healthy BE EAC P value (Healthy vs 
BE vs EAC) 
Gender All male All male All male  
Protein concentration (μg/μL) 95 ± 19 85 ± 13 82 ± 13 0.3641 
Gastritis* 1 (11.1%) 1 (11.1%) 1 (10.0%) 1.0000 
Peptic ulcer 3 (33.3%) 2 (20.0%) 3 (30.0%) 0.8792 
Hiatus hernia 0 (0.0%) 4 (40.0%) 6 (60.0%) 0.0217 
Other malignancy 1 (11.1%)  2 (20.0%) 2 (20.0%) 1.0000 
*All the analyses were performed based on available patient information. Gastritis status for one BE patient was 
missing. 
3.2.2 LeMBA 
 LeMBA was performed as described in section 2.5. Figure 3.1 below display typical layout 
of a plate for LeMBA pull-down and mass spectrometry runs. The samples were run in following 
order on mass spectrometer: A1 to G1, A2 to G2, ....., and A12 to G12. 
 
1 2 3 4 5 6 7 8 9 10 11 12 
 
Sample 1 Sample 2 Sample 3 Sample 4 
A Ctrl WFA PSA Ctrl WFA PSA Ctrl WFA PSA Ctrl WFA PSA 
B NPL MAA SNA NPL MAA SNA NPL MAA SNA NPL MAA SNA 
C STL DSA LPHA STL DSA LPHA STL DSA LPHA STL DSA LPHA 
D UEA WGA JAC UEA WGA JAC UEA WGA JAC UEA WGA JAC 
E HAA SBA AAL HAA SBA AAL HAA SBA AAL HAA SBA AAL 
F HPA ECA EPHA HPA ECA EPHA HPA ECA EPHA HPA ECA EPHA 
G GNL BPL ConA GNL BPL ConA GNL BPL ConA GNL BPL ConA 
H Empty row 
Figure 3.1. Typical plate layout for LeMBA pull-down and mass spectrometric run for 
biomarker discovery. 
3.2.3 Nano-HPLC-MS/MS for biomarker discovery 
 After LeMBA pull-down and on-bead trypsin digestion, the peptide samples were 
resuspended in 20 µl of 0.1% v/v formic acid for HPLC-MS/MS (Agilent 6520 quadrupole time of 
flight [QTOF] coupled with a Chip Cube and 1200 HPLC). Optimal volume of sample injection for 
HPLC-MS/MS analysis was previously optimized: 9 μL were loaded for HAA, HPA and UEA, 6 
μL for NPL, STL, GNL, 5 μL for BPL, DSA, ECA, MAA, SBA, WFA, and WGA, 4 μL for AAL, 
SNA, LPHA, PSA and JAC, 1 μL for EPHA and ConA. The nano pump was set at 0.3 µL/min and 
the capillary pump at 4 µL/min. The HPLC-chip used contains 160 nl C1  trapping column, and 75 
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μm  150 mm 300 Å C18 analytical column (G4240-62010 Agilent Technologies). Buffer A was 
0.1% v/v formic acid and Buffer B was 90% v/v acetonitrile containing 0.1% v/v formic acid. 
Peptides were eluted from the column using a gradient from 6% B to 46% B at 45 min. Nano pump 
%B was increased to 95 %B at 45.5 min and plateaued till 55.5 min, then decreased to 6% B at 58.5 
min. The mass spectrometer was operated in 2 GHz extended dynamic range and programmed to 
acquire 8 precursor MS1 spectra per second and 4 MS/MS spectra for each MS1 spectra. Dynamic 
exclusion was applied after 2 MS/MS within 0.25 min. Exclusion for lectin peptides was applied as 
reported previously (317). The QTOF was tuned and calibrated prior to analysis. One hundred 
femtomole/μL of pre-digested bovine serum albumin peptides were used as quality control, before 
and after each plate. Levels of reference ions 299.2945 and 1221.9906 were maintained at minimum 
5000 and 1000 counts respectively. Blank injection was run after each sample injection to minimize 
sample carry over. After running each patient sample on mass spectrometer, long column clean-up 
was performed. The samples were run on mass spectrometer at three different time points. At each 
time point, similar number of patients from 3 patient groups were run to avoid possible bias arising 
from mass spectrometry analysis.  
3.2.4 Database search 
 The raw data was extracted and searched using Spectrum Mill MS proteomics workbench 
(Agilent Technologies, Rev.B.04.00.127) against Swissprot human database containing total 20,242 
entries (release 3
rd
 Jan 2012). Similar MS/MS spectra acquired on the precursor m/z within ± 1.4 
m/z and within ± 15 sec were merged. The following parameters were used for the search: 2 
maximum missed cleavages, minimum matched peak intensity of 50%, precursor mass tolerance of 
± 20 ppm, product mass tolerance of ± 50 ppm, calculate reversed database scores enabled and 
dynamic peak thresholding enabled. Carbamidomethylation was selected as fixed modification and 
oxidized methionine was selected as a variable modification. Precursor mass shift range from -17.0 
Da to 177.0 Da was allowed for variable modification. Results were filtered by protein score > 15, 
peptide score > 6, and % scored peak intensity (% SPI) > 60. Automatic validation was used to 
validate proteins and peptides with default settings and false discovery rates (FDRs) were calculated 
using reversed hits. The same data was searched once again against chicken ovalbumin sequence. 
3.2.5 Data normalization using internal standard chicken ovalbumin 
 To account for experimental variations between pull-downs and during the mass 
spectrometric analysis, 10 pmol ovalbumin per lectin pull-down was spiked in as an internal 
standard in the first step at the stage of sample denaturation. The intensities of at least three out of 
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seven ovalbumin peptides listed in Table 3.3 were used for normalization. Peptides were selected 
based on their ability to meet the following criteria: (i) peptide sequence should be unique to 
chicken ovalbumin, (ii) peptides being compared across samples should have the same charge, (iii) 
peptides being compared should have scores higher than 10 based on Spectrum Mill, and (iv) 
PrecursorAveragineChiSquared should be higher than 0.85 as suggested by Spectrum Mill. The 
intensities of ovalbumin peptides were extracted from Spectrum Mill. Lectins for which Spectrum 
Mill failed to identify at least 3 consistent peptides across all samples, ovalbumin peptides (mass 
over charge m/z) were extracted at MS1 level from the raw data acquisition files using Mass Hunter 
Qualitative Analysis B.05.00 and manually integrated to obtain abundance values. As intensities 
given from Spectrum Mill and the Qualitative software varied, only one out of two methods was 
chosen for each peptide. For each sample, all ovalbumin peptide intensities for all lectins were 
compiled into a single comma-separated value (.csv) file and uploaded to GlycoSelector. 
Normalization for each peptide was performed within GlycoSelector. Since each lectin binds to 
ovalbumin with different affinity, normalization was performed for each lectin separately across all 
samples. Two different normalization approaches were examined; (i) based upon total protein 
intensity whereby individual ovalbumin peptide intensity was summed to get the total protein 
intensity. This total protein intensity was then utilized to calculate the normalization factor or (ii) 
using individual ovalbumin peptide intensity whereby a normalization factor is calculated 
individually based on each peptide and averaged to derive the final normalization factor. Both 
methods gave comparable results, the second approach based on individual peptide intensity was 
considered for further analysis. 
Table 3.3. List of ovalbumin peptides selected for data normalization. 
Peptide sequence Charge m/z 
Delta 
m/z 
Lectin Name 
(K)ISQAVHAAHAEINEAGR(E) 3 591.9737 0.007 All lectins 
(K)AFKDEDTQAMPFR(V) 2 778.3669 0.008 
DSA, GNL, HAA, JAC, MAA, 
NPL, PSA, SNA, STL, WFA, 
WGA 
(K)LTEWTSSNVMEER(K) 2 791.3667 0.011 
AAL, BPL, ConA, ECA, 
EPHA, GNL, HPA, JAC, 
MAA, NPL, PSA, SBA, SNA, 
UEA, WFA, WGA 
(R)GGLEPINFQTAADQAR(E) 2 844.4261 0.019 
AAL, BPL, ConA, DSA, ECA, 
EPHA, GNL, HPA, JAC, 
LPHA, MAA, NPL, PSA, 
SBA, SNA, STL, WFA, WGA 
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Peptide sequence Charge m/z 
Delta 
m/z 
Lectin Name 
(R)NVLQPSSVDSQTAMVLVNAIVFK(G) 3 820.782 0.01 SBA, STL, WGA 
(R)VTEQESKPVQMMYQIGLFR(V) 3 762.0587 0.011 
EPHA, LPHA, MAA, NPL, 
PSA, STL, WFA, WGA 
(K)ISQAVHAAHAEINEAGR(E) 4 444.2327 0.004 All lectins 
3.2.6 GlycoSelector analysis 
 GlycoSelector (http://glycoselector.di.uq.edu.au), a customized web-based portal to store 
and analyze multidimensional LeMBA-MS/MS discovery data was developed to select a list of 
biomarkers for verification phase. The workflow of using GlycoSelector for data analysis is 
presented in Figure 3.2. GlycoSelector stores patient information including age, gender, unique 
hospital reference number and categorizes each patient according to their phenotype. For each 
patient, multiple sample runs could be stored. Each run is given a unique run ID and stored with 
informative details such as patient phenotype (normal/esophageal etc.), source of sample 
(tissue/serum/urine), and diagnosis (normal/benign/malignant etc.). This information is used to 
define patient groups for the downstream comparison/statistical analyses. As an input data file, 
GlycoSelector stores protein list file obtained through a Spectrum Mill search. This file contains the 
lectin name, list of proteins identified, along with the total intensity for each protein identified for 
every individual patient sample. An internal standard file is stored together with protein list file for 
each sample run. It contains abundance values for individual ovalbumin peptide to be used for data 
normalization. 
Figure 3.2. Steps followed for 
data analysis using 
GlycoSelector 
(http://glycoselector.di.uq.edu.a
u) platform for biomarker 
discovery. 
  
 
 
3.2.6.1 Group binding difference analysis  
 GlycoSelector was programmed with a feature called "group binding difference" to compare 
proteins identified in one group of patient samples and absent in another group for each lectin pull-
down. As the main purpose of the biomarker discovery phase is to identify candidate biomarkers for 
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future verification, the criteria chosen for group comparisons were not very stringent. Lectin-protein 
combinations that were present in 60% of one patient group and absent in 40% of another group 
were selected. A comparison was made between healthy vs BE, BE vs EAC and healthy vs EAC 
patient cohorts.    
 An exclusion list of proteins was applied before group binding difference and statistical 
analysis in GlycoSelector. The exclusion list included common contaminant proteins like keratin, 
proteins like immunoglobulin and serum albumin which cannot be considered as biomarkers for 
clinical use hence eliminated from the analysis. 
3.2.6.2 Workflow for statistical analysis 
 The statistical tools for discovery and verification, namely GlycoSelector and Shiny 
mixOmics follow the same workflow. The first step is outlier detection, which aims to identify and 
therefore remove samples showing abnormally high or low protein intensities across many lectin 
pull-downs, thereby preventing any detrimental effect on downstream statistical analysis. Outliers 
may be due to improper sample handling, technical difficulties during mass spectrometric analysis, 
or due to batch/plate effect. Graphical outputs using unsupervised approaches, which do not take 
into account the patient phenotypes, were generated using lectin-protein intensities to visualize any 
potential outliers. Principal component analysis (PCA) (381) is a multivariate approach which 
highlights samples contributing to a large variance. Hierarchical clustering (using Euclidian 
distance and Ward agglomeration method) produces clusters amongst variables and samples that 
can be visually represented through a dendrogram on the left hand side (lectin-protein intensities) 
and the top (samples) of the heatmap, with red (green) color indicating low (high) intensities of the 
lectin-proteins. Boxplots of the scaled data enable to visualize the variability on each sample, and 
coefficient of variation for each sample across all lectin-proteins were calculated and represented in 
the form of barplots.   
 A supervised multivariate approach sparse partial least squares-discriminant analysis (sPLS-
DA) (382) was applied to select discriminative lectin-protein candidates able to classify patients 
into two different phenotypes. The approach outputs a selected ranked list of candidates per 
component along with sample representation to visualize the patient phenotypes. The method seeks 
for the best linear combination of lectin-proteins that can classify the sample into their respective 
groups. The model parameters (number of components in the model and number of variables to 
select on each component) are tuned using leave-one-out cross-validation (GlycoSelector) or 5-fold 
cross-validation repeated 1000 times (Shiny mixOmics). A stability measure that records the 
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frequency of each feature being selected across several data sets generated during the cross-
validation procedure. Candidates with high stability value (close to 100%) are robust biomarkers, as 
they are repeatedly selected across slight perturbations of the original data set. Only the robust 
lectin-protein candidates which passed an arbitrary cut-off of 70% were reported. Lectin-protein 
candidates that were not identified in more than 2/3
rd
 of the patient samples in at least one of the 
two groups being compared using sPLS-DA feature in GlycoSelector were eliminated from the 
analysis.  
3.3 Results  
3.3.1 LeMBA-GlycoSelector biomarker discovery pipeline 
 Prior to this study, Dr. Eunju Choi optimized LeMBA-nano-HPLC-MS/MS incorporating 
internal standard chicken ovalbumin at the very first step of sample preparation. As illustrated in the 
LeMBA workflow (Figure 1.6), serum samples were spiked with 10 picomole ovalbumin per lectin 
pull-down during sample denaturation. Internal standard chicken ovalbumin experimentally showed 
binding with all 20 lectins used in LeMBA. It was envisaged that total chicken ovalbumin intensity 
(sum of measured peptide intensity) can be used for normalization. Out of total 7 ovalbumin 
peptides listed in Table 3.3, anywhere between 3 and 7 peptides per lectin were selected for 
normalization e.g. 3 peptides for HAA while all 7 peptides for WGA. It was observed that amongst 
ovalbumin peptides qualified for using as an internal standard, raw peptide intensity varied in the 
magnitude up to 10 folds. This means that if total chicken ovalbumin intensity (sum of measured 
peptide intensity) is used for normalization then not all the peptides are given equal importance. In 
order to give equal weight to all the qualifying chicken ovalbumin peptide for purpose of internal 
standard normalization, second approach based on calculation of normalization factor using 
individual peptide was tried. As illustrated in Figure 3.3, normalization factor calculated by both 
approaches (i) based on total ovalbumin intensity and (ii) based on individual ovalbumin peptide 
intensity showed high correlation. The second approach based on individual peptide intensity was 
considered for further analysis as it gave equal weigh to individual peptides.  
Figure 3.3. Comparison of two normalization 
methods for biomarker discovery screen data. 
Normalization method 1 (Norm1) used the total 
protein intensity of ovalbumin protein (sum of 
minimum 3 individual peptide intensity) divided by 
the average total ovalbumin protein intensity of all 
samples for a particular lectin as normalization 
factor. Normalization method 2 (Norm 2) divided 
each ovalbumin peptide intensity with the average 
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peptide intensity across all samples for each lectin and has taken the average of at least 3 such 
normalization factors calculated for different ovalbumin peptides to determine final normalization 
factor. 
 To facilitate data analysis and biomarker candidate selection using LeMBA-MS/MS data, 
GlycoSelector database incorporating statistical analysis pipeline was developed. Prior to this 
thesis, Dr. Kim-Anh Lê Cao and Dr. David Chen with inputs from Dr. Eunju Choi created 
GlycoSelector which incorporated features like uploading raw LeMBA-MS/MS data including 
patient information, data normalization, outlier detection, group binding difference analysis and 
sPLS-DA. It was realized that along with multivariate feature selection using sPLS-DA, internal 
validation is required. So after several discussions with Dr. Lê Cao, leave-one-out cross-validation 
was incorporated into the statistical analysis pipeline and new GlycoSelector version was released. 
The leave-one-out cross-validation is repeated 1000 times by perturbation of original data set by 
leaving one sample out each time. The frequency of same feature selection across validation process 
is reported as a stability proportion where 100% (or stability value of 1) indicates selection of 
biomarker candidates all the time during cross-validation. Arbitrary cut-off of 70% was selected for 
the data analysis i.e. lectin-protein candidates showing stability proportion of more than 70% were 
selected for verification. On contrary to older version which used total ovalbumin intensity for data 
normalization, new GlycoSelector version uses normalization approach based on individual 
ovalbumin peptide intensity. Figure 3.2 illustrates steps followed to select lectin-protein biomarker 
candidates using GlycoSelector analysis.  
3.3.2 BE/EAC biomarker discovery 
 After inclusion of new features into GlycoSelector, serum samples from 29 patient samples 
were screened using LeMBA-GlycoSelector pipeline. Clinical characteristics of the patient cohort 
for biomarker discovery are described in Table 3.2. All samples were age matched and collected 
from male patients. BE and EAC patient groups had significantly higher proportion of patients with 
hiatus hernia compared to the healthy group, as has previously been reported (383), suggesting 
hiatus hernia to be a risk factor for BE/EAC. A total of 195 unique proteins were identified from the 
LeMBA-MS/MS screen. The glycoproteins bound several lectins suggesting heterogeneity and 
multiplicity of glycosylation. On average, 40 proteins per lectin pull-down were identified. Total 
number of proteins identified per lectin pull-down varied reflecting specificity of lectin-glycan 
interactions. HAA showed least binding (average number of proteins identified = 12) as compared 
to WGA which bound to maximum number of proteins (average number of proteins identified = 
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59). There was no difference between total number of proteins identified between healthy, BE and 
EAC patient groups (Figure 3.4). 
3.3.3 Glycoselector analysis 
 The results of main three steps followed using GlycoSelector data analysis platform are 
mentioned below.  
3.3.3.1 Outlier detection 
 The first step in GlycoSelector analysis is outlier detection using four different graphical 
visualization tools namely PCA, boxplots, hierarchical clustering, and barplots for coefficient of 
variation. Outlier may be due to improper sample collection and handling, differential sample 
preparation and LeMBA pull-down, technical difficulties during mass spectrometric analysis, or 
due to batch/plate effect. The main purpose of this analysis is to identify potentially an outlier 
sample run and to prevent its detrimental consequences on final statistical analysis.  
 When the outlier detection analysis was performed on biomarker discovery data set, sample 
run ID 63 was considered to be an outlier due to consistent anomalous results in all 4 graphical 
outputs (Figure 3.5A to 3.5D). This result was coincided with lower than cut-off scores and 
coverage for bovine serum albumin pre-digested quality control (QC) sample ran on mass 
spectrometer after the sample was run. The mass spectrometer was re-calibrated resulting into 
scores and coverage for QC above the threshold. The sample was analyzed again (run ID 68), 
resulting in no outliers being identified (Figure 3.5E to 3.5H). 
3.3.3.2 Group binding difference 
 A group binding difference feature identifies lectin-protein candidates present in one patient 
group and absent in the other. This feature was particularly useful for mass spectrometry data with 
many zeroes which either indicate a true absence of a protein in a sample, or the concentration was 
below the detection limit of the mass spectrometer. Lectin-protein candidates present in more than 
60% of one sample group but less than 40% of the other group and vice versa were identified. The 
analyses were performed comparing healthy vs BE, BE vs EAC and healthy vs EAC patient groups. 
The reason for choosing non-stringent cut-off for group binding difference analysis was to select as 
many candidates as possible for verification stage. Table 3.4 contains the list of biomarker 
candidates identified using group binding difference analysis. Total 37 unique lectin protein 
candidates were identified by this analysis. Except HAA, all 19 lectins appeared in the list and 
showed differential binding with one or more of 26 unique protein candidates. 
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Figure 3.4. Total number of proteins identified per individual lectin pull-down for each 
patient group for biomarker discovery screen. There was no statistical difference between the 
number of proteins identified between different phenotypes. The bar graph represents average 
(±SD) of total number of proteins identified for a particular lectin pull-down across patient samples. 
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Figure 3.5. Outlier detection feature of GlycoSelector allows the visualization of experimental 
errors using four different statistical tools. (A and E) Principal component analysis, (B and F) 
hierarchical clustering, (C and G) boxplots and (D and H) barplots representing the coefficient of 
variation. Unique numbers on the graph indicate the individual sample run identifier. Run number 
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63 (red arrow) in panel A to D was flagged as an outlier based on the visualization tools. The 
sample was re-analyzed on the mass spectrometer and outlier detection was performed again (panel 
E to H). 
Table 3.4. List of lectin-protein candidates identified using group binding difference analysis. 
The proteins are denoted using Uniprot accession numbers.  
Healthy vs BE BE vs EAC Healthy vs EAC 
AAL_P10909 AAL_P06396 GNL_P10643 AAL_P06396 EPHA_P02748 
AAL_P02747 AAL_O75636 HPA_P01042 JAC_P06396 GNL_P02746 
LPHA_P02774 GNL_P06396 LPHA_P01031 LPHA_P05090 HPA_P01042 
STL_P08519 JAC_P06396 LPHA_P02748 LPHA_P02774 HPA_P00450 
STL_O75636 JAC_P00748 SNA_P02748 PSA_P06396 HPA_P00747 
STL_P02765 LPHA_P05090 STL_P08519 STL_P06396 HPA_P00751 
AAL_O75636 PSA_P06396   STL_O75636 LPHA_P01031 
BPL_P0C0L5 SNA_P08697   UEA_P19823 LPHA_P02748 
EPHA_P02748 STL_P06396   WGA_P02746 MAA_P02748 
HPA_P00751 AAL_P02747   BPL_P0C0L5 NPL_P01008 
JAC_P00748 AAL_P10909   ConA_P02760 SNA_P02748 
NPL_P01008 ConA_P02760   DSA_P02748 WFA_P05546 
SBA_P04003 ECA_P00450   DSA_P04217   
SNA_P02743 GNL_P02746   ECA_P00450   
3.3.3.3 Statistical analysis 
 sPLS-DA combined with stability analysis based on leave-one-out validation was employed 
for multivariate feature selection. The methodology is unable to handle the dataset including many 
zero values. Hence lectin-protein candidates that were not identified in more than 2/3
rd
 of the patient 
samples in at least one of the two groups being compared were eliminated from sPLS-DA statistical 
analysis as they were already taken into consideration for group binding difference analysis. sPLS-
DA combined with stability analysis was performed to identify candidates that differentiate BE 
from healthy, EAC from BE and EAC from healthy phenotype. As illustrated in the sPLS-DA 
sample representation in Figure 3.6, top 100 lectin-protein candidates in the model, showed distinct 
clusters of samples according to their phenotype. To select the most consistent candidates across 
patients for taking to the second verification stage, stability analysis was employed, which utilizes a 
leave-one-out strategy to assess the robustness of each candidate biomarker. A relatively non-
stringent cut-off of 70% was chosen for this purpose. Out of the top 100 lectin-protein pairs, 57 
candidates passed the stability cut-off of 70% between healthy vs BE, 72 candidates passed for BE 
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vs EAC, and 76 candidates, passed for healthy vs EAC analysis (Figure 3.6). List of candidates 
identified using sPLS-DA along with stability values are presented in Table 3.5.  
 The summary of biomarker discovery screen results using GlycoSelector analysis is 
presented in Figure 3.7. Using sPLS-DA/stability analysis and group binding difference feature, the 
discovery screen identified 54 serum proteins with differential binding to one or more lectins 
between healthy, BE and EAC serum samples, resulting in a total of 183 unique lectin-protein 
combinations. Candidates identified using sPLS-DA and the group binding differences feature were 
complementary and showed no overlap between lectin-protein candidates, justifying the use of two 
different approaches for candidate selection. Each of the 20 lectins used in the biomarker discovery 
phase showed differential binding with at least one candidate protein glycoform, endorsing the use 
of multiple lectins for biomarker discovery (Figure 3.7A). There was considerable overlap between 
lectin protein candidates identified between healthy vs BE, BE vs EAC and healthy vs EAC patient 
groups (Figure 3.7B). 
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Figure 3.6. Results for sPLS-DA combined with stability analysis. (A), (C) and (E) Represent 
sPLS-DA plot for top 100 lectin-protein candidates. sPLS-DA differentiated (A) BE from healthy, 
(C) EAC from BE and (E) EAC from healthy phenotypes. Amongst these top 100 ranked lectin-
protein combinations identified using sPLS-DA, (B) 57 candidates for healthy vs BE, (D) 72 
candidates for BE vs EAC and (F) 76 candidates for healthy vs EAC passed the stability cut-off of 
70% based on leave-one-out cross-validation. 
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Table 3.5. Ranked list of lectin-protein candidates identified using sPLS-DA along with 
stability values. Proteins are represented using Uniprot accession numbers. 
Healthy vs BE BE vs EAC Healthy vs EAC 
sPLS-DA 
rank 
Candidate 
name 
Stability 
sPLS-
DA rank 
Candidate 
name 
Stability 
sPLS-
DA rank 
Candidate 
name 
Stability 
1 BPL_P01024 100.0% 1 STL_P02748 100.0% 1 EPHA_Q14624 100.0% 
2 NPL_P05155 100.0% 2 JAC_P00450 100.0% 2 MAA_Q14624 100.0% 
3 NPL_P19827 100.0% 3 PSA_Q14624 100.0% 3 EPHA_P00738 100.0% 
4 STL_P00450 100.0% 4 EPHA_Q14624 100.0% 4 JAC_P01031 100.0% 
5 EPHA_P01009 100.0% 5 WGA_P02765 100.0% 5 AAL_Q14624 100.0% 
6 STL_P04196 100.0% 6 AAL_Q14624 100.0% 6 WGA_P02765 100.0% 
7 JAC_P04004 100.0% 7 EPHA_P00738 100.0% 7 STL_P01031 100.0% 
8 PSA_P51884 100.0% 8 STL_P06681 100.0% 8 AAL_P02748 100.0% 
9 NPL_P01024 100.0% 9 HPA_P00747 100.0% 9 LPHA_P02765 100.0% 
10 NPL_P02774 100.0% 10 SNA_P02765 100.0% 10 SBA_P00738 100.0% 
11 ConA_P04114 100.0% 12 JAC_P00738 100.0% 11 STL_Q14624 100.0% 
12 NPL_P04217 100.0% 13 NPL_P02774 100.0% 12 STL_P08519 100.0% 
13 MAA_P01042 100.0% 14 NPL_P01031 100.0% 13 HPA_P08519 100.0% 
14 LPHA_P01009 100.0% 15 MAA_P00738 100.0% 14 HPA_P00734 100.0% 
15 STL_P10643 100.0% 16 SNA_P27169 100.0% 15 AAL_P01031 100.0% 
16 SNA_P04004 100.0% 17 BPL_P00738 100.0% 16 WGA_P03952 100.0% 
17 EPHA_P02760 100.0% 18 STL_P01031 100.0% 17 BPL_P00738 100.0% 
18 PSA_P0C0L5 100.0% 19 LPHA_P02749 100.0% 18 UEA_P01023 100.0% 
19 HPA_P08519 100.0% 20 AAL_P02748 100.0% 19 PSA_Q14624 100.0% 
20 NPL_P08603 100.0% 21 WGA_P02747 100.0% 20 NPL_P01031 100.0% 
21 EPHA_P02763 100.0% 22 WFA_P19823 100.0% 21 JAC_P00738 100.0% 
22 NPL_P02743 100.0% 23 LPHA_P00738 100.0% 22 PSA_P01031 100.0% 
23 LPHA_P04003 100.0% 24 JAC_P04003 100.0% 23 HAA_P01024 100.0% 
24 ConA_P0C0L5 100.0% 25 NPL_P19827 100.0% 25 SNA_P43652 100.0% 
25 WFA_Q5VTE0 94.7% 26 UEA_P01023 100.0% 26 LPHA_P01011 100.0% 
26 NPL_P02749 100.0% 27 NPL_P10643 100.0% 27 WGA_P02748 100.0% 
27 PSA_P02749 100.0% 28 UEA_P04196 100.0% 28 JAC_P00450 100.0% 
28 UEA_P62269 94.7% 29 JAC_P04004 100.0% 29 AAL_P02763 100.0% 
29 SNA_P08697 89.5% 30 JAC_P02765 100.0% 30 NPL_P02743 100.0% 
30 UEA_P04196 94.7% 31 LPHA_P01011 100.0% 31 AAL_P00738 100.0% 
31 NPL_P04196 100.0% 32 MAA_Q14624 100.0% 32 ECA_P00738 100.0% 
32 EPHA_Q14624 94.7% 33 NPL_P03952 100.0% 33 BPL_P01024 100.0% 
33 NPL_P02751 94.7% 34 WGA_P02748 100.0% 34 NPL_P02748 100.0% 
34 GNL_P03952 89.5% 35 SNA_P02743 100.0% 35 WGA_P06396 100.0% 
35 GNL_P02747 94.7% 36 SNA_P00738 100.0% 36 JAC_P02765 100.0% 
36 HPA_P04217 94.7% 37 NPL_P02765 100.0% 37 MAA_P10909 100.0% 
37 SBA_P01024 100.0% 38 JAC_Q14624 100.0% 38 MAA_P00738 100.0% 
38 NPL_P02787 94.7% 39 STL_Q14624 100.0% 39 ConA_P01008 100.0% 
40 NPL_P02790 89.5% 40 GNL_P02774 100.0% 40 SNA_P04004 100.0% 
41 NPL_P01011 94.7% 41 JAC_P01031 100.0% 41 NPL_P00450 100.0% 
42 STL_P06681 94.7% 42 JAC_Q7Z7A1 100.0% 42 NPL_Q14624 100.0% 
43 AAL_P04196 89.5% 43 STL_P10643 100.0% 43 DSA_P01031 100.0% 
44 HPA_P01009 84.2% 44 STL_P00738 100.0% 44 AAL_P0C0L5 100.0% 
45 DSA_P05546 89.5% 45 DSA_P00738 100.0% 45 GNL_P01031 100.0% 
46 ConA_P04004 89.5% 46 ConA_P02765 100.0% 46 LPHA_Q14624 100.0% 
47 STL_P02748 84.2% 47 UEA_P04275 100.0% 47 STL_P02748 94.7% 
49 PSA_P04217 79.0% 48 NPL_P02787 100.0% 48 ConA_P01011 100.0% 
86 
 
Healthy vs BE BE vs EAC Healthy vs EAC 
sPLS-DA 
rank 
Candidate 
name 
Stability 
sPLS-
DA rank 
Candidate 
name 
Stability 
sPLS-
DA rank 
Candidate 
name 
Stability 
50 ConA_P01023 73.7% 49 AAL_P01011 100.0% 49 UEA_Q969X6 89.5% 
51 AAL_P02751 79.0% 50 AAL_P00738 100.0% 50 AAL_P01011 100.0% 
52 AAL_P0C0L5 73.7% 51 AAL_P04196 100.0% 51 EPHA_P01011 100.0% 
53 ConA_P04003 73.7% 52 SNA_P10909 100.0% 52 WGA_P19823 89.5% 
54 ConA_P01011 89.5% 53 DSA_Q14624 100.0% 53 SNA_P02765 94.7% 
55 SBA_P01023 84.2% 54 MAA_P02790 100.0% 54 ConA_P02765 94.7% 
60 NPL_P01023 79.0% 55 STL_P00450 90.0% 55 PSA_P00738 100.0% 
61 GNL_P00751 73.7% 56 WFA_P02765 100.0% 56 PSA_P02765 100.0% 
65 ConA_P02749 84.2% 57 SNA_P43652 100.0% 57 EPHA_P02763 100.0% 
66 NPL_P06396 73.7% 60 JAC_P02748 90.0% 58 WGA_P00738 100.0% 
   
61 AAL_P02763 85.0% 59 WGA_P01009 100.0% 
   
62 DSA_P01023 85.0% 60 EPHA_P01031 100.0% 
   
63 ECA_P04004 85.0% 61 ConA_P00747 100.0% 
   
64 NPL_P01008 75.0% 62 AAL_P04217 100.0% 
   
65 DSA_P02760 80.0% 63 WFA_P01023 84.2% 
   
66 NPL_P19823 80.0% 64 UEA_P04196 84.2% 
   
67 WGA_P05090 80.0% 65 UEA_Q5VTE0 89.5% 
   
69 EPHA_P01023 70.0% 66 NPL_P00738 100.0% 
   
70 PSA_P02765 70.0% 67 EPHA_P01009 84.2% 
   
73 MAA_P05546 70.0% 69 PSA_P0C0L5 73.7% 
   
74 STL_P0C0L5 80.0% 70 BPL_P19823 79.0% 
   
76 MAA_P10909 75.0% 71 ConA_P00738 84.2% 
   
77 NPL_P06396 70.0% 72 GNL_P02748 89.5% 
   
79 JAC_P01011 80.0% 73 SNA_P00738 84.2% 
   
81 HPA_P00738 70.0% 75 LPHA_P00738 73.7% 
      
76 ConA_P05546 79.0% 
      
79 JAC_Q14624 73.7% 
      
84 JAC_P01011 89.5% 
      
86 HPA_P01011 79.0% 
Figure 3.7. 
Summary of 
biomarker 
discovery 
results. (A) 
Number of 
unique candidate 
proteins 
identified for 
each lectin in 
LeMBA-
GlycoSelector 
analysis. All 20 
lectins used for 
screening 
identified at least 
one protein candidate. (B) Overlap between lectin-protein candidates that differentiate BE from 
healthy, EAC from BE, and EAC from healthy phenotype.   
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3.3.4 LeMBA-western immunoblotting validation for top two candidates  
 Immunoblotting was used for orthogonal protein level confirmation of the LeMBA-MS/MS 
screen. Two protein candidates which showed altered binding to Aleuria aurantia lectin (AAL) and 
had antibodies available were chosen for protein level validation. AAL-haptoglobin (HP; Uniprot 
entry: P00738) was one of the top ranked candidates in sPLS-DA analysis for healthy vs EAC and 
BE vs EAC, while AAL-gelsolin (GSN; Uniprot entry: P06396) was identified using the group 
binding difference feature of GlycoSelector as on-off change between BE vs EAC and healthy vs 
EAC. Using the same set of discovery serum samples, LeMBA pull-down using AAL was 
performed. Haptoglobin and gelsolin binding was measured by immunoblotting in AAL pull-down. 
A control serum sample was loaded on every blot as a normalizer between membranes. LeMBA-
immunoblotting confirmed the MS/MS results (Figure 3.8), and showed higher sensitivity as it 
detected low levels of gelsolin in all patient samples, when some were undetectable by MS/MS 
[AAL-HP: label-free proteomics P value = 0.0868, western immunoblotting P value = 0.0267; 
AAL-GSN: label-free proteomics P value = 0.0254, western immunoblotting P value = 0.0019].   
Figure 3.8. Protein level 
validation for top two 
candidates using LeMBA-
western immunoblotting. 
(A) AAL-HP and (B) AAL-
GSN were the top two 
candidates identified using 
sPLS-DA and group binding 
difference tool, respectively. 
(A and B, top panel) 
Label-free proteomics 
relative quantitation results 
for AAL-HP and AAL-GSN 
respectively. (A and B, 
lower panel) Normalized 
intensity for AAL-HP and 
AAL-GSN using 
immunoblotting.   
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3.3.5 Lectin binding profile of candidates under different scenarios 
 Changes in the total glycoprotein candidate levels and/or a subtle change in the glycan 
structure may directly/indirectly induce a change in the binding pattern of lectins and create a lectin 
binding profile for each glycoprotein biomarker candidate. Figure 3.9 illustrates lectin binding 
profile of three such candidates namely haptoglobin (Figure 3.9A), gelsolin (Figure 3.9B) and α-2-
macroglobulin (A2M; Uniprot entry: P01023) (Figure 3.9C). For simplicity, only 8 out of total 20 
lectins are mentioned in the Figure 3.9. Haptoglobin was identified by sPLS-DA combined with 
stability analysis and showed differential binding with multiple lectins for BE vs EAC (EPHA, 
JAC, MAA, BPL, LPHA, SNA, STL, DSA, AAL, and HPA) and healthy vs EAC (EPHA, SBA, 
BPL, JAC, AAL, ECA, MAA, PSA, WGA, NPL, ConA, SNA, and LPHA) comparisons (Figure 
3.9A). For all the lectin pull-downs, as compared to healthy and BE patient groups, EAC samples 
showed higher levels of haptoglobin. This may be due to changes in the total protein levels of 
haptoglobin. Gelsolin was identified using the group binding difference analysis. It showed 
differential lectin binding for BE vs EAC (AAL, GNL, JAC, PSA, and STL) and healthy vs EAC 
(AAL, JAC, PSA, and STL) analysis (Figure 3.9B). Unlike haptoglobin which showed increased 
lectin binding in EAC samples, gelsolin showed reduced binding. In fact, gelsolin was not identified 
during the mass spectrometric analysis specifically in EAC patient sample lectin pull-downs which 
suggest that gelsolin was either absent in the samples or more likely it was present just below the 
detection limit of the mass spectrometer. Like haptoglobin, α-2-macroglobulin was identified using 
sPLS-DA combined with stability analysis. It showed differential binding with multiple lectins for 
all three, healthy vs BE (ConA, SBA, and NPL), BE vs EAC (UEA, DSA, and EPHA) and healthy 
vs EAC (UEA and WFA) comparisons (Figure 3.9C). The lectins with which it showed differential 
binding are different between all three comparisons suggesting progressive changes in glycosylation 
from healthy-BE-EAC development. A2M showed no difference between healthy, BE and EAC 
patient groups for AAL, JAC, and MAA lectin pull-downs. DSA-A2M was statistically 
significantly different between BE and EAC patient groups while UEA-A2M was significantly 
different in EAC patients as compared to healthy and BE patients. For the remaining lectin pull-
downs using EPHA, NPL and WFA, A2M was different according to sPLS-DA analysis but could 
not achieve statistical significance. It is noteworthy that although UEA and AAL lectin bind to 
similar glycan structure i.e. fucose, only UEA showed statistically significant differential binding 
with A2M while AAL showed no difference suggesting differential specificity of the lectins from 
the similar class to recognize the glycan structures.  
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Figure 3.9. Lectin binding signature of putative glycoprotein biomarker candidates. Log 
transformed normalized total intensity from LeMBA-GlycoSelector biomarker discovery screen for 
three candidates (A) haptoglobin, (B) gelsolin, and (C) α-2-macroglobulin is plotted against 8 
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different lectin pull-downs for all 29 samples belong to healthy, BE and EAC patient groups (
#
P < 
0.05 for BE vs EAC comparison; 
$
P < 0.05 for healthy vs EAC comparison).  
 
 
  
91 
 
3.4 Discussion 
3.4.1 Overview 
 This chapter describes identification of serum glycoproteins that show differential binding 
with one or more lectins between healthy, BE and EAC patient groups. Serum samples from 
healthy, BE and EAC patient samples were processed using LeMBA-LC-MS/MS workflow. 
GlycoSelector was upgraded with new normalization method and statistical analysis pipeline was 
modified to include internal validation in the form of stability analysis. GlycoSelector analysis 
identified total 183 unique lectin-protein pairs as potential diagnostic biomarker candidates. Mass 
spectrometric quantitation at peptide level was validated for top two candidates at protein level 
using western-immunoblotting. 
3.4.2 LeMBA-GlycoSelector biomarker discovery pipeline 
 Label-free quantitation was chosen for quantifying LeMBA results (317). Out of two main 
label-free approaches, (i) protein-based methods rely upon spectral count and related indices, and 
(ii) peptide-based methods rely upon ion intensities and protein correlation profiling (384), the latter 
was chosen for LeMBA workflow (317). Protein-based quantitation approaches using spectral count 
can be universally applied for diverse proteomics data sets. The main limitation of this approach is 
its limited applicability to relatively quantify proteins with few numbers of spectra. This situation 
arises in following two scenarios. (i) Very low abundance proteins yield only a few spectra, and (ii) 
Low molecular weight proteins result in fewer tryptic peptides hence only a few spectra (384, 385). 
On the contrary, peptide-based methods such as total ion intensities can cover extended dynamic 
range of quantitation (385). Peptide-based methods use MS/MS spectra from the discovery 
proteomics experiments to assign/identify a peptide sequences. The height or volume of a peak for 
each peptide ion is calculated by extracting a given m/z from corresponding MS spectrums and used 
for quantitation (384). Using this peptide-based intensities, Spectrum Mill search engine calculates 
mean and total protein intensities for each protein species. Earlier work by Dr. Choi and Dr. Lê Cao 
concluded that total protein intensity offers better quantitation over mean protein intensity (Dr. 
Eunju Choi, PhD thesis). 
 GlycoSelector data analysis platform uses sPLS-DA for multivariate analysis and to rank 
lectin-protein biomarker candidates. sPLS-DA cannot perform at its best when there are lots of zero 
values (when missing values are considered to be 0) which is the case for LeMBA-LC-MS/MS data. 
So during sPLS-DA analysis, cut-off was set to remove variables with many zero values. The 
removed variables with many zero values were separately analyzed using group binding difference 
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feature. Biomarker exploratory studies such as the one described in the present chapter analyze 
large number of variables in limited number of patient samples (133, 356). Considering its design, 
biomarker discovery studies are prone to false discovery due to low sample size and large number 
of variables analyzed. To keep the false discovery rate to minimum and to find out stable variables, 
leave-one-out cross-validation (386) was employed during sPLS-DA. 
 The result described in this chapter demonstrates the successful application of LeMBA-
GlycoSelector pipeline to discover diagnostic biomarker candidates for BE/EAC. Firstly, the assay 
is robust with % CV for the internal standard ovalbumin peptides below or around 40% for all the 
lectin pull-downs. Similar levels of variations have been observed by Plavina and colleagues in the 
multi-lectin chromatography platform they developed for plasma protein biomarker discovery 
(387). Compared to other established assays, the variation for internal standard appears to be high 
mainly because mass spectrometry technique employed was semi-quantitative. Secondly, the assay 
was consistent and reproducible, as demonstrated by similar number of protein candidates identified 
for each lectin pull-down across different patient samples. Thirdly, the outlier detection analysis 
successfully identified the outlier present in the dataset due to technical problem during the mass 
spectrometric run. Collectively, these three steps/results ensure that data acquired is of good enough 
quality for subsequent statistical analysis.  
 The tools incorporated in the GlycoSelector aimed to identify as many candidates as 
possible hence the criteria chosen to select a list of biomarkers were lenient. Out of total 54 unique 
glycoprotein candidates, 3 were identified by group binding difference analysis only, 28 identified 
by sPLS-DA analysis only and 23 by both sPLS-DA and group binding difference analysis. The 
complementary results justify the use of two methods for biomarker identification. 
3.4.3 Lectin binding signature of biomarker candidate 
 The glycoprotein biomarker candidates showed differential binding with one or more lectins 
under one of three possible scenarios. (i) Total glycoprotein level changes in the serum lead to 
overall increased/decreased binding with multiple lectins e.g. haptoglobin (Figure 3.9A). (ii) 
Changes in the glycan occupancy at a particular glycosylation site lead to differential binding with 
multiple lectins e.g. gelsolin (Figure 3.9B). (iii) Differential expression of a specific glycan 
structure altered binding of a glycoprotein to a particular lectin or a group of lectins (Figure 3.9C). 
Proof-of-concept LeMBA work published earlier suggested changes in the binding of glycoproteins 
with multiple lectins by neuraminidase treatment (317). Neuraminidase is an enzyme which cleaves 
the glycosidic linkages involving sialic acid residues. As expected, neuraminidase treatment led to 
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reduced binding of serum proteins with sialic acid binding lectins namely SNA and MAA. In 
addition, neuraminidase treatment led to considerable increase in binding of serum proteins with 
mannose, fucose and complex glycan structures binding lectins (317). Based on this it was proposed 
that disease related glycosylation changes will result in a differential binding of candidate 
glycoprotein with multiple lectins (lectin signature) due to impaired three-dimensional structure 
(317). Although many glycoprotein candidates identified in the biomarker discovery showed 
differential binding with multiple lectins, none of the candidates showed similar changes observed 
in the proof-of-concept work i.e. none of the candidate identified showed increased binding with 
one lectin and reduced binding with other lectins when comparing two different phenotypes. This 
suggests that the phenomena observed in the proof-of-concept work requires dramatic changes in 
the glycosylation, possible only with controlled experiments such as neuraminidase treatment as 
compared to subtle changes observed in the lectin binding between healthy, BE and EAC 
phenotypes.  
 Haptoglobin is a positive acute-phase hemoglobin scavenging protein primarily produced by 
liver in the body. It is a heterotetramer and consists of two α and two β chains. Haptoglobin binds 
free hemoglobin (388). The haptoglobin-hemoglobin complex is rapidly cleared by monocytes and 
macrophages via CD163 receptors present on their cell surface (389). The β Chain of haptoglobin 
harbor four sites for N-linked glycosylation and mainly express complex type glycans (390). 
Aberrant fucose and sialic acid expressing haptoglobin in serum has been demonstrated as potential 
biomarker for various cancers such as colon cancer (391), hepatocellular carcinoma (392), prostate 
cancer (393), and pancreatic cancer (394, 395). It would be interesting to study impact of this 
differential glycosylation on its functions mainly hemoglobin binding. The detailed mechanism of 
increased fucosylation of haptoglobin in pancreatic cancer is well studied. Apart from hepatocytes, 
pancreatic cancer cells themselves and infiltrating lymphocytes around pancreatic cancers express 
fucosylated haptoglobin (394). Mutations in oncogenic Ras are associated with pancreatic cancer 
(396). Activation of oncogenic Ras leads to expression of pro-inflammatory cytokine IL-6 (397) 
which exhibits two fold effects. IL-6 can induce expression of haptoglobin and it also up-regulates 
machinery related to fucosylation process resulting in increased serum fucosylated haptoglobin 
levels (394).  
 Gelsolin was not known to be glycosylated until very recently when Ma and colleagues 
using novel glycosite profiling strategy identified Asn at position 118 in the gelsolin sequence to be 
glycosylated (343). However, the detail glycan structure of gelsolin is remained to be characterized. 
In this biomarker discovery screen, gelsolin was identified in multiple lectin pull-downs (AAL, 
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DSA, EPHA, GNL, JAC, LPHA, MAA, NPL, PSA, SNA, STL, WFA, and WGA). Based on this 
result, it is very likely that gelsolin express complex type glycan structure. Gelsolin is a villin 
family member and exists in two forms namely plasma (mainly expressed by muscle cells) and 
cytoplasmic (ubiquitously expressed). It is a Ca
+2
 regulated actin filament severing, capping, and 
nucleating protein (398). Serum gelsolin levels are found to be low in patients with acute liver 
failure, myocardial infarction, sepsis, myonecrosis (399), and rheumatoid arthritis (400). Some of 
these pathological conditions involve tissue necrosis which causes release of actin. Free actin is 
neutralized by binding with gelsolin and these actin-gelsolin complexes are cleared by 
reticuloendothelial system leading to low levels of gelsolin in circulation (399, 401-403). 
Irrespective of the disease condition, low gelsolin levels is a marker of poorer patient prognosis 
(403). Cytoplasmic gelsolin has been found to be down-regulated in variety of cancers namely 
breast, colorectal, gastric, bladder, lung, prostate, kidney, ovarian, pancreatic, and oral cancers 
(398). As compared to cytoplasmic gelsolin, much less is known about plasma gelsolin. So once 
gelsolin is verified in an independent patient cohort, it would be interesting to characterize gelsolin 
glycan structure and its impact on function.   
 α-2-macroglobulin is a relatively large tetrameric molecule containing multiple 
glycosylation and cross-linking sites (404, 405). It is expressed by multiple cell types such as lung 
fibroblasts, monocytes, macrophages, hepatocytes, astrocytes and adrenocortical cells (404). Apart 
from rapid neutralization of proteinases released during tissue injury which is a primary function of 
A2M, presence of multiple reactive sites enable it to carry out secondary functions like binding, 
transportation and targeting of many biomolecules such as cytokines, hormones, and lipids (406). 
Due to its very complex physiological roles, it is not surprising to know that A2M level is altered in 
a variety of pathological conditions such as pancreatic cancer, rheumatoid arthritis, chronic liver 
disease, inflammatory joint disease, multiple sclerosis, myocardial infarction, pancreatitis and 
nephrotic syndrome etc (406, 407). From the A2M lectin binding signature between healthy, BE 
and EAC patients it is plausible that A2M is undergoing differential glycosylation without major 
changes at the total protein levels. 
 Collectively, lectin binding signatures for these three representative glycoprotein candidates 
suggest possible scenarios of differential lectin binding for the biomarker candidates identified. It is 
important to note that all three protein candidates mentioned vary significantly in terms of their 
molecular size with haptoglobin being smallest (42 kDa) and α-2-macroglobulin being largest (750 
kDa) while gelsolin being intermediate (90 kDa). Furthermore, gelsolin, haptoglobin and α-2-
macroglobulin contain 1, 4, and 8 known glycosylation sites suggesting LeMBA workflow is 
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applicable across heterogeneous species. Albeit at this moment it remained to be determined what 
are the exact glycosylation structures responsible for differential binding with the lectin-beads used 
in the LeMBA workflow. 
3.4.4 Protein level validation of mass spectrometric data        
 Many protein biomarker discovery workflows identify low abundant proteins as potential 
biomarker candidates using sophisticated sample preparation and proteomics technologies. Even 
though the candidates identified exhibit very high performance during the initial discovery stages, 
they are not suitable for further stages of biomarker development due to lack of high quality 
capture/detection affinity reagents such as antibodies required for assay development (408). 
Proteins identified in the LeMBA pull-down are medium to high abundant serum proteins for which 
well characterized antibodies are readily available commercially. Using the antibodies against two 
proteins, haptoglobin and gelsolin, two lectin-protein biomarker candidates were successfully 
validated. For AAL-HP, protein level validation using western immunoblotting showed very similar 
results as compared to mass spectrometric quantitation based on peptide level. AAL-GSN was 
identified using group binding difference analysis meaning gelsolin was not identified for many 
patient samples in AAL pull-down. Western immunoblotting results showed the presence of 
gelsolin in AAL pull-down for all patient samples although at lower levels and confirmed 
significant difference between EAC samples as compared to healthy and BE phenotypes. The total 
protein level changes in the glycoprotein candidates, if any, can be easily tested using 
unenriched/non-lectin bound sample approaches using techniques like LC-MS/MS, enzyme-linked 
immunosorbent assay (ELISA) or western immunoblotting. 
 In summary, this chapter describes identification of a list of lectin-protein diagnostic 
biomarker candidates using LeMBA-GlycoSelector pipeline. The next phase of this project went on 
to verify these candidates using targeted proteomics approach in an independent patient cohort.    
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Chapter 4. Development and validation of multiple reaction monitoring-mass spectrometry 
(MRM-MS) assay  
4.1 Introduction 
 Cancer biomarker discovery and development pipeline is formally divided into five phases 
(133). The goal of initial stages of biomarker discovery is to identify as many candidates as possible 
by screening relatively few numbers of clinical samples. Moving forward to later stages of 
development, the aim is to monitor a panel of biomarkers, packaged in the form of an in vitro 
diagnostic test (IVD), in large scale multi-center clinical trial to evaluate actual diagnostic 
performance in clinical setting (133, 356, 409). In the previous chapter, serum samples from 29 
patient samples were screened using LeMBA-GlycoSelector pipeline with a total 183 lectin-protein 
candidates discovered as potential biomarker candidates to distinguish between healthy, BE and 
EAC phenotype. The discovery proteomics technique employed in Chapter 3 is semi-quantitative. 
For biomarker verification, the aim is to screen relatively larger cohort of patient samples using 
targeted method which is quantitative, reproducible, rapid, and cost-effective. Multiple reaction 
monitoring-mass spectrometry (MRM-MS) has emerged as a preferred methodology for precise and 
accurate quantification of 10s to 100s of proteins in very short duration (410-413). The aim of this 
chapter is therefore to develop and validate MRM-MS assay for the glycoprotein candidates 
identified in Chapter 3.  
 Traditionally, antibody based methodologies have been extensively used for protein 
quantitation in complex backgrounds. As an example, enzyme-linked immunosorbent assay 
(ELISA) relies mainly on specificity of antibodies to recognize a particular protein epitope. 
According to Antibodypedia (http://www.antibodypedia.com/) (414), more than a million 
antibodies are now commercially available against 92% of the human genome. However, not all of 
these antibodies are of quality to be used for biomarker verification or in a diagnostic assay and the 
cost to screen the 100s of biomarker candidates using antibody based assay will be enormous. To 
monitor glycosylation status of a glycoprotein biomarker candidate, either capture or detection 
antibody in ELISA can be replaced with a particular lectin of interest. The lectin-antibody based 
assays are developed in a wide variety of formats using diverse chemistries for read-out e.g. 
antibody-overlay lectin microarray (ALM) (415), lectin-overlay antibody microarray (LAM) (416), 
lectin immunosorbent assay (417, 418), or AlphaLISA assay (419). Irrespective of chemistry of 
detection or assay platform, antibodies based assays lack multiplex capabilities and are unable to 
quantify 10s to 100s of protein analytes in a single assay, which is a primary requirement for 
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biomarker verification screen. Hence although antibody based methods are very precise, sensitive, 
and high-throughput, they are best suited for clinical laboratory but not for purpose of biomarker 
verification in research laboratories which requires quantitation of 10s to 100s of proteins (356). 
Earlier, it has been established that LeMBA platform is sensitive, high-throughput, semi-automated 
and able to meet the demand for sample preparation required for biomarker verification phase 
(317). When combine with powerful targeted proteomics technique such as MRM-MS, it can be 
used for biomarker verification. 
4.1.1 Multiple reaction monitoring-mass spectrometry (MRM-MS) 
 Multiple reaction monitoring-mass spectrometry (MRM-MS) has emerged from selected 
reaction monitoring (SRM) which was developed as targeted mass spectrometry technique to 
monitor mainly small molecules such as xenobiotics, metabolites or drugs (413). MRM-MS is 
usually coupled with liquid chromatography for best results whereby the chromatographic system is 
directly connected in-line with electrospray ionization (ESI) end of the mass spectrometer (Figure 
4.1). In a typical workflow (Figure 4.1), proteolytic digest of the complex biological sample is 
separated using liquid chromatography followed by ionization of the analytes. The ionized peptides 
undergo selection and fragmentation inside triple quadrupole mass spectrometer and fragmented 
ions are guided to electron multiplier detector which records the signal in digital format. The 
selection of ions occurs at two levels to provide assay specificity. (i) Precursor ions are gated in the 
first mass analyzer (Q1) which then undergoes fragmentation inside the collision cell (Q2) and (ii) 
resulting product ions are specifically selected inside the second quadrupole (Q3). The pair of 
precursor-product ion is called transition. The mass spectrometric data acquisition technology has 
improved remarkably in past few years. Modern day instruments allow repeated and sequential 
monitoring of several transitions that is fast as compared to chromatographic elution of an analyte 
(up to 200 transitions for 6490 triple quadrupole mass spectrometer, Agilent Technologies). These 
results in counts of number of fragment ions (also called intensity) in chromatographic time scale 
for several transitions that allow quantification of multiple analytes. 
 The major steps for configuring MRM-MS assays include (i) selection of peptides which are 
unique for the protein candidates and not shared with other proteins, (ii) selection of transitions for 
each peptide that do not show any interference (generally multiple product ions from same 
precursor ion are monitored), and (iii) determination of retention time to allow mass spectrometer to 
scan for a particular set of transitions in defined retention time window for improved multiplexing. 
Development of open-source software tool Skyline (http://skyline.maccosslab.org/) by MacLean 
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and colleagues of University of Washington is considered to be one of the key advancement in the 
field of targeted proteomics (420). Skyline is vendor neutral software that provides support not only 
for selecting peptides and optimization of transitions but also for downstream data analysis (420). 
 This chapter describes development of MRM-MS assay for candidates identified in Chapter 
3 for biomarker verification, including characterization of assay linearity and reproducibility.     
 
Figure 4.1. A typical workflow of LC-MRM-MS. The complex peptide mixture resulting from 
proteolytic digest of biological sample undergoes separation using reverse phase liquid 
chromatography. The LC is connected in-line with triple quadrupole mass spectrometer with 
electrospray ionization (ESI) interface. The molecular ions of a peptide of interest are selected in 
Q1 and fragmented in Q2 (Collision cell). The resulting product ions undergo selection in Q3 and 
travel to the electron multiplier detector which counts number of target fragments over a time 
resulting in MRM trace for each transition. Adapted from Picotti P. and Aebersold R. (411). 
4.2 Experimental procedures 
4.2.1 Comparison between nano-flow and standard-flow MRM-MS 
 Two instruments 1260 HPLC coupled with 6490 triple quadrupole mass spectrometer 
(Agilent Technologies, nano-flow HPLC-MRM-MS) and 1290 UHPLC coupled with 6490 triple 
quadrupole mass spectrometer (Agilent Technologies, standard-flow UHPLC-MRM-MS) were 
compared by running human serum albumin (HSA) peptides standard mix (Agilent Technologies, 
#G2455-85001). Peptide sequence LVNEVTEFAK (Transitions 575.3  937.5 and 575.3  
694.4; @ Collision energy (CE) 20 eV) was monitored. LC and mass spectrometer parameters for 
nano-flow and standard-flow MRM-MS are mentioned below.     
4.2.1.1 Nano-flow HPLC-MRM-MS parameters 
Chip detail: Polaris-HR-Chip-3C1  (G4240-62030, Agilent Technologies) contained 360 nl 
enrichment column and 75 μm  150 mm analytical column packed with Polaris C18-A, 1 0 Å, 3 μm 
stationary phase. 
LC parameters: 
Buffer A = 0.1% formic acid, Buffer B = 90% acetonitrile containing 0.1% formic acid 
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Capillary (loading) pump flow rate = 2.0 μL/min, Nano (analytical) pump flow rate = 0.3 μL/min 
LC gradient: 
Capillary pump Nano pump 
Time (min) Solvent % B Time (min) Solvent %B 
0.0 min 5% 0.0 min 3% 
0.5 min 5% 7.0 min 65% 
6.5 min 50% 7.5 min 95% 
7.0 min 5% 9.5 min 95% 
Stop time = 15 min 5% 10.5 min 3% 
  Stop time = 15.0 min 3% 
Chip cube parameter: 
Change inner valve position to enrichment = 11.0 min 
Source parameters: 
Gas temperature = 150 ˚C, Gas flow rate = 11 L/min, Capillary voltage = 1900 V       
4.2.1.2 Standard-flow UHPLC-MRM-MS parameters 
Column detail: ZORBAX Rapid resolution high definition Eclipse plus C18 2.1    50 mm, 1.8 µm 
(959757-902, Agilent Technologies) 
LC parameters: 
Buffer A = 0.1% formic acid, Buffer B = 0.1% formic acid in acetonitrile 
Flow rate = 400 μL/min, Column temperature = 50 ˚C 
LC gradient: 
Time (min) Solvent % B 
0.0 min 3% 
7.0 min 50% 
7.5 min 95% 
10.5 min 95% 
11.0 min 3% 
Stop time = 15 min 3% 
Source parameters: 
Gas temperature = 150 ˚C, Gas flow = 15 L/min, Nebulizer = 30 psi, Sheath gas heater = 250 ˚C, 
Sheath gas flow = 11 L/min, Capillary voltage = 3500 V, Nozzle voltage = 300 V 
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 HSA peptides standard mix was serially diluted 10 fold across 7 different concentrations 
ranging from 1 picomole/μL up to 1 attomole/μL. For nano-flow-HPLC-MRM-MS, HSA peptide 
standard mix ranging from 100 femtomole up to 1 attomole was injected in triplicate. While for 
standard-flow-UHPLC-MRM-MS, HSA peptide standard mix ranging from 1 picomole up to 10 
attomole was injected in triplicate. The peak area was extracted using Mass Hunter QQQ 
quantitative analysis software version B.05.02/Build 5.2.365.0. The retention time was compared 
using Skyline version 2.1.0.4936 (http://skyline.maccosslab.org/). 
4.2.2 MRM-MS assay development 
 MRM-MS assay was set up on the Agilent Technologies 6490 triple quadrupole mass 
spectrometer coupled with 1290 standard-flow Infinity UHPLC fitted with an ESI source (ESI Jet 
Stream). The following section describes details about assay development and validation.  Six 
lectins (AAL, EPHA, JAC, NPL, PSA, and WGA) were chosen for verification. MRM-MS assay 
was developed for 41 glycoprotein candidates identified in biomarker discovery. 
4.2.2.1 Selection of peptides and transitions 
 MRM selector function of Spectrum Mill was used to get a list of the top ten peptides per 
protein for MRM method development. A few runs from the LeMBA-QTOF discovery data set was 
used for this purpose. The parameters specified included 10 peptides per protein with a score of 
above 10 and % score peak intensity of 70%. The top four product y-ions for each precursor ion 
greater than precursor m/z were selected for MRM method development. The formula Collision 
energy (CE) = 0.036 m/z - 4.8 was used to calculate CE for each precursor. Multiple MRM methods 
consisting of maximum 200 transitions were created as a first step of method development. All 
methods were transferred across to Skyline for ease of data visualization and analysis (420). 
Subsequent steps of method refinement were performed using Skyline. Using LeMBA-MS/MS 
discovery data (.mzxml and .pepxml files), a reference spectral library was built in Skyline. This 
reference library was used to compare the peptide fragmentation pattern in the MRM method as 
compared to QTOF data, and also to rank transitions. LeMBA pull-down of multiple lectins was 
combined and run for each method to identify best MRM transitions. Each method incorporated 
transitions for internal standard chicken ovalbumin. Retention time prediction calculator iRT-C18 
of Skyline was used to increase confidence of peptide identification (421). iRT scale was calibrated 
using the known retention time of the peptides listed in Table 4.1. Based on the calibration plot, 
retention time for the peptides of interest was predicted.  
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 MRM transitions showing good response at the correct retention time without any 
interference were selected for the next step. After the first round of method development, three 
MRM methods were created and each of these methods was tested in triplicates to find transitions 
showing stable responses. Some product y-ions (greater than precursor m/z) showed considerably 
low response. So to find out transition with better response, up to five b- and y-ions less than 
precursor m/z were tried. Only transitions showing stable response during multiple runs were 
selected. Using retention time information for each peptide, one final dynamic MRM method was 
created incorporating a total of 145 peptides and 465 transitions with delta retention times of 2.5, 3 
or 4 min, to quantify 41 proteins. Table 4.2 contains a detailed list of transitions used in the method.    
Table 4.1. Peptides used as standards to plot retention time prediction calibration curve. 
Peptide sequence iRT value 
VASMASEK 0.00 
ISQAVHAAHAEINEAGR 33.91 
AVEVLPK 62.07 
GGLEPINFQTAADQAR 119.54 
LTEWTSSNVMEER 93.10 
VTSIQDWVQK 100.00 
4.2.2.2 LC and mass spectrometer parameters  
 The UHPLC system consisted of a reverse phase chromatographic column AdvanceBio 
Peptide Mapping (150  2.1 mm i.d., 2.7 µm, part number 653750-902, Agilent Technologies) with a 
5 mm long guard column, maintained at 60 °C temperature. Mobile phase A consisted of 0.1% 
formic acid, and mobile phase B consisted of 99.9% acetonitrile and 0.1% formic acid. The UHPLC 
system was operated at a flow rate of 0.4 mL/min. The gradient used for peptide separation was as 
follows: 3% B at 0 min; 30% B at 20 min; 40% B at 24 min; 95% B at 24.5 min; 95% B at 28.5 
min; 3% B at 29 min; followed by conditioning of column for 5 min at 3% B before injecting the 
next sample. 
 Agilent 6490 triple quadrupole mass spectrometer was operated in positive ion mode and 
controlled by MassHunter Workstation software (version B.06.00 build 6.0.6025.4 SP4, Agilent 
Technologies). The MRM acquisition parameters were 150 V high pressure RF, 60 V low pressure 
RF, 4000 V capillary voltage, 300 V nozzle voltage, 11 L/min sheath gas flow at a temperature of 
250 °C, 15 L/min drying gas flow at a temperature of 250 °C, 30 psi nebulizer gas flow, unit 
resolution [0.7 Da full width at half maximum in the first quadrupole (Q1) and the third quadrupole 
103 
 
(Q3)], and 200 V delta EMV (+). Fragmentor was set at 380 V and cell accelerator voltage was set 
at 5 V. 
4.2.3 Selection of heavy labeled internal standards and two-step normalization approach  
 Consistent with biomarker discovery, 10 pmol chicken ovalbumin was spiked-in as an 
internal standard per lectin pull-down. With the additional use of heavy labeled SIS ovalbumin 
peptide for MRM analysis, a two step normalization approach became feasible. These two steps 
separately accounted for variation due to mass spectrometry analysis and LeMBA pull-down. In 
step 1, the intensity of spiked-in internal standard chicken ovalbumin peptide was normalized using 
heavy labeled SIS ovalbumin peptide to account for mass spectrometric variation. In step 2, 
normalized intensity for all peptides for each sample was calculated based on the normalized 
intensity of spiked-in internal standard chicken ovalbumin, to account for variation during sample 
preparation steps. The two most consistent chicken ovalbumin peptides, based on discovery screen 
data, were selected for performing normalization (i) ISQAVHAAHAEINEAGR without methionine 
and (ii) VASMASEK which contains methionine. The reason for choosing the two separate 
peptides, one which contains methionine and another which does not, was to account for batch 
effect of methionine oxidation. To get normalized response of six methionine containing peptides in 
the final MRM-MS assay, ovalbumin peptide VASMASEK which includes methionine was used; 
while for normalization of the rest non-methionine containing peptides, ovalbumin peptide 
ISQAVHAAHAEINEAGR was used. C-terminal isotopic [
13
C6, 
15
N7] lysine or [
13
C6, 
15
N7] arginine 
labeled peptide for ISQAVHAAHAEINEAGR and VASMASEK with > 95% purity were obtained 
from Sigma. Two charge states +3 and +4 were monitored for natural and SIS 
ISQAVHAAHAEINEAGR peptide. The sum of both charge states was used for normalization. C-
terminal isotopic [
13
C6, 
15
N7] lysine labeled peptide AVEVLPK, which belongs to Gelsolin, and 
VTSIQDWVQK, which belongs to Haptoglobin were also incorporated as internal standard 
peptides. 
4.2.4 Determination of loading capacity for each lectin pull-down 
 Loading capacity for individual lectin pull-down was determined by injecting varying 
amounts of LeMBA pull-down and monitoring peptide responses using MRM-MS assay. Each 
LeMBA pull-down sample was resuspended in 20 μL 0.1% formic acid. 5 μL, 10 μL, and 15 μL of 
the LeMBA pull-down was injected into mass spectrometer for each lectin except EPHA (for EPHA 
2 μL, 4 μL, 6 μL,   μL, and 10 μL was injected). Using Skyline, individual peptide responses 
between different injection volumes were monitored carefully to look for peptides showing 
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saturated responses. Loading capacity for individual lectin pull-down was determined based on 
overall response for all the peptides monitored across different injection volumes.  
4.2.5 Determination of linearity and reproducibility of MRM-MR assay 
 Linearity of the MRM-MS method was determined by injecting varying concentrations of 
SIS peptides spiked-into combined LeMBA pull-down sample of multiple lectins. The amount of 
SIS peptide spiked-in for each of four peptides was adjusted in such a manner that the response 
from the 1X labeled peptide mix fell within a 5-fold range of the cognate natural peptide. The 
concentration of spiked-in SIS peptide varied from 0.008X to 25X covering 3125 fold linear range 
where 1X concentration indicates mixture of 150 femtomole of ISQAVHAAHAEINEAGR and 
VASMASEK each, 300 femtomole of VTSIQDWVQK, and 30 femtomole of AVEVLPK. All 
dilutions were run in triplicate on each day for three consecutive days (n = 9). The ratio of SIS 
peptide response/natural peptide response was plotted. 
 Reproducibility of MRM-MS assay was determined by injecting   μL of combined LeMBA 
pull-down sample of multiple lectins in quadruplicate on each day for four consecutive days (n = 
16). Percent coefficient of variation (% CV) between runs was calculated using peptide responses 
normalized with respect to ovalbumin peptide.  
Table 4.2. List of transitions included in the MRM-MS assay.  
Compound Name 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Ret 
Time 
(min) 
Delta 
Ret 
Time 
Collision 
Energy 
O75882_ALYVHGGYK 336.52 660.35 6.09 3 7.3 
O75882_ALYVHGGYK 336.52 561.28 6.09 3 7.3 
O75882_ALYVHGGYK 336.52 412.21 6.09 3 7.3 
O75882_GVKGDECQLCEVENR 598.27 806.35 6.94 3 16.7 
O75882_GVKGDECQLCEVENR 598.27 646.32 6.94 3 16.7 
O75882_GVKGDECQLCEVENR 598.27 517.27 6.94 3 16.7 
O75882_SEAACLAAGPGIR 636.82 641.37 9.46 3 18.1 
O75882_SEAACLAAGPGIR 636.82 499.30 9.46 3 18.1 
O75882_SEAACLAAGPGIR 636.82 288.20 9.46 3 18.1 
O75882_SVNNVVVR 443.76 700.41 6.37 3 11.2 
O75882_SVNNVVVR 443.76 586.37 6.37 3 11.2 
O75882_SVNNVVVR 443.76 472.32 6.37 3 11.2 
P00734_GQPSVLQVVNLPIVERPVCK 744.76 1024.09 18.14 3 22 
P00734_GQPSVLQVVNLPIVERPVCK 744.76 882.51 18.14 3 22 
P00734_GQPSVLQVVNLPIVERPVCK 744.76 683.06 18.14 3 22 
P00734_HQDFNSAVQLVENFCR 655.31 824.37 16.13 3 18.8 
P00734_HQDFNSAVQLVENFCR 655.31 800.33 16.13 3 18.8 
P00734_HQDFNSAVQLVENFCR 655.31 725.30 16.13 3 18.8 
P00734_SGIECQLWR 574.78 891.41 11.9 2.5 15.9 
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Compound Name 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Ret 
Time 
(min) 
Delta 
Ret 
Time 
Collision 
Energy 
P00734_SGIECQLWR 574.78 762.37 11.9 2.5 15.9 
P00734_SGIECQLWR 574.78 602.34 11.9 2.5 15.9 
P00738_FTDHLK 380.70 613.33 4.66 4 8.9 
P00738_FTDHLK 380.70 512.28 4.66 4 8.9 
P00738_FTDHLK 380.70 397.26 4.66 4 8.9 
P00738_ILGGHLDAK 308.52 349.19 6.79 3 6.3 
P00738_ILGGHLDAK 308.52 218.15 6.79 3 6.3 
P00738_ILGGHLDAK 308.52 109.58 6.79 3 6.3 
P00738_VGYVSGWGR 490.75 881.43 9.79 3 12.9 
P00738_VGYVSGWGR 490.75 661.34 9.79 3 12.9 
P00738_VGYVSGWGR 490.75 562.27 9.79 3 12.9 
P00738_VTSIQDWVQK 602.32 1003.52 11.8 2.5 16.9 
P00738_VTSIQDWVQK 602.32 803.40 11.8 2.5 16.9 
P00738_VTSIQDWVQK 602.32 675.35 11.8 2.5 16.9 
P00738_VTSIQDWVQK.heavy 606.33 1011.53 11.8 2.5 17 
P00738_VTSIQDWVQK.heavy 606.33 811.42 11.8 2.5 17 
P00738_VTSIQDWVQK.heavy 606.33 683.36 11.8 2.5 17 
P00747_LSSPAVITDK 515.79 917.49 9.02 3 13.8 
P00747_LSSPAVITDK 515.79 830.46 9.02 3 13.8 
P00747_LSSPAVITDK 515.79 743.43 9.02 3 13.8 
P00747_NLDENYCR 542.23 856.33 5.04 3 14.7 
P00747_NLDENYCR 542.23 741.30 5.04 3 14.7 
P00747_NLDENYCR 542.23 498.21 5.04 3 14.7 
P00747_VIPACLPSPNYVVADR 885.96 1117.56 14.89 2.5 27.1 
P00747_VIPACLPSPNYVVADR 885.96 933.48 14.89 2.5 27.1 
P00747_VIPACLPSPNYVVADR 885.96 779.89 14.89 2.5 27.1 
P00751_CLVNLIEK 494.78 715.43 13.16 2.5 13 
P00751_CLVNLIEK 494.78 616.37 13.16 2.5 13 
P00751_CLVNLIEK 494.78 389.24 13.16 2.5 13 
P00751_LEDSVTYHCSR 456.21 823.35 5.51 3 11.6 
P00751_LEDSVTYHCSR 456.21 627.26 5.51 3 11.6 
P00751_LEDSVTYHCSR 456.21 559.24 5.51 3 11.6 
P00751_YGLVTYATYPK 638.33 942.49 12.29 2.5 18.2 
P00751_YGLVTYATYPK 638.33 843.42 12.29 2.5 18.2 
P00751_YGLVTYATYPK 638.33 742.38 12.29 2.5 18.2 
P00751_YGQTIRPICLPCTEGTTR 708.35 921.41 12.13 2.5 20.7 
P00751_YGQTIRPICLPCTEGTTR 708.35 887.95 12.13 2.5 20.7 
P00751_YGQTIRPICLPCTEGTTR 708.35 837.43 12.13 2.5 20.7 
P01009_DTEEEDFHVDQVTTVK 631.29 838.39 10.51 2.5 17.9 
P01009_DTEEEDFHVDQVTTVK 631.29 773.87 10.51 2.5 17.9 
P01009_DTEEEDFHVDQVTTVK 631.29 709.35 10.51 2.5 17.9 
P01009_LSITGTYDLK 555.81 910.49 12.15 2.5 15.2 
P01009_LSITGTYDLK 555.81 797.40 12.15 2.5 15.2 
P01009_LSITGTYDLK 555.81 696.36 12.15 2.5 15.2 
P01009_SVLGQLGITK 508.31 829.51 13.39 2.5 13.5 
P01009_SVLGQLGITK 508.31 716.43 13.39 2.5 13.5 
P01009_SVLGQLGITK 508.31 531.35 13.39 2.5 13.5 
106 
 
Compound Name 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Ret 
Time 
(min) 
Delta 
Ret 
Time 
Collision 
Energy 
P01011_EIGELYLPK 531.30 819.46 13.44 2.5 14.3 
P01011_EIGELYLPK 531.30 633.40 13.44 2.5 14.3 
P01011_EIGELYLPK 531.30 520.31 13.44 2.5 14.3 
P01011_ITLLSALVETR 608.37 888.51 18.44 3 17.1 
P01011_ITLLSALVETR 608.37 775.43 18.44 3 17.1 
P01011_ITLLSALVETR 608.37 688.40 18.44 3 17.1 
P01011_NLAVSQVVHK 547.82 867.50 8.14 3 14.9 
P01011_NLAVSQVVHK 547.82 796.47 8.14 3 14.9 
P01011_NLAVSQVVHK 547.82 697.40 8.14 3 14.9 
P01012_AFKDEDTQAMPFR 778.36 850.42 10.21 2.5 23.2 
P01012_AFKDEDTQAMPFR 778.36 669.31 10.21 2.5 23.2 
P01012_AFKDEDTQAMPFR 778.36 419.24 10.21 2.5 23.2 
P01012_GGLEPINFQTAADQAR 844.42 1121.53 13.55 2.5 25.6 
P01012_GGLEPINFQTAADQAR 844.42 860.42 13.55 2.5 25.6 
P01012_GGLEPINFQTAADQAR 844.42 666.34 13.55 2.5 25.6 
P01012_ISQAVHAAHAEINEAGR 591.97 830.91 6.07 3 16.5 
P01012_ISQAVHAAHAEINEAGR 591.97 638.31 6.07 3 16.5 
P01012_ISQAVHAAHAEINEAGR 591.97 546.26 6.07 3 16.5 
P01012_ISQAVHAAHAEINEAGR 444.23 859.43 6.07 3 11.2 
P01012_ISQAVHAAHAEINEAGR 444.23 638.31 6.07 3 11.2 
P01012_ISQAVHAAHAEINEAGR 444.23 546.26 6.07 3 11.2 
P01012_ISQAVHAAHAEINEAGR.heavy 595.31 835.92 6.07 3 16.6 
P01012_ISQAVHAAHAEINEAGR.heavy 595.31 643.32 6.07 3 16.6 
P01012_ISQAVHAAHAEINEAGR.heavy 595.31 556.27 6.07 3 16.6 
P01012_ISQAVHAAHAEINEAGR.heavy 446.73 869.44 6.07 3 11.3 
P01012_ISQAVHAAHAEINEAGR.heavy 446.73 643.32 6.07 3 11.3 
P01012_ISQAVHAAHAEINEAGR.heavy 446.73 556.27 6.07 3 11.3 
P01012_LTEWTSSNVMEER 791.36 1052.47 11.22 2.5 23.7 
P01012_LTEWTSSNVMEER 791.36 951.42 11.22 2.5 23.7 
P01012_LTEWTSSNVMEER 791.36 564.24 11.22 2.5 23.7 
P01012_NVLQPSSVDSQTAMVLVNAIVFK 820.78 903.57 22.55 4 24.7 
P01012_NVLQPSSVDSQTAMVLVNAIVFK 820.78 790.48 22.55 4 24.7 
P01012_NVLQPSSVDSQTAMVLVNAIVFK 820.78 393.25 22.55 4 24.7 
P01012_VASMASEK 411.70 723.33 3.08 4 10 
P01012_VASMASEK 411.70 652.30 3.08 4 10 
P01012_VASMASEK 411.70 434.22 3.08 4 10 
P01012_VASMASEK.heavy 415.71 731.35 3.08 4 10.2 
P01012_VASMASEK.heavy 415.71 660.31 3.08 4 10.2 
P01012_VASMASEK.heavy 415.71 442.24 3.08 4 10.2 
P01012_YPILPEYLQCVK 761.90 1149.60 16.62 3 22.6 
P01012_YPILPEYLQCVK 761.90 1036.51 16.62 3 22.6 
P01012_YPILPEYLQCVK 761.90 324.18 16.62 3 22.6 
P01019_ALQDQLVLVAAK 634.88 956.58 14.34 2.5 18.1 
P01019_ALQDQLVLVAAK 634.88 600.41 14.34 2.5 18.1 
P01019_ALQDQLVLVAAK 634.88 501.34 14.34 2.5 18.1 
P01019_DPTFIPAPIQAK 649.36 837.52 14.57 2.5 18.6 
P01019_DPTFIPAPIQAK 649.36 724.44 14.57 2.5 18.6 
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P01019_DPTFIPAPIQAK 649.36 556.35 14.57 2.5 18.6 
P01019_FMQAVTGWK 534.27 789.43 12.09 2.5 14.4 
P01019_FMQAVTGWK 534.27 661.37 12.09 2.5 14.4 
P01019_FMQAVTGWK 534.27 491.26 12.09 2.5 14.4 
P01019_LDTEDKLR 330.51 531.32 5.02 3 7.1 
P01019_LDTEDKLR 330.51 438.72 5.02 3 7.1 
P01019_LDTEDKLR 330.51 416.30 5.02 3 7.1 
P01019_SLDFTELDVAAEK 719.36 975.50 15.22 3 21.1 
P01019_SLDFTELDVAAEK 719.36 745.41 15.22 3 21.1 
P01019_SLDFTELDVAAEK 719.36 316.67 15.22 3 21.1 
P01023_LPPNVVEESAR 605.82 1000.51 8.98 3 17 
P01023_LPPNVVEESAR 605.82 903.45 8.98 3 17 
P01023_LPPNVVEESAR 605.82 690.34 8.98 3 17 
P01023_SLFTDLEAENDVLHCVAFAVPK 825.75 1064.52 21.06 4 24.9 
P01023_SLFTDLEAENDVLHCVAFAVPK 825.75 1014.00 21.06 4 24.9 
P01023_SLFTDLEAENDVLHCVAFAVPK 825.75 899.94 21.06 4 24.9 
P01023_SLFTDLEAENDVLHCVAFAVPK 825.75 835.42 21.06 4 24.9 
P01023_YSDASDCHGEDSQAFCEK 702.60 971.86 5.58 3 20.5 
P01023_YSDASDCHGEDSQAFCEK 702.60 928.35 5.58 3 20.5 
P01023_YSDASDCHGEDSQAFCEK 702.60 835.31 5.58 3 20.5 
P01024_AAVYHHFISDGVR 491.25 665.34 8.21 3 12.9 
P01024_AAVYHHFISDGVR 491.25 534.27 8.21 3 12.9 
P01024_AAVYHHFISDGVR 491.25 533.27 8.21 3 12.9 
P01024_EVVADSVWVDVK 673.35 1018.52 14.06 2.5 19.4 
P01024_EVVADSVWVDVK 673.35 646.36 14.06 2.5 19.4 
P01024_EVVADSVWVDVK 673.35 246.18 14.06 2.5 19.4 
P01024_LLPVGR 327.72 428.26 8.4 3 7 
P01024_LLPVGR 327.72 331.21 8.4 3 7 
P01024_LLPVGR 327.72 214.63 8.4 3 7 
P01024_SGIPIVTSPYQIHFTK 596.66 1033.55 15.88 3 16.7 
P01024_SGIPIVTSPYQIHFTK 596.66 765.92 15.88 3 16.7 
P01024_SGIPIVTSPYQIHFTK 596.66 660.85 15.88 3 16.7 
P01031_IDTQDIEASHYR 483.23 990.46 7.75 3 12.6 
P01031_IDTQDIEASHYR 483.23 762.35 7.75 3 12.6 
P01031_IDTQDIEASHYR 483.23 633.31 7.75 3 12.6 
P01031_IDTQDIEASHYR 483.23 562.27 7.75 3 12.6 
P01031_IVACASYKPSR 417.89 737.39 5.75 3 10.2 
P01031_IVACASYKPSR 417.89 520.25 5.75 3 10.2 
P01031_IVACASYKPSR 417.89 484.73 5.75 3 10.2 
P01031_TLLPVSKPEIR 418.26 729.43 11.55 2.5 10.3 
P01031_TLLPVSKPEIR 418.26 514.30 11.55 2.5 10.3 
P01031_TLLPVSKPEIR 418.26 463.28 11.55 2.5 10.3 
P01042_DIPTNSPELEETLTHTITK 713.70 955.99 15.21 3 20.9 
P01042_DIPTNSPELEETLTHTITK 713.70 856.94 15.21 3 20.9 
P01042_DIPTNSPELEETLTHTITK 713.70 756.40 15.21 3 20.9 
P01042_ENFLFLTPDCK 692.33 993.51 16.6 3 20.1 
P01042_ENFLFLTPDCK 692.33 880.42 16.6 3 20.1 
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P01042_ENFLFLTPDCK 692.33 733.35 16.6 3 20.1 
P01042_IASFSQNCDIYPGK 800.38 966.43 10.84 2.5 24 
P01042_IASFSQNCDIYPGK 800.38 464.25 10.84 2.5 24 
P01042_IASFSQNCDIYPGK 800.38 301.19 10.84 2.5 24 
P01042_ICVGCPR 431.21 748.32 6.16 3 10.7 
P01042_ICVGCPR 431.21 588.29 6.16 3 10.7 
P01042_ICVGCPR 431.21 489.22 6.16 3 10.7 
P02748_AIEDYINEFSVR 728.36 1142.55 15.78 3 21.4 
P02748_AIEDYINEFSVR 728.36 864.46 15.78 3 21.4 
P02748_AIEDYINEFSVR 728.36 751.37 15.78 3 21.4 
P02748_FTPTETNKAEQCCEETASSISLHGK 707.07 859.72 9.18 3 20.7 
P02748_FTPTETNKAEQCCEETASSISLHGK 707.07 828.46 9.18 3 20.7 
P02748_FTPTETNKAEQCCEETASSISLHGK 707.07 741.43 9.18 3 20.7 
P02748_LSPIYNLVPVK 621.88 1042.63 16.82 3 17.6 
P02748_LSPIYNLVPVK 621.88 832.49 16.82 3 17.6 
P02748_LSPIYNLVPVK 621.88 521.82 16.82 3 17.6 
P02748_RPWNVASLIYETK 526.29 653.35 15.46 3 14.1 
P02748_RPWNVASLIYETK 526.29 540.27 15.46 3 14.1 
P02748_RPWNVASLIYETK 526.29 248.16 15.46 3 14.1 
P02749_TCPKPDDLPFSTVVPLK 638.67 927.42 16.51 3 18.2 
P02749_TCPKPDDLPFSTVVPLK 638.67 743.47 16.51 3 18.2 
P02749_TCPKPDDLPFSTVVPLK 638.67 743.47 16.51 3 18.2 
P02749_TCPKPDDLPFSTVVPLK 638.67 665.87 16.51 3 18.2 
P02749_TCPKPDDLPFSTVVPLK 638.67 665.87 16.51 3 18.2 
P02749_TFYEPGEEITYSCKPGYVSR 795.04 1067.99 11.88 2.5 23.8 
P02749_TFYEPGEEITYSCKPGYVSR 795.04 986.46 11.88 2.5 23.8 
P02749_TFYEPGEEITYSCKPGYVSR 795.04 921.94 11.88 2.5 23.8 
P02749_VCPFAGILENGAVR 751.89 928.52 16.53 3 22.3 
P02749_VCPFAGILENGAVR 751.89 758.42 16.53 3 22.3 
P02749_VCPFAGILENGAVR 751.89 622.34 16.53 3 22.3 
P02749_WSPELPVCAPIICPPPSIPTFATLR 940.49 805.46 22.63 4 29.1 
P02749_WSPELPVCAPIICPPPSIPTFATLR 940.49 648.87 22.63 4 29.1 
P02749_WSPELPVCAPIICPPPSIPTFATLR 940.49 600.34 22.63 4 29.1 
P02751_SYTITGLQPGTDYK 772.39 978.49 11.72 2.5 23 
P02751_SYTITGLQPGTDYK 772.39 808.38 11.72 2.5 23 
P02751_SYTITGLQPGTDYK 772.39 680.32 11.72 2.5 23 
P02751_VDVIPVNLPGEHGQR 543.96 893.46 13.56 2.5 14.8 
P02751_VDVIPVNLPGEHGQR 543.96 780.37 13.56 2.5 14.8 
P02751_VDVIPVNLPGEHGQR 543.96 602.32 13.56 2.5 14.8 
P02751_VTWAPPPSIDLTNFLVR 642.69 977.54 21.95 4 18.3 
P02751_VTWAPPPSIDLTNFLVR 642.69 749.43 21.95 4 18.3 
P02751_VTWAPPPSIDLTNFLVR 642.69 749.40 21.95 4 18.3 
P02751_VTWAPPPSIDLTNFLVR 642.69 734.91 21.95 4 18.3 
P02751_VTWAPPPSIDLTNFLVR 642.69 686.39 21.95 4 18.3 
P02765_CNLLAEK 424.22 573.36 7.38 3 10.5 
P02765_CNLLAEK 424.22 460.28 7.38 3 10.5 
P02765_CNLLAEK 424.22 347.19 7.38 3 10.5 
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P02765_EHAVEGDCDFQLLK 554.26 763.43 11.99 2.5 15.2 
P02765_EHAVEGDCDFQLLK 554.26 738.31 11.99 2.5 15.2 
P02765_EHAVEGDCDFQLLK 554.26 648.41 11.99 2.5 15.2 
P02765_FSVVYAK 407.23 666.38 9.54 3 9.9 
P02765_FSVVYAK 407.23 579.35 9.54 3 9.9 
P02765_FSVVYAK 407.23 480.28 9.54 3 9.9 
P02765_HTLNQIDEVK 598.82 1059.57 6.91 3 16.8 
P02765_HTLNQIDEVK 598.82 958.52 6.91 3 16.8 
P02765_HTLNQIDEVK 598.82 822.41 6.91 3 16.8 
P02774_SCESNSPFPVHPGTAECCTK 755.65 1009.40 9.4 3 22.4 
P02774_SCESNSPFPVHPGTAECCTK 755.65 944.92 9.4 3 22.4 
P02774_SCESNSPFPVHPGTAECCTK 755.65 800.87 9.4 3 22.4 
P02774_THLPEVFLSK 390.89 578.29 12.66 2.5 9.3 
P02774_THLPEVFLSK 390.89 494.30 12.66 2.5 9.3 
P02774_THLPEVFLSK 390.89 352.20 12.66 2.5 9.3 
P02774_VLEPTLK 400.25 700.42 9.03 3 9.6 
P02774_VLEPTLK 400.25 587.34 9.03 3 9.6 
P02774_VLEPTLK 400.25 458.30 9.03 3 9.6 
P02787_FDEFFSEGCAPGSK 789.33 1039.45 12.43 2.5 23.6 
P02787_FDEFFSEGCAPGSK 789.33 892.38 12.43 2.5 23.6 
P02787_FDEFFSEGCAPGSK 789.33 805.35 12.43 2.5 23.6 
P02787_IECVSAETTEDCIAK 863.39 1224.54 8.92 3 26.3 
P02787_IECVSAETTEDCIAK 863.39 1066.47 8.92 3 26.3 
P02787_IECVSAETTEDCIAK 863.39 937.43 8.92 3 26.3 
P02787_KPVEEYANCHLAR 529.60 841.41 6.11 3 14.3 
P02787_KPVEEYANCHLAR 529.60 770.37 6.11 3 14.3 
P02787_KPVEEYANCHLAR 529.60 729.84 6.11 3 14.3 
P02787_SAGWNIPIGLLYCDLPEPR 724.37 1049.47 22.07 4 21.3 
P02787_SAGWNIPIGLLYCDLPEPR 724.37 1009.55 22.07 4 21.3 
P02787_SAGWNIPIGLLYCDLPEPR 724.37 886.41 22.07 4 21.3 
P02787_SAGWNIPIGLLYCDLPEPR 724.37 771.90 22.07 4 21.3 
P02790_EVGTPHGIILDSVDAAFICPGSSR 833.42 1180.54 17.7 3 25.2 
P02790_EVGTPHGIILDSVDAAFICPGSSR 833.42 994.48 17.7 3 25.2 
P02790_EVGTPHGIILDSVDAAFICPGSSR 833.42 923.44 17.7 3 25.2 
P02790_LLQDEFPGIPSPLDAAVECHR 788.73 1351.64 18.29 3 23.6 
P02790_LLQDEFPGIPSPLDAAVECHR 788.73 957.42 18.29 3 23.6 
P02790_LLQDEFPGIPSPLDAAVECHR 788.73 883.44 18.29 3 23.6 
P02790_LLQDEFPGIPSPLDAAVECHR 788.73 809.90 18.29 3 23.6 
P02790_NFPSPVDAAFR 610.81 959.49 14.13 2.5 17.2 
P02790_NFPSPVDAAFR 610.81 862.44 14.13 2.5 17.2 
P02790_NFPSPVDAAFR 610.81 775.41 14.13 2.5 17.2 
P02790_YYCFQGNQFLR 748.34 1169.55 13.6 2.5 22.1 
P02790_YYCFQGNQFLR 748.34 1009.52 13.6 2.5 22.1 
P02790_YYCFQGNQFLR 748.34 862.45 13.6 2.5 22.1 
P03952_DSVTGTLPK 459.25 715.43 7.56 3 11.7 
P03952_DSVTGTLPK 459.25 616.37 7.56 3 11.7 
P03952_DSVTGTLPK 459.25 515.32 7.56 3 11.7 
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P03952_GVNVCQETCTK 648.29 926.37 5.22 3 18.5 
P03952_GVNVCQETCTK 648.29 766.34 5.22 3 18.5 
P03952_GVNVCQETCTK 648.29 509.24 5.22 3 18.5 
P03952_VLTPDAFVCR 589.31 864.40 13.04 2.5 16.4 
P03952_VLTPDAFVCR 589.31 483.23 13.04 2.5 16.4 
P03952_VLTPDAFVCR 589.31 432.71 13.04 2.5 16.4 
P04003_FSAICQGDGTWSPR 791.36 1163.49 11.3 2.5 23.7 
P04003_FSAICQGDGTWSPR 791.36 1003.46 11.3 2.5 23.7 
P04003_FSAICQGDGTWSPR 791.36 875.40 11.3 2.5 23.7 
P04003_LSLEIEQLELQR 735.91 1028.57 16.36 3 21.7 
P04003_LSLEIEQLELQR 735.91 915.49 16.36 3 21.7 
P04003_LSLEIEQLELQR 735.91 786.45 16.36 3 21.7 
P04004_DVWGIEGPIDAAFTR 823.91 1076.54 19.12 3 24.9 
P04004_DVWGIEGPIDAAFTR 823.91 947.49 19.12 3 24.9 
P04004_DVWGIEGPIDAAFTR 823.91 890.47 19.12 3 24.9 
P04004_FEDGVLDPDYPR 711.83 1146.54 12.33 2.5 20.8 
P04004_FEDGVLDPDYPR 711.83 875.43 12.33 2.5 20.8 
P04004_FEDGVLDPDYPR 711.83 762.34 12.33 2.5 20.8 
P04004_RVDTVDPPYPR 438.90 629.34 8.19 3 11 
P04004_RVDTVDPPYPR 438.90 532.29 8.19 3 11 
P04004_RVDTVDPPYPR 438.90 472.25 8.19 3 11 
P04004_VDTVDPPYPR 579.79 744.37 9.04 3 16.1 
P04004_VDTVDPPYPR 579.79 629.34 9.04 3 16.1 
P04004_VDTVDPPYPR 579.79 532.29 9.04 3 16.1 
P04114_GFEPTLEALFGK 654.85 975.55 19.33 3 18.8 
P04114_GFEPTLEALFGK 654.85 664.37 19.33 3 18.8 
P04114_GFEPTLEALFGK 654.85 535.32 19.33 3 18.8 
P04114_ILGEELGFASLHDLQLLGK 685.05 913.99 20.3 4 19.9 
P04114_ILGEELGFASLHDLQLLGK 685.05 756.43 20.3 4 19.9 
P04114_ILGEELGFASLHDLQLLGK 685.05 699.89 20.3 4 19.9 
P04114_ILGEELGFASLHDLQLLGK 685.05 317.22 20.3 4 19.9 
P04114_SPAFTDLHLR 386.21 653.37 11.84 2.5 9.1 
P04114_SPAFTDLHLR 386.21 538.35 11.84 2.5 9.1 
P04114_SPAFTDLHLR 386.21 425.26 11.84 2.5 9.1 
P04196_ALDLINKR 471.79 758.45 8.54 3 12.2 
P04196_ALDLINKR 471.79 643.42 8.54 3 12.2 
P04196_ALDLINKR 471.79 530.34 8.54 3 12.2 
P04196_DGYLFQLLR 562.81 789.50 19.07 3 15.5 
P04196_DGYLFQLLR 562.81 676.41 19.07 3 15.5 
P04196_DGYLFQLLR 562.81 529.35 19.07 3 15.5 
P04196_DSPVLIDFFEDTER 841.90 1284.61 20.25 4 25.5 
P04196_DSPVLIDFFEDTER 841.90 1171.53 20.25 4 25.5 
P04196_DSPVLIDFFEDTER 841.90 1058.44 20.25 4 25.5 
P04196_GGEGTGYFVDFSVR 745.85 1089.54 15.15 3 22.1 
P04196_GGEGTGYFVDFSVR 745.85 1032.51 15.15 3 22.1 
P04196_GGEGTGYFVDFSVR 745.85 869.45 15.15 3 22.1 
P04217_ATWSGAVLAGR 544.80 730.42 11.2 2.5 14.8 
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P04217_ATWSGAVLAGR 544.80 643.39 11.2 2.5 14.8 
P04217_ATWSGAVLAGR 544.80 586.37 11.2 2.5 14.8 
P04217_CEGPIPDVTFELLR 823.42 1299.73 19.7 3 24.8 
P04217_CEGPIPDVTFELLR 823.42 1089.59 19.7 3 24.8 
P04217_CEGPIPDVTFELLR 823.42 877.51 19.7 3 24.8 
P05090_NILTSNNIDVK 615.84 1003.54 11.02 2.5 17.4 
P05090_NILTSNNIDVK 615.84 890.46 11.02 2.5 17.4 
P05090_NILTSNNIDVK 615.84 789.41 11.02 2.5 17.4 
P05090_VLNQELR 436.25 772.43 6.59 3 10.9 
P05090_VLNQELR 436.25 659.35 6.59 3 10.9 
P05090_VLNQELR 436.25 545.30 6.59 3 10.9 
P05090_WYEIEK 434.22 681.35 9.17 3 10.8 
P05090_WYEIEK 434.22 518.28 9.17 3 10.8 
P05090_WYEIEK 434.22 389.24 9.17 3 10.8 
P05090_WYEIEK 434.22 350.15 9.17 3 10.8 
P05155_FQPTLLTLPR 593.35 910.57 16.56 3 16.6 
P05155_FQPTLLTLPR 593.35 712.47 16.56 3 16.6 
P05155_FQPTLLTLPR 593.35 599.39 16.56 3 16.6 
P05155_GVTSVSQIFHSPDLAIR 609.66 835.95 16.26 3 17.1 
P05155_GVTSVSQIFHSPDLAIR 609.66 785.42 16.26 3 17.1 
P05155_GVTSVSQIFHSPDLAIR 609.66 692.37 16.26 3 17.1 
P05155_HRLEDMEQALSPSVFK 472.49 664.37 13.77 2.5 12.2 
P05155_HRLEDMEQALSPSVFK 472.49 651.32 13.77 2.5 12.2 
P05155_HRLEDMEQALSPSVFK 472.49 577.33 13.77 2.5 12.2 
P05155_LLDSLPSDTR 558.80 890.42 10.34 2.5 15.3 
P05155_LLDSLPSDTR 558.80 775.39 10.34 2.5 15.3 
P05155_LLDSLPSDTR 558.80 575.28 10.34 2.5 15.3 
P05546_QFPILLDFK 560.82 845.51 19.79 3 15.4 
P05546_QFPILLDFK 560.82 635.38 19.79 3 15.4 
P05546_QFPILLDFK 560.82 522.29 19.79 3 15.4 
P05546_TLEAQLTPR 514.79 814.44 9.24 3 13.7 
P05546_TLEAQLTPR 514.79 685.40 9.24 3 13.7 
P05546_TLEAQLTPR 514.79 486.30 9.24 3 13.7 
P05546_YEITTIHNLFR 469.59 549.31 14.52 2.5 12.1 
P05546_YEITTIHNLFR 469.59 501.28 14.52 2.5 12.1 
P05546_YEITTIHNLFR 469.59 343.69 14.52 2.5 12.1 
P06396_AVEVLPK 378.24 585.36 8.52 3 8.8 
P06396_AVEVLPK 378.24 456.32 8.52 3 8.8 
P06396_AVEVLPK 378.24 244.17 8.52 3 8.8 
P06396_AVEVLPK.heavy 382.24 593.37 8.52 3 9 
P06396_AVEVLPK.heavy 382.24 464.33 8.52 3 9 
P06396_AVEVLPK.heavy 382.24 252.18 8.52 3 9 
P06396_DSQEEEKTEALTSAK 555.93 732.36 5.81 3 15.2 
P06396_DSQEEEKTEALTSAK 555.93 668.34 5.81 3 15.2 
P06396_DSQEEEKTEALTSAK 555.93 590.35 5.81 3 15.2 
P06396_QTQVSVLPEGGETPLFK 915.49 1373.73 15.81 3 28.2 
P06396_QTQVSVLPEGGETPLFK 915.49 1187.63 15.81 3 28.2 
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Compound Name 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Ret 
Time 
(min) 
Delta 
Ret 
Time 
Collision 
Energy 
P06396_QTQVSVLPEGGETPLFK 915.49 1074.55 15.81 3 28.2 
P06396_TGAQELLR 444.25 729.43 8.2 3 11.2 
P06396_TGAQELLR 444.25 658.39 8.2 3 11.2 
P06396_TGAQELLR 444.25 530.33 8.2 3 11.2 
P06396_VPFDAATLHTSTAMAAQHGMDDDGTGQK 719.08 893.06 11.79 2.5 21.1 
P06396_VPFDAATLHTSTAMAAQHGMDDDGTGQK 719.08 844.04 11.79 2.5 21.1 
P06396_VPFDAATLHTSTAMAAQHGMDDDGTGQK 719.08 360.66 11.79 2.5 21.1 
P06681_AVISPGFDVFAK 625.84 967.49 16.45 3 17.7 
P06681_AVISPGFDVFAK 625.84 880.46 16.45 3 17.7 
P06681_AVISPGFDVFAK 625.84 783.40 16.45 3 17.7 
P06681_DFHINLFR 354.52 549.31 15.45 3 8 
P06681_DFHINLFR 354.52 435.27 15.45 3 8 
P06681_DFHINLFR 354.52 400.23 15.45 3 8 
P08519_LFLEPTQADIALLK 786.46 1311.75 18.99 3 23.5 
P08519_LFLEPTQADIALLK 786.46 1198.67 18.99 3 23.5 
P08519_LFLEPTQADIALLK 786.46 1069.63 18.99 3 23.5 
P08519_NPDAVAAPYCYTR 749.34 1001.45 9.48 3 22.2 
P08519_NPDAVAAPYCYTR 749.34 930.41 9.48 3 22.2 
P08519_NPDAVAAPYCYTR 749.34 859.38 9.48 3 22.2 
P08603_IEGDEEMHCSDDGFWSK 681.27 964.86 16.76 3 19.7 
P08603_IEGDEEMHCSDDGFWSK 681.27 900.34 16.76 3 19.7 
P08603_IEGDEEMHCSDDGFWSK 681.27 685.27 16.76 3 19.7 
P08603_IEGDEEMHCSDDGFWSK 681.27 420.22 16.76 3 19.7 
P08603_LSYTCEGGFR 595.27 989.41 8.89 3 16.6 
P08603_LSYTCEGGFR 595.27 826.35 8.89 3 16.6 
P08603_LSYTCEGGFR 595.27 725.30 8.89 3 16.6 
P08603_SITCIHGVWTQLPQCVAIDK 776.06 930.47 15.93 3 23.1 
P08603_SITCIHGVWTQLPQCVAIDK 776.06 465.74 15.93 3 23.1 
P08603_SITCIHGVWTQLPQCVAIDK 776.06 262.14 15.93 3 23.1 
P08603_TGDEITYQCR 621.77 727.32 6.07 3 17.6 
P08603_TGDEITYQCR 621.77 463.21 6.07 3 17.6 
P08603_TGDEITYQCR 621.77 175.12 6.07 3 17.6 
P08603_VSVLCQENYLIQEGEEITCK 804.72 1206.57 16.93 3 24.2 
P08603_VSVLCQENYLIQEGEEITCK 804.72 1093.50 16.93 3 24.2 
P08603_VSVLCQENYLIQEGEEITCK 804.72 408.19 16.93 3 24.2 
P0C0L5_GLQDEDGYR 526.74 754.30 5.25 3 14.2 
P0C0L5_GLQDEDGYR 526.74 639.27 5.25 3 14.2 
P0C0L5_GLQDEDGYR 526.74 395.20 5.25 3 14.2 
P0C0L5_GSFEFPVGDAVSK 670.33 919.49 14.13 2.5 19.3 
P0C0L5_GSFEFPVGDAVSK 670.33 772.42 14.13 2.5 19.3 
P0C0L5_GSFEFPVGDAVSK 670.33 576.30 14.13 2.5 19.3 
P0C0L5_QGSFQGGFR 492.24 798.39 7.33 3 12.9 
P0C0L5_QGSFQGGFR 492.24 564.29 7.33 3 12.9 
P0C0L5_QGSFQGGFR 492.24 436.23 7.33 3 12.9 
P10643_ELSHLPSLYDYSAYR 605.30 774.34 14.25 2.5 17 
P10643_ELSHLPSLYDYSAYR 605.30 659.31 14.25 2.5 17 
P10643_ELSHLPSLYDYSAYR 605.30 496.25 14.25 2.5 17 
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P10643_ILPLTVCK 472.29 717.40 12.18 2.5 12.2 
P10643_ILPLTVCK 472.29 507.26 12.18 2.5 12.2 
P10643_ILPLTVCK 472.29 359.20 12.18 2.5 12.2 
P10643_LIDQYGTHYLQSGSLGGEYR 753.03 925.44 12.35 2.5 22.3 
P10643_LIDQYGTHYLQSGSLGGEYR 753.03 894.42 12.35 2.5 22.3 
P10643_LIDQYGTHYLQSGSLGGEYR 753.03 581.27 12.35 2.5 22.3 
P10643_LTPLYELVK 538.32 861.51 16.05 3 14.6 
P10643_LTPLYELVK 538.32 651.37 16.05 3 14.6 
P10643_LTPLYELVK 538.32 431.26 16.05 3 14.6 
P10909_FMETVAEK 477.73 807.39 7.5 3 12.4 
P10909_FMETVAEK 477.73 676.35 7.5 3 12.4 
P10909_FMETVAEK 477.73 547.31 7.5 3 12.4 
P10909_LFDSDPITVTVPVEVSR 937.50 1086.62 17.67 3 28.9 
P10909_LFDSDPITVTVPVEVSR 937.50 886.50 17.67 3 28.9 
P10909_LFDSDPITVTVPVEVSR 937.50 686.38 17.67 3 28.9 
P10909_VTTVASHTSDSDVPSGVTEVVVK 772.06 1201.53 11.55 2.5 23 
P10909_VTTVASHTSDSDVPSGVTEVVVK 772.06 1014.58 11.55 2.5 23 
P10909_VTTVASHTSDSDVPSGVTEVVVK 772.06 917.53 11.55 2.5 23 
P19823_FLHVPDTFEGHFDGVPVISK 747.72 872.93 16.75 3 22.1 
P19823_FLHVPDTFEGHFDGVPVISK 747.72 543.35 16.75 3 22.1 
P19823_FLHVPDTFEGHFDGVPVISK 747.72 398.22 16.75 3 22.1 
P19823_FYNQVSTPLLR 669.36 785.49 13.6 2.5 19.3 
P19823_FYNQVSTPLLR 669.36 686.42 13.6 2.5 19.3 
P19823_FYNQVSTPLLR 669.36 498.34 13.6 2.5 19.3 
P19823_IQPSGGTNINEALLR 791.93 1341.71 12.26 2.5 23.7 
P19823_IQPSGGTNINEALLR 791.93 1244.66 12.26 2.5 23.7 
P19823_IQPSGGTNINEALLR 791.93 1157.63 12.26 2.5 23.7 
P19827_AAISGENAGLVR 579.32 902.47 8.41 3 16.1 
P19827_AAISGENAGLVR 579.32 815.44 8.41 3 16.1 
P19827_AAISGENAGLVR 579.32 629.37 8.41 3 16.1 
P19827_EVAFDLEIPK 580.81 932.51 16.04 3 16.1 
P19827_EVAFDLEIPK 580.81 861.47 16.04 3 16.1 
P19827_EVAFDLEIPK 580.81 714.40 16.04 3 16.1 
P19827_FAHYVVTSQVVNTANEAR 669.34 874.44 10.78 2.5 19.3 
P19827_FAHYVVTSQVVNTANEAR 669.34 775.37 10.78 2.5 19.3 
P19827_FAHYVVTSQVVNTANEAR 669.34 661.33 10.78 2.5 19.3 
P27169_EVQPVELPNCNLVK 819.93 1086.56 13.39 2.5 24.7 
P27169_EVQPVELPNCNLVK 819.93 957.52 13.39 2.5 24.7 
P27169_EVQPVELPNCNLVK 819.93 844.43 13.39 2.5 24.7 
P27169_IQNILTEEPK 592.83 943.51 10.74 2.5 16.5 
P27169_IQNILTEEPK 592.83 716.38 10.74 2.5 16.5 
P27169_IQNILTEEPK 592.83 603.30 10.74 2.5 16.5 
P27169_YVYIAELLAHK 440.58 781.46 16.24 3 11.1 
P27169_YVYIAELLAHK 440.58 581.38 16.24 3 11.1 
P27169_YVYIAELLAHK 440.58 468.29 16.24 3 11.1 
P43652_AIPVTQYLK 516.81 848.49 12.99 2.5 13.8 
P43652_AIPVTQYLK 516.81 751.43 12.99 2.5 13.8 
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P43652_AIPVTQYLK 516.81 652.37 12.99 2.5 13.8 
P43652_ESLLNHFLYEVAR 530.95 637.33 18.46 3 14.3 
P43652_ESLLNHFLYEVAR 530.95 574.80 18.46 3 14.3 
P43652_ESLLNHFLYEVAR 530.95 517.77 18.46 3 14.3 
P51884_FNALQYLR 512.78 763.45 14.78 2.5 13.7 
P51884_FNALQYLR 512.78 692.41 14.78 2.5 13.7 
P51884_FNALQYLR 512.78 579.32 14.78 2.5 13.7 
P51884_ILGPLSYSK 489.29 864.48 11.63 2.5 12.8 
P51884_ILGPLSYSK 489.29 694.38 11.63 2.5 12.8 
P51884_ILGPLSYSK 489.29 597.32 11.63 2.5 12.8 
P51884_SVPMVPPGIK 512.80 610.39 12.41 2.5 13.7 
P51884_SVPMVPPGIK 512.80 511.32 12.41 2.5 13.7 
P51884_SVPMVPPGIK 512.80 419.75 12.41 2.5 13.7 
Q14624_EKAEAQAQYSAAVAK 522.27 908.48 5.54 3 14 
Q14624_EKAEAQAQYSAAVAK 522.27 709.39 5.54 3 14 
Q14624_EKAEAQAQYSAAVAK 522.27 546.32 5.54 3 14 
Q14624_EKAEAQAQYSAAVAK 522.27 459.29 5.54 3 14 
Q14624_ILDDLSPR 464.76 815.43 10.13 2.5 11.9 
Q14624_ILDDLSPR 464.76 702.34 10.13 2.5 11.9 
Q14624_ILDDLSPR 464.76 472.29 10.13 2.5 11.9 
Q14624_LGVYELLLK 524.33 934.56 17.84 3 14.1 
Q14624_LGVYELLLK 524.33 877.54 17.84 3 14.1 
Q14624_LGVYELLLK 524.33 778.47 17.84 3 14.1 
4.2.6 Determination of linearity of LeMBA pull-down 
 Serum sample (50 μg each) was spiked with 0.1 picomole, 0.5 picomole, 1 picomole, 10 
picomole, 100 picomole and 200 picomole of chicken ovalbumin per pull-down. Using this spiked-
in serum sample, LeMBA-MRM-MS was performed using NPL and JAC.    
4.2.7 Data processing 
 Raw data from MRM-MS experiment was processed using Skyline. All peaks were 
manually checked for correct integration, and peak area for each peptide (sum of all transitions) was 
exported for further analysis. For linearity experiments, the ratio of SIS:Natural peptide was 
calculated and plotted against SIS peptide spiked-in concentration. Median normalization was 
performed. Natural ovalbumin peptide peak intensity was first normalized with respective SIS 
labeled ovalbumin peptides. Next, using normalized intensity of natural ovalbumin peptide, the 
intensity of all other peptides was normalized. As mentioned in the methods above, methionine and 
non-methionine containing peptides were dealt with separately during normalization steps, to 
account for batch effects in methionine oxidation. For reproducibility experiments, the normalized 
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response with respect to ovalbumin peptide was calculated for each run, and the % CV of 16 
injections of the same sample run over a period of four days calculated.  
4.3 Results 
4.3.1 Nano-flow vs standard-flow LC-MRM-MS 
 The biomarker discovery was performed using LeMBA coupled with nano-HPLC-MS/MS 
(nano-HPLC-QTOF) system. For biomarker verification using LC-MRM-MS assay, two different 
systems were available. (i) nano-flow-HPLC-triple quadrupole mass spectrometer and (ii) standard-
flow-UHPLC-triple quadrupole mass spectrometer. The analytical performance of two instruments 
was compared for the MRM-MS based quantitation of a mix of 7 HSA peptide sample ran across 
range of dilutions. The chromatographic conditions for both instruments were optimized separately 
for this comparison. The result of one peptide is shown in Figure 4.2 as an example. Similar results 
were observed for the remaining 6 peptides, in terms of quantitation between nano-flow and 
standard-flow systems. Overall, the nano-flow system was found to be as much as 10-fold more 
sensitive as compared to standard-flow system.  
 Chromatographic peak shape and peak width are important analytical parameter to consider 
when comparing different chromatographic platforms. The chromatogram for peptide 
LVNEVTEFAK monitored using nano-flow and standard-flow MRM-MS is shown in Figure 4.3A 
and 4.3B respectively. The full width at half maxima (FWHM) for standard-flow chromatographic 
separation was 0.0333 min (2.00 sec) as compared to nano-flow chromatographic elution which was 
0.0961 min (5.77 sec) (Figure 4.3C). This means, in a complex biological sample such as human 
serum which contains ~10,000 proteins with a range of more than 10 order-of-magnitudes, 
standard-flow UHPLC will have better peak-to-peak resolution over nano-flow system. For the 
constant amount of sample injected, narrow and sharper peak over broader peak can be easy to 
distinguish from the background noise as well. It is proven that standard-flow UHPLC can handle 5 
to 10 times more samples in a single run as compared to nano-flow which means loss in analytical 
sensitivity can be compensated partly by injecting more amount of sample on column (422). It has 
also been demonstrated that along with narrower and sharper peak shapes, standard-flow UHPLC 
over nano-flow platform is less prone to interferences with the MRM transitions. Taken together, 
the appropriate system should be chosen based on sample availability i.e. if one is not limited by 
amount of sample than standard-flow UHPLC can provide equal sensitivity as compared to nano-
flow HPLC with additional benefits of robust and reproducible chromatography, better resolution 
and very low interferences for monitoring MRM transitions (422). LeMBA platform is not limited 
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by sample amount, so considering benefits of standard-flow system over nano-flow system; it was 
decided to set up MRM-MS assay on standard-flow-UHPLC coupled triple quadrupole mass 
spectrometer for biomarker verification.     
Figure 4.2. Comparison of nano-flow vs 
standard-flow coupled triple quadrupole mass 
spectrometer based on MRM-MS quantitation 
of HSA peptide LVNEVTEFAK.    
 
 
 
 
Figure 4.3. Chromatographic elution profile for nano-flow vs standard-flow LC-MRM-MS. 
Elution of HSA peptide LVNEVTEFAK (Transitions 575.3  937.5 and 575.3  694.4; @ 
Collision energy (CE) 20 eV) was monitored using MRM-MS for (A) nano-flow-HPLC and (B) 
standard-flow-UHPLC. (C) Demonstrates comparison between FWHM of 100 femtomole injection 
of HSA peptide mix on nano-flow and standard-flow LC-MRM-MS. 
4.3.2 MRM-MS assay development 
 Six lectins (AAL, EPHA, JAC, NPL, PSA, and WGA) were chosen for verification. The 
following three criteria were considered for choosing lectins. (i) Total number of candidates 
identified with each lectin in the biomarker discovery screen (Chapter 3), (ii) Previously published 
serum glycan profiling and lectin histochemistry studies that compared between healthy, BE and 
EAC phenotypes (169, 170, 175, 179), and (iii) Glycan reactivity group for each of the lectin. 
MRM-MS assay was developed for 41 glycoprotein candidates identified in biomarker discovery 
screen. Figure 4.4 illustrates the steps followed for developing MRM-MS assay. The discovery 
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proteomics data described earlier in Chapter 3 was used to select best possible peptides and 
transitions for developing MRM-MS assay. 
Figure 4.4. Steps followed for development of MRM-MS assay development.  
 To select 2-5 unique peptides per protein and 3 transitions per peptide for MRM-MS assay, 
a maximum of 10 peptides per protein and 5 transitions per peptide were imported from biomarker 
discovery data using MRM selector function of Spectrum Mill. Agilent triple quadrupole mass 
spectrometer can handle a maximum 200 transitions per MRM method. Collectively, 6 methods 
were created incorporating transitions to monitor peptides used as retention time prediction 
standards. LC gradient was kept constant throughout different stages of MRM method development. 
As a first step of method development, a combined LeMBA pull-down sample from multiple lectins 
was injected and around 1200 transitions in 6 different MRM methods were monitored. Peptides 
eluting at a retention time predicted by iRT and transitions showing no interferences were selected 
for the next round. In the second stage, 3 MRM methods were run in triplicates to qualify 
transitions showing reproducible responses and to determine retention time of each peptide. In the 
third and final step, MRM transitions were scheduled whereby retention time and delta retention 
time for each peptide was specified to create ultimate dynamic (schedule) MRM method. The 
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dynamic MRM method monitors 465 transitions in 34 min to quantify 145 peptides representing 41 
protein candidates. 
 Peptides with methionine in their sequence (which can undergo oxidation as variable 
modification) were excluded from MRM-MS assay as far as possible. For six of the proteins, 
peptides containing methionine showed stable response at least during the method development 
stages. So in final MRM-MS assay these six peptides containing methionine were chosen. It is 
important to highlight that for all of these six proteins at least two non-methionine containing 
peptides were monitored. In addition, four methionine containing peptides monitored were 
belonging to chicken ovalbumin. 
4.3.3 Retention time prediction 
 In a chromatographic separation, a peptide elutes at a particular retention time, adding one 
more dimension to the mass spectrometric data recordings. The peptide retention time parameter 
can be used as an independent way to qualify a peptide for MRM-MS assay development. The 
retention time of a peptide for a particular LC set up is determined by 3 factors (421). (i) Intrinsic 
properties of a peptide. It is determined by peptide sequence and structure along with the 
physicochemical interaction of the peptide with stationary phase and the solvent used for elution 
(423, 424), (ii) The set up of LC system which affects all peptides consistently and affected by 
parameters like column length, column temperature, mobile phase gradient, dead volume in the 
system (425), and (iii) variability in the LC system caused by varying amount of sample loading, 
variations due to pump pressure or column aging. In this thesis, the biomarker discovery was 
performed using nano-flow-HPLC-QTOF instrument while MRM-MS assay for biomarker 
verification was developed on standard-flow-UHPLC-triple quadrupole mass spectrometer. 
Considering the two LC platforms are different, it was anticipated that peptide retention time for the 
same peptide would vary between two systems. iRT retention time prediction tool (421) built in 
Skyline (420) was used as an independent parameter to qualify peptides and to increase peak 
identification confidence for MRM-MS assay development. The iRT scale was calibrated using 
known retention time of 6 peptides mentioned in Table 4.1. Transitions for each of these 6 peptides 
were monitored across all stages of MRM-MS assay development. 
 The serum/plasma proteome is complex hence it is possible to see interferences and similar 
looking peaks while selecting transitions for MRM-MS assay development. Figure 4.5A 
demonstrates practical application of retention time prediction tool. As can be seen from 
chromatogram, there are two identical looking peaks for peptide YGLVTYATYPK at retention 
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time 12.4 min and 13.7 min respectively. The predicted retention time according to iRT is 12.4 min 
suggesting response seen at 12.4 min is due to actual peptide YGLVTYATYPK while peak seen at 
13.7 min is due to interference. In the scenario where peptide retention time prediction tool would 
not be employed, this kind of transitions (or even peptides) would have been dropped from the 
MRM assay due to lack of confidence. Figure 4.5B and 4.5C shows regression analysis between 
iRT value and observed retention time of peptides for 1
st
 step of MRM-MS assay development and 
final MRM-MS assay. The majority of the peptides observed in 1
st
 stage of MRM-MS assay 
showed response at the retention time predicted by iRT. Peptides which didn't elute at the correct 
retention time were eliminated from the MRM-MS assay. The resulting dynamic MRM-MS assay 
showed a perfect correlation between iRT value and observed retention time in experiments. 
Figure 4.5. Implication of retention time prediction tool iRT on MRM-MS assay development. 
(A) Illustrates chromatographic elution profile of peptide YGLVTYATYPK [Transitions 638.3  
942.5, 843.4 and 742.4; @ Collision energy (CE) 18.2 eV]. Out of two peaks observed at retention 
time 12.4 min and 13.7 min, peak at 12.4 min corresponds with retention time predicted by iRT. 
Regression analysis between observed retention time and iRT value (B) for 1
st
 stage of MRM-MS 
assay development and, (C) for final dynamic MRM-MS assay.       
4.3.4 Incorporation of heavy labeled internal standard peptides 
 The nature of LC-MRM-MS assay allows incorporation of stable isotope labeled peptides 
(heavy amino acid labeled peptide bearing same sequence as natural peptide) as an internal 
standard. While synthesizing stable isotope standard (SIS) peptides, one or more amino acid in the 
natural peptide sequence is replaced with isotopic Carbon (
13
C6) and Nitrogen (
15
N7) atom counter 
parts. The resulting heavy labeled peptide carries same chemical properties as the natural peptide 
hence it elutes at the same time as the natural peptide during chromatography. However, SIS 
peptide differs in terms of its mass because of isotopic labeling. Trypsin is most commonly used 
proteolytic enzyme used in the proteomics workflows which digest proteins into peptides containing 
either lysine (K) or arginine (R) at C-terminus. Hence most common labeling for internal standard 
peptide uses either isotopically labeled lysine (K) or Arginine (R). In terms of mass, isotopic 
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Carbon and Nitrogen labeled lysine and arginine differ from natural peptide by 8 Da and 10 Da 
respectively. 
 SIS peptides are generally spiked-into the sample after the trypsin digest step and before 
mass spectrometric analysis. This allows absolute quantitation of peptides present in the samples 
using known concentration of spiked-in internal standard. Here, the purpose of incorporating SIS 
peptides into the workflow is to account for mass spectrometric variations over a period of time 
while screening patient samples for biomarker verification. Native chicken ovalbumin is spiked-in 
at the sample preparation step to account for variations due to sample processing and LeMBA pull-
down. In biomarker discovery (Chapter 3), ovalbumin peptides showed %CV around 40% which is 
accounted for variations due to sample preparation and LeMBA pull-down plus variations due to 
mass spectrometric analysis. For biomarker verification, the goal is to reduce this variation to allow 
better quantitation hence SIS peptides for chicken ovalbumin were incorporated into the workflow 
just before mass spectrometric analysis to separately account for mass spectrometric variation from 
variability arising due to sample preparation and LeMBA pull-down. Two ovalbumin peptides 
VASMASEK which contains methionine and ISQAVHAAHAEINEAGR without methionine were 
chosen. The methionine containing peptide was chosen to account for batch effect of methionine 
oxidation. Sum of two charge states +3 and +4 was used for normalization. In Chapter 3, gelsolin 
and haptoglobin were successfully validated using orthogonal technique LeMBA-western 
immunoblotting. So to be more confident, isotopic [
13
C6, 
15
N7] lysine labeled peptide AVEVLPK 
(belongs to gelsolin), and VTSIQDWVQK (belongs to haptoglobin) were also incorporated as 
internal standard peptides. Ideally, the concentration of spiked-in SIS peptide should be adjusted 
such that its response falls within 10-fold range of natural peptide (426). The optimized spiked-in 
amount was found to be 150 femtomole for ISQAVHAAHAEINEAGR and VASMASEK each, 
300 femtomole for VTSIQDWVQK, and 30 femtomole for AVEVLPK. Figure 4.6 illustrates 
examples of co-elution of SIS labeled peptides within 10-fold response of natural peptide. 
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Figure 4.6. Incorporation of stable isotope standard (SIS) peptides into MRM-MS assay. Co-
elution of heavy isotope labeled peptide and natural peptide for (A) VASMASEK, (B) 
ISQAVHAAHAEINEAGR, (C) AVEVLPK and (D) VTSIQDWVQK. Peak areas of heavy 
peptides fell within 10-fold of natural peptide levels.  
4.3.5 Linearity and reproducibility of MRM-MS assay 
 The linearity of the MRM-MS assay was evaluated by spiking a range of dilutions of 4 SIS 
peptides, spanning a 3125 fold dilution range, into a constant amount of LeMBA pull-down sample. 
As shown in Figure 4.7A, all 4 SIS peptides showed linear response from 25X dilution up to 
0.008X. The reproducibility of the MRM method was determined by running the same sample in 
quadruplicate for four consecutive days. As illustrated in Figure 4.7B, 86% of the peptides 
measured using MRM method showed percent coefficient of variation (%CV) below 10%, while 
9% of peptides showed %CV between 10-20%, and only 5% of the peptides were above 20%. Out 
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of 8 peptides that showed %CV greater than 20%, 7 of them were methionine containing peptides. 
The remaining peptide showed % CV of 20.1% which is just above empirical cut-off of 20%. 3 out 
of 10 methionine containing peptides showed %CV of 0.96% (VASMASEK), 3.84% 
(HRLEDMEQALSPSVFK) and 16.75% (NVLQPSSVDSQTAMVLVNAIVFK) suggesting 
variable oxidation of methionine may depend upon the peptide sequence. This experiment also 
determined the stability of the sample resuspended in 0.1% formic acid under the storage condition 
in the auto sampler. It was anticipated that once samples were resuspended in 96 well plates, they 
would be run within three days. Hence reproducibility was checked for four consecutive days after 
reconstituting samples. Taken together, MRM-MS assay developed was linear and reproducible. 
Figure 4.7. 
Determination of 
linearity and 
reproducibility of 
MRM-MS assay. 
(A) Linearity of 
MRM-MS assay 
was confirmed using 
SIS labeled peptide 
mix of 4 peptides 
diluted across 3125 
fold and spiked-into 
a constant amount of 
LeMBA pull-down sample. (B) Reproducibility of MRM-MS assay was determined for 16 replicate 
injections ran over 4 days period. 
4.3.6 Optimization of loading capacity for each lectin pull-down 
 Loading capacity (amount of peptide to be loaded on LC column) for each lectin pull-down 
was optimized individually. With increase in amount of peptide loaded on the column, the peak area 
from MRM-MS measurement show corresponding increase until certain threshold is reached. The 
optimal loading capacity is reached when the increase in sample amount no longer results in 
increase in the MRM-MS response (422). To determine the loading capacity for each lectin pull-
down, varying amount of LeMBA pull-down was mixed with SIS peptides and injected into the 
mass spectrometer. Peak areas across all peptides between different injection volumes were 
monitored to determine loading capacity for each lectin. Replicate comparison tool of Skyline was 
very useful to compare peak areas across different injection volumes. Based on this comparison, 
following protocol was used for final experiments.  10 μL of the LeMBA pull-down reconstituted in 
0.1% formic acid was mixed with 6 μL SIS peptide mixture containing 150 femtomole of 
ISQAVHAAHAEINEAGR and VASMASEK each, 300 femtomole of VTSIQDWVQK, and 30 
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femtomole of AVEVLPK. Out of the total 16 μL mixture, the optimized loading for AAL, JAC, 
NPL and PSA lectin was 13 μL, EPHA lectin was 11.5 μL and WGA lectin was found to be 12.5 
μL.     
4.3.7 Linearity of LeMBA pull-down 
 Earlier work from our laboratory determined linearity of LeMBA pull-down by spiking-in 
different amount of chicken ovalbumin into human serum, followed by pull-down using ConA 
lectin and nano-flow HPLC-MS/MS for quantitation (317). Here, the linearity of LeMBA pull-
down was tested by spiking 50 μg of serum proteins with 0.1 picomole (4.43 ng), 0.5 picomole 
(22.14 ng), 1 picomole (44.29 ng), 10 picomole (442. 7 ng), 100 picomole (4.43 μg) and 200 
picomole ( . 6 μg) of chicken ovalbumin at the time of sample denaturation. LeMBA pull-down 
was performed in triplicate using NPL and JAC lectin, followed by quantitation of ovalbumin 
peptide using standard-flow UHPLC-MRM-MS assay. As can be seen from graph in Figure 4.8, 
there was linear increase in MRM-MS response with increasing amount of ovalbumin titrated in the 
background of serum proteins. Below 0.5 picomole, the pull-down showed non-reproducible results 
while above 100 picomole the beads were getting saturated hence no more increase in response was 
observed.  
Figure 4.8. Linearity of LeMBA pull-down. The linearity of LeMBA pull-down was tested by 
titrating chicken ovalbumin in the background of serum protein for NPL and JAC LeMBA pull-
down. Quantitation was performed using standard-flow UHPLC-MRM-MS by monitoring 
transitions for peptides (A) VASMASEK, (B) ISQAVHAAHAEINEAGR, and (C) 
YPILPEYLQCVK. 
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4.4 Discussion 
4.4.1 Overview 
 While LeMBA-MS/MS using QTOF and GlycoSelector successfully identified candidate 
biomarkers (Chapter 3), QTOF is not optimal for biomarker verification as the measurements are 
semi-quantitative. Therefore, the aim of present chapter was to establish a targeted assay using 
MRM-MS for biomarker candidates identified in Chapter 3. MRM-MS assay was set up on 
UHPLC-coupled triple quadrupole mass spectrometer. Later on, SIS peptides were incorporated in 
the assay. The established MRM-MS assay demonstrated good linearity and reproducibility. After 
determining optimal loading for each lectin pull-down, linearity of LeMBA pull-down was also 
confirmed.  
4.4.2 Nano-flow vs standard-flow HPLC: Does it matter? 
 Nano-flow HPLC coupled mass spectrometry enables protein discovery using very minute 
quantity of biological sample. Now it has almost become a method of choice in protein biomarker 
discovery using limited quantity of available biological samples (427, 428). Compared with 
capillary (~50 μL/min) and standard-flow (~500 μL/min) HPLC, nano-flow HPLC (~500 nL/min) 
offers substantial increase in sensitivity and detection capabilities but at the cost of ease of use and 
system robustness (429). In addition, this technology is not mature enough to consistently analyze 
hundreds of samples in reproducible manner hence not ideal for biomarker verification purposes 
(429). Recently, it has been demonstrated that when sample amount is not limited, standard-flow 
UHPLC coupled triple quadrupole mass spectrometer can provide comparable sensitivity against 
nano-flow system with the additional benefits of increase in dynamic range (422). In my 
experience, standard-flow UHPLC coupled triple quadrupole mass spectrometer is very stable over 
a long period of time, requires less maintenance hence yield less system down time as compared to 
nano-flow coupled triple quadrupole mass spectrometer. Moreover, in agreement with observation 
made by Percy and colleagues (422), the result described in this chapter demonstrates narrow 
chromatographic peak width using standard-flow UHPLC over nano-flow HPLC and offers better 
quantitation and less interference while developing MRM-MS assay (422). 
 Running and maintaining sophisticated instruments like a mass spectrometer is very costly 
hence all possible efforts should be made during assay development to keep total run time of the 
method and overall screening as minimal as possible. With nano-flow HPLC coupled QTOF mass 
spectrometer used for biomarker discovery, blank had to be run after running each sample to reduce 
the carry-over of the sample which resulted in almost 30% increase in total time spent on the 
125 
 
instrument. Initial experiments using standard-flow UHPLC coupled mass spectrometer resulted in 
no carry-over of the sample during subsequent runs hence blank injection after each sample run was 
not required. Furthermore, over a long period of time, retention time reproducibility of the standard-
flow system is superior compared to the nano-flow system. This means the delta retention time for 
each transition can be minimized allowing better multiplexing, longer dwell time (amount of time 
spent to analyze and detect one ion) for each transition, and lower time for overall method. Taken 
together, as LeMBA methodology was not limited by sample size, it was decided to use standard-
flow UHPLC over nano-flow HPLC platform for biomarker verification study. 
4.4.3 MRM-MS assay  
 Multiple reaction monitoring has emerged as a practical alternative to antibody based 
platforms for accurate, rapid, reproducible and timely verification of protein biomarker candidates 
(410). This chapter demonstrates successful development of MRM-MS assay to monitor 41 
glycoprotein biomarker candidates in very short time duration of 34 min. iRT, a retention time 
prediction tool was successfully employed to predict peptide retention time and to increase 
confidence for peptide identification (421). Each peptide based on its sequence elutes at a specific 
retention time which can be predicted based upon its hydrophobicity. The most widely used 
algorithm to predict retention time was SSRCalc (430) until iRT was developed. iRT showed 
almost 4 times improvement over SSRCalc to predict retention time of the peptides (421). Skyline 
software version 1.2 and beyond incorporates iRT. Previous studies used a peptide mix of 
commercially available synthetic standards with different hydrophobicities (hence different 
retention times) to calibrate iRT scale (431). In contrast, the result described in this chapter used 
peptides from internal standard chicken ovalbumin that covered entire gradient and two other heavy 
labeled peptides to calibrate iRT scale, and lead to successful prediction of retention time. This 
result demonstrates an additional application of using internal standard such as chicken ovalbumin 
for retention time prediction. With the use of very powerful retention time prediction algorithm 
such as iRT it is very easy to transfer MRM methods across different instruments even from 
different vendors. This is very useful in later stages of biomarker development to conduct multi-
center evaluation of biomarker candidates in laboratories across the world with different instrument 
configurations (432). The iRT can also be applied to newly emerging data independent acquisition 
platforms such as SWATH-MS for biomarker discovery studies (433, 434).      
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4.4.3.1 Incorporation of relative quantitation in MRM-MS assay using stable isotope labeled 
peptides 
 Almost a decade after the entire human genome was sequenced, mass spectrometry based 
draft of the entire human proteome is now available (435, 436). With availability of this wealth of 
information and recent advancements in targeted proteomics techniques, it is now feasible to 
perform absolute or relative quantitation of proteins by accurately measuring the peptide 
constituents. Stable isotope labeled peptide standards (SIS) are widely used for the mass 
spectrometric quantitation purposes (437). One of the amino acid constituent of SIS peptide is 
labeled with isotopic carbon (
13
C6) and/or nitrogen (
15
N7) atom. This causes SIS peptide to share 
exactly same physicochemical properties as its light (natural) counterpart, with the exception of 
overall mass. Workflow such as stable isotope standards and capture by anti-peptide antibodies 
(SISCAPA) involves addition of SIS peptide to the sample as internal standard and uses a specific 
antibody to capture a target peptide from a tryptic digest of plasma (438). Although SISCAPA 
requires expertise to generate anti-peptide antibody of high quality, it is very sensitive, high-
throughput and has potential to overcome current limitations of immunoassays (439). In this 
chapter, SIS peptides for internal standard chicken ovalbumin were used to separately account for 
mass spectrometric variation from variation due to LeMBA pull-down. SIS peptides were spiked 
into the LeMBA pull-down at the time of reconstitution of the sample for mass spectrometric 
analysis. For best results, response of SIS peptide should fall within 10-fold of response observed 
for natural peptide (426). Each peptide based on its physicochemical properties has different 
ionization efficiency and column retention. This means, injecting same amount of different peptides 
sequences will result in varying responses hence the amount of each SIS peptide to be spiked-in was 
individually optimized with success as mentioned in the result section. 
4.4.3.2 Linearity and reproducibility of the assay 
 Plasma proteome is the most complex proteome and it extends over quantitative dynamic 
range of 10
10
 fold. High abundant proteins such as albumin is present at the level of 35 to 50 
mg/mL (3-5˟1010 pg/mL) while on the lower side interleukin-6 is present in the range of 
undetectable to 5 pg/mL levels (362). For the biomarker verification assay, it is necessary to cover 
at least part of this extended dynamic range. The result described in this chapter confirms linearity 
of the MRM-MS assay over 4 log10 range.  
 The acceptable %CV for a mass spectrometry based biomarker verification assay is less than 
20% (422). As mentioned in the result, the majority of the measured peptides show %CV of less 
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than 20% suggesting robust performance of MRM-MS. Figure 4.9 below shows further breakdown 
of the results of the MRM-MS reproducibility experiment. It is evident that normalizing raw peptide 
intensities using SIS peptide measurements resulted in lower % CV (better reproducibility) as 
compared to raw intensities itself. This means that small variations during mass spectrometry 
analysis are accounted for by inclusion of SIS peptides into the workflow. Over periods of time this 
will reduce the technical variations and improve the quantitation.  
Figure 4.9. Reproducibility of MRM-MS assay before 
and after normalization using SIS peptides.        
 
  
 
 
   
 Earlier work by Dr Choi optimized the amount of serum to be used for LeMBA pull-down 
while keeping amount of lectin-beads for pull-down constant. The amount of serum protein was 
optimized such that it falls within linear range of pull-down efficiency i.e. increase in amount of 
serum protein resulted into increased binding with the lectin-beads. This earlier work also 
determined linearity of LeMBA by spiking serum with increasing amount of chicken ovalbumin 
followed by pull-down using ConA lectin and nano-LC-MS/MS analysis (317). In this chapter, the 
linearity of LeMBA pull-down using NPL and JAC lectin has been tested. Chicken ovalbumin was 
spiked from 4.43 ng to  . 6 μg into 50 μg of serum proteins. A linear increase in response was 
observed up to 4.43 μg (100 picomole) of chicken ovalbumin amount, beyond which there was no 
increase in response suggesting saturation of lectin-beads at such a high concentration. According to 
an estimate, up to 50% of the proteins synthesized undergo glycosylation (327, 440). Except 
albumin which constitute ~50% of the proteome (362), if 50% of the remaining serum proteins are 
glycoproteins then approximately 12.5 μg out of 50 μg of serum proteins used per lectin pull-down 
are glycosylated.  . 6 μg of chicken ovalbumin is more than 50% of total serum glycoprotein used 
for the pull-down hence it was expected to see saturation of lectin-beads when ovalbumin was 
spiked-in at very high levels.  
 In conclusion, this chapter describes successful development of MRM-MS assay for 41 
glycoprotein candidates. The assay measures 2-5 peptides for each of 41 glycoprotein candidates in 
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a 34 min MRM-MS method. The assay showed linear response and was found to be reproducible. 
This targeted proteomics assay will be used for verification of biomarker candidates in an 
independent patient cohort.   
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Chapter 5. 
 
VERIFICATION OF LECTIN−GLYCOPROTEIN BIOMARKER CANDIDATES 
USING LEMBA−COUPLED MRM-MS   
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Chapter 5. Verification of lectin−glycoprotein biomarker candidates using LeMBA−coupled 
MRM-MS 
5.1 Introduction 
 The translation of candidate biomarker discovered in research laboratory based discovery 
screen to clinical use involves several stages of validation. As the potential candidates move 
forward from initial discovery stages to later validation stages, the list of number of candidate 
biomarkers screened gets smaller while the number of patient samples screened increases (133, 
409). Generally, anywhere from dozens up to hundreds of protein candidate biomarkers are selected 
as potential biomarkers after completion of biomarker discovery phase. The sample size of the 
biomarker discovery is small hence interindividual and intraindividual variations are overlooked. 
Moreover, the distribution of physiological levels of candidate biomarkers in healthy population 
may result in a bias during biomarker discovery. The presence of confounding risk factors add 
another layer of complexity and result in identification of false-positive candidates at this initial 
stage (358). In the recent past, literature has been flooded with publications describing outcome of 
biomarker discovery studies but evidence of verified list of biomarker candidates ready for clinical 
validation are seldom (358, 362, 441). Hence, for translational outcome it is essential to verify the 
biomarker candidates identified during biomarker discovery in an independent patient cohort before 
conducting large scale clinical validation.   
 The main goal of biomarker verification is to evaluate performance of the biomarker 
candidates in an independent patient cohort and establish sensitivity, specificity, area under receiver 
operating characteristics curve (AUROC) and statistical significance of an individual candidate. The 
sensitivity of a biomarker is defined as the proportion of patients with disease who will have a 
positive readout for the biomarker measurement (442). The specificity of a test is defined as the 
percentage of cohort without underlying disease who will have negative results when tested for a 
particular biomarker candidate (442). For continuous variables such as mass spectrometric 
measurements, sensitivity and specificity values vary according to the cut-off (threshold) set for 
classifying patients into disease or healthy phenotypes. The ROC curve is generated by plotting 
sensitivity of all possible cut-off points for the test on y-axis against 1-specificity on x-axis (443). 
The ROC curve is a graphical representation for assessing the ability of a test to discriminate 
between disease and healthy patient groups (444). It is widely accepted as a method of choice to 
decide test cut-off for diagnostic purposes (444, 445). AUROC is a reflection of how good the test 
is at distinguishing between healthy and disease condition and can be used as a single measure to 
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measure the discriminative ability of a test (446). A perfect biomarker will show AUROC of 1.0 
while AUROC of 0.5 indicates biomarker of no use. The biomarker with AUROC > 0.9 has a high 
accuracy, between 0.7-0.9 has moderate accuracy while between 0.5-0.7 indicates low accuracy 
(446). Quiet often, a panel of complementary biomarker candidates is identified to improve the 
diagnostic value of a single biomarker candidate. Similar to single biomarker candidate, sensitivity, 
specificity, and AUROC value can be determined for a panel of biomarker candidates. 
 The present chapter describes verification of lectin-protein diagnostic biomarker candidates 
identified in Chapter 3 using targeted MRM-MS assay developed in Chapter 4 in an independent 
patient cohort. Statistical significance and AUROC values were calculated for individual biomarker 
candidates. Furthermore, multivariate analysis was performed to identify a biomarker panel which 
discriminate between BE and EAC.  
5.2 Experimental procedures 
5.2.1 Sample information 
 Serum samples from 61 patients (healthy-20, BE-21 and EAC-20) were randomized for 
LeMBA pull-down. 19 Population control samples were not randomized. Total 80 serum samples 
were divided across 7 plates for LeMBA pull down and mass spectrometry analyses (Plate 1 - A1, 
A2, A3, A4, A5, A6, A7, A8, A9, B1, I7; Plate 2 - E9, E4, C2, F2, E5, C3, F3, E6, C4, F5, E7, C5; 
Plate 3 - E8, C6, F9, F1, C7, G1, F4, C8, G2; Plate 4 - D1, G6, F8, D2, G7, G3, D3, G9, G5, D4, 
H1, G8; Plate 5 - D5, H3, H2, D6, H5, H4, D7, H6, H7, D8, I1, H8; Plate 6 - I2, H9, D9, I3, I5, E1, 
I4, I8, E2, I6, I9, E3; and Plate 7 - F6, C9, G4, B2, B3, B4, B5, B6, B7, B8, B9, C1). Details 
regarding source of the serum samples is described in section 2.3. Table 5.1 contains details of the 
samples used for biomarker verification. All samples were collected from male patients and 
matched for age. Sample I7 was found to be an outlier after LeMBA-MRM-MS data analysis so 
now onwards remaining 79 patient samples are considered for data analysis. For categorical and 
numerical variables related to patient information, P values were calculated using Fisher's exact test 
and Kruskal-Wallis test respectively. Table 5.2 summarizes clinical characteristics of the patient 
cohort for biomarker verification.    
Table 5.1. Details of samples used for biomarker verification. 
Sample ID Phenotype Age* Body mass 
index#  
Smoking 
status 
Cumulative 
smoking 
history 
Alcohol 
consumption$ 
Reflux 
frequency& 
F3 43168 BE negative 50.43 Obese I (-<35) Current 30+ pack yrs 21+ std Daily 
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smoker drinks/wk 
G7 43316 BE negative 56.41 Obese I (-<35) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Never 
G2 43280 BE negative 57.11 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
21+ std 
drinks/wk 
<Once/month 
G6 48024 BE negative 58.53 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
<1 std 
drink/wk 
Monthly (few 
times/mo) 
H4 43302 BE negative 58.55 Overweight(-<30) Never 
Smoker 
Never smoked 1-6 std 
drinks/wk 
Monthly (few 
times/mo) 
H1 45295 BE negative 58.66 Obese I (-<35) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Never 
H9 48092 BE negative 62.77 Obese I (-<35) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Daily 
G1 45257 BE negative 64.04 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
Monthly (few 
times/mo) 
H8 48077 BE negative 64.25 Obese I (-<35) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Never 
F9 43202 BE negative 64.31 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
1-6 std 
drinks/wk 
Never 
H7 48072 BE negative 64.39 Obese I (-<35) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
Weekly (few 
times/wk) 
G4 43291 BE negative 70.57 Healthy wt (-<25) Never 
Smoker 
Never smoked 1-6 std 
drinks/wk 
<Once/month 
F2 45203 BE negative 71.85 Healthy wt (-<25) Ex-Smoker 1-29.9 pack 
yrs 
21+ std 
drinks/wk 
<Once/month 
G9 43325 BE negative 71.93 Healthy wt (-<25) . 1-29.9 pack 
yrs 
21+ std 
drinks/wk 
. 
I9 43668 BE negative 73.11 Healthy wt (-<25) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Monthly (few 
times/mo) 
I5 43552 BE negative 73.55 Obese I (-<35) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Weekly (few 
times/wk) 
H2 48051 BE negative 73.72 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
<1 std 
drink/wk 
Monthly (few 
times/mo) 
I8 43636 BE negative 74.66 Overweight(-<30) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Never 
E9 46070 BE negative 74.77 Overweight(-<30) Current 
smoker 
30+ pack yrs 7-20 std 
drinks/wk 
Monthly (few 
times/mo) 
F5 43211 BE negative 74.97 Healthy wt (-<25) Never 
Smoker 
Never smoked None Never 
F8 47034 BE positive 51.54 Overweight(-<30) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Daily 
H3 45303 BE positive 52.22 Overweight(-<30) Never 
Smoker 
Never smoked 21+ std 
drinks/wk 
Monthly (few 
times/mo) 
E7 43123 BE positive 55.16 Obese I (-<35) Ex-Smoker 1-29.9 pack 
yrs 
1-6 std 
drinks/wk 
Never 
E5 43059 BE positive 55.89 Overweight(-<30) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Daily 
E4 43014 BE positive 55.92 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
<1 std 
drink/wk 
Monthly (few 
times/mo) 
F1 46010 BE positive 57.25 Overweight(-<30) Current 
smoker 
30+ pack yrs 21+ std 
drinks/wk 
Never 
F4 46077 BE positive 57.77 Healthy wt (-<25) Ex-Smoker 1-29.9 pack 
yrs 
21+ std 
drinks/wk 
Weekly (few 
times/wk) 
E6 45062 BE positive 58.79 Overweight(-<30) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Monthly (few 
times/mo) 
E8 45159 BE positive 58.84 Overweight(-<30) Never Never smoked 21+ std Daily 
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Smoker drinks/wk 
I6 43563 BE positive 60.22 Healthy wt (-<25) Ex-Smoker 1-29.9 pack 
yrs 
21+ std 
drinks/wk 
Monthly (few 
times/mo) 
H5 45328 BE positive 60.33 Obese I (-<35) Never 
Smoker 
Never smoked 21+ std 
drinks/wk 
<Once/month 
I2 43477 BE positive 63.45 Overweight(-<30) Current 
smoker 
1-29.9 pack 
yrs 
21+ std 
drinks/wk 
Daily 
I1 48094 BE positive 64.06 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
1-6 std 
drinks/wk 
Monthly (few 
times/mo) 
H6 43380 BE positive 64.72 Overweight(-<30) Never 
Smoker 
Never smoked 1-6 std 
drinks/wk 
Never 
G5 48015 BE positive 70.47 Obese I (-<35) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Never 
I4 45421 BE positive 74 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
<1 std 
drink/wk 
<Once/month 
F6 45210 BE positive 74.34 Healthy wt (-<25) Never 
Smoker 
Never smoked 1-6 std 
drinks/wk 
Daily 
G8 43315 BE positive 74.46 Healthy wt (-<25) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
<Once/month 
I3 45435 BE positive 74.75 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
Monthly (few 
times/mo) 
G3 43269 BE positive 74.98 Healthy wt (-<25) Never 
Smoker 
Never smoked None Daily 
I7 46216 BE positive 74.65 Healthy wt (-<25) Never 
Smoker 
Never smoked 1-6 std 
drinks/wk 
Monthly (few 
times/mo) 
A4 93136 Control 53.45 Overweight(-<30) Never 
Smoker 
Never smoked 21+ std 
drinks/wk 
Monthly (few 
times/mo) 
A3 94236 Control 53.95 Obese I (-<35) Never 
Smoker 
Never smoked 1-6 std 
drinks/wk 
<Once/month 
B4 94424 Control 56.24 Obese I (-<35) Never 
Smoker 
Never smoked 21+ std 
drinks/wk 
<Once/month 
C1 95133 Control 56.61 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
<1 std 
drink/wk 
Never 
B9 94429 Control 56.72 Healthy wt (-<25) Current 
smoker 
30+ pack yrs 7-20 std 
drinks/wk 
<Once/month 
B5 95083 Control 58.84 Healthy wt (-<25) Never 
Smoker 
Never smoked 1-6 std 
drinks/wk 
Monthly (few 
times/mo) 
B8 95101 Control 59.8 Overweight(-<30) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Never 
A1 96061 Control 60.66 Obese I (-<35) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Daily 
A6 94259 Control 61.31 Obese II (-<40) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
Never 
A2 94126 Control 62.29 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
1-6 std 
drinks/wk 
Never 
A5 94261 Control 62.82 Healthy wt (-<25) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
<Once/month 
A7 94432 Control 63.11 Healthy wt (-<25) Ex-Smoker 30+ pack yrs 1-6 std 
drinks/wk 
<Once/month 
B3 95154 Control 70.57 Healthy wt (-<25) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Never 
A9 94449 Control 70.79 Overweight(-<30) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
<Once/month 
B7 96189 Control 72.76 Overweight(-<30) Ex-Smoker 30+ pack yrs 7-20 std 
drinks/wk 
Monthly (few 
times/mo) 
B6 92358 Control 73.05 Overweight(-<30) Ex-Smoker 1-29.9 pack 21+ std Monthly (few 
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yrs drinks/wk times/mo) 
B2 94452 Control 73.42 Healthy wt (-<25) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
Never 
B1 94458 Control 74.18 Overweight(-<30) Never 
Smoker 
Never smoked None <Once/month 
A8 94461 Control 74.19 Healthy wt (-<25) Ex-Smoker 1-29.9 pack 
yrs 
1-6 std 
drinks/wk 
Never 
C2 42094 EAC 52.52 Obese I (-<35) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
Daily 
C3 61017 EAC 54.96 Obese I (-<35) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
Weekly (few 
times/wk) 
E1 50231 EAC 55.67 Healthy wt (-<25) Current 
smoker 
1-29.9 pack 
yrs 
21+ std 
drinks/wk 
Daily 
D8 61189 EAC 57.29 Obese II (-<40) Ex-Smoker 1-29.9 pack 
yrs 
21+ std 
drinks/wk 
Weekly (few 
times/wk) 
D2 61093 EAC 57.51 Obese I (-<35) Ex-Smoker 1-29.9 pack 
yrs 
1-6 std 
drinks/wk 
Weekly (few 
times/wk) 
D6 21416 EAC 57.59 Obese I (-<35) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Daily 
C9 21283 EAC 58.97 Obese I (-<35) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Daily 
D3 35022 EAC 60.09 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
21+ std 
drinks/wk 
Daily 
D9 21420 EAC 60.54 Obese I (-<35) Current 
smoker 
30+ pack yrs 1-6 std 
drinks/wk 
Daily 
D4 40270 EAC 60.88 Overweight(-<30) Never 
Smoker 
Never smoked 1-6 std 
drinks/wk 
Weekly (few 
times/wk) 
D7 33168 EAC 61.72 Obese III (>=40) Ex-Smoker 30+ pack yrs 1-6 std 
drinks/wk 
Weekly (few 
times/wk) 
E3 33189 EAC 63.1 Overweight(-<30) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Weekly (few 
times/wk) 
E2 50272 EAC 70.14 Overweight(-<30) Ex-Smoker 30+ pack yrs 1-6 std 
drinks/wk 
Weekly (few 
times/wk) 
C4 42112 EAC 70.45 Obese I (-<35) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
Never 
C8 21252 EAC 70.46 Obese I (-<35) Ex-Smoker 1-29.9 pack 
yrs 
21+ std 
drinks/wk 
Weekly (few 
times/wk) 
C5 40173 EAC 70.72 Obese I (-<35) Ex-Smoker 1-29.9 pack 
yrs 
1-6 std 
drinks/wk 
Monthly (few 
times/mo) 
D5 40304 EAC 71.11 Obese I (-<35) Ex-Smoker 30+ pack yrs 21+ std 
drinks/wk 
Daily 
D1 21330 EAC 73.62 Obese I (-<35) Never 
Smoker 
Never smoked 7-20 std 
drinks/wk 
Monthly (few 
times/mo) 
C6 61065 EAC 73.76 Obese I (-<35) Never 
Smoker 
Never smoked None Monthly (few 
times/mo) 
C7 33078 EAC 74.16 Overweight(-<30) Ex-Smoker 1-29.9 pack 
yrs 
7-20 std 
drinks/wk 
<Once/month 
*For cases, age represent age at the time of diagnosis. For controls, age represent age at 1
st
 letter 
sent. 
#
Body mass index is according to data available one year before diagnosis. It is categorized into 6 
categories according to WHO.   
$
Alcohol consumption represents average number of standard drinks per week. 
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&
Reflux frequency is according to 10 years before diagnosis. 
Table 5.2. Clinical characteristics of the patient cohort for biomarker verification.  
Variables Healthy BE EAC P value 
(Healthy vs 
BE vs EAC) 
Population 
Control 
P value 
(Healthy vs 
Pop. 
Control) 
Sample size 20 20 20  19  
Gender All male All male All male  All male  
Age in years (Median ± SD) 64 ± 8 60 ± 8 61 ± 7 0.4283 62 ± 7 0.2793 
Protein concentration (μg/μl) 83 ± 10 78 ± 12 85 ± 13 0.6486 89 ± 13 0.0785 
Reflux frequency* (10 years before diagnosis) 0.0108  0.2155 
   <Once/month 9 (47.4%) 7 (35.0%) 2 (10.0%)  14 (73.7%)  
   Monthly (few times/month) 6 (31.6%) 6 (30.0%) 3 (15.0%)  4 (21.1%)  
   Weekly or daily 4 (21.0%) 7 (35.0%) 15 (75.0%)  1 (5.3%)  
Body mass index 0.0076  0.6090 
   Healthy (<25) 5 (25.0%) 5 (25.0%) 1 (5.0%)  7 (36.8%)  
   Overweight (25-30) 8 (40.0%) 12 (60.0%) 5 (25.0%)  8 (42.1%)  
   Obese (>=30) 7 (35.0%) 3 (15.0%) 14 (70.0%)  4 (21.1%)  
Smoking history 0.6116  0.7813 
   Never smoked 8 (40.0%) 8 (40.0%) 4 (20.0%)  7 (36.8%)  
   1-29.9 pack per year 8 (40.0%) 9 (45.0%) 10 (50.0%)  6 (31.6%)  
   30+ pack per year 4 (20.0%) 3 (15.0%) 6 (30.0%)  6 (31.6%)  
Alcohol consumption 0.6637  0.8379 
   <1 standard drink/week 3 (15.0%) 3 (15.0%) 1 (5.0%)  2 (10.5%)  
   1-6 standard drink/week 3 (15.0%) 4 (20.0%) 6 (30.0%)  5 (26.3%)  
   7-20 standard drink/week 8 (40.0%) 4 (20.0%) 6 (30.0%)  6 (31.6%)  
   21+ standard drink/week 6 (30.0%) 9 (45.0%) 7 (35.0%)   6 (31.6%)   
*All the analyses were performed based on available patient information. Reflux frequency for one 
healthy patient was missing. 
5.2.2 LeMBA-UHPLC-MRM-MS 
 LeMBA using 6 lectins (AAL, EPHA, JAC, NPL, PSA, and WGA) was performed as 
described in section 2.5. Each plate for LeMBA pull-down could handle 12 patient samples, with a 
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total of 7 plates required to process 80 patient samples. To reduce the variability due to sample 
preparation step, all 80 serum samples were denatured at the same time and spiked with 10 
picomole of internal standard chicken ovalbumin per lectin pull-down. Sufficient volume of serum 
was available to allow processing of double quantity of sample than actual requirement. After 
denaturation, samples were aliquoted in half and stored at -80 ˚C for later use. Lectin-beads 
conjugated in single batch were used across LeMBA pull-downs to reduce variability. On the day of 
LeMBA pull-down, the denatured serum samples were diluted in binding buffer. Lectins were 
arranged in an alphabetical order in 96 well-plate where each raw represent an individual lectin. 
After trypsin digestion, peptides were quantified using UHPLC-MRM-MS assay mentioned in 
Chapter 4. The samples were run according to lectin pull-down on mass spectrometer i.e. LeMBA 
pull-down samples for the same lectin on each plate were run one after another. After running every 
6 LeMBA pull-down samples, a column flush was performed for cleaning and maintenance. 
Column flush method contains a mixture of gradient and isocratic flow of solvents as mentioned in 
the table below. 100 femtomole of HSA peptide standard mix was injected as QC after each column 
flush run to monitor instrument performance.     
Time (min) Solvent % B 
0.0 min 3% 
2.0 min 15% 
4.5 min 15% 
6.5 min 25% 
9.0 min 25% 
11.0 min 35% 
13.5 min 35% 
15.5 min 45% 
19.5 min 45% 
21.5 min 60% 
24.0 min 60% 
26.0 min 95% 
32.0 min 95% 
34.0 min 3% 
Stop time = 40.0 min 3% 
5.2.3 Shiny mixOmics analysis 
 The raw data processing and normalization was performed as mentioned earlier in sections 
4.2.3 and 4.2.7. Briefly, peak area for each peptide (sum of all transitions) was extracted using 
Skyline. All peaks were manually checked for correct integration. Median normalization of native 
chicken ovalbumin peptide ISQAVHAAHAEINEAGR and VASMASEK was performed using 
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their isotopically labeled counterparts. Using normalized intensity of natural ovalbumin peptides, 
median normalization was performed for all the peptides measured in MRM-MS assay. The major 
steps for statistical analysis include: (i) converting peptide intensity to protein intensity, (ii) outlier 
detection (for details see section 3.2.6.2), (iii) univariate analysis using non-parametric tests such as 
Kruskal-Wallis tests (significance level set to 0.05) and ROC analysis for each lectin-protein 
biomarker candidate, and (iv) multivariate analysis using sPLS-DA combined with stability 
analysis. Normalized peptide response was calculated as mentioned above, using Microsoft excel. 
Further downstream statistical analysis was performed with a dedicated web application Shiny 
mixOmics (http://mixomics-projects.di.uq.edu.au/Shiny) using the R statistical software (447) and 
the R package mixOmics (448) implementing all the statistical data analysis steps described.    
 The first step in the data analysis pipeline is to infer protein measurements from normalized 
peptide intensities. 2 - 5 peptides per proteins were measured for each protein. In order to qualify 
for quantitation, more than 50% of the measured peptides from the same protein must have a 
Pearson correlation coefficient of more than 0.6. The normalized intensity for different peptides 
belonging to the same protein varied in the magnitude of more than 10 fold, suggesting simply 
summing up peptide intensity values to determine protein intensity values would lead to biased 
results. To overcome this problem, equal weight to each peptide was given irrespective of its 
absolute intensity when calculating a normalization factor. After converting peptide intensity into 
protein intensity, outlier detection was performed using the same approach as described previously 
during GlycoSelector analysis for biomarker discovery in section 3.2.6.2. 
 After removal of an outlier I7, univariate statistical analysis using non-parametric tests such 
as Kruskal-Wallis (significance level set to 0.05) and ROC analysis was performed between healthy 
vs BE, BE vs EAC, and healthy vs EAC patient groups, for each lectin-protein candidate. AUROC 
value determines the diagnostic ability of each individual lectin-protein candidate to differentiate 
between two different phenotypes. Sensitivity, specificity and likelihood ratio were calculated at a 
specified cut-off value for normalized protein response. A likelihood ratio of 10 indicates that the 
patients with the disease are 10 times more likely to be diagnosed compared to those without the 
disease (449).  
 Supervised multivariate approach sPLD-DA was applied to select a panel of biomarker 
candidate to distinguish patients into two different phenotypes. Stability analysis was carried out 
that measures frequency of each feature being selected across 5-fold cross-validation repeated 1000 
times. Only the robust lectin-protein candidates were reported. Besides the candidate selection and 
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the stability analysis, another numerical output from sPLS-DA was the classification error rate 
resulting from the cross-validation procedure. Receiver Operating Characteristic curve (ROC) was 
also reported for a combination of lectin-protein candidates selected by sPLS-DA. The results of the 
multivariate analysis were summarized in the form of sPLS-DA sample representation on the first 
two components using 95% confidence interval ellipses (450). The efforts were made to find out a 
multimarker panel that distinguish BE from healthy and EAC from BE. Unfortunately, the cross-
validation error-rate for healthy vs. BE analysis was very high meaning failure to identify a panel of 
biomarker candidates with high diagnostic potential. 
5.2.4 Analysis for confounders 
 To check the impact of confounding covariates [reflux frequency, body mass index (BMI), 
smoking, and alcohol consumption] on biomarker candidates, an additional 19 population control 
(electoral roll) serum samples were measured using LeMBA-MRM-MS, to achieve sufficient 
number of disease-free samples for statistical analysis. Healthy and population control sample 
groups were merged and categorized according to reflux frequency, BMI, cumulative smoking 
history and alcohol consumption. Kruskal-Wallis test was applied to all the qualified candidates for 
each confounding factor. Candidates that showed P < 0.05 for BMI, reflux, cumulative smoking 
history or alcohol consumption were considered as false positives and removed prior to multivariate 
analysis. 
5.3 Results 
 Based on biomarker discovery results, six lectins (AAL, EPHA, JAC, NPL, PSA, and 
WGA) and 41 protein candidates were selected for biomarker verification. As described in Chapter 
4, targeted proteomics assay MRM-MS was developed for quantitation of potential biomarker 
candidates using LeMBA pull-down. Serum samples from 80 subjects (healthy-20, BE-21, EAC-20, 
and population control-19) were screened using LeMBA-UHPLC-MRM-MS assay. Table 5.1 and 
5.2 depicts patient information used in the screen. The prevalence of reflux and obesity was higher 
in BE/EAC patient groups as compared to the healthy group, which reiterates fact that reflux and 
obesity are major risk factors for BE/EAC (451). Age matched electoral roll control and healthy 
groups were very similar across all measured covariates (Table 5.2). 
5.3.1 LeMBA-UHPLC-MRM-MS screen: Quality check 
 When using modern day technology like LC-mass spectrometer which involves very 
complex and sophisticated instrumentation, it is necessary to perform enough quality checks to 
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build confidence in the actual data that is being acquired. This was achieved in following two ways. 
(i) 100 femtomole of HSA peptide mix was run routinely (after every 6 samples) to monitor 
instrument performance, and (ii) %CV for SIS and natural chicken ovalbumin peptides was 
calculated after the screen to check reproducibility of LeMBA pull-down and mass spectrometric 
analysis. 
 Figure 5.1 depicts response of 100 femtomole HSA peptide mix analyzed routinely during 
biomarker verification screen. Total 7 peptides were monitored and showed reproducible response 
throughout the time period of biomarker verification. In Figure 5.1, response for only one out of 
seven peptides is displayed for simplicity. Secondly, % CV of the entire LeMBA-MRM-MS screen 
was calculated based on response of heavy labeled SIS peptides and internal standard natural 
chicken ovalbumin peptides before and after normalization. All three SIS peptides, except 
methionine containing heavy labeled peptides, showed a % CV of less than 20% suggesting 
reproducibility of MRM-MS over entire period of biomarker verification. Initially, % CV for 
internal standard chicken ovalbumin peptide was found to be around 40-60% which was much 
higher than the expected 20%. To find out the reason for this very high % CV, internal standard 
ovalbumin responses were compared using replicate comparison tool in Skyline across all samples. 
Interestingly, ovalbumin response from samples belongs to one particular plate was much higher as 
compared to remaining plates suggesting technical error during LeMBA pull-down. Later on, using 
the second remaining half of the frozen denatured samples, LeMBA pull-down was performed 
again for the 12 samples. After repeating LeMBA pull-down for samples because of which 
ovalbumin % CV was found to be high, %CV for normalized as well as non-normalized intensity of 
natural internal standard ovalbumin peptide was around or below 20% (Table 5.3), suggesting 
robust performance (422) of LeMBA-MRM-MS screen over several weeks. Interestingly, 
normalized intensity of natural methionine containing peptide VASMASEK showed less % CV as 
compared to non-normalized intensity, suggesting SIS peptide VASMASEK containing methionine 
was able to correct for batch effects in methionine oxidation.  
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Figure 5.1. Response of HSA peptide mix (QC) during biomarker verification screen. The 
figure displays peak area for peptide LVNEVTEFAK (Transitions 575.3 m/z  937.5 m/z, 694.4 
m/z, and 595.3 m/z; @ Collision energy (CE) 20 eV) monitored during biomarker verification 
screen. Replicate nomenclature indicates plate number_lectin name_run number. 
Table 5.3. % CV for SIS and natural chicken ovalbumin peptides for BE/EAC biomarker 
verification screen. 
AAL NPL 
Protein name_peptide sequence %CV Protein name_peptide sequence %CV 
P00738_VTSIQDWVQK_Heavy 9.98 P00738_VTSIQDWVQK_Heavy 16.46 
P01012_ISQAVHAAHAEINEAGR_Sum 15.92 P01012_VASMASEK 24.77 
P01012_ISQAVHAAHAEINEAGR_Sum_Heavy 12.92 P01012_VASMASEK_Heavy 25.09 
P01012_VASMASEK 21.51 P01012_ISQAVHAAHAEINEAGR_Sum 13.12 
P01012_VASMASEK_Heavy 23.66 P01012_ISQAVHAAHAEINEAGR_Sum_Heavy 10.92 
P06396_AVEVLPK_Heavy 9.83 P06396_AVEVLPK_Heavy 5.88 
Normalized intensity of natural   Normalized intensity of natural   
P01012_ISQAVHAAHAEINEAGR_Sum 20.75 P01012_ISQAVHAAHAEINEAGR_Sum 17.23 
P01012_VASMASEK 16.99 P01012_VASMASEK 14.31 
EPHA PSA 
Protein name_peptide sequence %CV Protein name_peptide sequence %CV 
P00738_VTSIQDWVQK_Heavy 14.39 P00738_VTSIQDWVQK_Heavy 13.58 
P01012_VASMASEK 25.41 P01012_VASMASEK 26.15 
P01012_VASMASEK_Heavy 25.45 P01012_VASMASEK_Heavy 23.97 
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P01012_ISQAVHAAHAEINEAGR_Sum 16.23 P01012_ISQAVHAAHAEINEAGR_Sum 13.27 
P01012_ISQAVHAAHAEINEAGR_Heavy_Sum 13.34 P01012_ISQAVHAAHAEINEAGR_Heavy_Sum 12.62 
P06396_AVEVLPK_Heavy 5.38 P06396_AVEVLPK_Heavy 5.43 
Normalized intensity of natural   Normalized intensity of natural   
P01012_ISQAVHAAHAEINEAGR_Sum 20.96 P01012_ISQAVHAAHAEINEAGR_Sum 18.06 
P01012_VASMASEK 18.62 P01012_VASMASEK 14.28 
JAC WGA 
Protein name_peptide sequence %CV Protein name_peptide sequence %CV 
P00738_VTSIQDWVQK_Heavy 16.50 P00738_VTSIQDWVQK_Heavy 20.50 
P01012_VASMASEK 23.62 P01012_VASMASEK 32.97 
P01012_VASMASEK_Heavy 25.82 P01012_VASMASEK_Heavy 31.04 
P01012_ISQAVHAAHAEINEAGR_Sum 11.78 P01012_ISQAVHAAHAEINEAGR_Sum 22.81 
P01012_ISQAVHAAHAEINEAGR_Sum_Heavy 12.42 P01012_ISQAVHAAHAEINEAGR_Sum_Heavy 17.57 
P06396_AVEVLPK_Heavy 6.86 P06396_AVEVLPK_Heavy 14.44 
Normalized intensity of natural   Normalized intensity of natural   
P01012_ISQAVHAAHAEINEAGR_Sum 18.17 P01012_ISQAVHAAHAEINEAGR_Sum 17.05 
P01012_VASMASEK 16.00 P01012_VASMASEK 17.61 
5.3.2 Shiny mixOmics analysis 
 So far, it has been demonstrated that LeMBA-MRM-MS showed very high linearity and 
reproducibility and passed all the quality checks which means the data acquired is of high quality. 
For each protein, 2-5 peptides were measured for quantitation. Ideally, all the peptides belong to 
same protein should give similar results when used for quantitation. To test this, Pearson correlation 
was performed between peptide responses from same proteins across all patient samples. In order to 
qualify for quantitation, more than 50% of the measured peptides from the same protein must have 
a Pearson correlation coefficient of more than 0.6. Figure 5.2 depicts the percentage of lectin-
protein candidates quantified with decreasing cut-off for Pearson correlation co-efficient. As shown 
in the figure, using a correlation cut-off of 0.9, 0.8, 0.7 and 0.6, respectively, 55%, 85%, 95% and 
96% of the lectin-protein candidates were quantified. The remaining 4% of the candidates which 
did not meet the criteria were discarded from further analysis. The normalized intensity for different 
peptides belonging to the same protein varied in the magnitude of more than 10 fold, suggesting 
simply summing up peptide intensity values to determine protein intensity values would lead to 
biased results. To overcome this problem, equal weight was given to each peptide irrespective of its 
absolute intensity when calculating protein intensity. After converting peptide intensity into protein 
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intensity, outlier detection was performed using the same approach as described previously during 
GlycoSelector analysis for biomarker discovery. Sample I7 was found to be an outlier and removed 
from further analysis.   
Figure 5.2. Correlation between peptide responses for 
individual proteins as measured by Pearson 
correlation, showing % of quantifiable candidates. 
 
 
 
 
5.3.2.1 Candidate selection: Univariate analysis  
 Two sequential steps were used to evaluate and select candidate biomarkers from the 
verification data; first, Kruskal-Wallis non-parametric test to assess statistical significance of each 
individual candidate, then AUROC value was used to measure the diagnostic potential of each 
marker. Comparisons were made between healthy vs BE, BE vs EAC and healthy vs EAC 
phenotypes. Out of total 246 lectin-protein candidates, 45 candidates were significantly different 
between two groups (P value < 0.05) (Table 5.4). Amongst them, 26 lectin-protein candidates 
showed AUROC of more than 0.7 in at least one of the three phenotype comparisons. Boxplots and 
ROC curves of the top candidate for healthy vs BE, BE vs EAC and healthy vs EAC are shown in 
Figure 5.3A to 5.3F respectively. Apolipoprotein B-100 (APOB; Uniprot entry: P04114) showed 
differential binding with NPL lectin between healthy and BE patient groups (P value = 0.0231, 
AUROC = 0.71). It showed sensitivity of 30%, specificity of 95%, and likelihood ratio of 6.0 at cut-
off value of 569508. Complement component C9 (C9; Uniprot entry: P02748) was the top 
candidate to differentiate EAC from BE phenotype (P value = 0.0001, AUROC = 0.85) with 
sensitivity of 55%, specificity of 95%, and likelihood ratio of 11 at cut-off value > 420932. EPHA-
Gelsolin was statistically significantly different between healthy and EAC patient groups (P value = 
0.0014, AUROC = 0.80, Sensitivity = 35%, Specificity = 95%, Likelihood ratio = 7.0, and Cut-off 
= 110686). Figure 5.4 depicts Venn diagram of number of candidates that can differentiate between 
healthy vs BE, BE vs EAC and healthy vs EAC patient groups. Out of total 45 candidates that 
showed statistically significant difference, 16 candidates overlapped between healthy vs EAC and 
BE vs EAC analysis and might be of greatest interest as they can differentiate EAC from healthy as 
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well as BE phenotype. α-2-Macroglobulin (A2M; Uniprot entry: P01023) was statistically 
significantly different in both healthy vs BE and healthy vs EAC analysis. 
Table 5.4. Verified list of candidates shown by lectin affinity-protein ID that were significantly 
different for either healthy vs BE or BE vs EAC or healthy vs EAC analysis. Proteins are 
denoted using gene symbol; number in the bracket denotes Uniprot accession number. AUROC 
values of more than 0.7 are highlighted in bold.   
Lectin-Protein Healthy vs BE BE vs EAC Healthy vs EAC 
P value AUROC P value AUROC P value AUROC 
AAL-APOB (P04114) 0.1368 0.6375 0.0453 0.6850 0.9569 0.4950 
AAL-C5 (P01031) 0.6073 0.5475 0.0483 0.6825 0.2340 0.6100 
AAL-C7 (P10643) 0.2793 0.6000 0.0063 0.7525 0.3169 0.5925 
AAL-C9 (P02748) 0.2793 0.6000 0.0001 0.8525 0.0161 0.7225 
AAL-GSN (P06396) 0.7455 0.5300 0.0087 0.7425 0.0265 0.7050 
AAL-HP (P00738) 0.8711 0.4850 0.0398 0.6900 0.0583 0.6750 
EPHA-A2M (P01023) 0.0248 0.7075 0.9138 0.4900 0.0186 0.7175 
EPHA-AHSG (P02765) 0.5162 0.5600 0.1941 0.6200 0.0483 0.6825 
EPHA-C7 (P10643) 0.1368 0.6375 0.0398 0.6900 0.6849 0.5375 
EPHA-C9 (P02748) 0.0583 0.6750 0.0003 0.8375 0.0265 0.7050 
EPHA-GSN (P06396) 0.2036 0.6175 0.0200 0.7150 0.0014 0.7950 
EPHA-HP (P00738) 0.7455 0.5300 0.0200 0.7150 0.0305 0.7000 
EPHA-SERPINA3 (P01011) 0.4171 0.5750 0.0265 0.7050 0.0620 0.6725 
EPHA-TF (P02787) 0.7455 0.4700 0.0326 0.6975 0.0935 0.6550 
JAC-A1BG (P04217) 0.6263 0.5450 0.0483 0.6825 0.1231 0.6425 
JAC-APOB (P04114) 0.0305 0.7000 0.0699 0.6675 0.5700 0.5525 
JAC-C4BPA (P04003) 0.7251 0.5325 0.0935 0.6550 0.0128 0.7300 
JAC-C5 (P01031) 0.6073 0.4525 0.0425 0.6875 0.0483 0.6825 
JAC-C7 (P10643) 0.2914 0.5975 0.0094 0.7400 0.0834 0.6600 
JAC-C9 (P02748) 0.2914 0.5975 0.0007 0.8125 0.0029 0.7750 
JAC-CFB (P00751) 0.9353 0.5075 0.0373 0.6925 0.0373 0.6925 
JAC-GSN (P06396) 0.8498 0.5175 0.0305 0.7000 0.0215 0.7125 
JAC-HP (P00738) 0.9569 0.5050 0.0483 0.6825 0.0583 0.6750 
JAC-HPX (P02790) 0.7868 0.5250 0.0742 0.6650 0.0200 0.7150 
JAC-SERPINA1 (P01009) 0.3040 0.5950 0.0453 0.6850 0.2448 0.6075 
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JAC-SERPINA3 (P01011) 0.9569 0.5050 0.0102 0.7375 0.0305 0.7000 
JAC-SERPIND1 (P05546) 0.1368 0.6375 0.4819 0.5650 0.0483 0.6825 
JAC-SERPING1 (P05155) 0.5518 0.5550 0.2559 0.6050 0.0200 0.7150 
NPL-AFM (P43652) 0.5338 0.5575 0.0483 0.6825 0.1762 0.6250 
NPL-APOB (P04114) 0.0231 0.7100 0.0231 0.7100 0.8924 0.5125 
NPL-C4BPA (P04003) 0.0989 0.6525 0.6849 0.5375 0.0231 0.7100 
NPL-C9 (P02748) 0.5885 0.5500 0.0049 0.7600 0.0074 0.7475 
NPL-GSN (P06396) 0.8924 0.5125 0.0173 0.7200 0.0583 0.6750 
NPL-HP (P00738) 0.8077 0.5225 0.0884 0.6575 0.0326 0.6975 
NPL-SERPINA3 (P01011) 0.5518 0.5550 0.0989 0.6525 0.0305 0.7000 
PSA-C5 (P01031) 0.4017 0.5775 0.0453 0.6850 0.3040 0.5950 
PSA-C7 (P10643) 0.2914 0.5975 0.0019 0.7875 0.0742 0.6650 
PSA-C9 (P02748) 0.2036 0.6175 0.0008 0.8100 0.0161 0.7225 
PSA-GSN (P06396) 0.3577 0.5850 0.0483 0.6825 0.0110 0.7350 
PSA-HP (P00738) 0.8498 0.4825 0.0483 0.6825 0.0425 0.6875 
PSA-SERPINA3 (P01011) 0.8077 0.5225 0.0425 0.6875 0.0834 0.6600 
WGA-C9 (P02748) 0.4819 0.5650 0.0032 0.7725 0.0053 0.7575 
WGA-GSN (P06396) 0.7868 0.5250 0.0119 0.7325 0.0742 0.6650 
WGA-HP (P00738) 0.7455 0.5300 0.0483 0.6825 0.0215 0.7125 
WGA-SERPINA3 (P01011) 0.4819 0.5650 0.0989 0.6525 0.0063 0.7525 
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Figure 5.3. Boxplots and ROC curves of top biomarker candidate for healthy vs BE, BE vs 
EAC and healthy vs EAC comparison respectively. (A to C) Boxplots and (D to F) ROC curves 
of NPL-APOB, AAL-C9 and EPHA-GSN which were top biomarker candidate for healthy vs BE, 
BE vs EAC, and healthy vs EAC comparison, respectively.  
Figure 5.4. Overlap between lectin-protein candidates that 
differentiate BE from healthy, EAC from BE, and EAC from 
healthy phenotype. P values were calculated using Kruskal-Wallis 
test and P < 0.05 was considered to be statistically significant. 
 
 
 
5.3.3 Comparison between LeMBA-MRM-MS and LeMBA-western immunoblotting 
 Orthogonal qualification at protein level using LeMBA-immunoblotting (IB) was performed 
for AAL-HP and AAL-GSN using samples from the qualification cohort. The relative quantitation 
for natural (light) peptide was performed with respect to SIS heavy labeled peptide for LeMBA-
MRM-MS data. Once again, there was agreement between peptide level quantitation using MRM-
MS and protein level quantitation using western immunoblotting (Figure 5.5), validating the 
LeMBA-MRM-MS workflow [AAL-HP: MRM-MS P value = 0.0235, western immunoblotting P 
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value = 0.1037, MRM-MS AUROC = 0.69, western immunoblotting AUROC = 0.69; AAL-GSN: 
MRM-MS P value = 0.0120, western immunoblotting P value = 0.0203, MRM-MS AUROC = 
0.70, western immunoblotting AUROC = 0.73].  
Figure 5.5. Comparison between 
LeMBA-MRM-MS and LeMBA-
western-immunoblotting 
quantitation for AAL-HP (left 
column) and AAL-GSN (right 
column). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.4 Identification of candidates affected by confounding covariates 
 As expected from the known risk factors, healthy, BE and EAC patient groups significantly 
differ according to BMI and reflux frequency (Table 5.2). In comparison with healthy patients, BE 
and EAC patient groups had a higher proportion of patients experiencing frequent GERD and of 
patients with obesity. Therefore, it may be possible that some of the candidates identified are due to 
confounding covariates rather than the actual disease phenotype. To evaluate this hypothesis, firstly 
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the cohort size of healthy phenotype was increased by LeMBA-MRM-MS measurement of an 
additional 19 serum samples collected as electoral roll control samples. These disease-free patient 
samples were then classified according to potential confounding variables (reflux frequency, BMI, 
cumulative smoking history and alcohol consumption). The statistical significance of each 45 
lectin-protein candidates for each of the four covariates was assessed using a Kruskal-Wallis test 
(Table 5.5). Most of the candidate biomarkers were not significantly correlated with the covariates. 
As examples, boxplots of the data for the top 3 biomarker candidates of the disease-free cohort 
classified according to covariates are shown in Figure 5.6. Out of the four covariates studied, reflux 
frequency is perhaps the most important factor to be considered in the context of BE/EAC. Notably, 
none of the candidates were affected by reflux frequency, suggesting specificity of the candidates to 
diagnose disease phenotype. Five candidates significantly correlated with covariates (Figure 5.7). 
APOB showed differential binding with lectins AAL, JAC, and NPL according to BMI 
classification. This is most likely due to increased levels of total APOB with increase in BMI, 
suggesting underlying changes in the lipoprotein metabolism (452). Plasma protease C1 inhibitor 
(SERPING1; Uniprot entry: P05155) showed significantly reduced binding with JAC lectin in 
samples classified as overweight and obese as compared to healthy while JAC-alpha-1B-
glycpoprotein (A1BG; Uniprot entry: P04217) varied according to alcohol consumption. This 
covariate analysis leads to eliminate 5 candidates from the qualified biomarker list, leaving 40 
putative biomarker candidates for future studies. Out of the 5 candidates that were eliminated, JAC-
APOB was identified in healthy vs BE analysis, AAL-APOB and JAC-A1BG were identified in BE 
vs EAC analysis, JAC-SERPING1 was identified in healthy vs EAC analysis while NPL-APOB 
was significantly different in heatlhy vs BE and BE vs EAC analysis. Notably, none of the 16 
lectin-protein candidates that distinguish EAC from BE and healthy phenotype were identified as 
confounding candidates. 
Table 5.5. Effect of covariates reflux frequency, BMI, cumulative smoking history and alcohol 
consumption on lectin-protein candidates (Boxplots and ROC curves in Appendix III). 
Candidates 
Kruskal-Wallis test P value 
Reflux BMI Smoking Alcohol 
AAL-HP (P00738) 0.4452 0.6956 0.9445 0.8134 
AAL-C5 (P01031) 0.659 0.269 0.9029 0.3398 
AAL-C9 (P02748) 0.5822 0.4072 0.4915 0.4829 
AAL-APOB (P04114) 0.6243 0.0186 0.8123 0.9948 
AAL-GSN (P06396) 0.4123 0.8594 0.1478 0.6315 
AAL-C7 (P10643) 0.6758 0.0739 0.0501 0.6401 
EPHA-HP (P00738) 0.431 0.4362 0.9714 0.9552 
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Candidates 
Kruskal-Wallis test P value 
Reflux BMI Smoking Alcohol 
EPHA-SERPINA3 (P01011) 0.0579 0.2047 0.9103 0.535 
EPHA-A2M (P01023) 0.397 0.5303 0.5812 0.7236 
EPHA-C9 (P02748) 0.4827 0.4094 0.9293 0.4872 
EPHA-AHSG (P02765) 0.2708 0.511 0.7131 0.4888 
EPHA-TF (P02787) 0.563 0.452 0.9709 0.4174 
EPHA-GSN (P06396) 0.5456 0.5501 0.4477 0.8568 
EPHA-C7 (P10643) 0.864 0.3541 0.1908 0.3607 
JAC-HP (P00738) 0.6961 0.7152 0.9893 0.9481 
JAC-CFB (P00751) 0.5286 0.7001 0.4301 0.2691 
JAC-SERPINA1 (P01009) 0.4182 0.5653 0.5733 0.3476 
JAC-SERPINA3 (P01011) 0.2744 0.2339 0.621 0.7416 
JAC-C5 (P01031) 0.9924 0.4983 0.2901 0.226 
JAC-C9 (P02748) 0.4713 0.2519 0.4643 0.8035 
JAC-HPX (P02790) 0.5113 0.9854 0.2554 0.4262 
JAC-C4BPA (P04003) 0.3084 0.8952 0.6967 0.8589 
JAC-APOB (P04114) 0.4739 0.0125 0.9127 0.9694 
JAC-A1BG (P04217) 0.3763 0.8237 0.7572 0.0232 
JAC-SERPING1 (P05155) 0.3262 0.0059 0.8609 0.5831 
JAC-SERPIND1 (P05546) 0.7649 0.9412 0.6738 0.9743 
JAC-GSN (P06396) 0.986 0.9915 0.2739 0.3497 
JAC-C7 (P10643) 0.8268 0.1254 0.1019 0.7597 
NPL-HP (P00738) 0.7445 0.5826 0.9835 0.8753 
NPL-SERPINA3 (P01011) 0.4498 0.629 0.6827 0.3815 
NPL-C9 (P02748) 0.6141 0.2782 0.6845 0.8707 
NPL-C4BPA (P04003) 0.3259 0.9849 0.369 0.9051 
NPL-APOB (P04114) 0.2792 0.022 0.822 0.9886 
NPL-GSN (P06396) 0.9189 0.9762 0.2807 0.5319 
NPL-AFM (P43652) 0.0915 0.2721 0.6962 0.694 
PSA-HP (P00738) 0.6289 0.4362 0.8631 0.9842 
PSA-SERPINA3 (P01011) 0.2951 0.2194 0.9087 0.2117 
PSA-C5 (P01031) 0.554 0.6758 0.7538 0.3677 
PSA-C9 (P02748) 0.425 0.0947 0.839 0.5174 
PSA-GSN (P06396) 0.7811 0.8824 0.4982 0.4654 
PSA-C7 (P10643) 0.8628 0.0744 0.0784 0.6652 
WGA-HP (P00738) 0.623 0.472 0.9861 0.5777 
WGA-SERPINA3 (P01011) 0.266 0.3595 0.6288 0.6383 
WGA-C9 (P02748) 0.5639 0.0635 0.6448 0.7164 
WGA-GSN (P06396) 0.8165 0.9591 0.4524 0.5606 
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Figure 5.6. Assessing effect of confounding covariates on the top 3 biomarker candidates. 
Levels of NPL-APOB, AAL-C9 and EPHA-GSN were monitored in 39 serum samples (healthy-20 
and population control-19) using MRM-MS. Samples were categorized according to (A) reflux 
frequency, (B) BMI, (C) smoking history and (D) alcohol consumption. P < 0.05 using Kruskal-
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Wallis test was considered to be statistically significant. Out of the top 3 candidates, only NPL-
APOB was significantly different according BMI categorization. 
Figure 5.7. Boxplots of candidates identified as false positives according to covariates analysis. 
(A) AAL-APOB (P value = 0.0186), (B) JAC-APOB (P value = 0.0125), (C) NPL-APOB (P value 
= 0.022), and (D) JAC-SERPING1 (P value = 0.0059) were significantly different according to 
BMI status. (E) JAC-A1BG levels varied according to alcohol consumption (P value = 0.0232). P 
values are calculated using Kruskal-Wallis test.   
 
5.3.5 Multimarker panel to distinguish EAC from BE 
 An individual lectin-protein biomarker candidate showed maximum AUROC of 0.85 to 
differentiate between EAC and BE phenotypes. For clinical requirement, a panel of biomarker with 
AUROC close to 1.0 is required. So next, multivariate analysis was performed to examine the 
potential of protein glycoforms as complementary biomarkers, focusing on differential diagnosis of 
EAC and BE, as the most urgent clinical need. After removal of confounding candidates, sPLS-DA 
was used to derive a multimarker panel that distinguish BE and EAC (Figure 5.8). The biomarker 
panel (BE vs EAC) included four unique proteins namely complement component C9 (C9; Uniprot 
entry: P02748), alpha-1B-glycoprotein (A1BG; Uniprot entry: P04217), complement C4-B (C4B; 
Uniprot entry: P0C0L5) and complement C2 (C2; Uniprot entry: P06681) with each of the six 
lectins appearing at least once in the panel. Using 5-fold cross-validation repeated 1000 times on 
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this multimarker panel, the model showed cross-validation error rate of 37.47% and moderate 
separation of the BE and EAC sample representations (Figure 5.8A). The combined signature of the 
eight candidates gave an AUROC of 0.9425 with 95% specificity and 80% sensitivity (Figure 
5.8B). 
Figure 5.8. Multimarker panel to distinguish EAC from BE. (A) sPLS-DA and (B) ROC curve 
analysis of a multimarker panel consists of AAL-C9, EPHA-A1BG, EPHA-C9, JAC-C9, NPL-C2, 
NPL-C4B, PSA-C9, and WGA-C9. 
5.4 Discussion 
5.4.1 Overview  
 The results in this chapter describe verification of lectin-protein diagnostic biomarker 
candidates in an independent patient cohort. LeMBA-MRM-MS-Shiny mixOmics workflow has 
been utilized for biomarker verification. Candidates affected by confounding covariates were also 
identified. Multivariate analysis revealed a biomarker panel with very high diagnostic potential to 
distinguish between EAC and BE.  
5.4.2 Quality check for biomarker verification dataset 
 For any sophisticated analytical instrument such as mass spectrometer, it is important to 
perform enough quality checks to consistently monitor its performance while running the samples. 
The triple quadrupole mass spectrometer used for the targeted proteomics approach can 
isolate/quantify peptide/fragment ions up to 1400 m/z ratio. All the precursor ions in the MRM-MS 
assay were below 1000 m/z ratio while some of the fragment ions were between 1000 m/z to 1400 
m/z. So collectively, precursor and fragment ions cover entire mass range of the instrument. This 
means that QC sample should ideally consist of mixture of peptides (or small molecules) to cover 
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the entire mass range to allow holistic evaluation of the instrument performance. Commercially 
available HSA synthetic peptide mix consist of peptides which can cover this entire mass range 
hence it was used as a QC and showed very consistent response throughout.  
 The internal standard ovalbumin and corresponding SIS labeled peptide showed minimal 
possible variation for such a high-throughput, sensitive and multiplexed workflow (422). In 
addition, correlation analysis was performed amongst the peptide responses from the same protein 
to allow better quantitation. In line with the observation made by Domanski and colleagues (453), 
absolute response for individual peptide from the same protein varied significantly. Despite these 
large differences between peptide responses, 85% of the lectin-protein candidates showed Pearson 
correlation co-efficient of more than 0.8 amongst peptides emerging from the same protein 
suggesting reproducibility in the trypsin digestion across the entire assay. Furthermore, western 
immunoblotting quantitation gave comparable results with mass spectrometric quantitation which 
further validate the quantitation approached employed here. Taken together, the biomarker 
verification data is of sufficiently high quality to provide reliable results. 
5.4.3 Differential glycosylation in EAC 
 Univariate analysis using Kruskal-Wallis tests discovered lectin-protein candidates between 
the three phenotypes compared. It is evident from the results that EAC phenotype is associated with 
glycosylation changes as many serum proteins showed differential lectin binding between EAC vs 
healthy/BE phenotype. Only three candidates showed statistically significant difference between 
healthy and BE patient groups. Overall the results raise the possibility of major glycosylation 
changes taking place during progression of BE to EAC but not from healthy to BE. The findings 
from genomic sequencing studies concluded that except few key mutations, the majority of 
mutations observed in EAC lesions are already present in BE condition suggesting common 
mutations are acquired early during the pathogenesis. At this stage these two results seem to 
contrast each other raising possibility that more functional level changes [e.g. gene/protein 
expression (241, 256, 454-456), protein glycosylation, metabolic changes etc.] driven by 
environmental factors and/or early genomic alterations to be associated with development of 
dysplasia/carcinoma from metaplastic condition. In line with this, studies have shown differential 
expression of glycan structures in tissue and serum samples during metaplasia-dysplasia-carcinoma 
sequence (167-170, 174-180, 457). 
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5.4.4 Confounding covariates 
 Ideally, biomarker discovery and development should be performed using human biological 
materials which differ according to disease of interest and matched for all other confounding 
covariates (356, 458). Practically, it is very difficult to match the cohorts being compared across all 
the co-morbidities. In addition, some of the confounding covariates such as GERD and obesity are 
risk factors for BE/EAC hence will always be present. So it is inevitable that some of the candidates 
verified are actually due to confounding covariates and not associated with the disease phenotypes. 
It is very important that these false positive candidates are identified early during the biomarker 
development. In this chapter, 5 such false positive candidates were identified by screening 
additional serum samples from population control. The population control patients were not 
endoscopically confirmed negative for columnar lined esophagus i.e. BE, but it was assumed that 
all the population control samples, otherwise healthy, are negative for BE as its prevalence is low 
(35). Identification of APOB as a false positive candidate affected by BMI further validate the 
results of biomarker verification as it is well known that APOB level is associated with obesity/BMI 
(452).    
5.4.5 Multivariate analysis 
 Preferably, biomarker verification datasets should be divided into training and test sets. The 
biomarker panel identified using the training set should be tested using the independent test dataset 
to accurately estimate the error-rates and performance of the biomarker panel (459, 460). Like the 
biomarker verification study described here, it is not always possible to get enough number of 
patient samples to categorize into two separate datasets namely test and training. In this scenario, 
another popular validation method is n-fold cross-validation (461-463). In cross-validation, the 
entire verification dataset is randomly divided into n mutually exclusive equal subsets and the 
model is trained multiple times (100s or even 1000s) each time keeping one of the folds out as an 
validation set (386). This method is useful in small sample size because the entire data are used both 
as training and validation purposes without wasting of the data in a holdout validation set (386). In 
comparison to existing approaches (statistical methods and machine learning workflows) for 
selection of biomarkers, sPLS-DA is superior in terms of graphical outputs hence offer easy 
interpretation of the results and it has demonstrated similar classification performance to other 
workflows (382). So collectively, sPLS-DA was employed for multivariate analysis with 5-fold 
cross-validation. The multimarker panel showed AUROC of 0.94 showing improved performance 
of a combination of biomarkers over individual lectin-protein candidates. 
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 In conclusion, LeMBA-MRM-MS-Shiny mixOmics biomarker verification pipeline was 
able to successfully verify the candidates identified using LeMBA-GlycoSlector biomarker 
discovery pipeline. The diagnostic ability of an individual lectin-protein biomarker candidate was 
determined. The panel of biomarker showed very high diagnostic potential to differentiate between 
EAC and BE. The biomarkers verified require further evaluation in an independent large patient 
cohort including dysplastic samples.  
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Chapter 6. Electrochemical detection of glycan and protein epitopes of glycoproteins in serum 
6.1 Manuscript information 
 Improvements in the lectin/non-lectin based glycoprotein enrichment methodologies along 
with rapid technological advancements in the chromatographic and mass spectrometry platforms led 
to identification of novel glycoprotein biomarker candidates for various diseases in the recent past 
including the work described so far in the thesis. However, these workflows are poorly suited for 
routine clinical use due to high complexity and cost. Alternatively, electrochemical detection 
methods can achieve rapid, cost-effective, sensitive, selective and accurate quantification of 
biomolecules (464-468). In fact commercially available glucose biosensors use the principle of 
electrochemical detection (468-470). Lectin based biosensors developed so far can monitor overall 
changes in the glycosylation profile but do not give any information about underlying glycoprotein 
to which glycan is attached (471-474). To increase the specificity and diagnostic applicability of 
lectin based biosensors, we developed label-free electrochemical detection method to monitor 
specific glycan event on a target glycoprotein (2). This chapter describes proof-of-concept study for 
interrogating glycan epitope of a model glycoprotein chicken ovalbumin using Sambucus nigra 
agglutinin (SNA lectin) and protein epitope by anti-ovalbumin antibody followed with label-free 
electrochemical detection in the background of diluted human serum. Chicken ovalbumin mainly 
express N-linked high mannose and hybrid type glycan (475, 476), with expression of terminal 
sialic acid modified complex glycan at very low levels (477, 478). SNA lectin used in the assay 
preferentially binds with α2-6 linked sialic acid residues (479). So only a fraction of total 
ovalbumin is anticipated to bind with SNA lectin. The ovalbumin and SNA lectin were chosen for 
this proof-of-concept study to test the ability of electrochemical detection to monitor minimal 
interaction between ovalbumin and SNA lectin.       
 The following manuscript was published in Analyst (2014), volume 139, issue 22, pages 
5970-5976. The candidate and first author on the paper, Alok K. Shah, was mainly responsible for 
conducting the research and writing the manuscript. The detailed contributions from co-authors 
namely Michelle M. Hill, Muhammad J. A. Shiddiky and Matt Trau is listed on page vii & viii of 
the thesis.  
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Chapter 7. 
 
DISCUSSION AND FUTURE DIRECTIONS  
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Chapter 7. Discussion and future directions  
7.1.1 Overview of the thesis 
 This thesis has made significant contribution in the following areas of research. (i) It has 
filled a gap in the proteomics biomarker research with development of integrated biomarker 
discovery and verification pipeline using LeMBA platform. (ii) With the help of LeMBA-
GlycoSelector and LeMBA-Shiny mixOmics pipeline, lectin-glycoprotein diagnostic biomarker 
candidates for BE/EAC were discovered and verified. This study demonstrates utility of the pipeline 
including statistical methods for discovery and verification of biomarker candidates. (iii) Provided 
proof-of-concept demonstration for using electrochemical detection techniques for glycoprotein 
interrogation. Collectively, this thesis describes innovative translational biomarker research for 
diagnosis of BE/EAC.  
7.1.2 Biomarker discovery and verification pipeline 
 Blood based in vitro diagnostics employing cancer biomarkers hold promise for early 
diagnosis and improved patient outcomes, hence there is extensive research on the identification 
and development of novel cancer biomarkers (480). Discovery and development of new biomarkers 
is a long and challenging process requiring multi-disciplinary collaborations. Despite intensive 
efforts, the rate of introduction of new candidate biomarker into clinical practice is on the decline 
due to multitude of reasons (362, 481, 482). One of the main reasons for failure of cancer biomarker 
research to deliver clinically applicable diagnostic tests is attributed to unavailability of in-depth 
biomarker discovery and validation pipeline (482). In addition, large number of false positives, 
unavailability of high quality patient samples, poor study design, inappropriate statistical analysis, 
patient heterogeneity, limited understanding of cancer pathogenesis at molecular level and lack of 
follow-up verification studies have been adversely affecting outcome of cancer biomarker research 
(130, 441, 482, 483). 
 Recent technological advancements in proteomics have accelerated the discovery of 
biomarkers, leading to numerous biomarker publications over the years (441, 484). However, only a 
handful of new cancer biomarkers have completed the long journey allowing translation into 
clinical practice (130). One possible way to overcome this challenge is to develop biomarker 
discovery and development pipeline that allows seamless transition for biomarkers identified 
through biomarker discovery to further stages of development (485-490). To avoid the high 
complexity of serum/plasma proteome and the associated requisite multi-dimensional sample 
separation, most of these workflows focused on tissues or proximal fluids during the discovery 
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phase, with the goal of extending the findings to plasma. This approach often leads to failure when 
the candidates are not detected in plasma due to the limited sensitivity of the available analytical 
methods, or the absence of candidates in the plasma (483). 
 In this thesis, an alternative workflow to identify glycosylation changes in medium to high 
abundant glycoproteins has been presented which uses serum as the sample source throughout 
discovery and verification stages (Figure 7.1). The workflow was designed to enhance the 
feasibility of glycoprotein biomarker discovery and translation, through scientific rigor while 
managing the experimental cost. Firstly, serum is used as the sample source throughout discovery 
and verification, hence eliminating the risk of switching tissue type during biomarker development. 
Secondly, single step enrichment using liquid handler assisted LeMBA-system reduces sample 
processing variability. Thirdly, comparatively inexpensive approach of label-free proteomics has 
been employed using relative quantitation with respect to a spiked-in internal standard chicken 
ovalbumin. This approach achieved the necessary analytical linearity and reproducibility throughout 
the more than 2000 hr of total mass spectrometer run time performed in the study. This cost-
effective approach can be applied across other existing proteomics platforms to not only account for 
variations during sample processing but also to reduce the cost of at least initial stages of biomarker 
studies when many candidates are selected for verification and absolute quantification using SIS 
labeled peptide would be costly. Fourthly, a sequential filtering approach (459) has been applied in 
which many candidates were selected from biomarker discovery proteomics data, and verified using 
MRM-MS with increasing sample size in a cost-effective manner. 
 Using the biomarker discovery workflow, a total of 183 unique lectin-protein candidates 
were identified that can distinguish between healthy, BE, and EAC phenotypes. All 20 lectins used 
in the discovery phase showed differential binding with anywhere between one [e.g. Helix aspersa 
agglutinin (HAA)] to twenty five [e.g. NPL] glycoprotein candidates for pairwise comparison 
between patient phenotypes suggesting widespread changes in the serum glycosylation profile 
between healthy, BE and EAC samples. These results are in clear agreement with previous serum 
glycan profiling studies which identified widespread changes in serum glycan structures between 
healthy, BE, dysplastic and EAC phenotypes (175-177, 179, 457). Many of 41 protein candidates 
selected for verification were not identified during biomarker discovery in all 6 lectin-pull downs 
due to low sensitivity of QTOF mass spectrometer. With increased sensitivity of MRM-MS assay, 
all 41 protein candidates were identified in all 6 lectin pull-downs for all the patient samples. So out 
of the total 246 lectin-protein candidates measured for verification, 45 candidates (18.3%) were 
verified in an independent cohort of patients. Interestingly, only 3 out of 45 candidates were 
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significantly different between healthy vs BE comparison, with the other 42 candidates 
differentially present in EAC as compared to either healthy or BE samples. This suggests that EAC 
phenotype is significantly different from BE and healthy in terms of serum glycoprotein profile. 
 
Figure 7.1. Generalized workflow schematic for serum glycoprotein biomarker discovery and 
qualification. Serum samples from healthy, BE and EAC patient groups were enriched for sub-
glycoproteomes using 20 individual lectin coated magnetic beads, followed by on-bead trypsin 
digest and tandem mass spectrometry for label-free quantitation referencing to internal standard 
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chicken ovalbumin. In-house database and statistical analysis pipeline "GlycoSelector" 
(http://glycoselector.di.uq.edu.au/) identified lectin-protein pairs present in one patient group and 
absent in the other. Sparse partial least squares-discriminant analysis (sPLS-DA) combined with 
stability analysis was used to generate ranked lists of lectin-protein candidates. For biomarker 
verification, selected candidates were measured using multiple reaction monitoring-mass 
spectrometry (MRM-MS) in an independent patient cohort for a subgroup of lectin pull-downs. 
Dedicated statistical analysis tool "Shiny mixOmics" (http://mixomics-projects.di.uq.edu.au/Shiny) 
was developed incorporating features to plot ROC curve and to perform univariate/multivariate 
statistical analyses. LeMBA-immunoblotting was used as an orthogonal method to verify peptide 
level MS data for selected candidates at the protein level. 
7.1.3 Getting biological insights from the candidate biomarkers 
 Although the main aim of the present study was to discover and verify the glycoprotein 
biomarker candidates with promising diagnostic ability, the verified biomarker proteins can provide 
novel insights on pathophysiology of the disease. 
7.1.3.1 Functional annotation analysis 
 To begin to assess the main functional differences between BE and EAC, functional 
annotation analysis using online bioinformatics tool DAVID (the database for annotation, 
visualization and integrated discovery) (http://david.abcc.ncifcrf.gov/) (491, 492) was performed on 
a list of candidates that differentiated EAC from BE in biomarker verification dataset. The final 
candidates were selected using univariate Kruskal-Wallis test (P < 0.05) and multivariate analysis 
using sPLS-DA (stability > 70%), and consisted of 17 unique proteins (P00738, P00751, P01009, 
P01011, P01024, P01031, P02748, P02787, P04114, P04217, P05155, P05546, P06396, P06681, 
P0C0L5, P10643, P43652) from 59 lectin-protein pairs. Plasma proteome gene list (493) was 
converted to DAVID IDs and used as a background. Setting the adjusted FDR P-values < 0.05 for 
ontology categories and cluster scores over 3 using functional annotation clustering function, the 
top Annotation Cluster with an Enrichment Score of 10.4 was found to be SP_PIR_KEYWORD 
glycoprotein (P = 1.82E-08) and the UP_SEQ_FEATURE glycosylation site:N-linked (GlcNAc...) 
(P = 2.32E-06), in agreement with the glycoprotein enrichment strategy.   
 Additional clusters related to acute inflammation, complement cascade pathway, and 
endopeptidase inhibition, were over-represented within the 17 genes that discriminated BE and 
EAC. KEGG “Complement and coagulation cascades” pathway (hsa04610) was significantly over-
represented (P = 4.6E-18). 
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7.1.3.2 Complement pathway in EAC 
 In early 2000s, the link between inflammation and cancer was proposed including novel 
roles of complement proteins in the malignancy (494). Like other cancer, EAC is no different in the 
sense that chronic inflammation plays central role in development of EAC (495-497) which is in 
agreement with the result of functional annotation analysis, and points to alterations in the 
complement cascade during EAC development. Classically, complement proteins have been 
considered as a central part of the innate immune response and it serves as first line defense of the 
body (498). Figure 7.2A illustrates the cascade of events during activation of complement system. 
The proteins highlighted in red are found as candidate proteins from the biomarker verification 
results.  
 
Figure 7.2. Overview of the complement cascade. (A) The complement system gets activated in 
tightly regulated fashion by one of the three pathways, alternative pathway, classical pathway or 
lectin pathway. All three pathways activate C3 by different mechanisms that lead to cleavage and 
activation of C5 into C5a and C5b. C5a is a potent anaphylactic peptide while C5b can initiate the 
terminal pathway of membrane attack complex formation which begins with the non-enzymatic 
assembly of the components C5b-C9. Adapted from Pio et al. (494) and Zipfel and Skerka (499). 
The complement proteins denoted in red [C5, C7, C9 and complement factor B (or CFB)] are found 
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to be up-regulated in one or more lectin pull-downs in EAC as compared to BE phenotype. (B) 
Denotes Kruskal-Wallis test P values of lectin-complement cascade protein biomarker candidates 
for BE vs EAC comparison.  
 There are three well-established pathways of complement activation namely the classical 
pathway, the lectin pathway and the alternative pathway (Figure 7.2A). All three pathways 
converge at complement C3 (C3) which eventually causes activation of complement C5 (C5) that 
leads to formation of membrane attack complex (MAC) consisting of complement C5b (C5b), 
complement component C6 (C6), complement component C7 (C7), complement component C8 
(C8) and complement component C9 (C9) and results in destruction of target antigen. The process 
of complement activation is kept under check by complement regulators namely plasma protease 
C1 inhibitor, factor I, C4b-binding protein, complement factor H, vitronectin, clusterin, complement 
receptor type 1, membrane cofactor protein (CD46), decay-accelerating factor (CD55), and CD59. 
It is very well accepted that complement proteins carry out effective immune surveillance to check 
tumor initiation and progression (494). Increased levels of complement proteins or activation of 
complement pathways in tumor tissue, tissue fluid and/or serum/plasma have been observed in lung 
cancer, ovarian cancer, colorectal cancer, neuroblastoma, myeloma, lymphoma and leukemia 
suggesting capacity of complement system to recognize malignant cells (494). At the same time, 
tumor cells express/secrete complement regulator molecules that help them to evade the 
complement surveillance (500). Many recently developed monoclonal antibodies based 
immunotherapy target the complement regulator proteins to facilitate complement mediated 
clearance of the tumor and also to increase effectiveness of conventional treatments (500).  
 In line with results described in this thesis, Narayanasamy and colleagues identified 
fucosylated complement component C9 in serum as a biomarker for squamous cell lung cancer 
(501). Very recently Song and colleagues (180) also identified changes in the glycosylation of 
complement proteins for EAC and HGD compared to healthy phenotype. They used lectin-affinity 
chromatography (a mix of fucose and sialic acid binding lectin) and hydrazide chemistry-based 
glycoprotein enrichment methods and identified complement C3 and complement C1r 
subcomponent as differentially present in HGD and EAC samples respectively, as compared to 
healthy blood serum. The differences between the complement proteins identified by Song and 
colleagues, and those that discriminate BE and EAC in this thesis may be the result of divergent 
sample processing steps. For example, Song and colleagues (180) used serum sample after 
depletion of the seven most abundant proteins as compared to the workflow mentioned in this thesis 
where the serum samples were denatured to break protein complexes without depletion of abundant 
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proteins. In the LeMBA workflow, an individual lectin has been used for enrichment of a particular 
type of glycan while Song and colleagues used a mixture of sialic acid binding SNA lectin and 
fucose specific AAL lectin for glycoprotein enrichment. Nonetheless, changes observed in the 
glycosylation or total protein levels of complement proteins may suggest a mechanism for 
inflammation and complement cascades in EAC pathogenesis (495). 
 Figure 7.2B summarizes statistical significance of all lectin-complement protein biomarker 
candidates for BE vs EAC analysis. It is interesting to observe that proteins belong to terminal 
complement cascade are showing differential binding with many lectins as compared to proteins 
involved in the initial steps of complement activation i.e. CFB showed differential binding with 
only one lectin whereas C5, C7, and C9 showed differential binding with 3, 4, and all 6 lectins 
respectively. The diverse cell/tissue types such as liver, blood monocytes, tissue macrophages, 
epithelial cells, cancer cells and fibroblasts can synthesize and secrete components of complement 
cascade (502). With activation of the complement cascade, it may be possible that same 
complement protein is now synthesized and secreted by a different cell/tissue type in addition to 
normal cell/tissue type with potentially different glycan expression resulting into differential lectin 
binding between two phenotypes. However, possibility of changes in total levels of the complement 
proteins between BE and EAC cannot be ruled out at this stage. Collectively, inflammation and 
complement cascade seems to be playing role in EAC development. Further studies in this regard 
may help understand the disease pathogenesis and it may allow targeting of EAC using currently 
available immunotherapy. Although altered glycosylation of complement proteins has been 
observed in quite a few cancers (180, 501, 503, 504) including EAC, the exact impact of 
glycosylation on complement cascade and function of complement proteins is yet to be determined.  
7.1.3.3 Bile acids, microbiome, diet and glycan: Is there a link? 
 Exposure of esophageal epithelium with bile acids due to gastroesophageal reflux can be a 
causative factor for changes in the expression of glycan. When Nehra and colleagues profiled 
esophageal aspirates in the patients suffering from erosive esophagitis and Barrett's esophagus and 
compared with that of healthy individuals, they found significantly increased proportion of 
secondary bile acids, deoxycholic acid and taurodeoxycholic acids to be present in patients with 
erosive esophagitis and BE (505). Bile acids (especially secondary bile acids) are known for their 
causative roles for many gastrointestinal cancers (506, 507). At physiological levels repeated and 
prolonged exposure of bile acids in esophageal tissue, which is not meant to deal with gastric/bile 
acid, can cause oxidative/nitrosative stress, DNA damage leading to generation of genomic 
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instability, apoptosis, and ultimately cancer (508, 509). In line with this fact, Byrne and colleagues 
demonstrated that secondary bile acid deoxycholic acid (DCA) exposure in cell lines derived from 
normal squamous epithelium (HET-1A) and Barrett’s metaplastic epithelium (QH) leads to 
disruption of Golgi structures and affects protein glycosylation suggesting possible mechanism for 
differential glycosylation at least at the tissue level (312). However, its impact on serum/plasma 
glycoproteome remains to be determined.  
 Bile acids are physiological detergents and enable absorption of lipids, cholesterol, and fat-
soluble vitamins from the gastrointestinal tract (507). Cholic acid and chenodeoxycholic acid are 
primary bile acids which are derived from cholesterol by a sequence of enzymatic reactions that 
involve 17 different enzymes and occur mainly in the liver (510). After synthesis they are 
conjugated with either glycine or taurine and excreted and then stored in the gall bladder. When 
dietary fat enters the proximal intestine, they are released into the intestinal tract and play a critical 
role for lipid absorption in the ileum. The majority of bile acids are reabsorbed in the terminal ileum 
by an active bile salt re-absorptive mechanism leaving less than 5% of bile acids to enter the colon 
(511). In the colon, they are converted into secondary bile acids namely deoxycholic acid and 
lithocholic acid by bacterial flora (512). Out of the two secondary bile acids, lithocholic acid is 
fairly insoluble and little of it is re-absorbed while deoxycholic acid is partly re-absorbed in the 
colon and enters the enterohepatic circulation (513). In the liver, it undergoes conjugation and is 
secreted again in the bile. So normally, the circulating bile acid pool is composed of 30-40% cholic 
and chenodeoxycholic acid (primary bile acid), 20-30% deoxycholic acid and 5% lithocholic acid 
(514). All the factors that affect bile composition leading to increased levels of secondary bile acid 
can create pro-cancerous phenotype. One of the well-known factors that affect the bile composition 
is diet. High fat diet can cause increased levels of bile acids in the gastrointestinal tract. Conversely, 
diets rich in fibers (fruits and vegetables) aid in excretion of secondary bile acid and lower the risk 
of cancer (515). In line with the fact that the diets rich in fruits and vegetables lower the risk for 
BE/EAC, it has been experimentally demonstrated that high animal fat intake enhances the 
development of BE/EAC and changes the composition of bile acid in an animal model (516).  
 Since decades ago when no "omics" techniques existed, it has been known that the 
microorganisms present in the large intestine are responsible for the conversion of primary bile 
acids into secondary (517). So any changes in this microbial flora can potentially affect bile 
composition and may have implications in EAC pathogenesis. Recent evidences suggest that food 
and obesity have huge impact on the intestinal microbiome and bile acid metabolism (518-521). 
However, the majority of studies published and cited in this section were conducted in the context 
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of colon cancer. So the implications of microbiome mediated changes in the bile composition on 
BE/EAC pathogenesis remains to be determined. Furthermore, the possible impact of changes in the 
bile composition on glycosylation changes both at tissue level and in the circulation has not been 
investigated.  
7.1.3.4 Diagnosis of BE/EAC: What does future look like? 
 The success of cancer screening programs in improving outcome for many cancer types in 
the past decades emphasize the importance of early diagnosis and the development of suitable 
screening/surveillance tools (6). Indeed, the lack of cost-effective screening/surveillance 
methodology to facilitate early diagnosis of EAC is one of the main reasons for the high mortality 
(522). Current endoscopy based screening is costly, requires specialist appointment, is not suitable 
for frequent large scale at risk population monitoring, hence not very effective (523). While white 
light endoscopy with biopsy is most widely used for screening/surveillance (524), several 
innovative methods are being evaluated for more economic screening, including advanced imaging, 
non-endoscopic sampling, and blood biomarkers. Novel advanced imaging techniques may improve 
yield of biopsies for dysplastic Barrett’s by targeting suspicious areas and may be more effective 
than random biopsies (525-527). These real time techniques like probe based confocal 
endomicroscopy (pCLE) (526, 527) with resolution up to 1 micron can potentially decrease 
sampling errors associated with endoscopic biopsies. Another potentially useful imaging technique 
is volumetric laser endomicroscopy (VLE). Based on the principle of backscattering of near infrared 
wavelength light to obtain an image of esophageal wall layers, which can scan 6 cm of esophagus in 
90 seconds to a depth of 2 mm with a resolution of 7 microns (525), VLE can potentially help target 
suspicious areas harbouring subsquamous glands which are proposed to be a risk for EAC (528). 
These imaging modalities can be performed during ongoing endoscopy and potentially improve 
surveillance and detection of dysplasia and EAC. While biomarkers could potentially risk stratify 
patient population, these invasive and expensive “red flagging” techniques could potentially benefit 
and improve screening and surveillance.  
 To enable safe, cheap, and minimally invasive diagnosis of BE in primary care setting, Lao-
Sirieix and colleagues developed a novel device called the capsule sponge, or Cytosponge (262, 
529). The gelatin capsule contains a polyurethane sponge and attached to a string. The capsule is 
swallowed which dissolves in the stomach within 5 min. The sponge is then retrieved by pulling out 
the string that samples cells from the stomach to the oropharynx. The cell samples obtained using 
Cytosponge can be subjected to histological characterization (524). Alternatively, Cytosponge 
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sample can be evaluated for more objective markers like expression level changes in TFF3 gene to 
diagnose underlying BE (262). In fact, Cytosponge sampling with immunohistochemical evaluation 
of trefoil factor 3 can diagnose BE > 2 cm in length with sensitivity of 90.0% and specificity of 
93.5% as compared to gastroscopy (524). As far as application of Cytosponge sampling in 
diagnosing dysplasia or EAC is concerned, because the majority of recurrently mutated genes in 
EAC are also mutated in BE (201, 204, 205), the opportunity to distinguish between BE and 
dysplasia/EAC based on genomic profiling alone might prove to be very limited. Validation of 
existing protein biomarkers in samples collected using Cytosponge may provide an alternative 
opportunity for diagnosis of dysplasia/EAC.  
 An ideal way to carry out routine screening/surveillance for BE/dysplasia/EAC will be by 
developing an in vitro diagnostic tool that uses blood as a sample type. Cell free circulating DNA, 
miRNA, glycan and metabolic changes have shown differential presence between healthy, BE, 
dysplastic and EAC phenotype in serum or plasma and all of them qualify for development of 
diagnostics (1, 530). In this thesis, serum glycoproteins showing differential binding with lectins 
have been identified to differentiate mainly between EAC and healthy/BE conditions. Now, the 
efforts are required to validate these changes using clinically applicable diagnostic tests in 
multicenter clinical trial to establish clear comparison between these circulatory biomarkers and 
existing endoscopy-biopsy screening. If found comparable, the blood based diagnostic can replace 
endoscopy-biopsy as a 1
st
 line screening/surveillance tool while there is no doubt that endoscopy-
biopsy will remain gold standard for confirmation and accurate staging of the disease.  
 Like other common cancers (531), it is likely that introduction of any new screening 
program for EAC will lead to false-positive identifications. However, blood based in vitro 
diagnostic will avoid endoscopy-biopsy in the patients who are currently monitored using these 
costly and inconvenient procedures multiple times per year. The cost-savings by avoiding frequent 
endoscopy-biopsy for monitoring purposes may compensate for an additional endoscopy-biopsy 
referred due to false-positive identifications. In this manner, using the same amount of funding, 
wider patient cohort can be screened that may lead to better patient outcomes and health benefits.     
7.1.4 Biomarker translation using electrochemical biosensor 
 Electrochemical methods were initially applied for accurate and sensitive detection of 
mainly redox analytes (532). The most successful application so far developed using 
electrochemical detection is glucose biosensor which is widely used in self-use point-of-care 
settings (533). Later on, electrochemical biosensors were modified for measurements of non-redox 
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analytes including protein biomarkers but their use is mainly confined to research laboratories (532, 
534). In this thesis, an electrochemical detection technique, faradaic electrochemical impedance 
spectroscopy (F-EIS), was successfully used for interrogation of a model glycoprotein chicken 
ovalbumin (2). While the study demonstrates the principle of electrochemical detection of a 
glycoprotein, several technological advancements and follow-up validation studies are required for 
using electrochemical biosensor as an in vitro diagnostic test in clinical application. (i) In the 
current format, macrodisk electrodes were reused after cleaning for all the experiments. This 
method worked for a proof-of-principle study but when it comes to testing actual biomarker 
candidates using real clinical sample, disposable electrodes are more suitable. (ii) The lectins and 
antibodies to monitor actual biomarker candidates need to be tested for interaction between glycans 
present on antibody surface and lectins. If there is any interaction, couple of strategies can be tried. 
Either un-reacted free lectin sites after glycoprotein capture can be blocked using unrelated IgG 
molecules (415) or alternatively, antibody glycans can be chemically oxidized to inhibit their 
interaction with the lectins (416). (iii) In the current format, biotin labeled bovine serum albumin 
(BSA) and multivalent streptavidin were used for capture of biotinylated lectins. Instead of BSA 
which is very large biomolecule, smaller chemical species such as thiol-PEG-biotin should be tested 
for enhanced performance of the biosensor. (iv) The electrochemical biosensor should be designed 
to allow multiplexing whereby multiple candidate biomarkers can be simultaneously monitored. 
Collectively, once the electrochemical detection technique is validated by monitoring actual 
biomarker using clinical sample and show comparable results with the mass spectrometric 
quantitation, they can replace the mass spectrometric quantitation in later phases of biomarker 
development. 
7.1.5 Limitations of the study 
 While lectins are very useful tool for glycoprotein studies, they are criticized for lack of 
specificity. Lectins generally recognize glycan structures with low affinity but with high avidity 
mainly through hydrogen bonding, hydrophobic interactions and van der Waals forces with a 
dissociation constant (Kd) value lies in the range of 10
-3
 M to 10
-7
 M as compared to antigen-
antibody interactions which shows Kd value in the range of 10
-6
 M to 10
-9
 M (344, 535). So only 
based on differential lectin binding it is difficult to predict structural changes in the glycosylation. 
The differential binding between serum glycoprotein biomarker candidates and lectins is indirect 
measure of glycosylation change. The lectin-based LeMBA workflow utilized in this thesis does not 
provide any direct evidence of changes in the expression of glyco-epitopes associated with the 
glycoprotein biomarker candidates. Moreover, the focus throughout this thesis was to identify 
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glycosylation changes in the medium to high abundant proteins meaning low abundant glycoprotein 
candidates could have been easily missed out.    
 A total of 29 and 60 samples were screened respectively from healthy, BE and EAC groups 
in biomarker discovery and verification phases. Although the number of samples is within a range 
of proposed sample size for biomarker discovery and verification (133), the verification phase did 
not include enough number of samples to divide them separately into training and validation sets for 
statistical analysis. Furthermore, samples from early or late dysplastic patients were not available 
for biomarker discovery and verification so at the moment relative timing of the changes in the 
biomarker levels in EAC development is not clear. The healthy along with population control 
samples (total n = 39) were combined to find out candidates affected by confounding covariates. 
Some of the subgroups for the statistical analyses had only few samples (e.g. n = 5 for patients with 
daily or weekly symptoms of reflux and n = 5 for patients with alcohol consumption with <1 
standard drink/week) resulting in limited statistical power. Even though reflux frequency was 
assessed as a confounding covariate, there was a lack of true inflammatory patient control group to 
confidently identify true EAC biomarker candidates from closely related inflammatory conditions. 
 Although electrochemical detection platform demonstrated applicability to monitor 
glycoprotein biomarker candidates in a proof-of-concept work, the reproducibility of measurements 
was far away from what is actually required for clinical assay. The biosensor construction relied 
upon reproducible adsorption of biomolecule bovine serum albumin that is relatively larger in size 
as compared to chemical based modifications. In addition, non-reacted electrode surface was not 
blocked so the possibility of non-specific interaction of proteins with the electrode surface in 
subsequent stages of the assay cannot be ruled out.            
7.1.6 Future opportunities 
7.1.6.1 Validation of lectin-protein biomarker candidates in an independent patient cohort 
including dysplastic samples 
 The findings of this study should be replicated in an independent patient cohort that include 
dysplastic patient samples to determine exact timing of change in the level of biomarker candidates 
during EAC development. Ideally, the patient cohort should be well characterized and findings of 
endoscopy-biopsy should be available for each patient to allow comparison between changes in the 
lectin-protein biomarker candidates in circulation with actual disease progression. Once the findings 
are replicated, the final biomarker panel can be evaluated in multi-centre prospective trial to 
determine actual positive predictive value of the test. 
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7.1.6.2 MRM-MS assay for biomarker discovery 
 The MRM-MS assay used for verification showed better reproducibility over discovery 
proteomics workflow employed in biomarker discovery. The MRM-MS assay includes transitions 
for proteins identified as candidates in biomarker discovery and excludes any additional proteins 
which are generally identified in LeMBA pull-down. The current MRM-MS assay can be optimized 
further to include transitions of these common proteins identified in LeMBA pull-down in addition 
to existing list of potential candidates and can be used for even biomarker discovery purposes. This 
may cause slight increase in the total duration of MRM-MS assay, but it will allow monitoring of 
many more candidates from LeMBA pull-down as compared to only significant ones at no extra 
cost. When an independent patient cohort that includes dysplastic patient samples will be screened 
using this proposed MRM-MS assay, it will widen the scope of the validation. This may lead to 
identification of new candidates specific for dysplasia which may not be present in the current list 
of candidates identified between healthy, BE and EAC phenotypes.  
7.1.6.3 Glycan/glycosite characterization of biomarker candidates 
 The biomarker candidate identified should be subjected to full glycomic characterization to 
determine the changes in the glycan structure and/or site of glycosylation between different disease 
states. This may help understand basis of the differential lectin binding between different 
phenotypes. 
7.1.6.4 Determine biological basis for changes in the biomarker levels 
 Along with screening serum samples, tissue samples from the matched patients (independent 
validation cohort) should be available to perform staining for candidate biomarkers in matched 
tissue sections. This will help to determine possible source of the biomarker candidates in the 
circulation i.e. tumor tissue or stromal components. This may also aid understand pathological basis 
of the cancer-associated glycosylation changes. 
7.1.7 Conclusions 
 The work presented in this thesis identified serum glycoprotein diagnostic biomarker 
candidates for Barrett's esophagus and esophageal adenocarcinoma using LeMBA-GlycoSelector 
pipeline. The targeted proteomics assay developed for candidate biomarkers demonstrated linearity 
and reproducibility for biomarker verification. The selected lectin-glycoprotein biomarker 
candidates were verified using LeMBA-MRM-MS-Shiny mixOmics workflow in an independent 
patient cohort leading to identification of a panel of serum glycoprotein biomarker candidate to 
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distinguish between BE and EAC. Lastly, results obtained using electrochemical detection 
methodology demonstrated the possibility of using electrochemical detection for developing cheap 
point-of-care diagnostics with high specificity and sensitivity for blood glycoprotein biomarkers. It 
is anticipated that this work will be extended further to develop an in vitro diagnostic test to screen 
and monitor patients at risk of EAC.      
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Review
Early Diagnostic Biomarkers for Esophageal
Adenocarcinoma—The Current State of Play
Alok Kishorkumar Shah1, Nicholas A. Saunders1, Andrew P. Barbour2, and Michelle M. Hill1
Abstract
Esophageal adenocarcinoma (EAC) is one of the two most common types of esophageal cancer with
alarming increase in incidence and very poor prognosis. Aiming to detect EAC early, currently high-risk
patients are monitored using an endoscopic-biopsy approach. However, this approach is prone to sampling
error and interobserver variability. Diagnostic tissue biomarkers related to genomic and cell-cycle abnormal-
ities have shown promising results, although with current technology these tests are difficult to implement in
the screening of high-risk patients for early neoplastic changes. Differential miRNA profiles and aberrant
protein glycosylation in tissue samples have been reported to improve performance of existing tissue-based
diagnostic biomarkers. In contrast to tissue biomarkers, circulating biomarkers are more amenable to
population-screening strategies, due to the ease and low cost of testing. Studies have already shown altered
circulating glycans and DNA methylation in BE/EAC, whereas disease-associated changes in circulating
miRNA remain to be determined. Future research should focus on identification and validation of these
circulating biomarkers in large-scale trials to develop in vitro diagnostic tools to screen population at risk for
EAC development. Cancer Epidemiol Biomarkers Prev; 22(7); 1185–209. 2013 AACR.
Introduction
Afterheart disease, cancer is the second leading cause of
death globally. Four major cancer sites account for half of
the cancer-related mortalities: lung, colorectal, prostate
in men, and breast in women. In past 2 decades, a steady
decrease in deaths of these 4 major site malignancies led
to an overall decrease in cancer-related death rates inmen
and women (1). In contrast, the incidence of esophageal
adenocarcinoma (EAC) is increasing faster than any other
cancer type. EAC togetherwith esophageal squamous cell
carcinoma (ESCC) is the eighth most-common cancer by
prevalence and sixth most-common cause of cancer-relat-
ed death globally (2). In 1970s, the incidence of EAC
represented less than 5% of total esophageal cancer, and
a majority of esophageal cancer cases diagnosed were
ESCC. Over a period of 3 decades, EAC incidences have
been increasing continuously, especially inwestern coun-
tries among Caucasians. Now almost half of the esoph-
ageal malignancy cases diagnosed are EAC (3, 4). EAC
and ESCC show marked differences in their geographic
spread. EAC is more common in developed countries
such as the United Kingdom (8 in 100,000 individuals;
ref. 5), Australia, and the United States. Within Europe,
southern Europe has the highest EAC incidence (5). On
the other side, ESCC is the most common type of esoph-
ageal cancer amongdevelopingAsian countries (6). Racial
disparity also occurs between the 2 types of esophageal
cancer. ESCC is more prevalent among Blacks, whereas
EAC is at least twice as common in Whites as compared
with other ethnic groups (7, 8). Once diagnosed, Black
patients showed poorer overall survival than Whites
(9, 10). Taken together, strong genetic and environmental
factors relating to ethnicity and geographic distribution
seem to be playing critical roles in the incidence of esoph-
ageal cancer. Studies also suggest possible links between
socioeconomic status and the prevalence of esophageal
cancer phenotype (6).
Risk Factors
In themajority of cases, EAC is diagnosed at a late stage,
leading to a poor 5-year survival of less than 15% (11).
Hence, recent research for EAC has focused on under-
standing risk factors and the identification of early diag-
nostic biomarkers.
Esophageal cancer is unlikely to develop in individuals
younger than 40 years of age; however, after that the
incidence increases significantly with each decade of life
(9). Changing lifestyle and food habits are primarily
responsible for the dramatic epidemiologic changes in
EAC as described in recent reviews (11–13). Known EAC
risk factors include accumulation of visceral fat in the
abdomen (14), male gender, high intake of dietary fat and
cholesterol with low intake of fruits and vegetables (15),
tobacco smoking (16), reduction in Helicobacter pylori
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infections (17), and Barrett’s esophagus (BE), a metaplas-
tic change to the esophageal lining. Individuals with
Barrett’s esophagus carry almost 30 to 125 times more
risk for EAC development, and 0.5% to 1% of patients
with Barrett’s esophagus are estimated to develop EAC
each year (18). Barrett’s esophagus is characterized by
replacement of normal stratified squamous epithelium
with metaplastic columnar epithelium and is considered
to be a successful adaptation of the distal esophagus in
response to chronic gastroesophageal reflux disorder
(GERD; ref. 19).
GERD is a very common condition in the western pop-
ulation with around 20% reporting weekly symptoms of
heartburn and acid regurgitation (20). Refluxate-contain-
ing bile acid, along with gastric acid, is considered to be
more harmful, leading to inflammation, ulceration, Bar-
rett’s esophagus, and ultimately EAC. Development of
Barrett’s esophagus is a slow process and distinctive
mucus-secreting goblet cell formation can take 5 to 10
years (21, 22). Typically, EAC develops through metapla-
sia–dysplasia–carcinoma sequence involving genetic and
epigenetic modifications, leading to uncontrolled cell
proliferation, and is characterized by the presence of
intestinal metaplasiawith low-grade (LGD) to high-grade
dysplasia (HGD), which eventuallymay progress to inva-
sive carcinoma (20).
Current Diagnosis Scenario
To detect pathologic changes leading to EAC develop-
ment before onset of disease, current clinical practice
involves endoscopic screening of patients with high-risk
GERD and to characterize the degree of dysplasia in
biopsy samples collected during endoscopy (23, 24).
Enrollment of patients into an endoscopic screening pro-
grammay be facilitated by a patient questionnaire of self-
evaluated symptoms/complications (25, 26). Once
enrolled into the screening program, a patient undergoes
endoscopy-biopsy every 3 months to 2 years depending
on the degree of dysplasia, during which 4 quadrant
biopsy samples are taken every 1 to 2 cm and evaluated
for histologic changes by expert pathologists (23, 24). As a
significant number of patients histologically diagnosed
with HGD develop EAC, endoscopic mucosal ablation or
esophageal resection (esophagectomy) are options to stop
further disease progression in those high-risk patients
(27, 28). Significantly improved survival is observed in
patients diagnosed at an early stage during surveillance
endoscopy program as compared with symptomatically
diagnosed EAC (29–32).
Although current screeningmethodology shows prom-
ise, outcome of endoscopy-biopsy in many cases is non-
reproducible due to interobserver variability and sam-
pling error (28, 33). Furthermore, histologic dysplastic
changes may be patchy and present heterogeneously in
the tissue sample. This makes the diagnosis challenging,
especially in the early stages of transition to LGD (28, 34).
In up to 40%of patients, invasive cancer has been found in
resected tissue despite negative endoscopic examination
for the malignancy (35). Moreover, false-positive results
also occur, meaning despite intramucosal carcinoma in a
biopsy, the subsequently resected tissue has no signs of
carcinoma (28). These evidence suggest dysplasia grading
is an imperfect measure of cancer risk.
Despite extensive screening with currently available
techniques, more than 80% of EACs are diagnosed with-
out any prior diagnosis of Barrett’s esophagus or GERD
(36, 37). According to an estimate, more than 80% of
Barrett’s esophagus cases are undiagnosed and therefore
are not getting the benefit of the screening program (38).
On the other hand, a large proportion of patients under-
going routine biopsy screening do not progress to EAC
(13). These suggest inability of current methodologies in
screening population to detect high-risk patients and to
distinguish between disease progressors from nonpro-
gressors. In addition, the screening procedure is not very
cost-effective (39). To overcome these challenges, adjunct
use of biomarker has been proposed to stratify the risk
associated with EAC development.
Biomarkers in EAC
According to United States’ NIH, a biomarker is "a
characteristic that is objectively measured and evaluated
as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic
intervention (40)."
In transit from intestinal metaplasia to LGD to HGD to
EAC, cells acquire abilities to become self-sufficient for
growth, evade apoptosis, proliferate uncontrollably, pro-
mote angiogenesis, invade underlined epithelium, and
start to metastasize. These changes are accompanied with
histologic changes in tissue architecture, genomic insta-
bility, development of tumor microenvironment, modu-
lation of immune response, and are therefore reflected in
body fluids (serum/plasma/mucus/urine) or tissue sam-
ples and differentiate in terms of their genome/prote-
ome/metabolome profile (41). Thus, a biomarker can be
from any of these sources and reflect underlying patho-
logic or homeostatic changes. Table 1 summarizes differ-
ent classes of biomarkers proposed for BE/EAC.
National Cancer Institute Early Detection Research
Network (EDRN) guidelines outline biomarker discovery
anddevelopment to a 5-phase process summarized below
(42) and depicted in Fig. 1.
Phase I—Preclinical exploratory study: it compares
normal versus cancer samples (body fluids/tissue)
using technologies such as genomics, microarray
expression, proteomics, immunohistochemistry, or
immunoblotting to detect significant changes in
proteins/genes/metabolites between the groups.
Phase II—Clinical assay development and validation: it is
aimed at developing a clinical assay using a minimally
invasive sample collection method. The assay is meant
to be robust, reproducible, and suitable for stored
clinical samples to be used in later phases of
development. At the end of this phase, one should
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expect high specificity and sensitivity for the assay.
However, it remains to be determined how early the
biomarker can predict the disease.
Phase III—Retrospective longitudinal repository studies:
the assay is applied on prospectively collected stored
samples to determine the ability of the biomarker to
detect the disease before clinical presentation. If so, then
criteria for positive screening is determined for future
use.
Phase IV—Prospective screening: the test is prospectively
applied to real population to detect the extent and
characteristic of disease detected by the biomarker. This
phase gives positive predictive value for the test and
gives an idea about feasibility for last phase of control
trials.
Phase V—Cancer control studies: it comprises large-scale
clinical trial to determine the impact of new screening
process on the disease burden in the community.
With respect to EAC, none of the biomarkers, including
high-grade dysplasia, have been evaluated in phase V,
whereas very feware evaluated in phase III and IV. Figure
1 summarizes proposed EAC biomarkers and how well
they are characterized in the process of biomarker dis-
covery. The following sections will discuss some of the
classes of BE/EAC biomarkers.
Genomic Instability
Many groups have studied genomic instability induced
by aneuploidy, tetraploidy, DNAmethylation, allelic loss
and shown some predictive power for these changes. A
role for hypermethylation in the promoter regions of
tumor-suppressor genes during the development of EAC
has also been well established. Table 2 summarizes DNA
methylation changes associated with metaplasia–dyspla-
sia–carcinoma development. In the majority of patients,
methylation changes are acquired very early during EAC
development, hence these alterations could be used as an
early diagnostic biomarker. Apart from discriminating
patients at different stages of EAC development, DNA
methylation signatures may be useful as predictors for
progression from Barrett’s esophagus to EAC (43, 44) and
for response to chemotherapy and survival in patients
with EAC (45, 46).
Although the individual genomic abnormality has the
potential to diagnose disease at different stages, best
results are obtained when they are used in combination
(47–49). LOH at chromosome 9p and 17p locus are con-
sidered to be early events during Barrett’s esophagus
pathogenesis (50). If present with other chromosomal
alterations such as aneuploidy and tetraploidy, it
increases the 10-year risk for development of EAC from
12% to approximately 80% (51). However, with the cur-
rent flow cytometry technology, it is technically very
challenging for clinical laboratories to assess these geno-
mic biomarkers in the samples, which limits widespread
use of these biomarkers in the clinic.
Alternatively, genomic alterations canbedetected at the
protein level using immunohistochemistry. One of the
most common and earliest genomic abnormality occurs at
chromosome 17p, which codes for tumor-suppressor p53
protein. Loss of p53 protein expression in tissue samples
correlates with disease progression (52). However, as p53
expression only reflects alterations at one particular gene,
it has lower predictive value as comparedwith techniques
monitoring multiple genomic abnormalities. Further-
more, sensitivity drops as mutations or deletions at geno-
mic level may not necessarily be detected at the protein
level (53).
In line with the genomic abnormalities described ear-
lier, single-nucleotide polymorphism (SNP)–based geno-
typing can also stratify cancer risk in patients with Bar-
rett’s esophagus. As summarized in Table 3, in the past
None
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Figure 1. Summary of current BE/EAC Biomarkers with respect to EDRN
clinical phase of development.
Table 1. Comprehensive summary of different
classes of BE/EAC biomarkers
Biomarker class Ref.
Tissue biomarkers
Genomic abnormalities
(ploidy and LOH)
(47–51)
DNA methylation Refer to Table 2
SNPs/expression array studies Refer to Table 3
Inflammatory markers
COX-2 (69, 72–77)
NF-kB (78–81)
Cytokines (67, 79, 81–86)
MMPs (87–93)
Cell-cycle abnormalities (94, 95, 101)
miRNA Refer to Table 4
Glycosylation changes (121, 123–125)
Circulatory biomarkers
DNA methylation changes (130–132)
Glycan alterations (135–138)
Metabolic profiling (142–145)
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decade, several studies conducted using advanced geno-
mic techniques such as array-comparative genomic
hybridization (aCGH) and SNP arrays confirmed previ-
ously reported copy number alterations and identified
novel genomic loci undergoing changes during process of
metaplasia–dysplasia–carcinoma development (54–60). It
has been shown that as the disease progresses from early
to late stages, SNP abnormalities increase from approxi-
mately 2% to 30% (54, 57). The total number of SNP
alterations in tissue samples is tightly correlated with
previously reported DNA abnormalities such as aneu-
ploidy, copy number alterations, and LOH highlighting
the application of SNP-based genotyping to assess geno-
mic abnormalities (54–60). Thus, SNP-based genotyping
provides an alternative way to assess genomic abnormal-
ities during EAC pathogenesis.
Studies on gene expression changes in EAC have been
propelled by recent progress in genomic technologies,
each identifying unique sets of gene expression profile,
which can be used as a biomarker panel for disease
diagnosis, prognosis, or to predict response to therapy
(Table 3).Moreover, determination of the gene expression
changes has been extremely helpful to understand
detailed pathogenesis and will form basis for developing
future therapies. However, future validation using inde-
pendent sample cohorts will be necessary for themajority
of these potential biomarkers.
Apart from genomic abnormalities associated with the
disease progression, inheriting genetic factors are also
implicated for EAC development. Risk for BE/EAC and
GERD is increased by 2- to 4-fold when a first-degree
relative is already affected by any of these conditions (61).
Recently, a study conducted by The Esophageal Adeno-
carcinoma Genetics Consortium and TheWellcome Trust
Case Control Consortium identified link between SNPs at
the MHC locus and chromosome 16q24.1 with risk for
Barrett’s esophagus (62). They also identified SNPs asso-
ciated with body weight measures that were present with
more than expected frequency in Barrett’s esophagus
samples supporting epidemiologic findings about obesity
as a risk factor for Barrett’s esophagus and EAC (62). Wu
and colleagues examined the relationship between pres-
ence of risk genotypes and the onset of EAC. They iden-
tified 10 SNPs associatedwith the age of EAConset. Genes
associated with 5 of 10 SNPs identified were known to be
involved in apoptosis (63).
Recently, published cancer genome–sequencing stud-
ies have given deeper insights into the genomic abnor-
malities associated with the EAC pathogenesis. The com-
parative genomic analysis between EAC and ESCC
reported by Agrawal and colleagues (64) confirmed pre-
viously verywell-described association of p53 genemuta-
tions with esophageal cancer development. The authors
also conducted comparative genome-wide analysis
between matched Barrett’s esophagus and EAC patient
tissue samples and concluded that the majority of geno-
mic changes occur early during EAC development, at the
stageofBarrett’s esophagus (64). Similar conclusionswere
made by next-generation sequencing of biopsy samples
obtained from the same patient at the stage of Barrett’s
esophagus and EAC (65). The authors also identified
ARID1A as novel tumor-suppressor gene and around
15% of patientswith EAC showed loss of ARID1Aprotein
in tissue samples. In vitro studies suggested it to be
associated with cell growth, proliferation, and invasion
(65). Very recently published high-resolution methylome
analysis has provided first evidence for methylation
changes at genomic regions that encodenoncodingRNAs.
The authors identified longnoncodingRNA,AFAP1-AS1,
to be severely hypomethylated in Barrett’s esophagus and
EAC tissue samples, silencing of which significantly
reduced aggressiveness of EAC cell lines OE33 and
SKGT4 (66).
Taken together, genomic abnormalities play key roles
during each stage of transformation from normal squa-
mous epithelium to EAC.
Cancer-Related Inflammation
Gastric and bile acid exposure in the esophageal epi-
thelium leads to the development of chronic inflamma-
tory conditions mainly driven by elevated levels of proin-
flammatory cytokines. Chronic inflammatory responses
induce cell survival and increase cell proliferation, hence
play key roles in the development of EAC (67, 68). Expres-
sions of various inflammatory molecules such as COX-2,
NF-kB, interleukin (IL)-6, IL-8, and matrix metalloprotei-
nases (MMP) have been evaluated as prognostic biomar-
kers for BE/EAC development.
Exposure to gastric/bile acid and cytokines leads to
increased COX-2 expression (69). COX-2 is a rate-limiting
enzyme that regulates synthesis of prostaglandins from
arachidonic acid. COX-2 directly increases cell prolifera-
tion and promotes tumor invasion (69), andCOX-2–medi-
ated increase in prostaglandin synthesis could result in
tumor growth and angiogenesis (70). COX-2 expression
has been detected in disease-free esophageal tissue homo-
genates using immunoblotting (69). In comparison with
GERD, patients suffering from erosive reflux show slight-
ly higher gene expressions of this enzyme in tissue sam-
ples (71). Several studies have shown significantly
increased COX-2 expression correlating with the disease
progression from Barrett’s esophagus to dysplasia and
EAC (69, 72–75). Furthermore, expression levels of COX-2
have been shown to have a prognostic value in EAC with
higher levels associated with poor survival and increased
chances of tumor relapse (76, 77).
Another well-studied inflammatory biomarker NF-kB
is activated in response to exposure with bile acid and
elevated NF-kB expression levels are found during Bar-
rett’s esophagus, dysplasia, and adenocarcinoma (78–80).
Activated NF-kB translocates from cytoplasm to nucleus
and upregulates transcription of the genes involved
in inflammatory processes. Moreover, nuclear NF-kB
expression has been shown to be correlated with the
patient response to chemoradiotherapy.All of thepatients
who showed complete response to chemoradiotherapy
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had elevated NF-kB levels pretreatment and showed lack
of active NF-kB posttreatment (81).
In line with NF-kB and COX-2, expression of indi-
vidual or combinations of proinflammatory cytokines
IL-1b, IL-6, IL-8, and TNF-a is significantly increased in
Barrett’s esophagus and EAC as compared with squa-
mous epithelium (82–84). IL-1b and IL-8 expression
levels also correlate with the stage of EAC (79). Patients
who responded to neoadjuvant chemotherapy treat-
ment showed significantly reduced expressions of IL-
8 and IL-1b in postchemotherapy esophageal tissue
sections (81). IL-6 is activated in response to reflux and
the IL-6/STAT3 antiapoptotic pathway may underlie
the development of dysplasia and tumor (85). Serum IL-
6 levels were reported to provide 87% sensitivity and
92% specificity for EAC diagnosis in a recent retrospec-
tive study (86). However, the study only compared
between healthy and EAC groups. It would be interest-
ing to see how early it can diagnose EAC during the
process of metaplasia–dysplasia. Combination of cyto-
kines IFN-g , IL-1a, IL-8, IL-21, and IL-23 along with
platelet proteoglycan and miRNA-375 expression pro-
filing has been shown to build an inflammatory risk
model, which has clinical use to determine prognosis for
patients with EAC (67).
MMPs are a family of proteolytic enzymes involved in
the degradation of extracellular matrix components.
MMPs play a role in both inflammation and tumormetas-
tasis. Immunohistochemical staining forMMP-1, MMP-2,
MMP-7, andMMP-9 has been reported to be significantly
higher in EAC as compared with healthy individuals (87,
88). Higher level of MMP-1 expression has been associ-
ated with the lymph node metastases and possibly poor
patient survival (89). Expression ofMMP-9 is shown to be
an early event during the EAC transformation and its
expression levels are correlated with the progression of
the disease (90–92). Activity of MMPs is inhibited by a
family of proteins called tissue inhibitors of metallopro-
teinases (TIMP). Specifically, TIMP-3 gene is methylated
in EAC development and its reduced expression is asso-
ciated with stage of the tumor and patient survival (93).
On contrary, Salmela and colleagues described elevated
TIMP-1 and TIMP-3 expression in EAC tumor samples
(88).
Although the underlying tissue inflammation is very
closely associated with EAC development and several
inflammation-related biomarkers have been identified,
these remain to be validated in large-scale biomarker
studies.
Cell Cycle–Related Abnormalities
To compensate for the tissue damage induced by gas-
tric/bile acid, the underlying epithelium starts to prolif-
erate rapidly and become uncontrolled resulting in neo-
plasia. To meet the proliferation requirements, the cells
have to overcome cell-cycle checkpoints. Cyclin D1 over-
expression is one such means by which cells overcome
G1–S checkpoint, and cyclin D1 immunohistochemical
staining has been proposed to identify patients with Bar-
rett’s esophagus with an increased risk for EAC (94). In
contrast to cyclin D1, expression of p16 protein results in
cell-cycle arrest in G1 phase as it has been shown to inhibit
cyclin-dependent kinase–induced phosphorylation of
retinoblastoma protein. Early genomic abnormalities dur-
ing EAC development significantly affect p16 protein
expression,which can bedeterminedusing immunostain-
ing and implemented as a potential biomarker (95). Fur-
ther large-scale trials are required to confirm cell-cycle
abnormalities during EAC development to implement
them as a biomarker.
Bottom of the pyramid in Fig. 1 represents list of
biomarkers in the initial stages of development. Tumors
harboring overexpression of growth factor receptors [EGF
receptor (EGFR) and HER-2] are associated with poor
patient survival (96, 97), whereas those overexpressing
apoptosis regulator Bcl-2 protein showed prolonged sur-
vival (98). Incipient angiogenesis is a marked feature of
Barrett’s esophagus and underlining tissue expresses
angiogenesis markers VEGF and its receptors (99). Neo-
vascularization continues as the disease progresses from
Barrett’s esophagus to EAC. Measuring the degree of
neovascularization correlated with histopathologic grade
of the tumor and associated with the patient survival
(100). Expression of 2 prominent cell proliferation mar-
kers, PCNA and Ki-67, has been described to be altered
during BE–EAC development (101).
miRNA
miRNA was first discovered in Caenorhabditis elegans
(102) and since then it has beenwidely studied in a variety
of biologic phenomena. These short stretches of approx-
imately 21 nucleotides do not code for protein but play
important roles in gene regulation by either suppressing
protein synthesis or causing mRNA cleavage. Unlike
siRNA, miRNA can target multiple genes on remote loci
and therefore control diverse group of proteins. Several
key properties of carcinogenesis have been shown to be
regulated via miRNA, for example, angiogenesis and
metastasis (103).
With increased biologic understanding ofmiRNAs and
their role in cancer, they have been proposed in several
different clinical applications including cancer diagnosis
and tumor prognosis, tumor classification, and also as a
therapeutic target for disease intervention. Differential
tissue miRNA expression has been observed in several
different malignancies and these changes can be used for
diagnosis and classification of the tumors (103). miRNA
bioarrays were first used to show differential miRNA
expression in healthy, Barrett’s esophagus, and EAC
tissue samples (104). Since then, a number of different
studies have identified miRNA changes associated with
the development of the BE–EAC. Table 4 summarizes
primary findings of miRNA expression profiling studies
along with statistical significance and fold-change values.
Biologic significance for some of the miRNA-related
changes is discussed later.
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Smith and colleagues identified reduced expression of
miR-200 and miR-141 in Barrett’s esophagus and EAC
tissue samples. They conducted bioinformatics analysis
and correlated these miRNA expression changes with
cellular processes such as cell cycle, cell proliferation,
apoptosis, and cell migration (105). miR-196a, which is
describedas amarker of progression fromBarrett’s esoph-
agus to EAC, can increase cell proliferation and anchor-
age-independent growth and inhibit apoptosis in EAC
cell lines in vitro (106). The downstream targets for miR-
196a are verified to be Annexin A1, S100 calcium-binding
protein A9, small proline-rich protein 2C, and Keratin 5,
which showed reduced expression in EAC patient tissue
samples as compared with normal epithelium (106, 107).
Several studies described in Table 4 report overexpression
of miR-192 during EAC carcinogenesis. miR-192 has been
reported tobe a target of p53 andhas been able to suppress
cancer progression in osteosarcoma and colon cancer cell
lines throughp21 accumulation and cell-cycle arrest (108).
As shown in Table 4,miR-21 is overexpressed during BE/
EAC and it can function as an oncogene as shown in
tumors of breast, brain, lung, prostate, pancreas, colon,
liver, and chronic lymphocytic leukemia. It negatively
regulates tumor- and metastasis-suppressor genes PTEN,
TPM1, PDCD4, and Sprouty2 (109–112). miR-194 expres-
sion is regulated by hepatocyte nuclear factor (HNF)-1a
transcription factor, which is induced during BE/EAC
and may lead to upregulation of miR-194 (109). Higher
expression of miR-194 is also observed in metastatic
pancreatic cell lines (113). Among miRNAs found to be
downregulated during EAC development, let-7 family of
miRNAs is tumor-suppressive and negatively regulates
Ras oncogene. Fassan and colleagues confirmed upregu-
lation of HMGA2, which is one of the target of let-7
miRNA, using immunohistochemistry in tissue samples
(110, 112, 114). Further studies in the regards of miRNA
andmiRNA target geneswill improve the biologic under-
standing of EAC pathogenesis and may also provide
novel molecular targets for disease intervention.
Notably, miRNAs are found to be stable in serum
encapsulated in microvesicles and can be accessed easily
(115). In fact, circulating miRNA profiling has shown
distinct expression patterns in a number of cancers, other
than EAC (116). This opens up new avenues for circulat-
ing miRNA changes as a potential biomarker for EAC.
Glycoproteins
Protein glycosylation is a common posttranslational
modification with almost half of the proteins synthesized
undergoing 1 of the 2 major types either N-linked or O-
linked glycan modifications. The biosynthetic process of
glycosylation is regulated by the expression and localiza-
tion of glycosyltransferases/glycosidases and the avail-
ability of substrate glycans (117).
Aberrant glycosylation changes have previously been
reported in several different cancers namelybreast cancer,
prostate cancer, melanoma, pancreatic cancer, ovarian
cancer, etc. (118, 119). These changes include truncated
forms of O-glycans, increased degree of branching in N-
glycans, and elevated sialylation, sulfation, and fucosyla-
tion with a range of other possible variations (119). The
differential glycosylation can alter protein interactions,
stability, trafficking, immunogenicity, and function (118).
Tumor-specific glycosylation changes are actively
involved in neoplastic progression, namely metastasis,
as glycoproteins are found abundantly on cell surfaces
and extracellularmatrices and therefore play a vital role in
cellular interactions.
Lectins are a family of glycan-binding proteins exten-
sively used in glycobiology due to preferential binding of
each lectin to recognize specific glycan structures (119,
120). The first effort to identify differential glycosylation
in the progression to Barrett’s esophagus and EAC was
made in 1987 by Shimamoto and colleagues using differ-
ential binding pattern to 5 lectins in tissue specimens
(121). The glycoconjugate expression profile in Barrett’s
esophagus was found to be significantly different from
normal esophageal epithelium. Interestingly, glycoconju-
gate expression between Barrett’s esophagus and normal
duodenum was quite similar. There were minimal glyco-
conjugate expression changes between Barrett’s esopha-
gus and LGD. However, EAC tissue samples showed
significantly different lectin-binding pattern than BE/
LGD (121). Using rabbit esophageal epithelium, Poor-
khalkali and colleagues showeddifferential lectin binding
in response to acid/pepsin exposure suggesting acid
exposure can induce cell surface glycosylation changes
(122). In 2008, Neumann and colleagues used 4 different
lectins to identify pathologic mucosal changes (123). They
observed 2 distinct lectin-binding patterns. Onewas asso-
ciated with the GERD, whereas the other pattern was
characteristic for Barrett’s esophagus mucosa. Specifical-
ly,UEA (Ulex europaeus) lectin bindingwasupregulated in
Barrett’s esophagus tissue sections, which suggests pos-
sible increase in fucosylation during the disease progress
(123). A recently published study has concluded that
dysplasia can alter glycan expression and lectin binding
to the tissue samples. Fluorescently labeled WGA (wheat
germ agglutinin) lectin-binding intensity was found to be
inversely related to the degree of dysplasia (124). Further-
more, the authors used fluorescent-capable endoscope ex
vivo in the study and followed all the protocols in a
manner that exactly mimics a clinical study in vivo. Fol-
lowed by topical fluorescein-labeled WGA spray, the
authors measured fluorescence in the tissue samples.
Measurement of lectin fluorescence was a more sensitive
approach to identify dysplastic lesions as compared with
white light endoscopic technique. Their data show clinical
use of such a lectin-based endoscopic technique if devel-
oped further (124). In a phase III biomarker clinical trial
study, Bird-Liberman and colleagues combined 3 differ-
ent abnormalities to predict EAC progression in patients
with Barrett’s esophagus. Along with using conventional
LGD and DNA content abnormalities they used AOL
(Aspergillus oryzae) lectin binding to the tissue samples,
which detects presence of a1-6 fucose on the cell surface
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Table 4. Summary of literature describing miRNA expression changes in BE/EAC
Sample size Upregulated in BE/EAC Downregulated in BE/EAC Ref.
71 (BE-12, Barrett's
esophagus without
dysplasia-20, LGD-27,
EAC/HGD-12)
miR-192 (P < 0.00001), miR-196a (P < 0.05):
upregulated in Barrett's esophagus as
compared with healthy tissue.miR-196a
expression is correlated with progression
from IM-LGD-HGD-EAC (P < 0.005).
miR203 (P < 0.00001): downregulation in
Barrett's esophagus as compared with
healthy tissue.
(209)
22 (Barrett's esophagus
without dysplasia-11,
Barrett's esophagus with
dysplasia-11)
miR-15b (3.3-fold; P < 0.05), miR-203 (5.7-
fold; P < 0.05): upregulated in dysplasia as
compared with nondysplastic Barrett's
esophagus.
miR-486-5p (4.8-fold; P < 0.05), miR-let-7a
(3.3-fold; P < 0.05): downregulated in
dysplasia as compared with nondysplastic
Barrett's esophagus.
(110)
100 (EAC-100, adjacent
normal tissue as control)
miR-21 (3-fold; P < 0.05), miR-223 (2-fold;
P < 0.05), miR-192 (3.5-fold; P < 0.05),
and miR-194 (3.5-fold; P < 0.05):
upregulated in EAC as compared with
adjacent normal tissue.
miR-203 (3-fold; P < 0.05): downregulated
in EAC as compared with adjacent normal
tissue.
(111)
25 (Healthy-9, BE-5,
HGD-1, EAC-10)
miR-192 (1.7-fold; FDR < 1 e07), miR-194
(2-fold; FDR < 1e07), miR-21 (3.7-fold;
FDR ¼ 0.0003), miR-200c (1.9-fold; FDR ¼
0.0015), miR-93 (1.3-fold; FDR ¼ 0.0108):
upregulated in EAC as compared with
Barrett's esophagus.
miR-27b (1.43-fold; FDR ¼ 0.0003), miR-342
(1.25-fold; FDR ¼ 0.0015), miR-125b (2-
fold; FDR ¼ 0.0108), miR-100 (1.25-fold;
FDR ¼ 0.011): downregulated in EAC as
compared with Barrett's esophagus.
(104)
75 (Healthy-15, BE-15,
LGD-15, HGD-15,
EAC-15)
miR-215 (62.8-fold; P < 1e07), miR-192
(6.34-fold; P < 1e07): upregulated in
Barrett's esophagus in comparison with
normal tissue and remained at similar levels
with disease progress.
miR-205 (10-fold; P ¼ 1.39e0.5), let-7c
(2.04-fold; P ¼ 3.11e05), miR-203 (6.67-
fold; P ¼ 3.2e0.5): downregulated in
Barrett's esophagus in comparison with
normal tissue and remained at similar levels
as disease progresses.
(114)
91 (LGD-31, HGD-29, EAC-
31, In all cases adjacent
normal tissue used as a
control)
miR-200a (13.5-fold; P ¼ 0.02), miR-513
(1.58-fold; P ¼ 0.03), miR-125b (9.2-fold; P
¼ 0.04), miR-101 (1.83-fold; P¼ 0.04), miR-
197 (1.61-fold; P ¼ 0.04): upregulated in
LGD to HGD transition.
miR-23b (1.45-fold; P ¼ 0.007), miR-20b
(1.56-fold; P¼ 0.01), miR-181b (2.22-fold;P
¼ 0.03), miR-203 (1.49-fold; P¼ 0.03), miR-
193b (2.70-fold; P ¼ 0.04), miR-636 (4.17-
fold; P ¼ 0.04): downregulated in LGD to
HGD transition. let-7a (1.75-fold; P ¼ 0.01),
let-7b (1.59-fold; P ¼ 0.009), let-7c (1.69-
fold; P ¼ 0.03), let-7f (1.69-fold; P ¼ 0.03),
miR-345 (2-fold; P ¼ 0.02), miR-494 (1.72-
fold; P ¼ 0.03), miR-193a (2.27-fold; P ¼
0.05): downregulated in HGD-EAC
development process.
(112)
48 (BE-19, EAC-29) miR-21 (2.8-fold; P < 0.05), miR-143
(11.3-fold;P<0.05),miR-145 (3.4-fold;P
< 0.05), miR-194 (126-fold; P < 0.05), miR-
215 (18-fold; P < 0.05): upregulated in
Barrett's esophagus as compared with
adjacent normal tissue.
miR-203 (17-fold; P < 0.05), miR-205
(175-fold; P < 0.05): downregulated in
Barrett's esophagus as compared with
adjacent normal tissue.miR-143 (3-fold; P
< 0.05), miR-145 (1.8-fold; P < 0.05), miR-
215 (3.1-fold; P < 0.05): Lower expression
in EAC as compared with Barrett's
esophagus.
(109)
49 (IM-15, HGD-14, and
EAC-20, adjacent normal
tissue)
— miR-31 (>4-fold; P < 0.02), miR-375 (>4-fold;
P < 0.001): downregulated in transition
from Barrett's esophagus to EAC.
(210)
37 (BE-17, EAC-20, 9
adjacent normal tissue
samples)
— miR-141 (2-fold; P ¼ 0.0126), miR-200a
(2.5-fold; P ¼ 0.0001), miR-200b (2.1-
fold; P < 0.0001), miR-200c (1.9-fold; P ¼
0.0014), miR-429 (1.8-fold; P ¼ 0.0031):
underexpressed in EAC as compared with
Barrett's esophagus.
(105)
(Continued on the following page)
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(125). Thus, monitoring tissue glycan changes can be
combined with existing biomarkers to improve the pre-
dictive power of the currently used biomarkers.
A potential mechanism responsible for these changes is
considered to be bile acid exposure-induced gene expres-
sion and secretory pathway changes in esophageal epi-
thelium. Using carbohydrate-specific lectins that detect
N- and O-linked glycosylation and core fucosylation,
Byrne and colleagues have shown differential lectin bind-
ing to the cell surface and differential intracellular local-
ization when normal squamous and Barrett’s metaplastic
cell lines were treated with deoxycholic acid (126). Nan-
carrowand colleagues profiledwhole-genome expression
in normal squamous esophageal epithelium, Barrett’s
esophagus, and EAC and concluded that Barrett’s esoph-
agus is a tissue with enhanced glycoprotein synthesis
machinery to provide strong mucosal defense against
acid exposure (127).
Outlook—Circulating Biomarkers
Last 3 decades showed continuously increased EAC
incidences and similar trend is expected in future because
of rising incidences of obesity and GERD in the popula-
tion.Current endoscopic screeningprogrammightbenefit
the highest risk population to monitor disease progres-
sion. Monitoring dysplasia in the tissue samples has not
provided fruitful outcome for early diagnosis; however,
inclusion of the genomic and cell-cycle biomarkers has
shown definite improvement in the predictive power
over currently used histologic technique. Any biomarker
Table 4. Summary of literature describing miRNA expression changes in BE/EAC (Cont'd)
Sample size Upregulated in BE/EAC Downregulated in BE/EAC Ref.
11 (EAC-11, different
lesions were collected
from these patients and
classified into Barrett's
esophagus, LGD, HGD,
and EAC)
miR-196a is overexpressed in early EAC
(151-fold) > HGD (62.2-fold; P ¼ 0.00002) >
LGD (31.1-fold; P ¼ 0.0005) > Barrett's
esophagus (28.9-fold; P ¼ 0.00001). Fold
changes are calculated as compared with
normal epithelium.
— (107)
45 (patients with EAC
undergoing surgery)
miR-143 (P ¼ 0.0148), miR-199a_3p (P ¼
0.0009), miR-199a_5p (P ¼ 0.0129), miR-
100 (P ¼ 0.0022) and miR-145 (P ¼ 0.1176)
expression predicted a worse survival
followed by esophagectomy.
Overexpression of miR-199a_3p/_5p and
miR-99b was associated with lymphnode
metastasis.
Downregulation of miR-143 (P ¼ 0.0049) and
miR-145 (P ¼ 0.0069) in EAC as compared
with adjacent normal tissue.
(211)
24 (BE-24, progression to
EAC-7, not progressed to
EAC-17 in at least 5-y
follow-up)
miR-192 (ROC AUC ¼ 0.61), 194 (ROC
AUC ¼ 0.70), 196a (ROC AUC ¼ 0.80), and
196b (ROC AUC ¼ 0.74) showed
significantly higher expression in Barrett's
esophagus samples from patients who
progressed to EAC as compared with those
who did not progress to EAC.
— (212)
5 (patients with EAC
undergoing surgery.
Adjacent benign tissue as
a control)
miR-296 is overexpressed 2-fold in EAC as
compared with adjacent benign tissue.
— (213)
22 patients with locally
advanced EAC tumor
undergoing surgery
Negative association between miR-148a
expression and tumor differentiation (P <
0.001). Significantly higher expression of
miR-148a in tumors located in the lower
esophagus as compared with tumors in the
middle esophagus (P ¼ 0.021).
— (214)
99 EAC patient tissue
samples undergoing
surgery
miR-30e (P ¼ 0.002) and miR-200a (P ¼
0.044) expression were associated with
poor overall survival. miR-16-2 (P ¼ 0.027)
and miR-30e (P ¼ 0.002) expression were
associated with poor disease-free survival.
— (215)
NOTE:Wherever needed, fold-change values are calculated/adapted from the expression/fold-change values described in the original
article to have uniform format for the purpose of this review.
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requiring tissue samples is going to be difficult to imple-
ment for population screening and will not be economi-
cally viable. An alternative to tissue-based techniques is to
investigate changes in circulating biomarkers. Blood is
relatively easy to access and can bemonitored frequently,
ultimately increasing the possibility of detecting early
dysplastic changes.
Circulating tumor cells could be one source of biomar-
kers. Although readily found in the blood, technological
advancements are required for sensitive early detection of
the low number of tumor cells present in the circulation
(128, 129).Alternative to thedetection of circulating tumor
cells, Zhai and colleagues applied genome-wide DNA
methylation profiling approach to cell-free circulating
DNA. They found that cell-free circulating DNA methyl-
ation profile is a replica of methylation profile found in
matched tumor tissue samples and can discriminate
between healthy, Barrett’s esophagus, and EAC condi-
tions (130). Kawakami and colleagues (131) studiedmeth-
ylation of APC gene in matched tumor samples and
plasma. Unlike tumor samples that showed hypermethy-
lation of APC DNA early during the EAC development,
matched plasma samples from patients suffering from
Barrett’s esophagus and gastritis were found to be neg-
ative for APC methylation changes. Moreover, as com-
paredwith 92% (48 of 52) of EAC tissue samples, only 25%
(13 of 52) of plasma samples were positive for circulatory
APC methylation changes. However, there was a strong
correlation between stage of the tumor and plasma pos-
itivity for methylated APC (131). In combination with
DAPK methylation, measurement of preoperative APC
methylation in peripheral blood was able to discriminate
between long (>2.5 years) and short survivors with a
sensitivity of 99.9% and specificity of 57.1% (132). Taken
together, tracking circulatory DNA methylation changes
during EACdevelopmentmay be an alternative approach
to predict early EAC.
Tumor cell moulds the microenvironment to support
oncogenesis by releasing soluble and vesicular compo-
nents, including enzymes, microvesicles, proteoglycans,
chemokines, and cytokines (133). The tumor microenvi-
ronment components are shed into the circulation and
may be extremely useful as an early diagnostic biomarker.
This concept was recently showed by Pitteri and collea-
gues using an inducible HER2/neu mouse model (134).
They showed that plasma proteome profiling has the
ability to detect cancer before it actually develops. Fur-
thermore, a linear correlationwas shown forplasma levels
of candidate biomarker proteins with the tumor progres-
sion, which were reversed upon tumor regression (134).
Both encapsulatedmiRNAs and secreted glycoproteins
are prime candidates for circulating biomarkers released
by the tumor microenvironment. Circulating miRNA is
secreted in nanometer-sized vesicles called exosomes or
microvesicles. An advantage of circulating miRNA over
protein biomarkers is the ability for amplication, increas-
ing the sensitivity of detection. Comparative analysis of
circulating miRNA can be conducted using miRNA
microarray and quantitative real-time PCR (116). Future
studies should aim to discover and validate circulating
miRNA changes associated with EAC development and
progression.
Glycan Profiling
For Barrett’s esophagus and EAC, serum glycan pro-
filing using mass spectrometry has identified differential
expression of glycan structures in different disease states.
Mechref and colleagues analyzed N-linked glycan diver-
sity present in 84 patient serum samples (Healthy-18, BE-
5, HGD-11, and EAC-50; ref. 135). They identified 98
glycan features with different intensities in disease onsets
and 26 of them correspond to known glycan structures.
They showed statistically significant glycan changes
between 4different conditions (Healthy/BE/HGD/EAC)
with 3 of the known potential N-glycan biomarkers pre-
dicting EAC with 94% sensitivity and 60% specificity
(135). Another study usedmicrochip electrophoresis with
laser-induced fluorescence detection for N-glycan profil-
ing and were able to differentiate between the healthy,
Barrett’s esophagus, HGD, and EAC conditions (136).
Similar to abovementioned N-glycan profiling studies,
very recently,Gaye andcolleagues showed that ionmobil-
ity-mass spectrometric analysis of serum N-glycan can
also distinguish between normal and EAC phenotype
(137). All of these studies unanimously suggest circula-
tory N-linked glycan changes during EAC pathogenesis.
Mann and colleagues enriched fucosylated serum glyco-
proteins using lectins and then used shot gun proteomics
to identify protein in different physiologic states, includ-
ing healthy samples, Barrett’s esophagus, and EAC (138).
Although the study showed promising trends, the statis-
tical power was not achieved because of the very low
number of samples. To improve the throughput of gly-
coproteomics studies, we developed lectin magnetic bead
array-mass spectrometry (LeMBA-MS), a high-through-
put platform where a panel of lectins individually immo-
bilized onmagnetic beads is used to capture glycoproteins
followed by on-bead trypsin digest and liquid chroma-
tography–tandem mass spectrometry for protein identi-
fication (139, 140). Parallel screening of a panel of lectins
may be helpful to identify differentially glycosylated
circulating proteins during EAC pathogenesis.
Metabolic Profiling
In recent past, efforts have been made to profile met-
abolic changes associated with EAC pathogenesis. Met-
abolic profiling studies have identified changes associ-
ated with nucleoside metabolism, tricarboxylic acid
cycle, fatty acid, and amino acid metabolism during EAC
development in tissue samples and more importantly
using easily accessible biofluids, blood and urine. Early
metabolic changes in the histologically normal epitheli-
um were observed, particularly for phosphocholine, glu-
tamate, myo-inositol, adenosine-containing compounds,
uridine-containing compounds, and inosine (141). Dju-
kovic and colleagues used targeted approach to profile 8
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different serum nucleosides between healthy subjects
(n ¼ 12) and patients with EAC (n ¼ 14) using high-
performance liquid chromatography coupled with triple
quadrupole mass spectrometer. Among 8 nucleosides
they profiled, 5 were significantly different between
the 2 groups. Three of 5 significantlydifferent nucleosides,
1-methyladenosine, N2,N2-dimethylguanosine, and N2
-methylguanosine, were methylated nucleosides indicat-
ing increased tRNA methylation, similar to DNA hyper-
methylation in EAC condition (142). Zhang and collea-
gues studied serum metabolomic changes using nuclear
magnetic resonance (NMR) alone and NMR in combina-
tion with liquid chromatography/mass spectrometry
(LC/MS) in EAC (n ¼ 67), HGD (n ¼ 9), Barrett’s esoph-
agus (n¼ 3), and healthy volunteers (n¼ 34). Their model
based on Partial Least Square Discrimination Analysis
was able to distinguish between different phenotypes by
achieving area under receiver operating characteristics
curve (AUROC) as high as 0.95. On the basis of candidate
metabolites, they identified altered pathways associated
with EAC development to be energy metabolism, fatty
acid metabolism, and amino acid metabolism (143, 144).
Urine metabolomics could also distinguish between
healthy, Barrett’s esophagus, and EACphenotypes. Davis
and colleagues generated urine metabolic signatures,
which were able to discriminate between healthy, Bar-
rett’s esophagus, and EAC phenotypes, as well as distin-
guish EAC from pancreatic cancer (145). These metabolic
profiling studiesopenupnewavenues todetect earlyEAC
using circulatory biomarkers.
Improved biologic understanding, in combinationwith
technical advancements in the field of genomics, proteo-
mics, glycomics, and metabolomics, has played key roles
in the identification and validation of circulatory biomar-
kers for EAC. Development of an assay platform, which
can be clinically used for these circulatory biomarkers,
will help to conduct the large scale multicentered trials
and transform the circulatory biomarkers into clinical use.
Summary and Future Perspectives
Clinical advancements in endoscopy and new tissue
sampling techniques such as brush cytology can improve
the endoscopic-biopsy management of BE/EAC in near
future. Genomic abnormalities and cell-cycle biomarkers
have already shown their potential use to diagnose early
pathologic changes using tissue samples.However,wider
clinical application will depend on the technical ability of
individual clinical pathology laboratories. As these
changes are detected in the tissue samples, it would be
difficult to implement them in large-scale high-risk pop-
ulation screening to identify early neoplastic changes.
Recent advancements in RNA sequencing, circulatory
DNAmethylation profiling, metabolic profiling, and gly-
coproteomics may provide ways for the development
of noninvasive in vitro diagnostic biomarker for routine
monitoring and identification of patients with non-
symptomatic BE/EAC. Future studies should focus to
combine different classes of circulatory biomarkers in
large-scale trials to improve the predictive power of the
individual marker. Development of novel cost-effective
assay platforms that can transform discoveries from
research laboratories to the clinics require equal empha-
sis for the widespread benefit from the circulatory
biomarkers.
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Abbreviations 
A1BG Alpha-1B-glycoprotein 
A2M Alpha-2-macroglobulin 
AAL Aleuria aurantia lectin  
APOB Apolipoprotein B-100 
AUROC Area under receiver operating characteristic curve 
BE Barrett's esophagus 
BMI Body mass index 
BPL Bauhinia purpurea lectin 
C2 Complement C2 
C4B Complement C4-B 
C9 Complement component C9 
ConA Concanavalin A from Canavalia ensiformis 
CV Co-efficient of variation 
DSA Datura stramonium agglutinin 
EAC Esophageal adenocarcinoma 
ECA Erythrina cristagalli agglutinin 
EPHA Erythroagglutinin Phaseolus vulgaris  
GalNAc N-acetylgalactosamine 
GERD Gastroesophageal reflux disease 
GlcNAc N-acetylglucosamine 
GNL Galanthus nivalis lectin 
GSN Gelsolin 
HAA Helix aspersa agglutinin 
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HGD High grade dysplasia 
HP Haptoglobin 
HPA Helix pomatia agglutinin 
JAC Jacalin from Artocarpus integrifolia 
LeMBA Lectin magnetic bead array 
LPHA Leukoagglutinating phytohemagglutinin 
MAA Maackia amurensis agglutinin 
NPL Narcissus pseudonarcissus lectin 
PSA Pisum sativum agglutinin  
SBA Soybean agglutinin 
SERPING1 Plasma protease C1 inhibitor  
SIS Stable isotope standard 
SNA Sambucus nigra agglutinin 
sPLS-DA Sparse partial least squares-discriminant analysis 
STL Solanum tuberosum lectin 
UEA Ulex europeus agglutinin-I 
WFA Wisteria floribunda agglutinin 
WGA Wheat germ agglutinin  
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Summary 
 We report an integrated pipeline for efficient serum glycoprotein biomarker candidate 
discovery and qualification that may be used to facilitate cancer diagnosis and management. 
The discovery phase used semi-automated lectin magnetic bead array (LeMBA)-coupled 
tandem mass spectrometry with a dedicated data-housing and analysis pipeline; 
GlycoSelector (http://glycoselector.di.uq.edu.au). The qualification phase used LeMBA-
multiple reaction monitoring-mass spectrometry incorporating an interactive web-interface, 
Shiny mixOmics (http://mixomics-projects.di.uq.edu.au/Shiny), for univariate and 
multivariate statistical analysis. Relative quantitation was performed by referencing to a 
spiked-in glycoprotein, chicken ovalbumin. We applied this workflow to identify diagnostic 
biomarkers for esophageal adenocarcinoma (EAC), a life threatening malignancy with poor 
prognosis in the advanced setting. EAC develops from metaplastic condition Barrett's 
esophagus (BE).  Currently diagnosis and monitoring of at-risk patients is through endoscopy 
and biopsy which is expensive and requires hospital admission. Hence there is a clinical need 
for a noninvasive diagnostic biomarker of EAC. In total 89 patient samples from healthy 
controls, and patients with BE or EAC were screened in discovery and qualification stages. 
Of the 246 glycoforms measured in the qualification stage, 40 glycoforms (as measured by 
lectin affinity) qualified as candidate serum markers. The top candidate for distinguishing 
healthy from BE patients' group was Narcissus pseudonarcissus lectin (NPL)-reactive 
Apolipoprotein B-100 (P value=0.0231; AUROC=0.71); BE vs EAC, Aleuria aurantia lectin 
(AAL)-reactive complement component C9 (P value=0.0001; AUROC=0.85); healthy vs 
EAC, Erythroagglutinin Phaseolus vulgaris (EPHA)-reactive gelsolin (P value=0.0014; 
AUROC=0.80). A panel of 8 glycoforms showed an improved AUROC of 0.94 to 
discriminate EAC from BE. Two biomarker candidates were independently verified by 
LeMBA-immunoblotting, confirming the validity of the relative quantitation approach. Thus, 
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we have identified candidate biomarkers which, following large-scale clinical evaluation, can 
be developed into diagnostic blood tests. A key feature of the pipeline is the potential for 
rapid translation of the candidate biomarkers to lectin-immunoassays.  
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Introduction 
 Biomarkers play a central role in health care by enabling accurate diagnosis and 
prognosis; hence there is extensive research on the identification and development of novel 
biomarkers. However, despite numerous biomarker publications over the years (1), only a 
handful of new cancer biomarkers have successfully completed the journey from discovery, 
qualification, to verification and validation (2-4). One possible way to overcome this 
challenge is to develop an integrated biomarker pipeline that facilitates the smooth and 
successful transition from discovery to validation (5-10). The first and foremost consideration 
in an integrated pipeline is the sample source. In general, most of the proteomics based 
workflows use tissues or proximal fluids during the discovery phase, with the goal of 
extending the findings to plasma. Although this approach avoid the high complexity 
serum/plasma proteome and the associated requisite multi-dimensional sample separation in 
discovery stages, it often leads to failure when the candidates are not detected in plasma due 
to the limited sensitivity of the available analytical methods, or the absence of candidates in 
the plasma (11). To overcome this pitfall, we have developed an integrated glycoprotein 
biomarker pipeline which can simply and rapidly isolate glycosylated proteins from serum to 
enable high throughput analysis of differentially glycosylated proteins in discovery and 
qualification stages.   
 The workflow utilizes naturally occurring glycan binding proteins, lectins, in a semi-
automated high throughput workflow called lectin magnetic bead array-tandem mass 
spectrometry (LeMBA-MS/MS) (12, 13). Although lectins have been well-utilized in 
glycobiology and biomarker discovery (14-17), the LeMBA-MS/MS workflow demonstrates 
several unique features. Firstly, serum glycoproteins are isolated in a single-step using 20 
individual lectin-coated magnetic beads in microplate format. Secondly, we have optimized 
the concentrations of salts and detergents for sample denaturation to avoid co-isolation of 
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protein complexes without adversely affecting lectin pull-down efficiency. Thirdly, a liquid 
handler is used for sample processing to facilitate high-throughput screening and increase 
reproducibility. In addition, we have optimized on-bead trypsin digestion and incorporated 
lectin-exclusion lists during nano-LC-MS/MS to identify non-glycosylated peptides from the 
isolated glycoproteins. With these innovations, LeMBA-MS/MS demonstrates nanomolar 
sensitivity and linearity, and applicability across species (12). Compared to existing single, 
serial or multi-lectin affinity chromatography (18, 19), LeMBA-MS/MS offers the capability 
to simultaneously screen 20 lectins in a semi-automated, high throughput manner. On the 
other hand, since LeMBA-MS/MS identifies the non-glycosylated peptides, it cannot be used 
for glycan site assignment and glycan structure elucidation (20-23). However, the main 
advantage of LeMBA, we believe, is as a part of an integrated translational biomarker 
pipeline leading to lectin immunoassays. The lack of glycan structure details is not critical for 
clinical translation, as exemplified by the alpha-fetoprotein-L3 (AFP-L3) test, which 
measures the Lens culinaris agglutinin (LCA) binding fraction of serum alpha-fetoprotein 
(24, 25), and has been approved by the U.S. Food and Drug Administration for detection of 
hepatocellular carcinoma.  
 In this study, we report the extension of the glycoprotein biomarker pipeline to the 
qualification phase with LeMBA-MRM-MS, and introduce statistical analysis pipelines 
GlycoSelector (http://glycoselector.di.uq.edu.au/) and Shiny mixOmics (http://mixomics-
projects.di.uq.edu.au/Shiny) for the discovery and qualification phases, respectively. The 
utility of this integrated serum glycoprotein biomarker pipeline is demonstrated using 
esophageal adenocarcinoma (EAC) with unmet clinical need for an in vitro diagnostic test. 
EAC is a lethal malignancy of the lower esophagus with very poor 5-year survival rate of less 
than 25% (26). EAC is becoming increasingly common and its incidence is associated with 
the prevalent precursor metaplastic condition Barrett's esophagus (BE), but with a low annual 
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conversion rate of up to 1% (27). A common set of risk factors are described for BE and 
EAC, include gastroesophageal reflux disease (GERD), obesity, male gender, and smoking 
(28, 29). The current endoscopy-biopsy based diagnosis is invasive and costly, leading to an 
ineffective surveillance program. A blood test employing serum biomarkers that can 
distinguish patients with EAC from those with either BE or healthy tissue would, potentially, 
change the paradigm for the way in which BE and EAC are managed in the population (30). 
Serum glycan profiling studies have shown differential expression of glycan structures 
between healthy, BE, early dysplastic and EAC patients (31-35). However, diagnostic serum 
glycoproteins showing differential glycosylation hence differential lectin binding remain to 
be discovered, making it a suitable disease model for this study. 
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Experimental Procedures 
Study design and sample information 
 The overall biomarker study design was based on the strategy proposed by Rifai et al. 
(3), with the current work spanning discovery and qualification of the described four-phase 
paradigm. Serum samples were collected as part of the Australian Cancer Study (ACS) (36) 
and Study of Digestive Health (SDH) (37). All patients in these studies gave written, 
informed consent, and the studies were approved by the Human Research Ethics Committees 
of Queensland Institute for Medical Research, the University of Queensland, and all 
participating hospitals. Identical SOPs were followed for collecting samples for SDH and 
ACS, and processed by the same person. All 29 serum samples (Healthy-9, BE-10 and EAC-
10) used for biomarker discovery phase and 79 serum samples (Healthy-20, BE-20, EAC-20 
and population control-19) used for biomarker qualification study were matched by age; all 
selected patients were male considering the high male-dominance of EAC (29). The samples 
were stored at -80°C until use. Healthy controls were individuals with no history of 
esophageal cancer and no evidence of esophageal histological abnormality at the time of 
endoscopic sample collection. BE patients had a histologically confirmed diagnosis of 
Barrett's mucosa. EAC patients had histologically confirmed adenocarcinoma within the 
distal esophagus or gastro-esophageal junction. EAC patient sera were collected prior to the 
commencement of cancer treatment. Population controls were volunteers with no self-
reported history of EAC or BE. Samples were randomized prior to all experiments. Table 1 
and 2 describes patient information used in this study. For categorical and numerical 
variables related to patient information, P values were calculated using Fisher's exact test and 
Kruskal-Wallis test respectively. 
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Materials 
 MyOne
TM
 Tosyl activated Dynabeads were from Life Technologies. Lectins AAL, 
BPL, DSA, EPHA, GNL, JAC, LPHA, MAA, NPL, SNA, STL and UEA were from Vector 
Laboratories. Modified sequencing grade trypsin was from Promega. Protein assay Bradford 
reagent, Triton X-100 and sodium dodecyl sulfate solution were from Bio-rad. Tris base, 
glycine, sodium chloride and acrylamide/bis-acrylamide solution 40% 29:1 were from 
Amresco. Glycerol, disodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate 
dihydrate, calcium chloride dihydrate and Tween-20 were from Ajax Finechem. Magnesium 
chloride and manganese chloride were from Univar. For quadrupole time of flight runs, 
acetonitrile, isocratic HPLC grade was from Scharlau and for triple quadrupole runs, 
acetonitrile CHROMASOLV
®
 gradient grade was from Sigma. Heavy labeled stable isotope-
labeled standard (SIS) peptides were from Sigma. All other reagents including lectins not 
listed above were from Sigma unless otherwise specified. 
Serum glycoprotein biomarker discovery and qualification pipeline 
 Figure 1 represents the integrated glycoprotein biomarker discovery and qualification 
pipeline developed using LeMBA. The discovery phase aimed to identify changes in the 
lectin binding of medium to high abundance serum proteins which can distinguish between 
different phenotypes. To enable economic and high throughput label-free quantitation while 
controlling for sample processing, including tryptic digestion, we employed a non-labeled 
spiked-in glycoprotein standard at the very first step of the workflow prior to denaturation 
(Figure 1). Pilot experiments identified chicken ovalbumin as a suitable internal standard, 
with low homology to species of interest (human or mouse) that bound to all 20 lectins 
experimentally. Optimization experiments determined that 10 picomole ovalbumin to be 
added to each sample (50 μg of serum) per lectin pull-down. Depending upon the individual 
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lectin, between 3 and 5 ovalbumin peptides (out of 7) were used for normalization 
(Supplemental Table 1). Details about the data normalization and statistical analyses 
platforms GlycoSelector and Shiny mixOmics can be found in Supplemental Methods.  
 Briefly, for discovery data, two different normalization approaches (i) based upon 
total ovalbumin protein intensity or (ii) using individual ovalbumin peptide intensity were 
evaluated (Supplemental Figure 1A). There was a strong correlation between the two 
normalization approaches (Supplemental Figure 1B), and we selected the second 
normalization method for the pipeline as it gave equal weighting to each peptide. For each 
patient sample in discovery stage, a two-dimensional dataset was generated, consisting of 
normalized intensity for proteins identified with each of the 20 lectin pull-down procedures. 
In general, glycoproteins bound several lectins, reflecting heterogeneity and multiplicity of 
glycosylation. GlycoSelector is a customized database with an incorporated statistical 
analysis pipeline coded in the R statistical programming language (38) and integrated in PHP 
server-side scripting language. The pipeline is based on tools developed in mixOmics (39), an 
R package dedicated to multivariate statistical analysis of ‘omics’ data, and includes several 
steps such as data normalization, sample outlier detection, multivariate statistical analysis and 
group binding analyses. The sample outlier detection step aims to identify possible errors in 
sample handling/processing (Supplemental Figure 2). As an example of its utility, sample run 
ID 63 shown in Supplemental Figure 2A to 2D was considered to be an outlier due to 
consistent anomalous results detected in all 4 graphical outputs. The error was at the mass 
spectrometry step, because when the sample was re-run after mass spectrometer re-
calibration, it was no longer detected as an outlier (Supplemental Figure 2E to 2H). To 
determine changes in the lectin binding of individual proteins between the different 
conditions, GlycoSelector was designed with two parallel approaches. Firstly, Group Binding 
Difference analyses were performed to identify on-off changes. In addition, multivariate 
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statistical analysis based on sparse partial least square-discriminant analysis (sPLS-DA) (40) 
coupled with stability analysis was used to identify qualitative changes, after the exclusion of 
common contaminant proteins (Supplemental Table 3).   
 Based on GlycoSelector analysis, a subset of 6 lectins and 41 glycoprotein candidates 
were selected for independent qualification (Figure 1). The steps included, (i) MRM-MS 
assay development including confirmation of linearity and reproducibility, (ii) screening an 
independent cohort of patient samples using customized LeMBA-MRM-MS, (iii) two-step 
data normalization (Supplemental Figure 1A and Supplemental Methods), and (iv) univariate 
and multivariate statistical analysis using Shiny mixOmics. 
Lectin magnetic bead array (LeMBA) 
 LeMBA was performed as previously reported (12, 13) with modifications detailed in 
Supplemental Methods section. 
LC-MS/MS and database search for biomarker discovery 
 The LeMBA pull-down samples were resuspended in 20 µl of 0.1% v/v formic acid 
for LC-MS/MS (Agilent 6520 quadrupole time of flight [QTOF] coupled with a Chip Cube 
and 1200 HPLC). Initial experiments were performed to determine the optimal amount of 
tryptic peptides for LC-MS/MS: 9 μl were loaded for HAA, HPA and UEA, 6 μl for NPL, 
STL, GNL, 5 μl for BPL, DSA, ECA, MAA, SBA, WFA, and WGA, 4 μl for AAL, SNA, 
LPHA, PSA and JAC, 1 μl for EPHA and ConA. The nano pump was set at 0.3 µL/min and 
the capillary pump at 4 µL/min. The HPLC-chip used contains 160 nl C1  trapping column, 
and  5 μm  150 mm 300 Å C18 analytical column (G4240-62010 Agilent Technologies). 
Buffer A was 0.1% v/v formic acid and Buffer B was 90% v/v acetonitrile containing 0.1% 
v/v formic acid. Peptides were eluted from the column using a gradient from 6% B to 46% B 
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at 45 min. Nano pump %B was increased to 95 %B at 45.5 min and plateaued till 55.5 min, 
then decreased to 6% B at 58.5 min. The mass spectrometer was operated in 2 GHz extended 
dynamic range and programmed to acquire 8 precursor MS1 spectra per second and 4 
MS/MS spectra for each MS1 spectra. Dynamic exclusion was applied after 2 MS/MS within 
0.25 min. Exclusion for lectin peptides was applied as reported previously (12). The QTOF 
was tuned and calibrated prior to analysis. One hundred femtomole/μl of pre-digested bovine 
serum albumin peptides were used as quality control, before and after each plate. Levels of 
reference ions 299.2945 and 1221.9906 were maintained at minimum 5000 and 1000 counts 
respectively. 
 The raw data was extracted and searched using Spectrum Mill MS proteomics 
workbench (Agilent Technologies, Rev.B.04.00.127) against Swissprot human database 
containing  20,242 entries (release 3
rd
 Jan 2012). Similar MS/MS spectra acquired on the 
precursor m/z within ± 1.4 m/z and within ± 15 sec were merged. The following parameters 
were used for the search: Trypsin for digestion of proteins, 2 maximum missed cleavages, 
minimum matched peak intensity of 50%, precursor mass tolerance of ± 20 ppm, product 
mass tolerance of ± 50 ppm, calculate reversed database scores enabled and dynamic peak 
thresholding enabled. Carbamidomethylation was selected as fixed modification and oxidized 
methionine was selected as a variable modification. Precursor mass shift range from -17.0 Da 
to 177.0 Da was allowed for variable modification. Results were filtered by protein score > 
15, peptide score > 6, and % scored peak intensity (% SPI) > 60. Automatic validation was 
used to validate proteins and peptides with default settings and false discovery rates (FDRs) 
were calculated using reversed hits.  
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BE-EAC biomarker qualification using LeMBA-MRM-MS 
 Multiple reaction monitoring-mass spectrometry (MRM-MS) assay was performed on 
Agilent Technologies 6490 triple quadrupole mass spectrometer coupled with 1290 standard-
flow infinity UHPLC fitted with a standard-flow ESI (Jet Stream) source to qualify candidate 
proteins for customized list of six lectin pull-downs (AAL, EPHA, JAC, NPL, PSA and 
WGA) in an independent patient cohort. LeMBA was performed as described in 
Supplemental Methods. During MRM method development and validation stages, LeMBA 
pull-down of multiple lectins was combined and injected.  
Protein, peptide and transition selection for MRM method development 
 Proteins identified using GlycoSelector with either of the above six lectins were 
selected for qualification. In addition, a few other proteins that were identified as candidate 
biomarkers with other lectins were also included for qualification.  
 MRM selector function of Spectrum Mill was used to retrieve the top ten peptides per 
protein for MRM method development, using several runs from the LeMBA-QTOF 
discovery data set. The parameters specified included 10 peptides per protein with a score of 
above 10 and % score peak intensity of 70%. The top four product y-ions for each precursor 
ion greater than precursor m/z were selected for MRM method development. The formula 
Collision energy (CE) = 0.036 m/z - 4.8 was used to calculate CE for each precursor. Multiple 
MRM methods consisting of maximum 200 transitions were created as a first step of method 
development. All methods were transferred across to Skyline software version 2.1.0.4936 
(http://skyline.maccosslab.org/) for visualization, subsequent method refinement and analysis 
(41). Using LeMBA-MS/MS discovery data (.mzxml and .pepxml files), a reference spectral 
library was built in Skyline. This reference library was used to compare the peptide 
fragmentation pattern in the MRM method as compared to QTOF data, and also to rank 
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transitions. LeMBA pull-down from each of the 6 lectins was combined and run for each 
method to identify best MRM transitions. Each method incorporated transitions for internal 
standard chicken ovalbumin. Retention time prediction calculator iRT-C18 of Skyline was 
used to increase confidence of peptide identification (42). iRT scale was calibrated using the 
known retention time of the peptides and based on this calibration plot, retention time for the 
peptide of interest was predicted. MRM transitions showing good response at the correct 
retention time without any interference were selected for the next step. After the first round of 
method development, three MRM methods were created and each of these methods was run 
three times to find transitions showing stable responses. Some product y-ions (greater than 
precursor m/z) showed considerably low response. So to find out transition with higher 
response, up to five b- and y-ions less than precursor m/z were tried. Only transitions 
showing stable response during multiple runs were selected. Using retention time information 
for each peptide, one final dynamic MRM method was created incorporating a total of 145 
peptides and 465 transitions with delta retention times of 2.5, 3 or 4 min, to quantify 41 
proteins. Supplemental Table 6 contains a detailed list of transitions used in the method. 
LC method development 
 The UHPLC system consisted of a reverse phase chromatographic column 
AdvanceBio Peptide Mapping (150×2.1 mm i.d., 2.7 µm, part number 653750-902, Agilent 
Technologies) with a 5 mm long guard column. Mobile phase A consisted of 0.1% formic 
acid, and mobile phase B consisted of 100% acetonitrile and 0.1% formic acid. The UHPLC 
system was operated at 60°C, with a flow rate of 0.4 mL/min. The gradient used for peptide 
separation was as follows: 3% B at 0 min; 30% B at 20 min; 40% B at 24 min; 95% B at 24.5 
min; 95% B at 28.5 min; 3% B at 29 min; followed by conditioning of columns for 5 min at 
3% B before injecting the next sample.  
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Mass spectrometer settings 
 Agilent 6490 triple quadrupole mass spectrometer was operated in positive ion mode 
and controlled by Agilent’s MassHunter Workstation software (version B.06.00 build 
6.0.6025.4 SP4). The MRM acquisition parameters were 150 V high pressure RF, 60 V low 
pressure RF, 4000 V capillary voltage, 300 V nozzle voltage, 11 L/min sheath gas flow at a 
temperature of 250 °C, 15 L/min drying gas flow at a temperature of 250 °C, 30 psi nebulizer 
gas flow, unit resolution (0.7 Da full width at half maximum in the first quadrupole (Q1) and 
the third quadrupole (Q3), and 200 V delta EMV (+).  
Loading capacity determination 
 Loading capacity for individual lectin pull-down was determined by injecting varying 
amounts of LeMBA pull-down and monitoring peptide responses using MRM-MS assay. 
Each LeMBA pull-down sample was resuspended in 20 μl 0.1% formic acid. 10 μl of this 
reconstituted sample was mixed with 6 μl SIS peptide mixture containing 150 femtomole of 
ISQAVHAAHAEINEAGR and VASMASEK each, 300 femtomole of VTSIQDWVQK, and 
30 femtomole of AVEVLPK. Out of the total 16 μl mixture, the optimized loading for AAL, 
JAC, NPL and PSA lectin was 13 μl, EPHA lectin was 11.5 μl and WGA lectin was 12.5 μl. 
Linearity and reproducibility of MRM-MS 
 Linearity of the MRM-MS method was determined by injecting varying 
concentrations of aforementioned four SIS peptides spiked-into combined LeMBA pull-down 
sample of multiple lectins. The amount of SIS peptide spiked-in for each of four peptides was 
adjusted in such a manner that the response from the 1X labeled peptide mix fell within a 5-
fold range of the cognate natural peptide. The concentration of spiked-in SIS peptide varied 
from 0.008X to 25X covering 3125 fold linear range where 1X concentration indicates 
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mixture of 150 femtomole of ISQAVHAAHAEINEAGR and VASMASEK each, 300 
femtomole of VTSIQDWVQK, and 30 femtomole of AVEVLPK. All dilutions were run in 
triplicate on each day for three consecutive days (n = 9). The ratio of SIS peptide 
response/natural peptide response was plotted. 
 Reproducibility of MRM-MS assay was determined by injecting combined LeMBA 
pull-down sample from the 6 lectins in quadruplicate on each day for four consecutive days 
(n = 16). This experiment also determined the stability of the sample resuspended in 0.1% 
formic acid under the storage condition in the auto sampler. It was anticipated that once 
samples were resuspended in 96 well plates, they would be run within three days. Hence 
reproducibility was checked for four consecutive days after reconstituting samples. Percent 
coefficient of variation (% CV) between runs was calculated using peptide responses 
normalized with respect to ovalbumin peptide. 
Screening samples for LeMBA-MRM-MS qualification 
 Lectin-beads sufficient for biomarker qualification experiments were made in a single 
batch to minimize experimental variation. Serum samples were randomized for LeMBA-
MRM-MS experiments. % CV of the entire LeMBA-MRM-MS screen was calculated based 
on response of heavy labeled SIS peptides and internal standard natural chicken ovalbumin 
peptides. All three SIS peptides, except methionine containing heavy labeled peptides, 
showed a % CV of less than 20% while % CV for normalized intensity of natural internal 
standard ovalbumin peptide was around or below 20% (Supplemental Table 8), suggesting 
robustness (43) of the LeMBA pull-down and mass spectrometric measurement. 
Interestingly, normalized intensity of natural methionine containing peptide VASMASEK 
showed less variation as compared to non-normalized intensity, suggesting SIS peptide 
VASMASEK containing methionine was able to correct for batch effects in methionine 
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oxidation. One hundred femtomole of synthetic peptides mixture (G2455-85001, Agilent 
technologies) containing seven different human serum albumin peptides was run regularly to 
check linearity and reproducibility of the mass spectrometer results. When necessary, the 
mass spectrometer was tuned and calibrated. 
Data processing 
 Raw data from MRM-MS experiment was processed using Skyline. All peaks were 
manually checked for correct integration, and peak area for each peptide (sum of all 
transitions) was exported for further analysis. For linearity experiments, the ratio of 
SIS:Natural peptide was calculated and plotted against SIS peptide spiked-in concentration. 
Median normalization was performed for each lectin dataset separately (Supplemental Figure 
1A). Natural ovalbumin peptide peak intensity was first normalized with respective SIS 
labeled ovalbumin peptides. Next, using normalized intensity of natural ovalbumin peptide, 
the intensity of all other peptides was normalized. Methionine and non-methionine containing 
peptides were dealt with separately during normalization steps, to account for batch effects in 
methionine oxidation. For reproducibility experiments, the normalized response with respect 
to ovalbumin peptide was calculated for each run, and the % CV of 16 injections of the same 
sample run over a period of four days calculated. Detailed statistical analysis was performed 
using normalized peptide intensity in the computing environment R. Supplemental Table 7 
contains normalized intensity of LeMBA-MRM-MS data. 
Biomarker qualification at protein level using LeMBA-western immunoblotting 
 The top two candidates AAL-HP and AAL-GSN, identified using sPLS-DA/stability 
analysis and the on/off change function of GlycoSelector, respectively, were verified using 
LeMBA-western immunoblotting in two sets of patient cohorts, firstly using serum samples 
from the same patients used for the discovery phase, and secondly using an independent set 
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of 60 serum samples used for qualification. After AAL lectin pull-down, beads were directly 
boiled in 2X Laemmli sample buffer to elute captured glycoproteins. The denatured samples 
were separated by SDS-PAGE and proteins were transferred to polyvinylidene difluoride 
membrane (Millipore) using wet transfer. To compare results across membranes, an AAL 
pull-down sample from one healthy volunteer serum (unrelated to samples used in screen) 
was loaded in equal amounts on all gels. Membranes were blocked with 5% bovine serum 
albumin (BSA) in Tris-buffered saline-0.1% Tween-20 (TBST) for 1 hr, and then carefully 
cut into two halves. The upper part of the membrane was incubated overnight with anti-
gelsolin antibody (Epitomics #EP1940Y; 1: 3000 dilution in 5% BSA/TBST), while the 
lower portion was incubated with anti-haptoglobin antibody (Gen Way Biotech #GWB-
16A7EA; 1: 1000 dilution in 5% BSA/TBST) at 4 ºC overnight. This was followed by three 
TBST washes and incubation with 1: 3000 dilution of HRP-labeled anti-rabbit secondary 
antibody for 1 hr at room temperature (Invitrogen #A10547). The blots were developed using 
SuperSignal West Pico chemiluminescence (Thermo Scientific), and captured on film (Fuji 
film; Developer and fixer solutions were from Kodak). Densitometric analysis was performed 
using ImageJ (NIH, USA) (44). Raw densitometric values were normalized using the internal 
control sample loaded onto each gel. 
Analysis for confounders 
 To check the impact of confounding covariates [reflux frequency, body mass index 
(BMI), smoking, and alcohol consumption] on biomarker candidates, an additional 19 
population control (electoral roll) serum samples were measured using LeMBA-MRM-MS, 
to achieve sufficient number of disease-free samples for statistical analysis. Healthy and 
population control sample groups were merged and categorized according to reflux 
frequency, BMI, cumulative smoking history and alcohol consumption. Kruskal-Wallis test 
was applied to all the qualified candidates for each confounding factor. Candidates that 
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showed P < 0.05 for BMI, reflux, cumulative smoking history or alcohol consumption were 
considered as false positives and removed prior to multivariate analysis. 
Functional annotation analysis 
 A list of candidates that differentiated EAC from BE was determined based on 
univariate Kruskal-Wallis test (P < 0.05) or multivariate analysis using sPLS-DA (stability > 
70%) (Supplemental Table 10). The combined list of differential proteins was used in order 
to assess gene ontology differences between sample groups. We used the plasma proteome 
gene list (45), converted to DAVID IDs as a background in order to test for ontology 
differences by over-representation analysis using the DAVID (http://david.abcc.ncifcrf.gov/) 
website (46, 47) with default feature and algorithm settings. Ontology categories with 
adjusted FDR P-values < 0.05 were recorded. While we report individual ontologies, we 
applied the built-in functional annotation clustering function to help select representative 
ontologies for each main cluster (cluster scores over 3).  
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Results  
Esophageal adenocarcinoma biomarker discovery 
 An overview of the integrated glycoprotein biomarker discovery and qualification 
pipeline is shown in Figure 1. The discovery phase used age-matched serum samples from 9 
healthy, 10 BE and 10 EAC male patients (Table 1). BE and EAC patient groups had a 
significantly higher proportions of patients with hiatus hernia compared to healthy controls, 
as has previously been reported (48). We identified a total of 195 unique proteins from the 
MS/MS data (Supplemental Table 2). There was no difference between total number of 
proteins identified between healthy, BE and EAC patient groups (Supplemental Figure 3). 
The discovery LeMBA-MS/MS data were uploaded to GlycoSelector for data housing and 
statistical analysis. The sPLS-DA sample representation, including the top 100 candidates 
(lectin-protein pairs) in the model, showed clear separation of the samples according to their 
phenotype (Figure 2A and Supplemental Figure 4).  
 To select the most consistent candidates across patients to the qualification stage, we 
used the stability function built into GlycoSelector, which utilizes a leave-one-out strategy to 
assess the utility of each candidate biomarker. A relatively non-stringent cut-off of 70% was 
chosen for this purpose. Out of the top 100 lectin-protein pairs, 57 candidates passed the 
stability cut-off of 70% between healthy vs BE, 72 candidates passed for BE vs EAC, and 76 
candidates, passed for healthy vs EAC (Figure 2B, Supplemental Figure 4, and Supplemental 
Table 4). A second, parallel approach used the group binding difference tool in 
GlycoSelector, to select on-off candidates which may not be selected by the statistical 
approach. Using relatively non-stringent criteria of 60%/40% presence/absence, this approach 
identified another 14, 20 and 26 candidates respectively for healthy vs BE, BE vs EAC and 
healthy vs EAC analyses (Supplemental Table 4). Candidates identified using sPLS-DA and 
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the group binding differences tools were complementary and showed no overlap between 
lectin-protein candidates, justifying the use of two different approaches for candidate 
selection. All 20 lectins used in the discovery phase showed differential binding with 
anywhere between one [e.g. Helix aspersa agglutinin (HAA)] to twenty five [e.g. Narcissus 
pseudonarcissus lectin (NPL)] glycoprotein candidates for pair-wise comparison between 
patient phenotypes (Figure 2C). This suggests widespread changes in the serum glycosylation 
profile between healthy, BE and EAC samples in agreement with previous studies (31-35). 
There was considerable overlap between glycoprotein candidates identified between healthy 
vs BE, BE vs EAC and healthy vs EAC patient groups (Figure 2D).  
 Immunoblotting was used for orthogonal protein level confirmation of the LeMBA-
MS/MS screen. We chose two protein candidates which showed altered binding to Aleuria 
aurantia lectin (AAL) and for which antibodies were commercially available. AAL-
haptoglobin (HP; Uniprot entry: P00738) was one of the top ranked candidates in sPLS-DA 
analysis for healthy vs EAC and BE vs EAC, while AAL-gelsolin (GSN; Uniprot entry: 
P06396) was identified using the group binding difference function of GlycoSelector as on-
off change between BE vs EAC and healthy vs EAC. Using the same set of discovery serum 
samples, we performed pull-down using AAL and measured haptoglobin and gelsolin binding 
by immunoblotting. A control serum sample was loaded on every blot as a normalizer 
between membranes. LeMBA-immunoblotting confirmed the MS/MS results (Figure 2E, 2F 
and Supplemental Table 5), and showed higher sensitivity as it detected low levels of gelsolin 
in all patient samples, when some were undetectable by MS/MS [AAL-HP: label-free 
proteomics P value = 0.0868, western immunoblotting P value = 0.0267; AAL-GSN: label-
free proteomics P value = 0.0254, western immunoblotting P value = 0.0019]. 
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Biomarker qualification 
 Multiple reaction monitoring-mass spectrometry (MRM-MS) assay was optimized for 
41 target protein candidates based on the GlycoSelector results with 2-3 peptides per protein 
and 2-3 transitions per peptide (Figure 3A,  list of transitions in Supplemental Table 6). The 
linearity of this multiplexed assay was evaluated by spiking 4 stable isotope standard (SIS) 
peptides spanning a 3125 fold dilution range (Figure 3B). The reproducibility of the MRM-
MS assay was determined by running the same sample in quadruplicate for four consecutive 
days. As illustrated in Figure 3C, 86% of the peptides measured using MRM-MS assay 
showed % CV below 10%, while 9% of peptides showed % CV between 10-20%, and only 
5% of the peptides were above 20% suggesting overall reproducibility of MRM-MS assay.  
 For the qualification cohort (20 healthy, 20 BE, and 20 EAC; Table 2), the prevalence 
of reflux and obesity was consistent with a previous report (49) showing higher frequency in 
BE/EAC patient groups compared to the healthy group. Age matched electoral roll control 
and healthy groups were very similar across all measured covariates (Table 2). Based on the 
GlycoSelector results, we selected 6 lectins (AAL, Erythroagglutinin Phaseolus vulgaris 
[EPHA], jacalin [JAC], NPL, Pisum sativum agglutinin [PSA], and wheat germ agglutinin 
[WGA]) for qualification in this independent cohort of samples using MRM-MS assay for 41 
target proteins, hence measuring a total of 246 lectin-protein candidates. 
 Two sequential steps were used to evaluate and select candidate biomarkers from the 
qualification data; first, Kruskal-Wallis non-parametric test to assess statistical significance 
of each individual candidate, then area under receiver operating characteristic (AUROC) 
curve was used to measure the diagnostic potential of each marker. Pairwise comparisons 
were made between the three phenotypes: healthy vs BE, BE vs EAC and healthy vs EAC. 
Out of 246 lectin-protein candidates, 45 candidates were significantly different between any 
two groups (FDR < 0.05) (Table 3). Amongst them, 26 lectin-protein candidates showed 
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AUROC of more than 0.7 in at least one of the three phenotype comparisons. Boxplots and 
ROC curves of the top candidates for healthy vs BE, BE vs EAC and healthy vs EAC are 
shown in Figure 4A to 4F respectively. Supplemental Figure 5 and 6 contain boxplots and 
ROC curves for all the candidates. As shown in Figure 4G, 16 candidates overlapped between 
healthy vs EAC and BE vs EAC analysis and might be of greatest interest as they can 
differentiate EAC from healthy as well as BE phenotype.  
Orthogonal qualification at protein level using LeMBA-immunoblotting (IB) was 
performed for AAL-HP and AAL-GSN using samples from the qualification cohort. Once 
again, there was agreement between peptide level quantitation using MRM-MS and protein 
level quantitation using IB (Supplemental Figure 7 and Supplemental Table 9), validating the 
LeMBA-MRM-MS workflow [AAL-HP: MRM-MS P value = 0.0235, western 
immunoblotting P value = 0.1037, MRM-MS AUROC = 0.69, western immunoblotting 
AUROC = 0.69; AAL-GSN: MRM-MS P value = 0.0120, western immunoblotting P value = 
0.0203, MRM-MS AUROC = 0.70, western immunoblotting AUROC = 0.73]. For further 
evaluation, we undertook functional enrichment analysis of the list of candidates that 
differentiated EAC from BE, which included 17 unique proteins from 59 lectin-protein pairs 
(Supplemental Table 10). In agreement with the glycoprotein enrichment strategy, the top 
Annotation Cluster with an Enrichment Score of 10.4 included SP_PIR_KEYWORD 
glycoprotein (P = 1.82E-08) and the UP_SEQ_FEATURE glycosylation site:N-linked 
(GlcNAc...) (P = 2.32E-06). Additional clusters related to acute inflammation, complement 
cascade pathway, and endopeptidase inhibition, were over-represented within the 17 genes 
that discriminated BE and EAC. KEGG "Complement and coagulation cascades” pathway 
(hsa04610) was significantly over-represented (P = 4.6E-18), including ten genes compared 
to the full list of plasma proteins. This result is in agreement with the involvement of 
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inflammation in BE to EAC pathogenesis (50, 51), and points to alterations in the 
complement cascade in EAC development. 
Identification of candidates affected by confounding covariates 
As expected from the known risk factors, healthy, BE and EAC patient groups 
significantly differ according to BMI and reflux frequency (Table 2). Compared to healthy 
patients, BE and EAC patient groups had a higher proportion of patients who were obese or 
experienced frequent GERD. Moreover, functional annotation analysis suggest enrichment of 
the pathways related to inflammation between BE and EAC. Therefore, it may be possible 
that some of the candidates identified are due to confounding covariates rather than the actual 
disease phenotype. To evaluate this hypothesis, firstly the cohort size of healthy phenotype 
was increased by LeMBA-MRM-MS measurement of an additional 19 control serum samples 
collected as disease-free, electoral roll samples. These 39 disease-free patient samples were 
then classified according to potential confounding variables (reflux frequency, BMI, 
cumulative smoking history and alcohol consumption). The statistical significance of each 45 
lectin-protein candidates for each of the four covariates was assessed using a Kruskal-Wallis 
test. Most of the candidate biomarkers were not significantly correlated with the covariates. 
As examples, boxplots of the data for the top 3 biomarker candidates of the disease-free 
cohort classified according to covariates are shown in Figure 5. Out of the four covariates 
studied, reflux frequency is perhaps the most important factor to be considered in the context 
of BE/EAC. Notably, none of the candidates were affected by reflux frequency, suggesting 
specificity of the candidates to diagnose disease phenotype. Five candidates significantly 
correlated with covariates (Supplemental Table 11 and Supplemental Figure 8). 
Apolipoprotein B-100 (APOB; Uniprot entry: P04114) showed differential binding with 
lectins AAL, JAC, and NPL according to BMI classification. This is most likely due to 
increased levels of total APOB with increase in BMI, suggesting underlying changes in the 
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lipoprotein metabolism (52). Plasma protease C1 inhibitor (SERPING1; Uniprot entry: 
P05155) showed significantly reduced binding with JAC lectin in samples classified as 
overweight and obese as compared to healthy while JAC-alpha-1B-glycpoprotein (A1BG; 
Uniprot entry: P04217) varied according to alcohol consumption. This covariate analysis led 
us to eliminate 5 candidates from the qualified biomarker list, leaving 40 biomarker 
candidates for future studies. Out of the 5 candidates that were eliminated, JAC-APOB was 
identified in healthy vs BE analysis, AAL-APOB and JAC-A1BG were identified in BE vs 
EAC analysis, JAC-SERPING1 was identified in healthy vs EAC analysis while NPL-APOB 
was significantly different in healthy vs BE and BE vs EAC analysis. Notably, none of the 16 
lectin-protein candidates that distinguish EAC from BE and healthy phenotype were 
identified as confounding candidates.  
Multimarker panel for EAC 
Next we examined the potential of protein glycoforms as complementary biomarkers, 
focusing on differential diagnosis of EAC and BE, since this is critical for making clinical 
decisions. After removal of confounding candidates, sPLS-DA was used to derive a 
multimarker panel that distinguish BE and EAC (Figure 6A). The biomarker panel (BE vs 
EAC) included four unique proteins namely complement component C9 (C9; Uniprot entry: 
P02748), alpha-1B-glycoprotein (A1BG; Uniprot entry: P04217), complement C4-B (C4B; 
Uniprot entry: P0C0L5) and complement C2 (C2; Uniprot entry: P06681) with each of the six 
lectins appearing at least once in the panel. Using 5-fold cross-validation repeated 1000 times 
on this multimarker panel, the model showed cross-validation error rate of 37.47% and 
moderate separation of the BE and EAC sample representations (Figure 6A). The combined 
signature of the eight candidates gave an AUROC of 0.9425 with 95% specificity and 80% 
sensitivity (Figure 6B). 
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Discussion 
 In this study we present an alternative workflow to identify glycosylation changes in 
medium to high abundant glycoproteins using serum as the sample source and lectins to 
interrogate glycan moieties throughout discovery and qualification. Our workflow was 
designed to enhance the feasibility of glycoprotein biomarker discovery and translation, 
through scientific rigor while managing the experimental cost. Firstly, serum was used as the 
sample source throughout discovery and qualification, hence eliminating the risk of switching 
tissue type during biomarker development. Secondly, single step enrichment using liquid 
handler assisted LeMBA-system reduced sample processing variability. Thirdly, we utilized 
the comparatively inexpensive approach of label-free proteomics using relative quantitation 
with respect to a spiked-in internal standard chicken ovalbumin. This approach achieved the 
necessary analytical linearity and reproducibility throughout the more than 2000 hr of total 
mass spectrometer run time performed in the study. This cost-effective strategy can be 
applied across other existing proteomics platforms to account for variations during sample 
processing and enable relative quantitation for a large number of candidates without costly 
SIS labeled peptides. Fourthly, we applied a sequential filtering approach (53) in which many 
candidates were selected from biomarker discovery proteomics data, and qualified using 
MRM-MS with increasing sample size in a cost-effective manner. Finally, we introduced 
software tools for data visualization and statistical analysis in the form of web-interfaces. 
Both GlycoSelector (http://glycoselector.di.uq.edu.au) and Shiny mixOmics 
(http://mixomics-projects.di.uq.edu.au/Shiny) platforms are publicly available, user-friendly 
and require minimal and no background in statistics or computer programming.  
The main feature of both these web-interfaces is the use of multivariate sPLS-DA 
method which enables data dimension reduction, insightful graphical outputs and the 
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identification of key discriminative features with respect to the biological outcome of interest. 
In Shiny mixOmics we have added important preliminary data mining steps for ‘omics’ data 
visualization such as sample boxplots, coefficient of variation barplots, hierarchical 
clustering, PCA in order to identify potential outliers prior to statistical analyses. The 
univariate statistical analysis step includes Krukal-Wallis, ANOVA tests as well as ROC 
analysis that can be performed efficiently on thousands of variables and results can also be 
output in a common file format. While similar sorts of analyses can be performed using 
commercially available software packages such as GraphPad Prism or Origin, these require 
additional computer programming skills in order to automate the analysis for hundreds of 
data points. Finally, the multivariate statistical analysis step with sPLS-DA (also separately 
available in the R package mixOmics) (39) has been shown to identify relevant biological 
features, with a classification performance similar to other statistical approaches (40). The 
major advantage of such an approach is graphical representation of the results that univariate 
approaches cannot provide. Importantly, in this study we have shown that such multivariate 
methods can be used efficiently and reliably on proteomics data characterized by highly 
skewed and non normal distributions. Collectively, the two web-interface statistical tools that 
we propose enable data mining, univariate and multivariate statistical analyses which can be 
applied to other ‘omics’ datasets.                   
 The success of cancer screening programs in improving outcomes for many cancer 
types emphasizes the importance of early diagnosis and the development of  
screening/surveillance tools (54). The lack of cost-effective screening/surveillance 
methodology to facilitate early diagnosis of EAC is one of the main reasons for the high 
mortality. Current endoscopy-based screening is costly, requires specialist appointment, and 
is not suitable for frequent large scale at risk population monitoring (27, 30). Several 
innovative screening methods are being evaluated, including advanced imaging (55, 56), non-
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endoscopic sampling (57, 58), and blood biomarkers (30). Recently conducted genome 
profiling studies using next-generation sequencing platforms have concluded that the 
majority of key mutations are already acquired at the metaplastic stage of BE and only few 
driver mutations lead to progression of dysplasia and EAC (59, 60). This suggests that 
genomics-based screening approaches may have limitations as a screening technology. 
Despite this, the evidence for limited genomic changes between BE and EAC raises the 
possibility that more functional level changes (e.g. protein expression, protein glycosylation, 
metabolic changes etc.) may be driving the development of dysplasia/carcinoma from 
metaplastic condition. In line with this, studies have shown differential expression of glycan 
structures in tissue and serum samples during metaplasia-dysplasia-carcinoma sequence (23, 
31-35, 61-65).  
 Out of the 246 lectin-protein candidates measured for qualification, 45 candidates 
(18.3%) were qualified in an independent cohort of patients. Interestingly, only 3 out of 45 
candidates were significantly different between healthy vs BE comparison, with the other 42 
candidates differentially present in EAC as compared to either healthy or BE samples. This 
suggests that EAC phenotype is significantly different from BE and healthy in terms of serum 
glycan expression. The lack of glycosylation changes between healthy and BE was somewhat 
surprising because genomic studies suggest that BE and EAC share a common mutational 
profile that differs from healthy samples (59, 60). The top candidate that differentiated 
between healthy and BE, NPL-APOB, was influenced by BMI. Hence, except EPHA-Alpha-
2-macroglobulin (A2M), this study did not find any candidate that can differentiate BE from 
healthy, suggesting little or no change in glycosylation of serum proteins in the development 
of BE. However, the critical diagnostic need is to identify patients at early dysplasia or early 
stages of EAC, or those at high risk of progression.  To progress towards this goal, the lectin-
protein biomarker candidates should be evaluated in a patient cohort including low grade 
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dysplasia (LGD) and high grade dysplasia (HGD) phenotypes to precisely determine what 
disease stage can actually be diagnosed by the glycoprotein biomarker candidates.   
 Previous serum glycan profiling studies found reductions in total N-linked 
fucosylation in EAC as compared to healthy patient groups (33, 35). Here we used two 
fucose specific lectins AAL and PSA, both of them showed differential binding with 6 
glycoproteins for BE vs EAC pair-wise comparison. Out of 6 glycoproteins that showed 
differential binding to fucose specific lectins, 4 showed increased levels in EAC samples for 
AAL lectin pull-down, while 5 candidates showed increased levels in EAC samples as 
compared to BE for PSA lectin pull-down. These data suggest that serum glycan changes are 
specific to the glycoprotein of origin, and this property could be exploited as a specific 
biomarker compared to overall changes in serum fucosylation.  
 Apart from the major goal of translating the biomarkers for diagnosis, the verified 
biomarkers could shed light on the pathogenesis of EAC. To this end, functional annotation 
analysis of the candidates was able to distinguish between EAC and BE through enrichment 
of "complement and coagulation cascades" pathway. Very recently Song and colleagues (23) 
also identified changes in the glycosylation of complement proteins for EAC and high grade 
dysplasia compared to a healthy phenotype. They used lectin-affinity chromatography (a mix 
of fucose and sialic acid binding lectin) and hydrazide chemistry-based glycoprotein 
enrichment methods to identify complement C3 and complement C1r subcomponent as 
differentially present in HGD and EAC samples respectively, as compared to serum from 
healthy cohort. The differences between these complement proteins, and those that 
discriminate BE and EAC, in our results, may be the result of divergent sample processing 
steps.  For example, Song et al. (23) used serum sample after depletion of the seven most 
abundant proteins as compared to our workflow where as we denatured the serum samples to 
break protein complexes without depletion of abundant proteins. In our workflow we used an 
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individual lectin for enrichment of a particular type of glycan while Song and colleagues used 
a mixture of sialic acid binding Sambucus nigra agglutinin (SNA) and fucose specific AAL 
lectin for glycoprotein enrichment. Nonetheless, changes observed in the glycosylation of 
complement proteins may suggest a role for inflammation in EAC pathogenesis (50).    
 While lectins are a useful tool for discovery and translation, a limitation of our 
pipeline is the lack of identification of the actual glycosylation sites and glycan structures. 
For rapid translation of the verified biomarkers using a simple lectin-immunoassay format 
that can be readily achieved, the only information required is the lectin affinity and the 
protein identity. Hence, we have not incorporated detailed glycosylation site or glycan 
structure analysis to the current pipeline. Following further clinical evaluation, the final 
glycoprotein candidates could be subjected to full glycomics characterization to determine 
the changes in the glycan structure and/or site of glycosylation between different disease 
states. This may provide additional insight into the pathological basis of the cancer-associated 
glycosylation changes. We anticipate 3 possible scenarios for a glycoprotein to show 
differential lectin binding in our LeMBA based workflow. (i) Total glycoprotein level 
changes would lead to overall increased/decreased binding with multiple lectins. (ii) Changes 
in the glycan occupancy at a particular glycosylation site will lead to differential binding with 
multiple lectins. (iii) Differential expression of a specific glycan structure will alter binding 
of a glycoprotein to a particular lectin or a group of lectins. Further studies following 
biomarker qualification will be required to identify the exact mechanism of differential lectin 
binding for each candidate. 
 In summary, we have developed novel tools for glycoprotein biomarker discovery 
using serum. The cross-sectional pre-clinical biomarker exploratory study conducted using 
our workflow has identified a list of serum glycoprotein candidate biomarkers that can 
distinguish EAC from healthy and BE phenotype. These candidates will need to be further 
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evaluated in independent cohorts of patient samples that include different disease grades and 
subtypes, prior to prospective trials. The pipeline developed can be applied to other diseases 
with software tools GlycoSelector and Shiny mixOmics available online at 
http://glycoselector.di.uq.edu.au/ and http://mixomics-projects.di.uq.edu.au/Shiny. 
 The raw mass spectrometry data along with database search results including 
sequence database used for searches have been deposited to the publicly accessible platform 
ProteomeXchange Consortium (66) via the PRIDE partner repository with the dataset 
identifier PXD002442. The peptide identification results can be viewed using MS-Viewer 
(http://prospector2.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msviewer) (67), using 
search key jn7qafftux.   
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Figure Legends  
Figure 1. Generalized workflow schematic for serum glycoprotein biomarker discovery 
and qualification. Serum samples from respective patient groups were enriched for sub-
glycoproteomes using 20 individual lectin coated magnetic beads, followed by on-bead 
trypsin digest and tandem mass spectrometry for label-free quantitation referencing to 
internal standard chicken ovalbumin. In-house database and statistical analysis pipeline 
"GlycoSelector" (http://glycoselector.di.uq.edu.au/) identified lectin-protein pairs present in 
one patient group and absent in the other. Sparse partial least squares-discriminant analysis 
(sPLS-DA) combined with stability analysis was used to generate ranked lists of lectin-
protein candidates. For biomarker qualification, selected candidates were measured using 
multiple reaction monitoring-mass spectrometry (MRM-MS) in an independent patient cohort 
for a subgroup of lectin pull-downs. Dedicated statistical analysis tool "Shiny mixOmics" 
(http://mixomics-projects.di.uq.edu.au/Shiny) was developed incorporating tools to plot 
receiver operating characteristic (ROC) curve and to perform univariate/multivariate 
statistical analyses. LeMBA-immunoblotting (IB) was used as an orthogonal method to verify 
peptide level MS data for selected candidates at the protein level. 
Figure 2. Biomarker discovery and protein level qualification of two candidates. Serum 
samples from 29 patients (healthy-9, BE-10 and EAC-10) were screened using the LeMBA-
GlycoSelector pipeline. (A) The sPLS-DA sample representation based on the top 100 lectin-
protein candidates that differentiate EAC from BE. (B) Amongst the top 100 sPLS-DA 
candidates, 72 candidates passed the stability criteria of 70% based on leave-one-out cross-
validation. Results of sPLS-DA and stability analysis for healthy vs BE and healthy vs EAC 
are available in Supplemental Figure 4. (C) Number of unique candidate proteins identified 
for each lectin in LeMBA-GlycoSelector analysis. All 20 lectins used for screening identified 
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at least one protein candidate. (D) Overlap between lectin-protein candidates that differentiate 
BE from healthy, EAC from BE, and EAC from healthy phenotype. (E) AAL-HP and (F) 
AAL-GSN were the top two candidates identified using sPLS-DA and group binding 
difference tool, respectively. (E and F, top panel) Label-free proteomics relative quantitation 
results for AAL-HP and AAL-GSN respectively. (E and F, lower panel) Normalized 
intensity for AAL-HP and AAL-GSN using immunoblotting. Raw densitometry values are 
provided in Supplemental Table 5. 
Figure 3. Multiple reaction monitoring-mass spectrometry (MRM-MS) assay 
development outline including determination of assay linearity and reproducibility. (A) 
Outline of MRM-MS assay development. (B) Linearity of MRM-MS assay confirmed using 
SIS labeled peptide mix of 4 peptides diluted across 3125 fold and spiked-into a constant 
amount of LeMBA pull-down sample. (C) Reproducibility of MRM-MS assay for 16 
replicate injections ran over 4 days period. 
Figure 4. Qualification of lectin-protein biomarker candidates in an independent patient 
cohort. (A to F) Boxplots and ROC curves of top biomarker candidate for healthy vs BE, BE 
vs EAC, and healthy vs EAC comparison, respectively. (G) Overlap between lectin-protein 
candidates that differentiate BE from healthy, EAC from BE, and EAC from healthy 
phenotype. P values were calculated using Kruskal-Wallis test and P < 0.05 was considered 
to be statistically significant. 
Figure 5. Assessing effect of confounding covariates on the top 3 biomarker candidates. 
Levels of NPL-APOB, AAL-C9 and EPHA-GSN were monitored in 39 serum samples 
(healthy-20 and population control-19) using MRM-MS. Samples were categorized according 
to (A) reflux frequency, (B) BMI, (C) smoking history and (D) alcohol consumption. P < 
0.05 using Kruskal-Wallis test was considered to be statistically significant. Out of the top 3 
candidates, only NPL-APOB was significantly different according BMI categorization. 
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Figure 6. Multimarker panel to distinguish EAC from BE. (A) sPLS-DA and (B) ROC 
curve analysis of a multimarker panel consists of AAL-C9, EPHA-A1BG, EPHA-C9, JAC-
C9, NPL-C2, NPL-C4B, PSA-C9, and WGA-C9. 
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Tables 
Table 1. Clinical characteristics of the patient cohort for biomarker discovery. For categorical 
and numerical variables, P values were calculated using Fisher's exact test and Kruskal-
Wallis test respectively. 
Variables Healthy BE EAC 
P value 
(Healthy vs BE 
vs EAC) 
Sample size 9 10 10  
Age (Median ± SD) 66 ± 10 62 ± 15 66 ± 8 0.9311 
Gender All male All male All male  
Protein concentration 
(μg/μl) 
95 ± 19 85 ± 13 82 ± 13 0.3641 
Gastritis* 1 (11.1%) 1 (11.1%) 1 (10.0%) 1.0000 
Peptic ulcer 3 (33.3%) 2 (20.0%) 3 (30.0%) 0.8792 
Hiatus hernia 0 (0.0%) 4 (40.0%) 6 (60.0%) 0.0217 
Other malignancy 1 (11.1%)  2 (20.0%) 2 (20.0%) 1.0000 
*All the analyses were performed based on available patient information. Gastritis status for one BE 
patient was missing. 
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Table 2. Clinical characteristics of the patient cohort for biomarker qualification. For 
categorical and numerical variables, P values were calculated using Fisher's exact test and 
Kruskal-Wallis test respectively.  
Variables Healthy BE EAC 
P value 
(Healthy 
vs BE vs 
EAC) 
Population 
Control 
P value 
(Healthy 
vs Pop. 
Control) 
Sample size 20 20 20 
 
19 
 Gender All male All male All male 
 
All male 
 Age in years (Median ± SD) 64 ± 8 60 ± 8 61 ± 7 0.4283 62 ± 7 0.2793 
Protein concentration (μg/μl) 83 ± 10 78 ± 12 85 ± 13 0.6486 89 ± 13 0.0785 
Reflux frequency* (10 years before diagnosis) 
 
0.0108 
 
0.2155 
   <Once/month 9 (47.4%) 7 (35.0%) 2 (10.0%) 
 
14 (73.7%) 
    Monthly (few times/month) 6 (31.6%) 6 (30.0%) 3 (15.0%) 
 
4 (21.1%) 
    Weekly or daily 4 (21.0%) 7 (35.0%) 15 (75.0%) 
 
1 (5.3%) 
 Body mass index 
   
0.0076 
 
0.6090 
   Healthy (<25) 5 (25.0%) 5 (25.0%) 1 (5.0%) 
 
7 (36.8%) 
    Overweight (25-30) 8 (40.0%) 12 (60.0%) 5 (25.0%) 
 
8 (42.1%) 
    Obese (>=30) 7 (35.0%) 3 (15.0%) 14 (70.0%) 
 
4 (21.1%) 
 Smoking history 
   
0.6116 
 
0.7813 
   Never smoked 8 (40.0%) 8 (40.0%) 4 (20.0%) 
 
7 (36.8%) 
    1-29.9 pack per year 8 (40.0%) 9 (45.0%) 10 (50.0%) 
 
6 (31.6%) 
    30+ pack per year 4 (20.0%) 3 (15.0%) 6 (30.0%) 
 
6 (31.6%) 
 Alcohol consumption 
   
0.6637 
 
0.8379 
   <1 standard drink/week 3 (15.0%) 3 (15.0%) 1 (5.0%) 
 
2 (10.5%) 
    1-6 standard drink/week 3 (15.0%) 4 (20.0%) 6 (30.0%) 
 
5 (26.3%) 
    7-20 standard drink/week 8 (40.0%) 4 (20.0%) 6 (30.0%) 
 
6 (31.6%) 
    21+ standard drink/week 6 (30.0%) 9 (45.0%) 7 (35.0%)  6 (31.6%)  
*All the analyses were performed based on available patient information. Reflux frequency for one healthy 
patient was missing.  
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Table 3. Verified list of candidates shown by lectin affinity-protein ID that were significantly 
different for either healthy vs BE or BE vs EAC or healthy vs EAC analysis. Proteins are 
denoted using gene symbol; number in the bracket denotes Uniprot accession number. 
AUROC values of more than 0.7 are highlighted in bold.   
Lectin-Protein 
Healthy vs BE BE vs EAC Healthy vs EAC 
P value AUROC P value AUROC P value AUROC 
AAL-APOB (P04114) 0.1368 0.6375 0.0453 0.6850 0.9569 0.4950 
AAL-C5 (P01031) 0.6073 0.5475 0.0483 0.6825 0.2340 0.6100 
AAL-C7 (P10643) 0.2793 0.6000 0.0063 0.7525 0.3169 0.5925 
AAL-C9 (P02748) 0.2793 0.6000 0.0001 0.8525 0.0161 0.7225 
AAL-GSN (P06396) 0.7455 0.5300 0.0087 0.7425 0.0265 0.7050 
AAL-HP (P00738) 0.8711 0.4850 0.0398 0.6900 0.0583 0.6750 
EPHA-A2M (P01023) 0.0248 0.7075 0.9138 0.4900 0.0186 0.7175 
EPHA-AHSG (P02765) 0.5162 0.5600 0.1941 0.6200 0.0483 0.6825 
EPHA-C7 (P10643) 0.1368 0.6375 0.0398 0.6900 0.6849 0.5375 
EPHA-C9 (P02748) 0.0583 0.6750 0.0003 0.8375 0.0265 0.7050 
EPHA-GSN (P06396) 0.2036 0.6175 0.0200 0.7150 0.0014 0.7950 
EPHA-HP (P00738) 0.7455 0.5300 0.0200 0.7150 0.0305 0.7000 
EPHA-SERPINA3 (P01011) 0.4171 0.5750 0.0265 0.7050 0.0620 0.6725 
EPHA-TF (P02787) 0.7455 0.4700 0.0326 0.6975 0.0935 0.6550 
JAC-A1BG (P04217) 0.6263 0.5450 0.0483 0.6825 0.1231 0.6425 
JAC-APOB (P04114) 0.0305 0.7000 0.0699 0.6675 0.5700 0.5525 
JAC-C4BPA (P04003) 0.7251 0.5325 0.0935 0.6550 0.0128 0.7300 
JAC-C5 (P01031) 0.6073 0.4525 0.0425 0.6875 0.0483 0.6825 
JAC-C7 (P10643) 0.2914 0.5975 0.0094 0.7400 0.0834 0.6600 
JAC-C9 (P02748) 0.2914 0.5975 0.0007 0.8125 0.0029 0.7750 
JAC-CFB (P00751) 0.9353 0.5075 0.0373 0.6925 0.0373 0.6925 
JAC-GSN (P06396) 0.8498 0.5175 0.0305 0.7000 0.0215 0.7125 
JAC-HP (P00738) 0.9569 0.5050 0.0483 0.6825 0.0583 0.6750 
JAC-HPX (P02790) 0.7868 0.5250 0.0742 0.6650 0.0200 0.7150 
JAC-SERPINA1 (P01009) 0.3040 0.5950 0.0453 0.6850 0.2448 0.6075 
JAC-SERPINA3 (P01011) 0.9569 0.5050 0.0102 0.7375 0.0305 0.7000 
JAC-SERPIND1 (P05546) 0.1368 0.6375 0.4819 0.5650 0.0483 0.6825 
JAC-SERPING1 (P05155) 0.5518 0.5550 0.2559 0.6050 0.0200 0.7150 
NPL-AFM (P43652) 0.5338 0.5575 0.0483 0.6825 0.1762 0.6250 
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Lectin-Protein 
Healthy vs BE BE vs EAC Healthy vs EAC 
P value AUROC P value AUROC P value AUROC 
NPL-APOB (P04114) 0.0231 0.7100 0.0231 0.7100 0.8924 0.5125 
NPL-C4BPA (P04003) 0.0989 0.6525 0.6849 0.5375 0.0231 0.7100 
NPL-C9 (P02748) 0.5885 0.5500 0.0049 0.7600 0.0074 0.7475 
NPL-GSN (P06396) 0.8924 0.5125 0.0173 0.7200 0.0583 0.6750 
NPL-HP (P00738) 0.8077 0.5225 0.0884 0.6575 0.0326 0.6975 
NPL-SERPINA3 (P01011) 0.5518 0.5550 0.0989 0.6525 0.0305 0.7000 
PSA-C5 (P01031) 0.4017 0.5775 0.0453 0.6850 0.3040 0.5950 
PSA-C7 (P10643) 0.2914 0.5975 0.0019 0.7875 0.0742 0.6650 
PSA-C9 (P02748) 0.2036 0.6175 0.0008 0.8100 0.0161 0.7225 
PSA-GSN (P06396) 0.3577 0.5850 0.0483 0.6825 0.0110 0.7350 
PSA-HP (P00738) 0.8498 0.4825 0.0483 0.6825 0.0425 0.6875 
PSA-SERPINA3 (P01011) 0.8077 0.5225 0.0425 0.6875 0.0834 0.6600 
WGA-C9 (P02748) 0.4819 0.5650 0.0032 0.7725 0.0053 0.7575 
WGA-GSN (P06396) 0.7868 0.5250 0.0119 0.7325 0.0742 0.6650 
WGA-HP (P00738) 0.7455 0.5300 0.0483 0.6825 0.0215 0.7125 
WGA-SERPINA3 (P01011) 0.4819 0.5650 0.0989 0.6525 0.0063 0.7525 
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9.3 Appendix III: Boxplots and ROC curves of the verified candidates  
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